WO2010100144A1 - Fused bicyclic compounds as inhibitors for pi3 kinase - Google Patents
Fused bicyclic compounds as inhibitors for pi3 kinase Download PDFInfo
- Publication number
- WO2010100144A1 WO2010100144A1 PCT/EP2010/052615 EP2010052615W WO2010100144A1 WO 2010100144 A1 WO2010100144 A1 WO 2010100144A1 EP 2010052615 W EP2010052615 W EP 2010052615W WO 2010100144 A1 WO2010100144 A1 WO 2010100144A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- het
- denotes
- mmol
- title compound
- butyl
- Prior art date
Links
- 125000002619 bicyclic group Chemical group 0.000 title claims description 12
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 title description 23
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 title description 23
- 239000003112 inhibitor Substances 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 422
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 230000033228 biological regulation Effects 0.000 claims abstract description 4
- -1 Hal Chemical group 0.000 claims description 119
- 239000000203 mixture Substances 0.000 claims description 110
- 238000000034 method Methods 0.000 claims description 99
- 229910052739 hydrogen Inorganic materials 0.000 claims description 86
- 125000004432 carbon atom Chemical group C* 0.000 claims description 77
- 125000000217 alkyl group Chemical group 0.000 claims description 65
- 150000003839 salts Chemical class 0.000 claims description 64
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 56
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 53
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 50
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 40
- 238000011282 treatment Methods 0.000 claims description 32
- 229910052757 nitrogen Inorganic materials 0.000 claims description 31
- 239000004480 active ingredient Substances 0.000 claims description 24
- 108091007960 PI3Ks Proteins 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- 239000012453 solvate Substances 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 125000002950 monocyclic group Chemical group 0.000 claims description 13
- 208000006673 asthma Diseases 0.000 claims description 12
- 229910052786 argon Inorganic materials 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 9
- 210000004072 lung Anatomy 0.000 claims description 9
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 125000004434 sulfur atom Chemical group 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 238000011321 prophylaxis Methods 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 5
- 238000002054 transplantation Methods 0.000 claims description 5
- 229910052720 vanadium Inorganic materials 0.000 claims description 5
- 206010033645 Pancreatitis Diseases 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims description 4
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 3
- 210000003679 cervix uteri Anatomy 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 210000000981 epithelium Anatomy 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 210000000867 larynx Anatomy 0.000 claims description 3
- 210000004324 lymphatic system Anatomy 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 229910052701 rubidium Inorganic materials 0.000 claims description 3
- 230000019491 signal transduction Effects 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 229910052721 tungsten Inorganic materials 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 229910052727 yttrium Inorganic materials 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000004852 Lung Injury Diseases 0.000 claims description 2
- 229910052770 Uranium Inorganic materials 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 231100000515 lung injury Toxicity 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 229910052705 radium Inorganic materials 0.000 claims description 2
- 230000019100 sperm motility Effects 0.000 claims description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 150000003906 phosphoinositides Chemical class 0.000 abstract description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 264
- 239000000543 intermediate Substances 0.000 description 155
- 230000015572 biosynthetic process Effects 0.000 description 154
- 239000000243 solution Substances 0.000 description 137
- 238000005160 1H NMR spectroscopy Methods 0.000 description 136
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 136
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 119
- 239000007787 solid Substances 0.000 description 117
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 115
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 103
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 93
- 239000011541 reaction mixture Substances 0.000 description 89
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 88
- 238000000132 electrospray ionisation Methods 0.000 description 82
- 239000002904 solvent Substances 0.000 description 77
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 73
- 235000019439 ethyl acetate Nutrition 0.000 description 64
- 238000004128 high performance liquid chromatography Methods 0.000 description 59
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 56
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 52
- 230000002829 reductive effect Effects 0.000 description 52
- 235000002639 sodium chloride Nutrition 0.000 description 52
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 45
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
- 239000012267 brine Substances 0.000 description 39
- 239000007788 liquid Substances 0.000 description 39
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 39
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 37
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 37
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 229910052938 sodium sulfate Inorganic materials 0.000 description 35
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 34
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 33
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 32
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 32
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 27
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 26
- 235000011152 sodium sulphate Nutrition 0.000 description 25
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 125000002883 imidazolyl group Chemical group 0.000 description 24
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 24
- 125000004076 pyridyl group Chemical group 0.000 description 24
- 239000002585 base Substances 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- 239000012044 organic layer Substances 0.000 description 21
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 21
- 238000003818 flash chromatography Methods 0.000 description 20
- 239000000377 silicon dioxide Substances 0.000 description 20
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 19
- 239000003921 oil Substances 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 17
- 238000000746 purification Methods 0.000 description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 15
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000002253 acid Substances 0.000 description 15
- AGSPXMVUFBBBMO-UHFFFAOYSA-N beta-aminopropionitrile Chemical compound NCCC#N AGSPXMVUFBBBMO-UHFFFAOYSA-N 0.000 description 15
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 15
- 239000002244 precipitate Substances 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- 238000009472 formulation Methods 0.000 description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 14
- 150000001412 amines Chemical class 0.000 description 13
- 235000019341 magnesium sulphate Nutrition 0.000 description 13
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- 239000012299 nitrogen atmosphere Substances 0.000 description 12
- 230000037361 pathway Effects 0.000 description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
- VZEBSJIOUMDNLY-UHFFFAOYSA-N 6-bromo-1,3-benzothiazol-2-amine Chemical compound C1=C(Br)C=C2SC(N)=NC2=C1 VZEBSJIOUMDNLY-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 11
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 239000007832 Na2SO4 Substances 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 9
- 102000038030 PI3Ks Human genes 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 125000002252 acyl group Chemical group 0.000 description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 125000001841 imino group Chemical group [H]N=* 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 229960002930 sirolimus Drugs 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 239000003643 water by type Substances 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 7
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 7
- 229910052796 boron Inorganic materials 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000012458 free base Substances 0.000 description 7
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 7
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 7
- 239000012442 inert solvent Substances 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 7
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 7
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 6
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 6
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229960004132 diethyl ether Drugs 0.000 description 6
- 229940052303 ethers for general anesthesia Drugs 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 6
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 6
- 229940086542 triethylamine Drugs 0.000 description 6
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
- WCFJUSRQHZPVKY-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NCCC(O)=O WCFJUSRQHZPVKY-UHFFFAOYSA-N 0.000 description 5
- WCCLUBJCLSIZOC-UHFFFAOYSA-N 5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-amine Chemical compound C1=C(Cl)N=C2SC(N)=NC2=C1 WCCLUBJCLSIZOC-UHFFFAOYSA-N 0.000 description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 230000001363 autoimmune Effects 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 5
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 5
- 235000011056 potassium acetate Nutrition 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- NBKZGRPRTQELKX-UHFFFAOYSA-N (2-methylpropan-2-yl)oxymethanone Chemical compound CC(C)(C)O[C]=O NBKZGRPRTQELKX-UHFFFAOYSA-N 0.000 description 4
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 4
- PWQLYPCPQHHIEQ-UHFFFAOYSA-N 2,2-dimethylpropanehydrazide;hydrochloride Chemical compound Cl.CC(C)(C)C(=O)NN PWQLYPCPQHHIEQ-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- DTXVKPOKPFWSFF-UHFFFAOYSA-N 3(S)-hydroxy-13-cis-eicosenoyl-CoA Chemical compound NC1=CC=C(Cl)N=N1 DTXVKPOKPFWSFF-UHFFFAOYSA-N 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- XHBQNLHFUPSZNL-UHFFFAOYSA-N 6-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound C1=CC(Br)=CN2N=C(N)N=C21 XHBQNLHFUPSZNL-UHFFFAOYSA-N 0.000 description 4
- LAUJNLOJYLUKCP-UHFFFAOYSA-N 6-bromoimidazo[1,2-a]pyridin-2-amine Chemical compound C1=C(Br)C=CC2=NC(N)=CN21 LAUJNLOJYLUKCP-UHFFFAOYSA-N 0.000 description 4
- AZFYLSFUALTNAY-UHFFFAOYSA-N 7,8-dihydro-6h-imidazo[1,5-c]pyrimidin-5-one Chemical compound O=C1NCCC2=CN=CN12 AZFYLSFUALTNAY-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 229930105110 Cyclosporin A Natural products 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 210000001956 EPC Anatomy 0.000 description 4
- 206010018364 Glomerulonephritis Diseases 0.000 description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 239000012828 PI3K inhibitor Substances 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 4
- 206010046851 Uveitis Diseases 0.000 description 4
- JQXXHWHPUNPDRT-KCFDLMDRSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(Z)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N/N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C JQXXHWHPUNPDRT-KCFDLMDRSA-N 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- 229960001265 ciclosporin Drugs 0.000 description 4
- 238000006880 cross-coupling reaction Methods 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 4
- 229940043237 diethanolamine Drugs 0.000 description 4
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- CWUSWANRIVVXCI-UHFFFAOYSA-N ethyl n-[(5-bromopyridin-2-yl)carbamothioyl]carbamate Chemical compound CCOC(=O)NC(=S)NC1=CC=C(Br)C=N1 CWUSWANRIVVXCI-UHFFFAOYSA-N 0.000 description 4
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 4
- 229960000556 fingolimod Drugs 0.000 description 4
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 230000004957 immunoregulator effect Effects 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 235000001055 magnesium Nutrition 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229940091250 magnesium supplement Drugs 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 4
- 229960004866 mycophenolate mofetil Drugs 0.000 description 4
- NUAXTWPIAKMSBX-UHFFFAOYSA-N n-(6-bromoimidazo[1,2-a]pyrazin-2-yl)-2,2,2-trifluoroacetamide Chemical compound C1=C(Br)N=CC2=NC(NC(=O)C(F)(F)F)=CN21 NUAXTWPIAKMSBX-UHFFFAOYSA-N 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 4
- 229940067631 phospholipid Drugs 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 201000000306 sarcoidosis Diseases 0.000 description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 235000015424 sodium Nutrition 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
- 229960001967 tacrolimus Drugs 0.000 description 4
- KKMOEIDLWVEXCW-UHFFFAOYSA-N tert-butyl n-[2-(5-cyclopropyltetrazol-2-yl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCN1N=NC(C2CC2)=N1 KKMOEIDLWVEXCW-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- SZPQTEWIRPXBTC-KFOWTEFUSA-N 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'D-myo-inositol-3'-phosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H]1O SZPQTEWIRPXBTC-KFOWTEFUSA-N 0.000 description 3
- FHFWXQRDZLCNSG-UHFFFAOYSA-N 1-(6-bromo-1,3-benzothiazol-2-yl)-3-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)ethyl]urea Chemical compound O1C(C(C)(C)C)=NC(CCNC(=O)NC=2SC3=CC(Br)=CC=C3N=2)=N1 FHFWXQRDZLCNSG-UHFFFAOYSA-N 0.000 description 3
- CRTRUQUJSMFWPD-UHFFFAOYSA-N 1-amino-3,3-dimethylbutan-2-one Chemical compound CC(C)(C)C(=O)CN CRTRUQUJSMFWPD-UHFFFAOYSA-N 0.000 description 3
- KCJOPIVLAZXTNN-UHFFFAOYSA-N 2-(2-methylprop-2-enyl)-7,8-dihydro-6h-imidazo[1,5-c]pyrimidin-2-ium-5-one;bromide Chemical compound [Br-].C1CNC(=O)N2C=[N+](CC(=C)C)C=C21 KCJOPIVLAZXTNN-UHFFFAOYSA-N 0.000 description 3
- JKDPLFGIJDQIBW-UHFFFAOYSA-N 2-[3-(2-aminoethyl)-1,2,4-oxadiazol-5-yl]-2-methylpropan-1-ol Chemical compound OCC(C)(C)C1=NC(CCN)=NO1 JKDPLFGIJDQIBW-UHFFFAOYSA-N 0.000 description 3
- HENXUFOAGXNWKH-UHFFFAOYSA-N 3-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=CN=CC(B2OC(C)(C)C(C)(C)O2)=C1 HENXUFOAGXNWKH-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- PEZBQJGUGRKHEV-UHFFFAOYSA-N 4-(5-tert-butyl-1,3-oxazol-2-yl)butanoic acid Chemical compound CC(C)(C)C1=CN=C(CCCC(O)=O)O1 PEZBQJGUGRKHEV-UHFFFAOYSA-N 0.000 description 3
- WGOLHUGPTDEKCF-UHFFFAOYSA-N 5-bromopyridin-2-amine Chemical compound NC1=CC=C(Br)C=N1 WGOLHUGPTDEKCF-UHFFFAOYSA-N 0.000 description 3
- NCNORXZSXNZHQG-UHFFFAOYSA-N 6-chloro-[1,3]thiazolo[4,5-c]pyridin-2-amine Chemical compound N1=C(Cl)C=C2SC(N)=NC2=C1 NCNORXZSXNZHQG-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 206010019663 Hepatic failure Diseases 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 206010034277 Pemphigoid Diseases 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001263 acyl chlorides Chemical class 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 208000000594 bullous pemphigoid Diseases 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 235000001465 calcium Nutrition 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 239000007810 chemical reaction solvent Substances 0.000 description 3
- 230000035605 chemotaxis Effects 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 3
- 229960002436 cladribine Drugs 0.000 description 3
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 3
- 229940012017 ethylenediamine Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 238000007327 hydrogenolysis reaction Methods 0.000 description 3
- 206010021198 ichthyosis Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 208000007903 liver failure Diseases 0.000 description 3
- 231100000835 liver failure Toxicity 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 150000003915 phosphatidylinositol 4,5-bisphosphates Chemical class 0.000 description 3
- 150000003905 phosphatidylinositols Chemical class 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 235000007686 potassium Nutrition 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- NORLFIHQJFOIGS-UHFFFAOYSA-N tert-butyl n-(2-cyanoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCC#N NORLFIHQJFOIGS-UHFFFAOYSA-N 0.000 description 3
- VGHSPQRQZCTSEN-UHFFFAOYSA-N tert-butyl n-[2-(2-propan-2-yltetrazol-5-yl)ethyl]carbamate Chemical compound CC(C)N1N=NC(CCNC(=O)OC(C)(C)C)=N1 VGHSPQRQZCTSEN-UHFFFAOYSA-N 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 3
- 229960000281 trometamol Drugs 0.000 description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- NVOLYUXUHWBCRJ-UHFFFAOYSA-N (2-methoxypyridin-3-yl)boronic acid Chemical compound COC1=NC=CC=C1B(O)O NVOLYUXUHWBCRJ-UHFFFAOYSA-N 0.000 description 2
- HZFFUMBZBGETES-UHFFFAOYSA-N (3-methylsulfonylphenyl)boronic acid Chemical compound CS(=O)(=O)C1=CC=CC(B(O)O)=C1 HZFFUMBZBGETES-UHFFFAOYSA-N 0.000 description 2
- ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 2
- CZJXBZPJABCCRQ-BULBTXNYSA-N (8s,9r,10s,11s,13s,14s,17r)-9,11-dichloro-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1C=C[C@]2(C)[C@@]3(Cl)[C@@H](Cl)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 CZJXBZPJABCCRQ-BULBTXNYSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- HKWJHKSHEWVOSS-OMDJCSNQSA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O HKWJHKSHEWVOSS-OMDJCSNQSA-N 0.000 description 2
- XJTQZLRUGPQOHJ-UHFFFAOYSA-N 1-(6-bromoimidazo[1,2-a]pyridin-2-yl)-3-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)ethyl]urea Chemical compound O1C(C(C)(C)C)=NC(CCNC(=O)NC=2N=C3C=CC(Br)=CN3C=2)=N1 XJTQZLRUGPQOHJ-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- CDGOQPHBNHRUMA-UHFFFAOYSA-N 1-[3-(2-aminoethyl)-1,2,4-oxadiazol-5-yl]ethanol;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC(O)C1=NC(CCN)=NO1 CDGOQPHBNHRUMA-UHFFFAOYSA-N 0.000 description 2
- CEDIFJKUTKENCU-UHFFFAOYSA-N 2,2-difluorocyclobutane-1-carboxylic acid Chemical compound OC(=O)C1CCC1(F)F CEDIFJKUTKENCU-UHFFFAOYSA-N 0.000 description 2
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- XAAFONSKHSPTMW-UHFFFAOYSA-N 2-(2-propan-2-yltetrazol-5-yl)ethanamine Chemical compound CC(C)N1N=NC(CCN)=N1 XAAFONSKHSPTMW-UHFFFAOYSA-N 0.000 description 2
- QKSMDLAGAOVFJZ-UHFFFAOYSA-N 2-(3-tert-butyl-1,2,4-oxadiazol-5-yl)ethanamine;hydrochloride Chemical compound Cl.CC(C)(C)C1=NOC(CCN)=N1 QKSMDLAGAOVFJZ-UHFFFAOYSA-N 0.000 description 2
- SYSXQGPWUZOKLK-UHFFFAOYSA-N 2-(4-tert-butyl-1,3-oxazol-2-yl)ethanamine Chemical compound CC(C)(C)C1=COC(CCN)=N1 SYSXQGPWUZOKLK-UHFFFAOYSA-N 0.000 description 2
- BSAKATHFNCNNSS-UHFFFAOYSA-N 2-(5-ethyl-1,3-oxazol-2-yl)ethanamine Chemical compound CCC1=CN=C(CCN)O1 BSAKATHFNCNNSS-UHFFFAOYSA-N 0.000 description 2
- UYEBLECHPNAUEM-UHFFFAOYSA-N 2-(5-tert-butyl-1,3-oxazol-2-yl)ethanamine;hydrochloride Chemical compound Cl.CC(C)(C)C1=CN=C(CCN)O1 UYEBLECHPNAUEM-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical group COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
- MYFYYHWRYZOQHY-UHFFFAOYSA-N 2-[5-(1-fluoro-2-methylpropan-2-yl)-1,2,4-oxadiazol-3-yl]ethanamine Chemical compound FCC(C)(C)C1=NC(CCN)=NO1 MYFYYHWRYZOQHY-UHFFFAOYSA-N 0.000 description 2
- YNMRDQFGDBGXFE-UHFFFAOYSA-N 2-[5-(methoxymethyl)-1,2,4-oxadiazol-3-yl]ethanamine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COCC1=NC(CCN)=NO1 YNMRDQFGDBGXFE-UHFFFAOYSA-N 0.000 description 2
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 2
- NZDOWZQRNZLBOY-UHFFFAOYSA-N 2-fluoro-2-methylpropanoic acid Chemical compound CC(C)(F)C(O)=O NZDOWZQRNZLBOY-UHFFFAOYSA-N 0.000 description 2
- ZVZPFTCEXIGSHM-UHFFFAOYSA-N 2-fluoropropanoic acid Chemical compound CC(F)C(O)=O ZVZPFTCEXIGSHM-UHFFFAOYSA-N 0.000 description 2
- FVKFHMNJTHKMRX-UHFFFAOYSA-N 3,4,6,7,8,9-hexahydro-2H-pyrimido[1,2-a]pyrimidine Chemical compound C1CCN2CCCNC2=N1 FVKFHMNJTHKMRX-UHFFFAOYSA-N 0.000 description 2
- SOSPMXMEOFGPIM-UHFFFAOYSA-N 3,5-dibromopyridine Chemical compound BrC1=CN=CC(Br)=C1 SOSPMXMEOFGPIM-UHFFFAOYSA-N 0.000 description 2
- XNMKWWHNOUBLMF-UHFFFAOYSA-N 3-(5-tert-butyl-1,3-oxazol-2-yl)propanoic acid Chemical compound CC(C)(C)C1=CN=C(CCC(O)=O)O1 XNMKWWHNOUBLMF-UHFFFAOYSA-N 0.000 description 2
- MHVMTRAWUNOISV-UHFFFAOYSA-N 3-(hydroxymethyl)pyrrolidine-1-carboxylic acid Chemical compound OCC1CCN(C(O)=O)C1 MHVMTRAWUNOISV-UHFFFAOYSA-N 0.000 description 2
- TWQWRHIQRAZHPR-XNXCGYEVSA-N 3-[2-[(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]carbonylbenzenesulfonic acid Chemical compound O=C([C@]1(O)[C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)COC(=O)C1=CC=CC(S(O)(=O)=O)=C1 TWQWRHIQRAZHPR-XNXCGYEVSA-N 0.000 description 2
- COKLILJYNZTJSO-UHFFFAOYSA-N 3-amino-1-(3-azabicyclo[2.2.1]heptan-3-yl)propan-1-one Chemical compound C1CC2N(C(=O)CCN)CC1C2 COKLILJYNZTJSO-UHFFFAOYSA-N 0.000 description 2
- CNAIMMQZMLBREW-UHFFFAOYSA-N 3-bromo-5-methylsulfonylpyridine Chemical compound CS(=O)(=O)C1=CN=CC(Br)=C1 CNAIMMQZMLBREW-UHFFFAOYSA-N 0.000 description 2
- BFWBUXKEBXAKDE-UHFFFAOYSA-N 3-methylsulfonyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN=CC(S(C)(=O)=O)=C1 BFWBUXKEBXAKDE-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- OBUKEMPWKGDRJV-UHFFFAOYSA-N 4,4,4-trifluoro-2-methylbutanoic acid Chemical compound OC(=O)C(C)CC(F)(F)F OBUKEMPWKGDRJV-UHFFFAOYSA-N 0.000 description 2
- AFLWPAGYTPJSEY-CODXZCKSSA-N 4-[2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoic acid;hydrate Chemical compound O.O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 AFLWPAGYTPJSEY-CODXZCKSSA-N 0.000 description 2
- KRRTXVSBTPCDOS-UHFFFAOYSA-N 5-bromopyrazin-2-amine Chemical compound NC1=CN=C(Br)C=N1 KRRTXVSBTPCDOS-UHFFFAOYSA-N 0.000 description 2
- FTFFHWWIPOQCBC-UHFFFAOYSA-N 5-bromopyridine-3-carbonitrile Chemical compound BrC1=CN=CC(C#N)=C1 FTFFHWWIPOQCBC-UHFFFAOYSA-N 0.000 description 2
- JOMBXHCJYIMCPC-UHFFFAOYSA-N 5-cyclopropyl-2h-tetrazole Chemical compound C1CC1C1=NNN=N1 JOMBXHCJYIMCPC-UHFFFAOYSA-N 0.000 description 2
- FZAPPEYUWVVTMM-UHFFFAOYSA-N 5-pyridin-3-yl-[1,3]thiazolo[5,4-b]pyridin-2-amine Chemical compound N1=C2SC(N)=NC2=CC=C1C1=CC=CN=C1 FZAPPEYUWVVTMM-UHFFFAOYSA-N 0.000 description 2
- UZEVZZYLLIUJIR-UHFFFAOYSA-N 6-(2-methoxypyridin-3-yl)-1,3-benzothiazol-2-amine Chemical compound COC1=NC=CC=C1C1=CC=C(N=C(N)S2)C2=C1 UZEVZZYLLIUJIR-UHFFFAOYSA-N 0.000 description 2
- RLQYYIGRFSCELR-UHFFFAOYSA-N 6-(5-morpholin-4-ylpyridin-3-yl)-1,3-benzothiazol-2-amine Chemical compound C1=C2SC(N)=NC2=CC=C1C(C=1)=CN=CC=1N1CCOCC1 RLQYYIGRFSCELR-UHFFFAOYSA-N 0.000 description 2
- KZSMVBXMRASCPO-UHFFFAOYSA-N 6-[5-(trifluoromethyl)pyridin-3-yl]-1,3-benzothiazol-2-amine Chemical compound C1=C2SC(N)=NC2=CC=C1C1=CN=CC(C(F)(F)F)=C1 KZSMVBXMRASCPO-UHFFFAOYSA-N 0.000 description 2
- AILRPZSDKRTHDU-UHFFFAOYSA-N 6-bromo-2-tert-butyl-3h-1,2-benzothiazole 1,1-dioxide Chemical compound C1=C(Br)C=C2S(=O)(=O)N(C(C)(C)C)CC2=C1 AILRPZSDKRTHDU-UHFFFAOYSA-N 0.000 description 2
- VEHNVCGISXDBIG-UHFFFAOYSA-N 6-chloroimidazo[1,2-b]pyridazin-2-amine Chemical compound N1=C(Cl)C=CC2=NC(N)=CN21 VEHNVCGISXDBIG-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- GWKQSBXDFHODNU-UQPSFNCESA-N 6z83r2hm9l Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@@H]2O GWKQSBXDFHODNU-UQPSFNCESA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000015790 Asparaginase Human genes 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 206010004659 Biliary cirrhosis Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 108091007958 Class I PI3Ks Proteins 0.000 description 2
- 108091007963 Class III PI3Ks Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 2
- 108010036941 Cyclosporins Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- PQVDYPCHUGFHAR-PKWREOPISA-N Dexamethasone Tebutate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC(C)(C)C)(O)[C@@]1(C)C[C@@H]2O PQVDYPCHUGFHAR-PKWREOPISA-N 0.000 description 2
- HHJIUUAMYGBVSD-YTFFSALGSA-N Diflucortolone valerate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)CCCC)[C@@]2(C)C[C@@H]1O HHJIUUAMYGBVSD-YTFFSALGSA-N 0.000 description 2
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 2
- WHZRCUIISKRTJL-YTZKRAOUSA-N Fluocortolone caproate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)CCCCC)[C@@]2(C)C[C@@H]1O WHZRCUIISKRTJL-YTZKRAOUSA-N 0.000 description 2
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 208000003084 Graves Ophthalmopathy Diseases 0.000 description 2
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 206010024305 Leukaemia monocytic Diseases 0.000 description 2
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- HIEKJRVYXXINKH-ADVKXBNGSA-N N1([C@H]2CC[C@H](C[C@H]2OC)/C=C(\C)[C@H]2OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]3(O)O[C@@H]([C@H](C[C@H]3C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]2C)=O)CC)C=NN=N1 Chemical compound N1([C@H]2CC[C@H](C[C@H]2OC)/C=C(\C)[C@H]2OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]3(O)O[C@@H]([C@H](C[C@H]3C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]2C)=O)CC)C=NN=N1 HIEKJRVYXXINKH-ADVKXBNGSA-N 0.000 description 2
- ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- HYRKAAMZBDSJFJ-LFDBJOOHSA-N Paramethasone acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]2(C)C[C@@H]1O HYRKAAMZBDSJFJ-LFDBJOOHSA-N 0.000 description 2
- 244000025272 Persea americana Species 0.000 description 2
- 235000008673 Persea americana Nutrition 0.000 description 2
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 description 2
- 101710096503 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000012317 TBTU Substances 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- XGMPVBXKDAHORN-RBWIMXSLSA-N Triamcinolone diacetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](OC(C)=O)[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O XGMPVBXKDAHORN-RBWIMXSLSA-N 0.000 description 2
- TZIZWYVVGLXXFV-FLRHRWPCSA-N Triamcinolone hexacetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@@H]2O TZIZWYVVGLXXFV-FLRHRWPCSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- ZSZXYWFCIKKZBT-ZVDPZPSOSA-N [(2r)-3-[[(2s,3s,5r,6s)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OC1[C@H](O)[C@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O ZSZXYWFCIKKZBT-ZVDPZPSOSA-N 0.000 description 2
- DPHFJXVKASDMBW-RQRKFSSASA-N [2-[(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate;hydrate Chemical compound O.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O DPHFJXVKASDMBW-RQRKFSSASA-N 0.000 description 2
- WBNNIURTBZHJTI-WDCKKOMHSA-N [2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] dihydrogen phosphate;2-[(2-propan-2-ylphenoxy)methyl]-4,5-dihydro-1h-imidazole Chemical compound CC(C)C1=CC=CC=C1OCC1=NCCN1.O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 WBNNIURTBZHJTI-WDCKKOMHSA-N 0.000 description 2
- DNSAKUGJOSFARZ-FOMYWIRZSA-N [2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] hexanoate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CCCCC)(O)[C@@]1(C)C[C@@H]2O DNSAKUGJOSFARZ-FOMYWIRZSA-N 0.000 description 2
- IQRGVVFHCYWXNF-UHFFFAOYSA-N [5-(2-amino-1,3-benzothiazol-6-yl)pyridin-3-yl]methyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCC1=CN=CC(C=2C=C3SC(N)=NC3=CC=2)=C1 IQRGVVFHCYWXNF-UHFFFAOYSA-N 0.000 description 2
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
- MGVGMXLGOKTYKP-ZFOBEOMCSA-N acetic acid;(6s,8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound CC(O)=O.C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 MGVGMXLGOKTYKP-ZFOBEOMCSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 229960004229 alclometasone dipropionate Drugs 0.000 description 2
- DJHCCTTVDRAMEH-DUUJBDRPSA-N alclometasone dipropionate Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DJHCCTTVDRAMEH-DUUJBDRPSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 229960003099 amcinonide Drugs 0.000 description 2
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
- 229960001220 amsacrine Drugs 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000027746 artery morphogenesis Effects 0.000 description 2
- 229960003272 asparaginase Drugs 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229960004669 basiliximab Drugs 0.000 description 2
- 229950000210 beclometasone dipropionate Drugs 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- 229940050390 benzoate Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- PDBPYLJEZLMMMI-UHFFFAOYSA-N benzyl n-[2-(4-propan-2-yl-1,3-oxazol-2-yl)ethyl]carbamate Chemical compound CC(C)C1=COC(CCNC(=O)OCC=2C=CC=CC=2)=N1 PDBPYLJEZLMMMI-UHFFFAOYSA-N 0.000 description 2
- JGWWYTRUHAQRFA-UHFFFAOYSA-N benzyl n-[2-(5-ethyl-1,3-oxazol-2-yl)ethyl]carbamate Chemical compound O1C(CC)=CN=C1CCNC(=O)OCC1=CC=CC=C1 JGWWYTRUHAQRFA-UHFFFAOYSA-N 0.000 description 2
- ZSSDRFJMEMCPOC-UHFFFAOYSA-N benzyl n-[3-(2-hydroxybutylamino)-3-oxopropyl]carbamate Chemical compound CCC(O)CNC(=O)CCNC(=O)OCC1=CC=CC=C1 ZSSDRFJMEMCPOC-UHFFFAOYSA-N 0.000 description 2
- SVBNXOJZADJRFP-UHFFFAOYSA-N benzyl n-[3-[(1-hydroxy-3-methylbutan-2-yl)amino]-3-oxopropyl]carbamate Chemical compound CC(C)C(CO)NC(=O)CCNC(=O)OCC1=CC=CC=C1 SVBNXOJZADJRFP-UHFFFAOYSA-N 0.000 description 2
- CQYKJWNMHRDORG-UHFFFAOYSA-N benzyl n-[3-[(3,3-dimethyl-2-oxobutyl)amino]-3-oxopropyl]carbamate Chemical compound CC(C)(C)C(=O)CNC(=O)CCNC(=O)OCC1=CC=CC=C1 CQYKJWNMHRDORG-UHFFFAOYSA-N 0.000 description 2
- SRHOIQQMBKOMFP-UHFFFAOYSA-N benzyl n-[3-[(3-methyl-1-oxobutan-2-yl)amino]-3-oxopropyl]carbamate Chemical compound CC(C)C(C=O)NC(=O)CCNC(=O)OCC1=CC=CC=C1 SRHOIQQMBKOMFP-UHFFFAOYSA-N 0.000 description 2
- XTLKSHYHXUMEKS-UHFFFAOYSA-N benzyl n-[3-oxo-3-(2-oxobutylamino)propyl]carbamate Chemical compound CCC(=O)CNC(=O)CCNC(=O)OCC1=CC=CC=C1 XTLKSHYHXUMEKS-UHFFFAOYSA-N 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 229960004648 betamethasone acetate Drugs 0.000 description 2
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 description 2
- 229960001102 betamethasone dipropionate Drugs 0.000 description 2
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 2
- VQODGRNSFPNSQE-DVTGEIKXSA-N betamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-DVTGEIKXSA-N 0.000 description 2
- 229950006991 betamethasone phosphate Drugs 0.000 description 2
- 229960004311 betamethasone valerate Drugs 0.000 description 2
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229950005499 carbon tetrachloride Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
- 229960002023 chloroprocaine Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 229960004703 clobetasol propionate Drugs 0.000 description 2
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 2
- 229960003290 cortisone acetate Drugs 0.000 description 2
- 229960003840 cortivazol Drugs 0.000 description 2
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000006638 cyclopentyl carbonyl group Chemical group 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 108010019249 cyclosporin G Proteins 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 229960002806 daclizumab Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229960003662 desonide Drugs 0.000 description 2
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 2
- 229960002593 desoximetasone Drugs 0.000 description 2
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003657 dexamethasone acetate Drugs 0.000 description 2
- 229960000524 dexamethasone isonicotinate Drugs 0.000 description 2
- 229960004833 dexamethasone phosphate Drugs 0.000 description 2
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 2
- 229950009888 dichlorisone Drugs 0.000 description 2
- 229960003970 diflucortolone valerate Drugs 0.000 description 2
- 229960004875 difluprednate Drugs 0.000 description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- LZCLXQDLBQLTDK-BYPYZUCNSA-N ethyl (2S)-lactate Chemical compound CCOC(=O)[C@H](C)O LZCLXQDLBQLTDK-BYPYZUCNSA-N 0.000 description 2
- BDTDECDAHYOJRO-UHFFFAOYSA-N ethyl n-(sulfanylidenemethylidene)carbamate Chemical compound CCOC(=O)N=C=S BDTDECDAHYOJRO-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 208000024711 extrinsic asthma Diseases 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229960003721 fluclorolone acetonide Drugs 0.000 description 2
- NJNWEGFJCGYWQT-VSXGLTOVSA-N fluclorolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1Cl NJNWEGFJCGYWQT-VSXGLTOVSA-N 0.000 description 2
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 2
- 229960004511 fludroxycortide Drugs 0.000 description 2
- 229940042902 flumethasone pivalate Drugs 0.000 description 2
- JWRMHDSINXPDHB-OJAGFMMFSA-N flumethasone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]2(C)C[C@@H]1O JWRMHDSINXPDHB-OJAGFMMFSA-N 0.000 description 2
- 229960000676 flunisolide Drugs 0.000 description 2
- 229960001347 fluocinolone acetonide Drugs 0.000 description 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 2
- 229960000785 fluocinonide Drugs 0.000 description 2
- 229960003973 fluocortolone Drugs 0.000 description 2
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 description 2
- 229960005283 fluocortolone pivalate Drugs 0.000 description 2
- XZBJVIQXJHGUBE-HZMVJJPJSA-N fluocortolone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]2(C)C[C@@H]1O XZBJVIQXJHGUBE-HZMVJJPJSA-N 0.000 description 2
- 229960003336 fluorocortisol acetate Drugs 0.000 description 2
- 229960001048 fluorometholone Drugs 0.000 description 2
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 2
- 229960002650 fluprednidene acetate Drugs 0.000 description 2
- DEFOZIFYUBUHHU-IYQKUMFPSA-N fluprednidene acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC(=C)[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O DEFOZIFYUBUHHU-IYQKUMFPSA-N 0.000 description 2
- 229960000289 fluticasone propionate Drugs 0.000 description 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229960002383 halcinonide Drugs 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229960001067 hydrocortisone acetate Drugs 0.000 description 2
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 2
- 229950006240 hydrocortisone succinate Drugs 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 229960001388 interferon-beta Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 208000023589 ischemic disease Diseases 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960000681 leflunomide Drugs 0.000 description 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- 229960003194 meglumine Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960001810 meprednisone Drugs 0.000 description 2
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- RMIODHQZRUFFFF-UHFFFAOYSA-N methoxyacetic acid Chemical compound COCC(O)=O RMIODHQZRUFFFF-UHFFFAOYSA-N 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- QWWJTOGTXSAJIW-UHFFFAOYSA-N methyl 3-(5-tert-butyl-1,3-oxazol-2-yl)propanoate Chemical compound COC(=O)CCC1=NC=C(C(C)(C)C)O1 QWWJTOGTXSAJIW-UHFFFAOYSA-N 0.000 description 2
- TUUAGDSXTKDETL-UHFFFAOYSA-N methyl 4-[(3,3-dimethyl-2-oxobutyl)amino]butanoate Chemical compound COC(=O)CCCNCC(=O)C(C)(C)C TUUAGDSXTKDETL-UHFFFAOYSA-N 0.000 description 2
- AAJZXPWBILCHAW-UHFFFAOYSA-N methyl 5-bromopyridine-3-carboxylate Chemical compound COC(=O)C1=CN=CC(Br)=C1 AAJZXPWBILCHAW-UHFFFAOYSA-N 0.000 description 2
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 229960001293 methylprednisolone acetate Drugs 0.000 description 2
- IMBXEJJVJRTNOW-XYMSELFBSA-N methylprednisolone succinate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC(O)=O)CC[C@H]21 IMBXEJJVJRTNOW-XYMSELFBSA-N 0.000 description 2
- 229950009831 methylprednisolone succinate Drugs 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229960005249 misoprostol Drugs 0.000 description 2
- 229950000844 mizoribine Drugs 0.000 description 2
- 201000006894 monocytic leukemia Diseases 0.000 description 2
- 229960003816 muromonab-cd3 Drugs 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- FPWWTEMQIYEEQX-UHFFFAOYSA-N n-(6-chloropyridazin-3-yl)-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=CC=C(Cl)N=N1 FPWWTEMQIYEEQX-UHFFFAOYSA-N 0.000 description 2
- YNTOKMNHRPSGFU-UHFFFAOYSA-N n-Propyl carbamate Chemical compound CCCOC(N)=O YNTOKMNHRPSGFU-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 229960000865 paramethasone acetate Drugs 0.000 description 2
- 235000019371 penicillin G benzathine Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000009038 pharmacological inhibition Effects 0.000 description 2
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 150000003911 phosphatidylinositol 4-phosphates Chemical class 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229950010765 pivalate Drugs 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229960001297 prednazoline Drugs 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 229960002800 prednisolone acetate Drugs 0.000 description 2
- 229960004786 prednisolone phosphate Drugs 0.000 description 2
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 2
- WVKSUFYQOHQCMM-YGZHYJPASA-N prednisolone sulfobenzoate Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)C1=CC=CC(S(O)(=O)=O)=C1 WVKSUFYQOHQCMM-YGZHYJPASA-N 0.000 description 2
- 229950004954 prednisolone sulfobenzoate Drugs 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960001917 prednylidene Drugs 0.000 description 2
- WSVOMANDJDYYEY-CWNVBEKCSA-N prednylidene Chemical group O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](C(=C)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WSVOMANDJDYYEY-CWNVBEKCSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000002412 selectin antagonist Substances 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 150000003460 sulfonic acids Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- TZRQZPMQUXEZMC-UHFFFAOYSA-N tert-butyl n-(2-bromoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCBr TZRQZPMQUXEZMC-UHFFFAOYSA-N 0.000 description 2
- MCNMZLIJAOGTJQ-UHFFFAOYSA-N tert-butyl n-(5-bromopyridin-3-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CN=CC(Br)=C1 MCNMZLIJAOGTJQ-UHFFFAOYSA-N 0.000 description 2
- VZPOHASZICQBDX-UHFFFAOYSA-N tert-butyl n-[(5-bromopyridin-3-yl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CN=CC(Br)=C1 VZPOHASZICQBDX-UHFFFAOYSA-N 0.000 description 2
- LKRNXALNNNPRNS-UHFFFAOYSA-N tert-butyl n-[2-(1-propan-2-yltetrazol-5-yl)ethyl]carbamate Chemical compound CC(C)N1N=NN=C1CCNC(=O)OC(C)(C)C LKRNXALNNNPRNS-UHFFFAOYSA-N 0.000 description 2
- ZYPILARRRSBZLJ-UHFFFAOYSA-N tert-butyl n-[3-(3-azabicyclo[2.2.1]heptan-3-yl)-3-oxopropyl]carbamate Chemical compound C1CC2N(C(=O)CCNC(=O)OC(C)(C)C)CC1C2 ZYPILARRRSBZLJ-UHFFFAOYSA-N 0.000 description 2
- ZJTQSVMZOJGUGA-UHFFFAOYSA-N tert-butyl n-[3-[2-(2,2-dimethylpropanoyl)hydrazinyl]-3-oxopropyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCC(=O)NNC(=O)C(C)(C)C ZJTQSVMZOJGUGA-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- FYOWZTWVYZOZSI-UHFFFAOYSA-N thiourea dioxide Chemical compound NC(=N)S(O)=O FYOWZTWVYZOZSI-UHFFFAOYSA-N 0.000 description 2
- BISFDZNIUZIKJD-XDANTLIUSA-N tixocortol pivalate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CSC(=O)C(C)(C)C)(O)[C@@]1(C)C[C@@H]2O BISFDZNIUZIKJD-XDANTLIUSA-N 0.000 description 2
- 229960003114 tixocortol pivalate Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- GUYPYYARYIIWJZ-CYEPYHPTSA-N triamcinolone benetonide Chemical compound O=C([C@]12[C@H](OC(C)(C)O1)C[C@@H]1[C@@]2(C[C@H](O)[C@]2(F)[C@@]3(C)C=CC(=O)C=C3CC[C@H]21)C)COC(=O)C(C)CNC(=O)C1=CC=CC=C1 GUYPYYARYIIWJZ-CYEPYHPTSA-N 0.000 description 2
- 229950006782 triamcinolone benetonide Drugs 0.000 description 2
- 229960004320 triamcinolone diacetate Drugs 0.000 description 2
- 229960004221 triamcinolone hexacetonide Drugs 0.000 description 2
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- AZKYTDMFISVQOT-UHFFFAOYSA-N (1-amino-1-hydroxyimino-4,4-dimethylpentan-3-yl) carbamate Chemical compound NC(=O)OC(C(C)(C)C)CC(N)=NO AZKYTDMFISVQOT-UHFFFAOYSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- RFQHMNWNEOZRLK-UHFFFAOYSA-N (2,5-dimethylthiophen-3-yl)boronic acid Chemical compound CC1=CC(B(O)O)=C(C)S1 RFQHMNWNEOZRLK-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- JUSWZYFYLXTMLJ-JTQLQIEISA-N (2s)-1-(benzenesulfonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1S(=O)(=O)C1=CC=CC=C1 JUSWZYFYLXTMLJ-JTQLQIEISA-N 0.000 description 1
- RQYKQWFHJOBBAO-JTQLQIEISA-N (2s)-1-benzoylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)C1=CC=CC=C1 RQYKQWFHJOBBAO-JTQLQIEISA-N 0.000 description 1
- JBULSURVMXPBNA-RXMQYKEDSA-N (2s)-2-amino-3,3-dimethylbutan-1-ol Chemical compound CC(C)(C)[C@H](N)CO JBULSURVMXPBNA-RXMQYKEDSA-N 0.000 description 1
- WDGWHKRJEBENCE-UHFFFAOYSA-N (3-carbamoylphenyl)boronic acid Chemical compound NC(=O)C1=CC=CC(B(O)O)=C1 WDGWHKRJEBENCE-UHFFFAOYSA-N 0.000 description 1
- OYNDLOJPYURCJG-UHFFFAOYSA-N (3-fluoro-4-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(O)C(F)=C1 OYNDLOJPYURCJG-UHFFFAOYSA-N 0.000 description 1
- RMBFBZIEXCTPDB-UHFFFAOYSA-N (3-fluoro-5-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC(O)=CC(F)=C1 RMBFBZIEXCTPDB-UHFFFAOYSA-N 0.000 description 1
- MCYOYCLLZQYKDW-UHFFFAOYSA-N (4-methoxy-3-morpholin-4-ylsulfonylphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1S(=O)(=O)N1CCOCC1 MCYOYCLLZQYKDW-UHFFFAOYSA-N 0.000 description 1
- WDVDHJLKXYCOFS-UHFFFAOYSA-N (5-bromopyridin-3-yl)methanol Chemical compound OCC1=CN=CC(Br)=C1 WDVDHJLKXYCOFS-UHFFFAOYSA-N 0.000 description 1
- SCYSEAYDCSQGCF-UHFFFAOYSA-N (5-bromopyridin-3-yl)methyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCC1=CN=CC(Br)=C1 SCYSEAYDCSQGCF-UHFFFAOYSA-N 0.000 description 1
- ZCUFJAORCNFWOF-UHFFFAOYSA-N (5-formylthiophen-3-yl)boronic acid Chemical compound OB(O)C1=CSC(C=O)=C1 ZCUFJAORCNFWOF-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- OPFACPYRADVFOS-UHFFFAOYSA-N 1-(5-bromopyridin-3-yl)sulfonylpyrrolidin-3-ol Chemical compound C1C(O)CCN1S(=O)(=O)C1=CN=CC(Br)=C1 OPFACPYRADVFOS-UHFFFAOYSA-N 0.000 description 1
- GLOYSVCBMGZPQC-UHFFFAOYSA-N 1-(6-bromo-1,3-benzothiazol-2-yl)-1-[3-(3,3-difluoroazetidin-1-yl)-3-oxopropyl]urea Chemical compound N=1C2=CC=C(Br)C=C2SC=1N(C(=O)N)CCC(=O)N1CC(F)(F)C1 GLOYSVCBMGZPQC-UHFFFAOYSA-N 0.000 description 1
- HNPDJOYONLZZFT-UHFFFAOYSA-N 1-(6-bromo-1,3-benzothiazol-2-yl)-3-[2-(5-tert-butyl-1,3-oxazol-2-yl)ethyl]urea Chemical compound O1C(C(C)(C)C)=CN=C1CCNC(=O)NC1=NC2=CC=C(Br)C=C2S1 HNPDJOYONLZZFT-UHFFFAOYSA-N 0.000 description 1
- VEYXIZNQALHXFT-UHFFFAOYSA-N 1-(6-bromo-1,3-benzothiazol-2-yl)-3-[2-[5-(1-fluoro-2-methylpropan-2-yl)-1,2,4-oxadiazol-3-yl]ethyl]urea Chemical compound O1C(C(C)(CF)C)=NC(CCNC(=O)NC=2SC3=CC(Br)=CC=C3N=2)=N1 VEYXIZNQALHXFT-UHFFFAOYSA-N 0.000 description 1
- YEUOXMRNQDPGOB-UHFFFAOYSA-N 1-(6-bromo-1,3-benzothiazol-2-yl)-3-[2-[5-(1-hydroxy-2-methylpropan-2-yl)-1,2,4-oxadiazol-3-yl]ethyl]urea Chemical compound O1C(C(C)(CO)C)=NC(CCNC(=O)NC=2SC3=CC(Br)=CC=C3N=2)=N1 YEUOXMRNQDPGOB-UHFFFAOYSA-N 0.000 description 1
- UNKFFQZWYFVUSN-UHFFFAOYSA-N 1-(6-bromoimidazo[1,2-a]pyridin-2-yl)-3-[2-(5-phenyl-1,2,4-oxadiazol-3-yl)ethyl]urea Chemical compound C=1N2C=C(Br)C=CC2=NC=1NC(=O)NCCC(N=1)=NOC=1C1=CC=CC=C1 UNKFFQZWYFVUSN-UHFFFAOYSA-N 0.000 description 1
- OYLPKHMWODGIMQ-UHFFFAOYSA-N 1-(6-bromoimidazo[1,2-a]pyridin-2-yl)-3-[2-(5-tert-butyl-1,3-oxazol-2-yl)ethyl]urea Chemical compound O1C(C(C)(C)C)=CN=C1CCNC(=O)NC1=CN(C=C(Br)C=C2)C2=N1 OYLPKHMWODGIMQ-UHFFFAOYSA-N 0.000 description 1
- CXUAEBDTJFKMBV-UHFFFAOYSA-N 1-(chloromethyl)-2,3,4,5,6-pentamethylbenzene Chemical compound CC1=C(C)C(C)=C(CCl)C(C)=C1C CXUAEBDTJFKMBV-UHFFFAOYSA-N 0.000 description 1
- IPZHMBLLXUYFBC-UHFFFAOYSA-N 1-[2-(4-methylpiperazin-1-yl)ethyl]-3-[6-(3-methylsulfonylphenyl)-1,3-benzothiazol-2-yl]urea Chemical compound C1CN(C)CCN1CCNC(=O)NC1=NC2=CC=C(C=3C=C(C=CC=3)S(C)(=O)=O)C=C2S1 IPZHMBLLXUYFBC-UHFFFAOYSA-N 0.000 description 1
- BQCISGYCKJFZLL-UHFFFAOYSA-N 1-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)ethyl]-3-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzothiazol-2-yl]urea Chemical compound O1C(C(C)(C)C)=NC(CCNC(=O)NC=2SC3=CC(=CC=C3N=2)B2OC(C)(C)C(C)(C)O2)=N1 BQCISGYCKJFZLL-UHFFFAOYSA-N 0.000 description 1
- ZGPZZFAYUXESKF-UHFFFAOYSA-N 1-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)ethyl]-3-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyridin-2-yl]urea Chemical compound O1C(C(C)(C)C)=NC(CCNC(=O)NC=2N=C3C=CC(=CN3C=2)B2OC(C)(C)C(C)(C)O2)=N1 ZGPZZFAYUXESKF-UHFFFAOYSA-N 0.000 description 1
- PZILFEDJAUQZJD-UHFFFAOYSA-N 1-[2-(5-tert-butyl-1,3-oxazol-2-yl)ethyl]-3-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzothiazol-2-yl]urea Chemical compound O1C(C(C)(C)C)=CN=C1CCNC(=O)NC1=NC2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2S1 PZILFEDJAUQZJD-UHFFFAOYSA-N 0.000 description 1
- FFPLFDMDNZCMNI-UHFFFAOYSA-N 1-[4-(2-aminoethyl)imidazol-1-yl]-2-methylpropan-2-ol Chemical compound CC(C)(O)CN1C=NC(CCN)=C1 FFPLFDMDNZCMNI-UHFFFAOYSA-N 0.000 description 1
- LBDAFTJTEJSGQN-UHFFFAOYSA-N 1-[4-(2-aminoethyl)imidazol-1-yl]-2-methylpropan-2-ol;dihydrochloride Chemical compound Cl.Cl.CC(C)(O)CN1C=NC(CCN)=C1 LBDAFTJTEJSGQN-UHFFFAOYSA-N 0.000 description 1
- IGLWXVHONQKIHS-UHFFFAOYSA-N 1-[6-(4-hydroxy-3-methoxyphenyl)-1,3-benzothiazol-2-yl]-3-[2-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)ethyl]urea Chemical compound C1=C(O)C(OC)=CC(C=2C=C3SC(NC(=O)NCCC=4ON=C(N=4)C(C)C)=NC3=CC=2)=C1 IGLWXVHONQKIHS-UHFFFAOYSA-N 0.000 description 1
- HDRQZNITZRMMEM-UHFFFAOYSA-N 1-[6-[3-(2-hydroxyethylsulfamoyl)phenyl]-1,3-benzothiazol-2-yl]-3-[2-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)ethyl]urea Chemical compound CC(C)C1=NOC(CCNC(=O)NC=2SC3=CC(=CC=C3N=2)C=2C=C(C=CC=2)S(=O)(=O)NCCO)=N1 HDRQZNITZRMMEM-UHFFFAOYSA-N 0.000 description 1
- TYNQHCHTYGJVNW-UHFFFAOYSA-N 1-[6-[3-(dimethylsulfamoyl)phenyl]-1,3-benzothiazol-2-yl]-3-[2-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)ethyl]urea Chemical compound CC(C)C1=NOC(CCNC(=O)NC=2SC3=CC(=CC=C3N=2)C=2C=C(C=CC=2)S(=O)(=O)N(C)C)=N1 TYNQHCHTYGJVNW-UHFFFAOYSA-N 0.000 description 1
- KODLUXHSIZOKTG-UHFFFAOYSA-N 1-aminobutan-2-ol Chemical compound CCC(O)CN KODLUXHSIZOKTG-UHFFFAOYSA-N 0.000 description 1
- GOKUDEWVRNZXDZ-UHFFFAOYSA-N 1-bromo-3-(3-bromopropoxy)propane Chemical compound BrCCCOCCCBr GOKUDEWVRNZXDZ-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical compound CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- INAPMGSXUVUWAF-UOTPTPDRSA-N 1D-myo-inositol 1-phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-UOTPTPDRSA-N 0.000 description 1
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 1
- CAFROQYMUICGNO-UHFFFAOYSA-N 2,2,2-trifluoroethyl formate Chemical compound FC(F)(F)COC=O CAFROQYMUICGNO-UHFFFAOYSA-N 0.000 description 1
- VUAXHMVRKOTJKP-UHFFFAOYSA-M 2,2-dimethylbutanoate Chemical compound CCC(C)(C)C([O-])=O VUAXHMVRKOTJKP-UHFFFAOYSA-M 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- MJVZSRZTBDMYLX-UHFFFAOYSA-N 2,6-dichloropyridin-3-amine Chemical compound NC1=CC=C(Cl)N=C1Cl MJVZSRZTBDMYLX-UHFFFAOYSA-N 0.000 description 1
- IDWZESHNJMMWTR-UHFFFAOYSA-N 2-(1,2,4-triazol-1-yl)ethanamine Chemical compound NCCN1C=NC=N1 IDWZESHNJMMWTR-UHFFFAOYSA-N 0.000 description 1
- QIZAQAIZJDBTJR-UHFFFAOYSA-N 2-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)ethanamine Chemical compound CC(C)C1=NOC(CCN)=N1 QIZAQAIZJDBTJR-UHFFFAOYSA-N 0.000 description 1
- GOWUDHPKGOIDIX-UHFFFAOYSA-N 2-(4-methyl-1-piperazinyl)ethanamine Chemical compound CN1CCN(CCN)CC1 GOWUDHPKGOIDIX-UHFFFAOYSA-N 0.000 description 1
- CGOPTNLRTOSGMF-UHFFFAOYSA-N 2-(4-propan-2-yl-1,3-oxazol-2-yl)ethanamine Chemical compound CC(C)C1=COC(CCN)=N1 CGOPTNLRTOSGMF-UHFFFAOYSA-N 0.000 description 1
- PNZCIPIQLMYAIX-UHFFFAOYSA-N 2-(5-butan-2-yl-1,2,4-oxadiazol-3-yl)ethanamine hydrochloride Chemical compound Cl.CCC(C)c1nc(CCN)no1 PNZCIPIQLMYAIX-UHFFFAOYSA-N 0.000 description 1
- VBEBAQBCSWGMAR-UHFFFAOYSA-N 2-(5-cyclopentyl-1,2,4-oxadiazol-3-yl)ethanamine Chemical compound NCCC1=NOC(C2CCCC2)=N1 VBEBAQBCSWGMAR-UHFFFAOYSA-N 0.000 description 1
- QXECDRQEGUJPBW-UHFFFAOYSA-N 2-(5-cyclopentyl-1,2,4-oxadiazol-3-yl)ethanamine;hydrochloride Chemical compound Cl.NCCC1=NOC(C2CCCC2)=N1 QXECDRQEGUJPBW-UHFFFAOYSA-N 0.000 description 1
- RMUABEPMDOCNLF-UHFFFAOYSA-N 2-(5-cyclopropyltetrazol-2-yl)ethanamine Chemical compound NCCN1N=NC(C2CC2)=N1 RMUABEPMDOCNLF-UHFFFAOYSA-N 0.000 description 1
- ZNFCQJPXAHYSCR-UHFFFAOYSA-N 2-(5-cyclopropyltetrazol-2-yl)ethanamine;hydrochloride Chemical compound Cl.NCCN1N=NC(C2CC2)=N1 ZNFCQJPXAHYSCR-UHFFFAOYSA-N 0.000 description 1
- HHJBRXVFIGCXRO-UHFFFAOYSA-N 2-(5-ethyl-1,2,4-oxadiazol-3-yl)ethanamine;hydrochloride Chemical compound Cl.CCC1=NC(CCN)=NO1 HHJBRXVFIGCXRO-UHFFFAOYSA-N 0.000 description 1
- YYIPYSVIEZUEFD-UHFFFAOYSA-N 2-(5-ethyl-1,3,4-thiadiazol-2-yl)ethanamine;hydrochloride Chemical compound Cl.CCC1=NN=C(CCN)S1 YYIPYSVIEZUEFD-UHFFFAOYSA-N 0.000 description 1
- IDVABVYUYJKBOL-UHFFFAOYSA-N 2-(5-ethyltetrazol-2-yl)ethanamine Chemical compound CCC=1N=NN(CCN)N=1 IDVABVYUYJKBOL-UHFFFAOYSA-N 0.000 description 1
- UFWHHYCAKCEBGJ-UHFFFAOYSA-N 2-(5-ethyltetrazol-2-yl)ethanamine;hydrochloride Chemical compound Cl.CCC=1N=NN(CCN)N=1 UFWHHYCAKCEBGJ-UHFFFAOYSA-N 0.000 description 1
- HBDLQCGZQMJSNW-UHFFFAOYSA-N 2-(5-methyl-1,2-oxazol-3-yl)ethanamine Chemical compound CC1=CC(CCN)=NO1 HBDLQCGZQMJSNW-UHFFFAOYSA-N 0.000 description 1
- NKHMJXMKJQIJBL-UHFFFAOYSA-N 2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-n-methylethanamine;hydrochloride Chemical compound Cl.CNCCC1=NOC(C(C)(C)C)=N1 NKHMJXMKJQIJBL-UHFFFAOYSA-N 0.000 description 1
- KHDOXPYPDQYYMF-UHFFFAOYSA-N 2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)ethanamine Chemical compound CC(C)(C)C1=NC(CCN)=NO1 KHDOXPYPDQYYMF-UHFFFAOYSA-N 0.000 description 1
- DPBYPLXYGDRFAC-UHFFFAOYSA-N 2-(5-tert-butyl-1,3,4-oxadiazol-2-yl)ethanamine;hydrochloride Chemical compound Cl.CC(C)(C)C1=NN=C(CCN)O1 DPBYPLXYGDRFAC-UHFFFAOYSA-N 0.000 description 1
- GGXCORZYCGXJIP-UHFFFAOYSA-N 2-(5-tert-butyl-1,3,4-thiadiazol-2-yl)ethanamine;hydrochloride Chemical compound Cl.CC(C)(C)C1=NN=C(CCN)S1 GGXCORZYCGXJIP-UHFFFAOYSA-N 0.000 description 1
- UUHUAUUJDWURLC-UHFFFAOYSA-N 2-(5-tert-butyl-1,3-oxazol-2-yl)ethanamine Chemical compound CC(C)(C)C1=CN=C(CCN)O1 UUHUAUUJDWURLC-UHFFFAOYSA-N 0.000 description 1
- UZYQSNQJLWTICD-UHFFFAOYSA-N 2-(n-benzoylanilino)-2,2-dinitroacetic acid Chemical compound C=1C=CC=CC=1N(C(C(=O)O)([N+]([O-])=O)[N+]([O-])=O)C(=O)C1=CC=CC=C1 UZYQSNQJLWTICD-UHFFFAOYSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- YICNLHWRPGUSFF-UHFFFAOYSA-N 2-[(2,6-dichloropyridin-3-yl)carbamothioyl]benzamide Chemical compound NC(=O)C1=CC=CC=C1C(=S)NC1=CC=C(Cl)N=C1Cl YICNLHWRPGUSFF-UHFFFAOYSA-N 0.000 description 1
- PUGBSRGMLXOMEC-VKAVYKQESA-N 2-[(2z)-5-bromo-2-(4-methylphenyl)sulfonyliminopyridin-1-yl]acetamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)\N=C\1N(CC(N)=O)C=C(Br)C=C/1 PUGBSRGMLXOMEC-VKAVYKQESA-N 0.000 description 1
- QVBPXXMOWUPBAE-LGMDPLHJSA-N 2-[(6z)-3-chloro-6-(4-methylphenyl)sulfonyliminopyridazin-1-yl]acetamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)\N=C\1N(CC(N)=O)N=C(Cl)C=C/1 QVBPXXMOWUPBAE-LGMDPLHJSA-N 0.000 description 1
- ZPRUYKZNEWLGGH-UHFFFAOYSA-N 2-[1-(2-methylpropyl)imidazol-4-yl]ethanamine Chemical compound CC(C)CN1C=NC(CCN)=C1 ZPRUYKZNEWLGGH-UHFFFAOYSA-N 0.000 description 1
- QCXJSEMAVNOSAC-UHFFFAOYSA-N 2-[3-(2-aminoethyl)-1,2,4-oxadiazol-5-yl]-2-methylpropan-1-ol;hydrochloride Chemical compound Cl.OCC(C)(C)C1=NC(CCN)=NO1 QCXJSEMAVNOSAC-UHFFFAOYSA-N 0.000 description 1
- WNOUYGVLTCYMBW-UHFFFAOYSA-N 2-[3-(2-aminoethyl)-1,2,4-oxadiazol-5-yl]-N,N-dimethylpropan-2-amine 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.CN(C)C(C)(C)c1nc(CCN)no1 WNOUYGVLTCYMBW-UHFFFAOYSA-N 0.000 description 1
- WBGZWYDHKDECJB-UHFFFAOYSA-N 2-[3-(2-aminoethyl)-1,2,4-oxadiazol-5-yl]-n,n,2-trimethylpropan-1-amine;dihydrochloride Chemical compound Cl.Cl.CN(C)CC(C)(C)C1=NC(CCN)=NO1 WBGZWYDHKDECJB-UHFFFAOYSA-N 0.000 description 1
- PDRLGQLVCFOCGQ-UHFFFAOYSA-N 2-[5-(1-fluoro-2-methylpropan-2-yl)-1,2,4-oxadiazol-3-yl]ethanamine;hydrochloride Chemical compound Cl.FCC(C)(C)C1=NC(CCN)=NO1 PDRLGQLVCFOCGQ-UHFFFAOYSA-N 0.000 description 1
- LECWDZVAUXUGNF-UHFFFAOYSA-N 2-[5-(1-fluoroethyl)-1,2,4-oxadiazol-3-yl]ethanamine;hydrochloride Chemical compound Cl.CC(F)C1=NC(CCN)=NO1 LECWDZVAUXUGNF-UHFFFAOYSA-N 0.000 description 1
- SXKBTGFFSGMYCK-UHFFFAOYSA-N 2-[5-(2,2,2-trifluoroethyl)-1,2,4-oxadiazol-3-yl]ethanamine;hydrochloride Chemical compound Cl.NCCC1=NOC(CC(F)(F)F)=N1 SXKBTGFFSGMYCK-UHFFFAOYSA-N 0.000 description 1
- WKKUHGCBEPDVHM-UHFFFAOYSA-N 2-[5-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-3-yl]ethanamine;hydrochloride Chemical compound Cl.CC(C)(F)C1=NC(CCN)=NO1 WKKUHGCBEPDVHM-UHFFFAOYSA-N 0.000 description 1
- NSPPMKHZAZGWLF-UHFFFAOYSA-N 2-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]ethanamine;hydrochloride Chemical compound Cl.NCCC1=NOC(C2CC(F)(F)C2)=N1 NSPPMKHZAZGWLF-UHFFFAOYSA-N 0.000 description 1
- ARRYZNNECIFGQO-UHFFFAOYSA-N 2-[5-(oxolan-3-yl)-1,2,4-oxadiazol-3-yl]ethanamine;hydrochloride Chemical compound Cl.NCCC1=NOC(C2COCC2)=N1 ARRYZNNECIFGQO-UHFFFAOYSA-N 0.000 description 1
- FNHYCVUEJKVUDP-UHFFFAOYSA-N 2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethanamine;hydrochloride Chemical compound Cl.NCCC1=NOC(C(F)(F)F)=N1 FNHYCVUEJKVUDP-UHFFFAOYSA-N 0.000 description 1
- IKNPVOCSVYGOLC-UHFFFAOYSA-N 2-amino-1-morpholin-4-ylethanone Chemical compound NCC(=O)N1CCOCC1 IKNPVOCSVYGOLC-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- SUZZEFBECOIRIY-UHFFFAOYSA-N 2-amino-3-methylbutan-1-ol Chemical compound CC(C)C(N)CO.CC(C)C(N)CO SUZZEFBECOIRIY-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- CWFMGEWBDIDVPZ-UHFFFAOYSA-N 2-bromo-6-methylsulfanylpyridine Chemical compound CSC1=CC=CC(Br)=N1 CWFMGEWBDIDVPZ-UHFFFAOYSA-N 0.000 description 1
- WJAXXWSZNSFVNG-UHFFFAOYSA-N 2-bromoethanamine;hydron;bromide Chemical compound [Br-].[NH3+]CCBr WJAXXWSZNSFVNG-UHFFFAOYSA-N 0.000 description 1
- ZSEOXYGSFYWPNA-UHFFFAOYSA-N 2-carboxypropan-2-yl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)C(C)(C)C(O)=O ZSEOXYGSFYWPNA-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- NJRXVEJTAYWCQJ-UHFFFAOYSA-L 2-mercaptosuccinate Chemical compound OC(=O)CC([S-])C([O-])=O NJRXVEJTAYWCQJ-UHFFFAOYSA-L 0.000 description 1
- QOGNDJLSYMJGPP-UHFFFAOYSA-N 2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound C1=NC(OC)=CC=C1B1OC(C)(C)C(C)(C)O1 QOGNDJLSYMJGPP-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- XRPVXVRWIDOORM-UHFFFAOYSA-N 2-methylbutanoyl chloride Chemical compound CCC(C)C(Cl)=O XRPVXVRWIDOORM-UHFFFAOYSA-N 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- KSNKQSPJFRQSEI-UHFFFAOYSA-N 3,3,3-trifluoropropanoic acid Chemical compound OC(=O)CC(F)(F)F KSNKQSPJFRQSEI-UHFFFAOYSA-N 0.000 description 1
- CBXMULHQEVXJDI-UHFFFAOYSA-N 3,4-dihydro-2h-1,5-benzodioxepine Chemical compound O1CCCOC2=CC=CC=C21 CBXMULHQEVXJDI-UHFFFAOYSA-N 0.000 description 1
- ODMXVAMWMHHNPC-UHFFFAOYSA-N 3-(2-acetamido-1,3-benzothiazol-6-yl)benzamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C1=CC=CC(C(N)=O)=C1 ODMXVAMWMHHNPC-UHFFFAOYSA-N 0.000 description 1
- CFUNOYAKCJZSNW-UHFFFAOYSA-N 3-(2-aminoethyl)-n-propan-2-yl-1,2,4-oxadiazol-5-amine;hydrochloride Chemical compound Cl.CC(C)NC1=NC(CCN)=NO1 CFUNOYAKCJZSNW-UHFFFAOYSA-N 0.000 description 1
- OHKKUZJVWWPUNY-UHFFFAOYSA-N 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC(S(N)(=O)=O)=C1 OHKKUZJVWWPUNY-UHFFFAOYSA-N 0.000 description 1
- XEMDFESAXKSEGI-UHFFFAOYSA-N 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CN=C1 XEMDFESAXKSEGI-UHFFFAOYSA-N 0.000 description 1
- SWFRUSQUOVBPRQ-UHFFFAOYSA-N 3-(dimethylamino)-2,2-dimethylpropanoic acid Chemical compound CN(C)CC(C)(C)C(O)=O SWFRUSQUOVBPRQ-UHFFFAOYSA-N 0.000 description 1
- LGKOINQLLQVENB-UHFFFAOYSA-N 3-(methylsulfonyloxymethyl)piperidine-1-carboxylic acid Chemical compound CS(=O)(=O)OCC1CCCN(C(O)=O)C1 LGKOINQLLQVENB-UHFFFAOYSA-N 0.000 description 1
- GEVGRLPYQJTKKS-UHFFFAOYSA-N 3-(phenylmethoxycarbonylamino)propanoic acid Chemical compound OC(=O)CCNC(=O)OCC1=CC=CC=C1 GEVGRLPYQJTKKS-UHFFFAOYSA-N 0.000 description 1
- OKKUUZUMRIFHPT-UHFFFAOYSA-N 3-(propan-2-yloxymethyl)piperidine;hydrochloride Chemical compound Cl.CC(C)OCC1CCCNC1 OKKUUZUMRIFHPT-UHFFFAOYSA-N 0.000 description 1
- PWUHPFFANHLNPI-UHFFFAOYSA-N 3-(propan-2-yloxymethyl)pyrrolidine;hydrochloride Chemical compound Cl.CC(C)OCC1CCNC1 PWUHPFFANHLNPI-UHFFFAOYSA-N 0.000 description 1
- GZNKRNQUWKBFEO-UHFFFAOYSA-N 3-amino-1-(3,3-difluoroazetidin-1-yl)propan-1-one Chemical compound NCCC(=O)N1CC(F)(F)C1 GZNKRNQUWKBFEO-UHFFFAOYSA-N 0.000 description 1
- GYLMCBOAXJVARF-UHFFFAOYSA-N 3-azabicyclo[2.2.1]heptane Chemical compound C1C2CCC1NC2 GYLMCBOAXJVARF-UHFFFAOYSA-N 0.000 description 1
- QOQDSBJXAZTXDO-UHFFFAOYSA-N 3-bromo-2,2-dimethylpropanoic acid;3-(dimethylamino)-2,2-dimethylpropanoic acid Chemical compound BrCC(C)(C)C(O)=O.CN(C)CC(C)(C)C(O)=O QOQDSBJXAZTXDO-UHFFFAOYSA-N 0.000 description 1
- USEGQJLHQSTGHW-UHFFFAOYSA-N 3-bromo-2-methylprop-1-ene Chemical compound CC(=C)CBr USEGQJLHQSTGHW-UHFFFAOYSA-N 0.000 description 1
- JJLCNEOPNGKTQE-UHFFFAOYSA-N 3-bromo-5-(2-methoxyethoxy)pyridine Chemical compound COCCOC1=CN=CC(Br)=C1 JJLCNEOPNGKTQE-UHFFFAOYSA-N 0.000 description 1
- HEDHNDVPKRVQPN-UHFFFAOYSA-N 3-bromo-5-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CN=CC(Br)=C1 HEDHNDVPKRVQPN-UHFFFAOYSA-N 0.000 description 1
- AKFNVEXSYXJWQX-UHFFFAOYSA-N 3-bromo-5-methylsulfanylpyridine Chemical compound CSC1=CN=CC(Br)=C1 AKFNVEXSYXJWQX-UHFFFAOYSA-N 0.000 description 1
- SHTGZBWYHRHZHT-UHFFFAOYSA-N 3-bromo-8-methylquinoline Chemical compound BrC1=CN=C2C(C)=CC=CC2=C1 SHTGZBWYHRHZHT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- WJYGHWXWQSCONR-UHFFFAOYSA-N 4,5-dibromothiophene-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC(Br)=C(Br)S1 WJYGHWXWQSCONR-UHFFFAOYSA-N 0.000 description 1
- ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 description 1
- FBGVTWONYOCYGA-UHFFFAOYSA-N 4,6-dichloropyridin-3-amine Chemical compound NC1=CN=C(Cl)C=C1Cl FBGVTWONYOCYGA-UHFFFAOYSA-N 0.000 description 1
- YRPXZCWDXBNPBD-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-indazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC2=C1C=NN2 YRPXZCWDXBNPBD-UHFFFAOYSA-N 0.000 description 1
- COIOXTGXIQKWBH-UHFFFAOYSA-N 4-(5-bromopyridin-3-yl)morpholine Chemical compound BrC1=CN=CC(N2CCOCC2)=C1 COIOXTGXIQKWBH-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- SRYXZVWRMOFVCO-UHFFFAOYSA-N 4-bromo-1-methyl-2-methylsulfonylbenzene Chemical compound CC1=CC=C(Br)C=C1S(C)(=O)=O SRYXZVWRMOFVCO-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- SVWCVXFHTHCJJB-UHFFFAOYSA-N 4-methylpentanoyl chloride Chemical compound CC(C)CCC(Cl)=O SVWCVXFHTHCJJB-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- AVEJNIQVEFAONJ-UHFFFAOYSA-N 5-(2-amino-1,3-benzothiazol-6-yl)pyridine-3-carbonitrile Chemical compound C1=C2SC(N)=NC2=CC=C1C1=CN=CC(C#N)=C1 AVEJNIQVEFAONJ-UHFFFAOYSA-N 0.000 description 1
- CIWPDRFCMHKQPU-UHFFFAOYSA-N 5-(3-methylsulfonylphenyl)-[1,3]thiazolo[5,4-b]pyridin-2-amine Chemical compound CS(=O)(=O)C1=CC=CC(C=2N=C3SC(N)=NC3=CC=2)=C1 CIWPDRFCMHKQPU-UHFFFAOYSA-N 0.000 description 1
- YOMGURQJFJUNPQ-UHFFFAOYSA-N 5-(5-methoxypyridin-3-yl)-[1,3]thiazolo[5,4-b]pyridin-2-amine Chemical compound COC1=CN=CC(C=2N=C3SC(N)=NC3=CC=2)=C1 YOMGURQJFJUNPQ-UHFFFAOYSA-N 0.000 description 1
- DKOXDMLDVHPXAR-UHFFFAOYSA-N 5-(5-methylsulfonylpyridin-3-yl)-[1,3]thiazolo[5,4-b]pyridin-2-amine Chemical compound CS(=O)(=O)C1=CN=CC(C=2N=C3SC(N)=NC3=CC=2)=C1 DKOXDMLDVHPXAR-UHFFFAOYSA-N 0.000 description 1
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 1
- DBSKAQFBXKVSSH-UHFFFAOYSA-N 5-bromo-2-(bromomethyl)-n-tert-butylbenzenesulfonamide Chemical compound CC(C)(C)NS(=O)(=O)C1=CC(Br)=CC=C1CBr DBSKAQFBXKVSSH-UHFFFAOYSA-N 0.000 description 1
- AHUXEFWSXHFQIP-UHFFFAOYSA-N 5-bromo-n-tert-butyl-2-methylbenzenesulfonamide Chemical compound CC1=CC=C(Br)C=C1S(=O)(=O)NC(C)(C)C AHUXEFWSXHFQIP-UHFFFAOYSA-N 0.000 description 1
- VNYBIBSZZDAEOK-UHFFFAOYSA-N 5-bromopyridin-3-ol Chemical compound OC1=CN=CC(Br)=C1 VNYBIBSZZDAEOK-UHFFFAOYSA-N 0.000 description 1
- FQIUCPGDKPXSLL-UHFFFAOYSA-N 5-bromopyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=CC(Br)=C1 FQIUCPGDKPXSLL-UHFFFAOYSA-N 0.000 description 1
- ZJAYGKNATMSZHZ-UHFFFAOYSA-N 5-bromopyridine-3-sulfonamide Chemical compound NS(=O)(=O)C1=CN=CC(Br)=C1 ZJAYGKNATMSZHZ-UHFFFAOYSA-N 0.000 description 1
- AVILRJQPDYPXFQ-UHFFFAOYSA-N 5-bromopyridine-3-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CN=CC(Br)=C1 AVILRJQPDYPXFQ-UHFFFAOYSA-N 0.000 description 1
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 1
- KYRMPMCAOPMOIR-UHFFFAOYSA-N 5-ethyl-2h-tetrazole Chemical compound CCC=1N=NNN=1 KYRMPMCAOPMOIR-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- HEEBETLBSDGAGR-UHFFFAOYSA-N 6-(3-methylsulfonylphenyl)-1,3-benzothiazol-2-amine Chemical compound CS(=O)(=O)C1=CC=CC(C=2C=C3SC(N)=NC3=CC=2)=C1 HEEBETLBSDGAGR-UHFFFAOYSA-N 0.000 description 1
- BHIWUGCQRJSEHU-UHFFFAOYSA-N 6-(3-methylsulfonylphenyl)-[1,3]thiazolo[4,5-c]pyridin-2-amine Chemical compound CS(=O)(=O)C1=CC=CC(C=2N=CC=3N=C(N)SC=3C=2)=C1 BHIWUGCQRJSEHU-UHFFFAOYSA-N 0.000 description 1
- QZGBBHPQXHZHOM-UHFFFAOYSA-N 6-(3-methylsulfonylphenyl)imidazo[1,2-a]pyrazin-2-amine Chemical compound CS(=O)(=O)C1=CC=CC(C=2N=CC3=NC(N)=CN3C=2)=C1 QZGBBHPQXHZHOM-UHFFFAOYSA-N 0.000 description 1
- MIKZCIHELYRUGQ-UHFFFAOYSA-N 6-(3-methylsulfonylphenyl)imidazo[1,2-b]pyridazin-2-amine Chemical compound CS(=O)(=O)C1=CC=CC(C2=NN3C=C(N)N=C3C=C2)=C1 MIKZCIHELYRUGQ-UHFFFAOYSA-N 0.000 description 1
- DXADLWKZPHZPHS-UHFFFAOYSA-N 6-(5-ethoxypyridin-3-yl)-1,3-benzothiazol-2-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC1=CN=CC(C=2C=C3SC(N)=NC3=CC=2)=C1 DXADLWKZPHZPHS-UHFFFAOYSA-N 0.000 description 1
- BVODAWMMRGDBMI-UHFFFAOYSA-N 6-(5-methoxypyridin-3-yl)-1,3-benzothiazol-2-amine Chemical compound COC1=CN=CC(C=2C=C3SC(N)=NC3=CC=2)=C1 BVODAWMMRGDBMI-UHFFFAOYSA-N 0.000 description 1
- IXZVFLLZGVPASN-UHFFFAOYSA-N 6-(5-methoxypyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound COC1=CN=CC(C2=CN3N=C(N)N=C3C=C2)=C1 IXZVFLLZGVPASN-UHFFFAOYSA-N 0.000 description 1
- KCZKGYFLHBVLMU-UHFFFAOYSA-N 6-(5-methylsulfonylpyridin-3-yl)-1,3-benzothiazol-2-amine Chemical compound CS(=O)(=O)C1=CN=CC(C=2C=C3SC(N)=NC3=CC=2)=C1 KCZKGYFLHBVLMU-UHFFFAOYSA-N 0.000 description 1
- CBBGVZCNBLEQID-UHFFFAOYSA-N 6-(6-methoxypyridin-3-yl)-1,3-benzothiazol-2-amine Chemical compound C1=NC(OC)=CC=C1C1=CC=C(N=C(N)S2)C2=C1 CBBGVZCNBLEQID-UHFFFAOYSA-N 0.000 description 1
- LHUSZKHBZJQUHO-UHFFFAOYSA-N 6-[5-(2-methoxyethoxy)pyridin-3-yl]-1,3-benzothiazol-2-amine Chemical compound COCCOC1=CN=CC(C=2C=C3SC(N)=NC3=CC=2)=C1 LHUSZKHBZJQUHO-UHFFFAOYSA-N 0.000 description 1
- HDHWDOMFULLEJI-UHFFFAOYSA-N 6-bromoimidazo[1,2-a]pyrazin-2-amine Chemical compound C1=C(Br)N=CC2=NC(N)=CN21 HDHWDOMFULLEJI-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000002110 C2 domains Human genes 0.000 description 1
- 108050009459 C2 domains Proteins 0.000 description 1
- BBNWSSHMNQWUEG-UHFFFAOYSA-N CC[S](N)CC Chemical compound CC[S](N)CC BBNWSSHMNQWUEG-UHFFFAOYSA-N 0.000 description 1
- 102000043139 CK2 family Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010066968 Corneal leukoma Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 108010009306 Forkhead Box Protein O1 Proteins 0.000 description 1
- 102100035427 Forkhead box protein O1 Human genes 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010021074 Hypoplastic anaemia Diseases 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 201000002287 Keratoconus Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010024380 Leukoderma Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000012309 Linear IgA disease Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 206010027910 Mononeuritis Diseases 0.000 description 1
- 208000024599 Mooren ulcer Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- ONXPDKGXOOORHB-BYPYZUCNSA-N N(5)-methyl-L-glutamine Chemical compound CNC(=O)CC[C@H](N)C(O)=O ONXPDKGXOOORHB-BYPYZUCNSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- WSLBJQQQZZTFBA-MLUQOLBVSA-N PIP[4'](17:0/20:4(5Z,8Z,11Z,14Z)) Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(O)(=O)OC1C(O)C(O)C(OP(O)(O)=O)[C@@H](O)C1O WSLBJQQQZZTFBA-MLUQOLBVSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102000013353 Phosphoinositide Phosphatases Human genes 0.000 description 1
- 108010090786 Phosphoinositide Phosphatases Proteins 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 102100021273 Protein Mpv17 Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- FCLZCOCSZQNREK-UHFFFAOYSA-N Pyrrolidine, hydrochloride Chemical compound Cl.C1CCNC1 FCLZCOCSZQNREK-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000026214 Skeletal muscle atrophy Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 231100000579 Toxinosis Toxicity 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 101100082060 Xenopus laevis pou5f1.1 gene Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- UIVURGZOKUKTRX-UHFFFAOYSA-N [(6-bromoimidazo[1,2-a]pyridin-2-yl)amino] benzoate Chemical compound C=1N2C=C(Br)C=CC2=NC=1NOC(=O)C1=CC=CC=C1 UIVURGZOKUKTRX-UHFFFAOYSA-N 0.000 description 1
- PHTMVIAGTMTVSK-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound C1=CC=CN2N=C(N)N=C21 PHTMVIAGTMTVSK-UHFFFAOYSA-N 0.000 description 1
- RQQIRMLGKSPXSE-WIPMOJCBSA-N [1-acetyloxy-2-[[(2s,3r,5s,6s)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxyethyl] acetate Chemical compound CC(=O)OC(OC(C)=O)COP(O)(=O)OC1[C@H](O)[C@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O RQQIRMLGKSPXSE-WIPMOJCBSA-N 0.000 description 1
- HSOUGLHWSPWPOM-UHFFFAOYSA-N [3-(2-hydroxyethylsulfamoyl)phenyl]boronic acid Chemical compound OCCNS(=O)(=O)C1=CC=CC(B(O)O)=C1 HSOUGLHWSPWPOM-UHFFFAOYSA-N 0.000 description 1
- SGERXKCDWJPIOS-UHFFFAOYSA-N [3-(dimethylsulfamoyl)phenyl]boronic acid Chemical compound CN(C)S(=O)(=O)C1=CC=CC(B(O)O)=C1 SGERXKCDWJPIOS-UHFFFAOYSA-N 0.000 description 1
- VPQGUZSIKYKFNS-UHFFFAOYSA-N [3-(ethylsulfamoyl)phenyl]boronic acid Chemical compound CCNS(=O)(=O)C1=CC=CC(B(O)O)=C1 VPQGUZSIKYKFNS-UHFFFAOYSA-N 0.000 description 1
- XUIQQIRLFMCWLN-UHFFFAOYSA-N [3-(methanesulfonamido)phenyl]boronic acid Chemical compound CS(=O)(=O)NC1=CC=CC(B(O)O)=C1 XUIQQIRLFMCWLN-UHFFFAOYSA-N 0.000 description 1
- MYYURIOPMYBZFX-UHFFFAOYSA-N [3-(morpholin-4-ylsulfamoyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(S(=O)(=O)NN2CCOCC2)=C1 MYYURIOPMYBZFX-UHFFFAOYSA-N 0.000 description 1
- RTANFUBXTVMRGY-UHFFFAOYSA-N [5-[2-[(2-methylpropan-2-yl)oxycarbonylamino]-1,3-benzothiazol-6-yl]pyridin-3-yl]methyl 2,2-dimethylpropanoate Chemical compound C1=C2SC(NC(=O)OC(C)(C)C)=NC2=CC=C1C1=CN=CC(COC(=O)C(C)(C)C)=C1 RTANFUBXTVMRGY-UHFFFAOYSA-N 0.000 description 1
- WVDFZCFECXBUQP-UHFFFAOYSA-N [Na].BrC=1C=C(C=NC1)CO Chemical compound [Na].BrC=1C=C(C=NC1)CO WVDFZCFECXBUQP-UHFFFAOYSA-N 0.000 description 1
- WXIONIWNXBAHRU-UHFFFAOYSA-N [dimethylamino(triazolo[4,5-b]pyridin-3-yloxy)methylidene]-dimethylazanium Chemical compound C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 WXIONIWNXBAHRU-UHFFFAOYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- BGYVHCTZMBPEBN-UHFFFAOYSA-N acetic acid;2-amino-n,n-dimethylacetamide Chemical compound CC(O)=O.CN(C)C(=O)CN BGYVHCTZMBPEBN-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- POEXERAQSHGAMH-UHFFFAOYSA-N ardine Natural products Cn1cc(Cc2c[nH]c3ccccc23)c2ccccc12 POEXERAQSHGAMH-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- UMYVAYGOGYLVKT-UHFFFAOYSA-N benzyl n-[2-(4-tert-butyl-1,3-oxazol-2-yl)ethyl]carbamate Chemical compound CC(C)(C)C1=COC(CCNC(=O)OCC=2C=CC=CC=2)=N1 UMYVAYGOGYLVKT-UHFFFAOYSA-N 0.000 description 1
- ZPDSYARSYGFACM-UHFFFAOYSA-N benzyl n-[2-(5-tert-butyl-1,3-oxazol-2-yl)ethyl]carbamate Chemical compound O1C(C(C)(C)C)=CN=C1CCNC(=O)OCC1=CC=CC=C1 ZPDSYARSYGFACM-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 108010015046 cell aggregation factors Proteins 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 125000004965 chloroalkyl group Chemical group 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940124446 critical care medicine Drugs 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- WEPUZBYKXNKSDH-UHFFFAOYSA-N cyclopentanecarbonyl chloride Chemical compound ClC(=O)C1CCCC1 WEPUZBYKXNKSDH-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- AUQDITHEDVOTCU-UHFFFAOYSA-N cyclopropyl cyanide Chemical compound N#CC1CC1 AUQDITHEDVOTCU-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 125000003374 diacylglycerol group Chemical group 0.000 description 1
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 1
- JGFBRKRYDCGYKD-UHFFFAOYSA-N dibutyl(oxo)tin Chemical compound CCCC[Sn](=O)CCCC JGFBRKRYDCGYKD-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical compound CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- ABRFAUWJOIHZRQ-UHFFFAOYSA-N ethyl 2-[[6-(3-methylsulfonylphenyl)-1,3-benzothiazol-2-yl]amino]-2-oxoacetate Chemical compound C1=C2SC(NC(=O)C(=O)OCC)=NC2=CC=C1C1=CC=CC(S(C)(=O)=O)=C1 ABRFAUWJOIHZRQ-UHFFFAOYSA-N 0.000 description 1
- RKEGOHBIKJWROO-UHFFFAOYSA-N ethyl 3-[(3,3-dimethyl-2-oxobutyl)amino]-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NCC(=O)C(C)(C)C RKEGOHBIKJWROO-UHFFFAOYSA-N 0.000 description 1
- ACMSEWQYSBPPPJ-UHFFFAOYSA-N ethyl 4-(5-tert-butyl-1,3-oxazol-2-yl)butanoate Chemical compound CCOC(=O)CCCC1=NC=C(C(C)(C)C)O1 ACMSEWQYSBPPPJ-UHFFFAOYSA-N 0.000 description 1
- LKHYFCSSVZVVNF-UHFFFAOYSA-N ethyl hexanoate;sodium Chemical compound [Na].CCCCCC(=O)OCC LKHYFCSSVZVVNF-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000005454 flavour additive Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 201000002597 ichthyosis vulgaris Diseases 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 150000004001 inositols Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 230000003903 intestinal lesions Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000010659 intrinsic asthma Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 208000023569 ischemic bowel disease Diseases 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 231100000149 liver necrosis Toxicity 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000008172 membrane trafficking Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- AXLHVTKGDPVANO-UHFFFAOYSA-N methyl 2-amino-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound COC(=O)C(N)CNC(=O)OC(C)(C)C AXLHVTKGDPVANO-UHFFFAOYSA-N 0.000 description 1
- QSJRUSBNJCOWEQ-UHFFFAOYSA-N methyl 3-(2-acetamido-1,3-benzothiazol-6-yl)benzoate Chemical compound COC(=O)C1=CC=CC(C=2C=C3SC(NC(C)=O)=NC3=CC=2)=C1 QSJRUSBNJCOWEQ-UHFFFAOYSA-N 0.000 description 1
- XZBCOQIYUAFYLL-UHFFFAOYSA-N methyl 3-[(3,3-dimethyl-2-oxobutyl)amino]-3-oxopropanoate Chemical compound COC(=O)CC(=O)NCC(=O)C(C)(C)C XZBCOQIYUAFYLL-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- SURZCVYFPAXNGN-UHFFFAOYSA-N methyl-carbamic acid ethyl ester Chemical compound CCOC(=O)NC SURZCVYFPAXNGN-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- JCDWETOKTFWTHA-UHFFFAOYSA-N methylsulfonylbenzene Chemical compound CS(=O)(=O)C1=CC=CC=C1 JCDWETOKTFWTHA-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- IBMRTYCHDPMBFN-UHFFFAOYSA-N monomethyl glutaric acid Chemical compound COC(=O)CCCC(O)=O IBMRTYCHDPMBFN-UHFFFAOYSA-N 0.000 description 1
- 208000013734 mononeuritis simplex Diseases 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CVOGFMYWFRFWEQ-UHFFFAOYSA-N n'-hydroxy-2,2-dimethylpropanimidamide Chemical compound CC(C)(C)C(N)=NO CVOGFMYWFRFWEQ-UHFFFAOYSA-N 0.000 description 1
- YFYZLFQXQXISAJ-UHFFFAOYSA-N n-(5-bromopyrazin-2-yl)-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=CN=C(Br)C=N1 YFYZLFQXQXISAJ-UHFFFAOYSA-N 0.000 description 1
- UMFVGVQNRKEYEY-UHFFFAOYSA-N n-(5-bromopyridin-2-yl)-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=CC=C(Br)C=N1 UMFVGVQNRKEYEY-UHFFFAOYSA-N 0.000 description 1
- LOADQEKXKUUQOQ-UHFFFAOYSA-N n-(5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl)benzamide Chemical compound S1C2=NC(Cl)=CC=C2N=C1NC(=O)C1=CC=CC=C1 LOADQEKXKUUQOQ-UHFFFAOYSA-N 0.000 description 1
- FCZNNZIJGNFDRK-UHFFFAOYSA-N n-(6-bromo-1,3-benzothiazol-2-yl)-4-(5-tert-butyl-1,3-oxazol-2-yl)butanamide Chemical compound O1C(C(C)(C)C)=CN=C1CCCC(=O)NC1=NC2=CC=C(Br)C=C2S1 FCZNNZIJGNFDRK-UHFFFAOYSA-N 0.000 description 1
- BUYPVRDWQVLXDL-UHFFFAOYSA-N n-(6-bromoimidazo[1,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide Chemical compound C1=C(Br)C=CC2=NC(NC(=O)C(F)(F)F)=CN21 BUYPVRDWQVLXDL-UHFFFAOYSA-N 0.000 description 1
- PKOXDOJCCYKJKN-UHFFFAOYSA-N n-(6-bromoimidazo[1,2-a]pyridin-2-yl)acetamide Chemical compound C1=C(Br)C=CC2=NC(NC(=O)C)=CN21 PKOXDOJCCYKJKN-UHFFFAOYSA-N 0.000 description 1
- KRQUGHYFTCYRNV-UHFFFAOYSA-N n-(6-chloro-[1,3]thiazolo[4,5-c]pyridin-2-yl)benzamide Chemical compound N=1C=2C=NC(Cl)=CC=2SC=1NC(=O)C1=CC=CC=C1 KRQUGHYFTCYRNV-UHFFFAOYSA-N 0.000 description 1
- QIQOLQVNKVXLHR-UHFFFAOYSA-N n-(6-chloroimidazo[1,2-b]pyridazin-2-yl)-2,2,2-trifluoroacetamide Chemical compound N1=C(Cl)C=CC2=NC(NC(=O)C(F)(F)F)=CN21 QIQOLQVNKVXLHR-UHFFFAOYSA-N 0.000 description 1
- HXFHHZLESQDBEB-UHFFFAOYSA-N n-(6-chloroimidazo[1,2-b]pyridazin-2-yl)-2,2,2-trifluoroacetamide;(2,2,2-trifluoroacetyl) 2,2,2-trifluoroacetate Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F.N1=C(Cl)C=CC2=NC(NC(=O)C(F)(F)F)=CN21 HXFHHZLESQDBEB-UHFFFAOYSA-N 0.000 description 1
- WTTXVRLJTSDMJZ-UHFFFAOYSA-N n-[(2,6-dichloropyridin-3-yl)carbamothioyl]benzamide Chemical compound ClC1=NC(Cl)=CC=C1NC(=S)NC(=O)C1=CC=CC=C1 WTTXVRLJTSDMJZ-UHFFFAOYSA-N 0.000 description 1
- CINWMOMRIYRLCT-UHFFFAOYSA-N n-[2-[[6-(3-methylsulfonylphenyl)-1,3-benzothiazol-2-yl]carbamoylamino]ethyl]acetamide Chemical compound C1=C2SC(NC(=O)NCCNC(=O)C)=NC2=CC=C1C1=CC=CC(S(C)(=O)=O)=C1 CINWMOMRIYRLCT-UHFFFAOYSA-N 0.000 description 1
- NDQOJWVIZJHBBL-UHFFFAOYSA-N n-[6-(3-methylsulfonylphenyl)-1,3-benzothiazol-2-yl]formamide Chemical compound CS(=O)(=O)C1=CC=CC(C=2C=C3SC(NC=O)=NC3=CC=2)=C1 NDQOJWVIZJHBBL-UHFFFAOYSA-N 0.000 description 1
- GSUDYXDJOWHVCJ-UHFFFAOYSA-N n-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyridin-2-yl]acetamide Chemical compound C1=CC2=NC(NC(=O)C)=CN2C=C1B1OC(C)(C)C(C)(C)O1 GSUDYXDJOWHVCJ-UHFFFAOYSA-N 0.000 description 1
- NHMLHCHDPOWUSS-UHFFFAOYSA-N n-[6-(4-fluoro-3-methylsulfonylphenyl)-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C1=CC=C(F)C(S(C)(=O)=O)=C1 NHMLHCHDPOWUSS-UHFFFAOYSA-N 0.000 description 1
- JKWWHJHYNUJUGH-UHFFFAOYSA-N n-[6-(6-methylsulfonylpyridin-2-yl)-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C1=CC=CC(S(C)(=O)=O)=N1 JKWWHJHYNUJUGH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 150000004866 oxadiazoles Chemical class 0.000 description 1
- BOTREHHXSQGWTR-UHFFFAOYSA-N oxolane-3-carboxylic acid Chemical compound OC(=O)C1CCOC1 BOTREHHXSQGWTR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000004261 periodontium Anatomy 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- OWTCGJRBQMOICX-UHFFFAOYSA-M phenacyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1C(=O)C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 OWTCGJRBQMOICX-UHFFFAOYSA-M 0.000 description 1
- OEGXFPFNERJPHT-UHFFFAOYSA-N phenyl n-(6-bromo-1,3-benzothiazol-2-yl)carbamate Chemical compound S1C2=CC(Br)=CC=C2N=C1NC(=O)OC1=CC=CC=C1 OEGXFPFNERJPHT-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 208000002440 photoallergic dermatitis Diseases 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- JAMNHZBIQDNHMM-UHFFFAOYSA-N pivalonitrile Chemical compound CC(C)(C)C#N JAMNHZBIQDNHMM-UHFFFAOYSA-N 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- SKPCWIPJONWFGF-UHFFFAOYSA-N propan-2-yloxymethyl piperidine-1-carboxylate Chemical compound C(C)(C)OCOC(=O)N1CCCCC1 SKPCWIPJONWFGF-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical compound NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- HZFPPBMKGYINDF-UHFFFAOYSA-N pyrimidin-5-ylboronic acid Chemical compound OB(O)C1=CN=CN=C1 HZFPPBMKGYINDF-UHFFFAOYSA-N 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000022932 ruffle assembly Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000004003 siderosis Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000025185 skeletal muscle atrophy Effects 0.000 description 1
- 230000025175 skeletal muscle hypertrophy Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229960003339 sodium phosphate Drugs 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- DHHKPEUQJIEKOA-UHFFFAOYSA-N tert-butyl 2-[6-(nitromethyl)-6-bicyclo[3.2.0]hept-3-enyl]acetate Chemical compound C1C=CC2C(CC(=O)OC(C)(C)C)(C[N+]([O-])=O)CC21 DHHKPEUQJIEKOA-UHFFFAOYSA-N 0.000 description 1
- KLZLZEAYTFYNAS-UHFFFAOYSA-N tert-butyl 3-(methylsulfonyloxymethyl)piperidine-1-carboxylate;methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O.CC(C)(C)OC(=O)N1CCCC(COS(C)(=O)=O)C1 KLZLZEAYTFYNAS-UHFFFAOYSA-N 0.000 description 1
- XFRHYGNZDGDQST-UHFFFAOYSA-N tert-butyl 3-(methylsulfonyloxymethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(COS(C)(=O)=O)C1 XFRHYGNZDGDQST-UHFFFAOYSA-N 0.000 description 1
- LHPIPLYTBBHDDC-UHFFFAOYSA-N tert-butyl 3-[[6-(3-methylsulfonylphenyl)-1,3-benzothiazol-2-yl]carbamoylamino]propanoate Chemical compound C1=C2SC(NC(=O)NCCC(=O)OC(C)(C)C)=NC2=CC=C1C1=CC=CC(S(C)(=O)=O)=C1 LHPIPLYTBBHDDC-UHFFFAOYSA-N 0.000 description 1
- WRPDGNSGXXJFJC-UHFFFAOYSA-N tert-butyl 3-[[6-(4-hydroxy-3-methoxyphenyl)-1,3-benzothiazol-2-yl]carbamoylamino]propanoate Chemical compound C1=C(O)C(OC)=CC(C=2C=C3SC(NC(=O)NCCC(=O)OC(C)(C)C)=NC3=CC=2)=C1 WRPDGNSGXXJFJC-UHFFFAOYSA-N 0.000 description 1
- FNLCXXQPCKQGDU-UHFFFAOYSA-N tert-butyl 3-[[6-[3-(2-hydroxyethylsulfamoyl)phenyl]-1,3-benzothiazol-2-yl]carbamoylamino]propanoate Chemical compound C1=C2SC(NC(=O)NCCC(=O)OC(C)(C)C)=NC2=CC=C1C1=CC=CC(S(=O)(=O)NCCO)=C1 FNLCXXQPCKQGDU-UHFFFAOYSA-N 0.000 description 1
- YJMUEUFGLBGDFU-UHFFFAOYSA-N tert-butyl 3-[[6-[3-(dimethylsulfamoyl)phenyl]-1,3-benzothiazol-2-yl]carbamoylamino]propanoate Chemical compound CN(C)S(=O)(=O)C1=CC=CC(C=2C=C3SC(NC(=O)NCCC(=O)OC(C)(C)C)=NC3=CC=2)=C1 YJMUEUFGLBGDFU-UHFFFAOYSA-N 0.000 description 1
- DOMTZTVJNZKUNX-UHFFFAOYSA-N tert-butyl 3-aminopropanoate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)CCN DOMTZTVJNZKUNX-UHFFFAOYSA-N 0.000 description 1
- CMIBWIAICVBURI-UHFFFAOYSA-N tert-butyl 3-aminopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)C1 CMIBWIAICVBURI-UHFFFAOYSA-N 0.000 description 1
- AAJBYOUMVJIDHR-UHFFFAOYSA-N tert-butyl N-(5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl)carbamate 5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-amine Chemical compound ClC1=CC=C2C(=N1)SC(=N2)N.ClC2=CC=C1C(=N2)SC(=N1)NC(OC(C)(C)C)=O AAJBYOUMVJIDHR-UHFFFAOYSA-N 0.000 description 1
- LRVPQNLWNPXRLF-UHFFFAOYSA-N tert-butyl N-[2-[5-[2-(dimethylamino)propan-2-yl]-1,2,4-oxadiazol-3-yl]ethyl]carbamate Chemical compound CN(C)C(C)(C)c1nc(CCNC(=O)OC(C)(C)C)no1 LRVPQNLWNPXRLF-UHFFFAOYSA-N 0.000 description 1
- NBRKLOOSMBRFMH-UHFFFAOYSA-N tert-butyl chloride Chemical compound CC(C)(C)Cl NBRKLOOSMBRFMH-UHFFFAOYSA-N 0.000 description 1
- CFXLEMZNWBHNQV-UHFFFAOYSA-N tert-butyl n-(2,2-dimethylpropanoylamino)carbamate Chemical compound CC(C)(C)OC(=O)NNC(=O)C(C)(C)C CFXLEMZNWBHNQV-UHFFFAOYSA-N 0.000 description 1
- UTRZCIJAPSBNIF-UHFFFAOYSA-N tert-butyl n-(3-amino-3-hydroxyiminopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC\C(N)=N/O UTRZCIJAPSBNIF-UHFFFAOYSA-N 0.000 description 1
- ZEOIPSMHUAVNIX-UHFFFAOYSA-N tert-butyl n-[2-(3-tert-butyl-1,2,4-oxadiazol-5-yl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCC1=NC(C(C)(C)C)=NO1 ZEOIPSMHUAVNIX-UHFFFAOYSA-N 0.000 description 1
- HOGLCQYSVNUIBY-UHFFFAOYSA-N tert-butyl n-[2-(5-cyclopentyl-1,2,4-oxadiazol-3-yl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCC1=NOC(C2CCCC2)=N1 HOGLCQYSVNUIBY-UHFFFAOYSA-N 0.000 description 1
- HFQMHKPEMIUENA-UHFFFAOYSA-N tert-butyl n-[2-(5-ethyltetrazol-1-yl)ethyl]carbamate Chemical compound CCC1=NN=NN1CCNC(=O)OC(C)(C)C HFQMHKPEMIUENA-UHFFFAOYSA-N 0.000 description 1
- WUECIQMOVPGFJA-UHFFFAOYSA-N tert-butyl n-[2-(5-ethyltetrazol-2-yl)ethyl]carbamate Chemical compound CCC=1N=NN(CCNC(=O)OC(C)(C)C)N=1 WUECIQMOVPGFJA-UHFFFAOYSA-N 0.000 description 1
- SKXNNLKUOVUVBU-UHFFFAOYSA-N tert-butyl n-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)ethyl]-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)CCC1=NOC(C(C)(C)C)=N1 SKXNNLKUOVUVBU-UHFFFAOYSA-N 0.000 description 1
- RCWCADXFSKPOCV-UHFFFAOYSA-N tert-butyl n-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCC1=NOC(C(C)(C)C)=N1 RCWCADXFSKPOCV-UHFFFAOYSA-N 0.000 description 1
- LGDYCZZOCDRKAA-UHFFFAOYSA-N tert-butyl n-[2-(5-tert-butyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCC1=NN=C(C(C)(C)C)O1 LGDYCZZOCDRKAA-UHFFFAOYSA-N 0.000 description 1
- UJFJHAVRSBXKRA-UHFFFAOYSA-N tert-butyl n-[2-(5-tert-butyl-1,3,4-thiadiazol-2-yl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCC1=NN=C(C(C)(C)C)S1 UJFJHAVRSBXKRA-UHFFFAOYSA-N 0.000 description 1
- QTMPZMGTWPYGQH-UHFFFAOYSA-N tert-butyl n-[2-[5-(1-fluoro-2-methylpropan-2-yl)-1,2,4-oxadiazol-3-yl]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCC1=NOC(C(C)(C)CF)=N1 QTMPZMGTWPYGQH-UHFFFAOYSA-N 0.000 description 1
- WWGGAGXDQFBUHM-UHFFFAOYSA-N tert-butyl n-[2-[5-(1-hydroxyethyl)-1,2,4-oxadiazol-3-yl]ethyl]carbamate Chemical compound CC(O)C1=NC(CCNC(=O)OC(C)(C)C)=NO1 WWGGAGXDQFBUHM-UHFFFAOYSA-N 0.000 description 1
- VVTRTCDNIBJYKG-UHFFFAOYSA-N tert-butyl n-[2-[5-(methoxymethyl)-1,2,4-oxadiazol-3-yl]ethyl]carbamate Chemical compound COCC1=NC(CCNC(=O)OC(C)(C)C)=NO1 VVTRTCDNIBJYKG-UHFFFAOYSA-N 0.000 description 1
- JDOOLFXRXGJQOQ-UHFFFAOYSA-N tert-butyl n-[2-[5-(propan-2-ylamino)-1,2,4-oxadiazol-3-yl]ethyl]carbamate Chemical compound CC(C)NC1=NC(CCNC(=O)OC(C)(C)C)=NO1 JDOOLFXRXGJQOQ-UHFFFAOYSA-N 0.000 description 1
- HAAITOQYIPYARY-UHFFFAOYSA-N tert-butyl n-[2-[5-[1-(dimethylamino)-2-methylpropan-2-yl]-1,2,4-oxadiazol-3-yl]ethyl]carbamate Chemical compound CN(C)CC(C)(C)C1=NC(CCNC(=O)OC(C)(C)C)=NO1 HAAITOQYIPYARY-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-O tert-butylammonium Chemical compound CC(C)(C)[NH3+] YBRBMKDOPFTVDT-UHFFFAOYSA-O 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 230000036575 thermal burns Effects 0.000 description 1
- 150000007979 thiazole derivatives Chemical class 0.000 description 1
- 150000003548 thiazolidines Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- WTVXIBRMWGUIMI-UHFFFAOYSA-N trifluoro($l^{1}-oxidanylsulfonyl)methane Chemical group [O]S(=O)(=O)C(F)(F)F WTVXIBRMWGUIMI-UHFFFAOYSA-N 0.000 description 1
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 201000005539 vernal conjunctivitis Diseases 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the invention relates to novel compounds of formula I and related formulae, their use as medicament and their use for treating autoimmune diseases, inflammatory disorders, multiple sclerosis and other diseases such as cancers.
- the invention relates to compounds of formula I:
- U denotes CR C , CH, or S
- V denotes C or N
- W denotes N or CR 1
- X denotes CO, SO, SO 2 , CS or a bond
- Y denotes CR 2 or N
- R a denotes NH-A b , NA 2 , -NH-(CH 2 ) P -A b , -NH-(CH 2 ) P -Ar, -NH-(CH 2 ) P -Het 4 , -NH- (CH 2 ) p CHOR 6 -Het 1 , , -NH-(CH 2 ) p COAr, -NH-(CH 2 ) p COHet 1 , -NH-cycloalkyl, COHet 1 ,
- R a also denotes A, -(CH 2 ) S -Ar, -(CH 2 ) S -Het 1 ,
- Het 1 , Het 4 , or perfluoroalkyl or if R D denotes Ar, R a is also -OA or cycloalkyl.
- R b denotes Ar, Het 2 , Het 3 or
- R', R" are independently hydrogen, alkyl, Ar, Het 1 , Het 2 or A.
- R and R together with the nitrogen atom to which they are attached, can optionally form a 3-8- membered heterocyclic ring.
- R c denotes H, A, alkyl, Ar, Het 1 ,
- Ar denotes a monocyclic or bicyclic, aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by, Hal, CF 3 , OCF 3 , NO 2 , CN, perfluoroalkyl, A, OA, OH, NH 2 , COH,
- Het 1 denotes a monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms and/or 1 CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by alkyl having 1 to 8 carbon atoms, alkoxy having 1 to 8 carbon atoms, Hal, CF 3 , OCF 3 , NO 2 , CN, perfluoroalkyl, A, OA, O(CH 2 ) s Ar, O(CH 2 ) s Het 1 , -(CH 2 ) p Het 2 , OH, amino, CONH 2 , - NHCOA, -NHCO 2 A, -NHCO 2 (CH 2 ) s Ar, -NHSO 2 -N(H) 2-m (A) m , COA, COOA, -SO 2 A, - SO 2 N(H) 2-m (A)
- Het 2 denotes a monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms and/or 1 CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by alkyl having 1 to 8 carbon atoms, alkoxy having 1 to 8 carbon atoms, Hal, CF 3 , OCF 3 , NO 2 , CN, perfluoroalkyl, A, OA, O(CH 2 ) s Ar, O(CH 2 ) s Het 1 , -(CH 2 ) p Het 1 , OH, NA 2 , CONH 2 , - NHCOA, -NHCO 2 A, , -NHCO 2 (CH 2 ) s Het 1 , -NHCO 2 (CH 2 ) s Ar, -NHSO 2 -N(H) 2-m (A) m , COA, COOA
- Het 3 denotes a monocyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms and/or 1 CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by NO 2 , CN, perfluoroalkyl, OH, CONH 2 , -NHCOA, -NHCO 2 A, -NHCO 2 (CH 2 ) s Het 1 , -NHCO 2 (CH 2 ) s Ar, -NHSO 2 A, - NHSO 2 -N(H) 2-m (A) m , COA, COOA, -COH, -SO 2 A, -SO 2 N(H) 2-m (A) m , -SO 2 Het 1 , SO 2 NHHet 2 , or cycloalkyl or Het 3 denotes one of the following groups:
- Het 4 denotes a monocyclic or bicyclic unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms and/or 1 CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by alkyl having 1 to 8 carbon atoms, alkoxy having 1 to 8 carbon atoms, Hal, CF 3 , OCF 3 , NO 2 , CN, perfluoroalkyl, A, OA, O(CH 2 ) s Ar, O(CH 2 ) s Het 1 , -(CH 2 ) p Het 2 , OH, amino, CONH 2 , -NHCOA, -NHCO 2 A, - NHCO 2 (CH 2 ) s Ar, -NHSO 2 -N(H) 2-m (A) m , COA, COOA, -SO 2 A, -SO 2 N(H) 2-m (A) m
- cycloalkyl or Het 4 denotes one of the following groups:
- n denotes O, 1 or 2;
- n denotes 1 , 2 ,3 or 4;
- p denotes O, 1 , 2, 3, 4;
- q denotes O or 1 s denotes 1 , 2, 3 , 4
- A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by Hal, Ar, Het 1 , Het 2 , OR 6 , CN, NHCO, CONR'R" COOR 6 or NR R and wherein one or more, preferably 1 to 7 non-adjacent
- R 1 , R 2 are each independently H, Hal, CF 3 , A; Ar Het 1 or Het 2
- R 3 is H or Hal
- R , R denote each independently H, Ar, Het 1 , Het 2 , or A, and if R'or R" is bond to a C atom also OA.
- R 6 is H, a branched or linear alkyl or hydroxyalkyl having 1 to 12 C-atoms
- the present invention provides compounds of Formula (I) wherein R b is Ar or a pyridine group optionally substituted by the groups listed in the definitions of Het 2 , preferably, the group represented by R b , i.e. Ar or pyridine, is optionally substituted with OA, preferably OCH 3 , or SO 2 A, preferably SO 2 CH 3 ; and wherein R a is -NH-(CH 2 ) P -Het 4 .
- R a and R are as defined above.
- the present invention provides compounds of Formula (I-Z)
- G 1 is C or N
- G 2 is H, OA, preferably OCH 3 , SO 2 A, preferably SO 2 CH 3 , G 3 is a linear or branched alkyl group optionally substituted with 1 to 3 groups selected from OH, OMe, Hal, preferably F, N(CH 3 ) 2 , G 4 is O or S, G 5 is N or C, and pharmaceutically acceptable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.
- the present invention provides compounds of Formula (I-Z * )
- G 1 is C or N
- G 2 is H, OA, preferably OCH 3 , SO 2 A, preferably SO 2 CH 3
- G 6 is H, Hal, preferably F, and pharmaceutically acceptable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.
- R a also denotes A, perfluoroalkyl, -NH-A, -NH(CH 2 ) P -A, (CH 2 ) s Ar, -(CH 2 ) s Het 1 , -NH(CH 2 ) P -Het 1 , OA, cycloalkyl, Het 1 -alkyl, when R b is not Ar or Het 3 .
- R a also denotes CO-Het 1 or COOA when X is a bond.
- the invention provides compounds of formula I wherein R a denotes Perfluoroalkyl, A, -NH-A, Het, R b denotes Ar, Het 2 ;
- the invention provides compounds of formula I wherein R a denotes A, -NH-A, wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , N(R 6 ) 2 , Het 1 , Het 2 , or denotes cycloalkyl, R b denotes Ar, Het 2 ;
- the invention provides compounds of formula I wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het 1 , Het 2 , or denotes cycloalkyl, R b denotes Ar, Het 2 wherein Ar and Het 2 may be unsubstituted or substituted by a group selected from (R 4 ) n and/or
- the invention provides compounds of formula I wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het 1 , Het 2 , or denotes cycloalkyl, R b denotes Ar, Het 2 wherein Ar and Het 2 may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H, wherein Ar is phenyl, Het 2 is imidazolyl, pyridinyl, wherein n and m are as defined above; In another specific embodiment the invention provides compounds of formula I wherein R a denotes Perfluoroalkyl, A, -N-A wherein A is a branched or linear alkyl having 1 to 5 C-atom
- R 5 (R 5 ) n , wherein R 6 is H, wherein Ar is phenyl, Het 2 is imidazolyl, pyridinyl, wherein R 4 and/or R 5 are selected from OH, OA, -SO 2 -N (H ) 2 - m (A)m, -SO 2 -Het 1 or NO 2 ,wherein n and m are as defined above;
- the invention provides compounds of formula I wherein R a denotes methyl, R b denotes Ar, Het 2 wherein Ar and Het 2 may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H, wherein Ar is phenyl, Het 2 is imidazolyl, pyridinyl, wherein R 4 and/or R 5 are selected from OH, OMe, -SO 2 -NHMe and -SO 2 -NH-CH 2 -CH 2 -OH;
- the invention provides compounds of formula l-a wherein R a denotes Perfluoroalkyl, A, -NHA, Het, R b denotes Ar, Het 2 ;
- the invention provides compounds of formula l-a wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het 1 , Het 2 , or denotes cycloalkyl, R b denotes Ar, Het 2 ;
- the invention provides compounds of formula l-a wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het 1 , Het 2 , or denotes cycloalkyl, R b denotes Ar, Het 2 wherein Ar and Het 2 may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H or Me;
- the invention provides compounds of formula l-a wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het 1 , Het 2 , or denotes cycloalkyl, R b denotes Ar, Het 2 wherein Ar and Het 2 may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H, wherein Ar is phenyl, Het 2 is imidazolyl, pyridinyl, wherein n and m are as defined above;
- the invention provides compounds of formula l-a wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 5 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het 1 , Het 2 , or denotes cycloalkyl, R b denotes Ar, Het 2 wherein Ar and Het 2 may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H, wherein Ar is phenyl, Het 2 is imidazolyl, pyridinyl, wherein R 4 and/or R 5 are selected from OH, OA, -SO 2 -N(H) 2 - m (A) m , -SO 2 -Het 1 or NO 2 ,wherein n and m are as defined
- the invention provides compounds of formula l-a wherein R a denotes methyl, R b denotes Ar, Het 2 wherein Ar and Het 2 may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H, wherein Ar is phenyl, Het 2 is imidazolyl, pyridinyl, wherein R 4 and/or R 5 are selected from OH, OMe, -SO 2 -NHMe and -SO 2 -NH-CH 2 -CH 2 -OH;
- the invention provides compounds of formula l-b wherein R a denotes Perfluoroalkyl, A, -NHA, Het, R b denotes Ar, Het 2 ;
- the invention provides compounds of formula l-b wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het 1 , Het 2 , or denotes cycloalkyl, R b denotes Ar, Het 2 ;
- the invention provides compounds of formula l-b wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het 1 , Het 2 , or denotes cycloalkyl, R b denotes Ar, Het 2 wherein Ar and Het 2 may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H;
- the invention provides compounds of formula l-b wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het 1 , Het 2 , or denotes cycloalkyl, R b denotes Ar, Het 2 wherein Ar and Het 2 may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H, wherein Ar is phenyl, Het 2 is imidazolyl, pyridinyl, wherein n amd m are as defined above;
- the invention provides compounds of formula l-b wherein R a denotes Perfluoroalkyl, A, -NH-A, wherein A is a branched or linear alkyl having 1 to 5 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het 1 , Het 2 , or denotes cycloalkyl, R b denotes Ar, Het 2 wherein Ar and Het 2 may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H, wherein Ar is phenyl, Het 2 is imidazolyl, pyridinyl, morpholino, wherein R 4 and/or R 5 are selected from OH, OA, -S ⁇ 2 -N(H) 2 - m (A)m, - SO 2 -Het 1 or NO 2 , wherein n and
- the invention provides compounds of formula l-b wherein R a denotes methyl, R b denotes Ar, Het 2 wherein Ar and Het 2 may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H, wherein Ar is phenyl, Het 2 is imidazolyl, pyridinyl, morpholino, wherein R 4 and/or R 5 are selected from OH, OMe, -SO 2 -NHMe and -SO 2 -NH-CH 2 -CH 2 -OH;
- the invention provides compounds of formula l-c wherein R a denotes Perfluoroalkyl, A, -NHA, Het, R b denotes Ar, Het 2 ;
- the invention provides compounds of formula l-d wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het 1 , Het 2 , or denotes cycloalkyl, R b denotes Ar, Het 2 ;
- the invention provides compounds of formula l-c wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het 1 , Het 2 , or denotes cycloalkyl, R b denotes Ar, Het 2 wherein Ar and Het 2 may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H;
- R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het 1 , Het
- the invention provides compounds of formula l-c wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 5 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het 1 , Het 2 , or denotes cycloalkyl, R b denotes Ar, Het 2 wherein Ar and Het 2 may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H, wherein Ar is phenyl, Het 2 is imidazolyl, pyridinyl, wherein R 4 and/or R 5 are selected from OH, OA, -SO 2 -N (H ) 2 - m (A)m, -SO 2 -Het 1 or NO 2 ,wherein n and m are as defined above
- the invention provides compounds of formula l-c wherein R a denotes methyl, R b denotes Ar, Het 2 wherein Ar and Het 2 may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H, wherein Ar is phenyl, Het 2 is imidazolyl, pyridinyl, wherein R 4 and/or R 5 are selected from OH, OMe, -SO 2 -NHMe and -SO 2 -NH-CH 2 -CH 2 -OH;
- the compounds of formula I and related formulae modulate activity of Phosphoinositide 3-kinases such as Pi3K ⁇ and Pi3K ⁇ or other isoforms Phosphoinositide 3-kinases (PI3Ks) have a critical signalling role in cell proliferation, cell survival, vascularization, membrane trafficking, glucose transport, neurite outgrowth, membrane ruffling, superoxide production, actin reorganization and chemotaxis (Cantley, 2000, Science, 296, 1655-1657).
- Phosphoinositide 3-kinases such as Pi3K ⁇ and Pi3K ⁇ or other isoforms Phosphoinositide 3-kinases (PI3Ks) have a critical signalling role in cell proliferation, cell survival, vascularization, membrane trafficking, glucose transport, neurite outgrowth, membrane ruffling, superoxide production, actin reorganization and chemotaxis (Cantley, 2000, Science, 296, 1655-1657).
- PI3K is given to a family of lipid kinases which, in mammals, consists in eight identified PI3Ks that are divided into three sub-families according to their structure and their substrate specificity.
- Class I group of PI3Ks consists in two sub-groups, Class IA and Class IB.
- Class IA are a family of heterodimeric lipid kinases consisting in a 85 kDa regulatory unit (responsible for protein-protein interactions via the interaction of Src homology 2 (SH2) domain with phosphotyrosine residues of other proteins) and a catalytic sub- unit of 110kDa that generate second messenger signals downstream of tyrosine kinases, thereby controlling cell metabolism, growth, proliferation, differentiation, motility and survival.
- Three catalytic forms p110a, p110 ⁇ and p110 ⁇
- five regulatory isoforms p85 ⁇ , p85 ⁇ , p55 ⁇ , p55 ⁇ and p50 ⁇
- Class IB are stimulated by G protein ⁇ sub-units of heterodimeric G proteins.
- the only characterized member of Class IB is PI3K ⁇ (p1 10 ⁇ catalytic sub-unit complex with a 101 -kDa regulatory protein, p101 ).
- Class 1A PI3Ks comprises ⁇ , ⁇ and ⁇ isoforms, which are approximately of 170 kDa and characterized by the presence of a C-terminal C2 domain.
- Class III PI3Ks includes the phosphatidylinositol specific 3-kinases.
- the evolutionary conserved isoforms p1 10 ⁇ and ⁇ are ubiquitously expressed, while ⁇ and ⁇ are more specifically expressed in the haematopoetic cell system, smooth muscle cells, myocytes and endothelial cells (Vanhaesebroeck et al., 2001 , Annu. Rev. Biochem., 70, 535-602). Their expression might also be regulated in an inducible manner depending on the cellular-, tissue type and stimuli as well as disease context.
- PI3Ks are enzymes involved in phospholipid signalling and are activated in response to a variety of extra-cellular signals such as growth factors, mitogens, integrins (cell-cell interactions) hormones, cytokines, viruses and neurotransmitters and also by intra-cellular cross regulation by other signalling molecules (cross-talk, where the original signal can activate some parallel pathways that in a second step transmit signals to PI3Ks by intra-cellular signalling events), such as small GTPases, kinases or phosphatases for example.
- extra-cellular signals such as growth factors, mitogens, integrins (cell-cell interactions) hormones, cytokines, viruses and neurotransmitters and also by intra-cellular cross regulation by other signalling molecules (cross-talk, where the original signal can activate some parallel pathways that in a second step transmit signals to PI3Ks by intra-cellular signalling events), such as small GTPases, kinases or phosphatases for example.
- Phosphatidylinositol is the basic building block for the intracellular inositol lipids in eukaryotic cells, consisting of D-myo-inositol-1 -phosphate (Insi P) linked via its phosphate group to diacylglycerol.
- the inositol head group of Ptdlns has five free hydroxy groups and three of these are found to be phosphorylated in cells in different combinations.
- Ptdlns and its phosphorylated derivatives are collectively referred as inositol phospholipids or phosphoinositides (PIs).
- PIs all reside in membranes and are substrates for kinases, phosphatases and lipases.
- PI3Ks phosphorylate the 3-hydroxyl group of the inositol ring in three different substrates: phosphatidylinositol (Ptdlns), phosphatidylinositol-4-phosphate (PI(4)P) and phosphatidylinositol-4,5-biphosphate (PI(4,5)P 2 ), respectively generating three lipid products, namely phosphatidylinositol 3-monophosphate (PI(3)P), phosphatidylinositol 3,4-bisphosphate (PI(3,4)P 2 ) and phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P 3 (see Scheme A below).
- Class I PI3Ks The preferred substrate for Class I PI3Ks is PI(4,5)P 2 .
- Class Il PIKs have a strong prefererence for Ptdlns as substrate over PI(4)P and PI(4,5)P 2
- Class III PI3Ks can only use Ptdlns as substrate in vivo and are likely to be responsible for the generation of most PI(3)P in cells (Vanhaesebroeck et al., 2001 , above).
- the phosphoinositides intracellular signalling pathway begins with the binding of a signalling molecule (extracellular ligands, stimuli, receptor dimidiation, transactivation by heterologous receptor (e.g. receptor tyrosine kinase)) to a G- protein linked transmembrane receptor integrated into the plasma membrane resulting in the activation of PI3Ks.
- a signalling molecule extracellular ligands, stimuli, receptor dimidiation, transactivation by heterologous receptor (e.g. receptor tyrosine kinase)
- heterologous receptor e.g. receptor tyrosine kinase
- PI3Ks convert the membrane phospholipid PI(4,5)P 2 into PI(3,4,5)P 3 which in turn can be further converted into another 3' phosphorylated form of phosphoinositides by 5'-specific phosphoinositide phosphatases, thus PI3K enzymatic activity results either directly or indirectly in the generation of two 3'- phosphoinositide sub-types that function as second messengers in intra-cellular signal transduction (Toker et al., 2002, Cell MoI. Life Sci. 59(5) 761-79).
- the role as second messengers of phosphorylated products of Ptdlns act is involved in a variety of signal transduction pathways, including those essential to cell proliferation, cell differentiation, cell growth, cell size, cell survival, apoptosis, adhesion, cell motility, cell migration, chemotaxis, invasion, cytoskeletal rearrangement, cell shape changes, vesicle trafficking and metabolic pathway (Stein, 2000, MoI. Med. Today 6(9) 347-57).
- Chemotaxis the directed movement of cells toward a concentration gradient of chemical attractants, also called chemokines is involved in many important diseases such as inflammation/auto- immunity, neurodegeneration, angiogenesis, invasion/metastasis and wound healing
- PI3-kinase activation is therefore believed to be involved in a range of cellular responses including cell growth, differentiation, migration and apoptosis (Parker et al., 1995, Current Biology, 5, 577-99; Yao et al., 1995, Science, 267, 2003-05).
- PI3Ks appear to be involved in a number of aspects of leukocyte activation.
- a p85- associated PI3-kinase activity has been shown to physically associate with the cytoplasmic domain of CD28, which is an important co-stimulatory molecule for the activation of T-cells in response to antigen.
- CD28 interleukin-2
- T cell growth factor Fraser et al., 1991 , Science, 251 , 313-16.
- Mutation of CD28 such that it can longer interact with PI3-kinase leads to a failure to initiate IL-2 production, suggesting a critical role for PI3-kinase in T cell activation.
- PI3Ks Cellular processes in which PI3Ks play an essential role include suppression of apoptosis, reorganization of the actin skeleton, cardiac myocyte growth, glycogen synthase stimulation by insulin, TNF ⁇ -mediated neutrophil priming and superoxide generation, and leukocyte migration and adhesion to endothelial cells.
- Class I PI3Ks e.g. Class IB isoform PI3K ⁇
- Class IB isoform PI3K ⁇ are dual-specific kinase enzymes, i.e. they display both lipid kinase activity (phosphorylation of phospho-inositides) as well as protein kinase activity, as they are able to induce the phosphorylation of other protein as substrates, including auto- phosphorylation as intra-molecular regulatory mechanism.
- PI3K ⁇ relays inflammatory signals through various G(i)-coupled receptors (Laffargue et al., 2002, Immunity 16(3) 441-51 ) and its central to mast cell function, stimuli in context of leukocytes, immunology includes cytokines, chemokines, adenosines, antibodies, integrins, aggregation factors, growth factors, viruses or hormones for example (Lawlor et al., 2001 , J. Cell. ScL, 1 14 (Pt 16) 2903-10).
- thromboembolism is a major cause of a variety of pathological processes such as artherosclerosis, occlusion of vascular grafts, or acute restenosis after angioplasty Emilio Hirsch et al.The FASEB journal vol.15 September 2001 2019-2021 ). Also the severity of Secretagogue-lnduced Acute pancreatitis is reduced in Mice lacking PI3K ⁇ .pancreatic damage and neutrophil infiltration resulted significantly reduced in PI3K ⁇ " ' " compared to wild-type mice.
- PI3K ⁇ gene deletion or pharmacologic inhibition of PI3K ⁇ leads to perturbations of critical innate immune responses of the lung to challenge with S. pneumoniae.
- PI3K ⁇ Gene Knockout Impairs Postischemic Neovascularization and Endothelial Progenitor Cell Functions. Capillarization and arteriogenesis were reduced in PI3K ⁇ (" ⁇ ) ischemic muscles resulting in delayed reperfusion compared with WT, whereas reparative neovascularization was preserved in PI3K ⁇ (kDa/kDa). In PI3K ⁇ (" ⁇ ) muscles, endothelial cell proliferation was reduced, apoptosis was increased, and interstitial space was infiltrated with leukocytes but lacked cKit(+) progenitor cells that in WT muscles typically surrounded arterioles.
- PI3Kgamma is constitutively expressed by WT EPCs, with expression levels being upregulated by hypoxia.
- PI3Kgamma(-/-) EPCs showed a defect in proliferation, survival, integration into endothelial networks, and migration toward SDF-1.
- the dysfunctional phenotype was associated with nuclear constraining of FOXO1 , reduced Akt and eNOS phosphorylation, and decreased nitric oxide (NO) production.
- Pretreatment with an NO donor corrected the migratory defect of PI3K ⁇ (" ⁇ ) EPCs.
- PI3K ⁇ (kDa/kDa) EPCs showed reduced Akt phosphorylation, but constitutive activation of eNOS and preserved proliferation, survival, and migration consequently PI3K ⁇ modulates angiogenesis, arteriogenesis, and vasculogenesis by mechanisms independent from its kinase activity (Paolo Madeddu et al. Arterioscler Thromb Vase Biol. 2007 Oct 25).
- Two compounds, LY294002 and Wortmannin (cf.hereinafter) have been widely used as PI3-kinase inhibitors. These compounds are non-specific PI3K inhibitors, as they do not distinguish among the four members of Class I PI3-kinases.
- IC 50 values of Wortmannin against each of the various Class I PI3-kinases are in the range of 1-10 nM and IC 5 O values for LY294002 against each of these PI3-kinases are about 15-20 ⁇ M (Fruman et al., 1998, Ann. Rev. Biochem., 67, 481-507), also 5- 10 mM on CK2 protein kinase and some inhibitory activity on phospholipases.
- Wortmannin is a fungal metabolite which irreversibly inhibits PI3K activity by binding covalently to the catalytic domain of this enzyme.
- PI3K inhibitors for example, LY294002
- LY294002 can increase the in vivo antitumor activity of certain cytotoxic agents (e.g. paclitaxel) (Grant, 2003, Current Drugs, 6(10), 946-948).
- PI3K inhibitors in general have been developed: thiazole derivatives (WO 2005/021519; and WO 04/078754), thiazolidine derivatives (WO 2004/007491 and WO 2004/056820) and quinazolinones derivatives (WO 03 /035075) and more recently imidazolopyridine or benzothiazole derivatives (WO2007/095588).
- Immunosuppressive agents are further useful in a wide variety of autoimmune and chronic inflammatory diseases, including systemic lupus erythematosus, chronic rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel diseases, biliary cirrhosis, uveitis and other disorders such as Crohn's diseases, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, Graves ophthalmopathy, atopic dermatitis and asthma. They are also useful as part of chemotherapeutic regimens for the treatment of cancers, lymphomas and leukemias.
- the compounds of the present invention are modulating PI3K inhibitor with improved pharmacological and/ or other properties.
- the present invention preferably comprises compounds which are inhibitors of the PI3K receptor, especially having selectivity for the PI3K ⁇ receptor.
- a PI3K ⁇ receptor selective inhibitor has advantages over current therapies and extends the therapeutic window of lymphocyte sequestration agents, allowing better tolerability with higher dosing and thus improving efficacy.
- the inventions further relates to the use of compounds according to formula I in combination with immunomodulating agents for example Fingolimod; cyclosporins, rapamycins or ascomycins, or their immunosuppressive analogs, e.g. cyclosporin A, cyclosporin G, FK-506, ABT-281 , ASM981 , rapamycin, 40-O-(2-hydroxy)ethyl- rapamycin etc.; corticosteroids; cyclophosphamide; azathioprene; methotrexate; leflunomide; mizoribine; mycophenolic add; mycophenolate mofetil; 15- deoxyspergualine; diflucortolone valerate; difluprednate; Alclometasone dipropionate; amcinonide; amsacrine; asparaginase; azathioprine; basiliximab; beclometasone dipropionate; betamethasone; betamet
- CTLA41g or other adhesion molecule inhibitors, e.g. mAbs or low molecular weight inhibitors including Selectin antagonists and VLA-4 antagonists.
- a preferred composition is with Cyclosporin A, FK506, rapamycin or 40-(2-hydroxy)ethyl- rapamycin and Fingolimod.
- the compounds according to formula I and related formulae may be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred experimental conditions (i.e. reaction temperatures, time, stoechiometry of reagents, solvents etc.) are given, other experimental conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by the person skilled in the art, using routine optimisation procedures.
- the compounds according to formula I and related formulae of this invention may be prepared from readily available starting materials. If such starting materials are not commercially available they may be prepared by standard synthetic techniques. The following general methods and procedures described hereinafter in the examples may be employed to prepare compounds of formula I and related formulae.
- the compounds according to Formula (I) may be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred experimental conditions (i.e. reaction temperatures, time, stoechiometry of reagents, solvents, etc.) are given, other experimental conditions can also be used unless otherwise stated. Generally, the compounds according to the general Formula (I) may be obtained by several processes using both solution-phase and/or solid-phase chemistry protocols.
- the compounds according to Formula (I) may be prepared following the synthetic pathways described in the general scheme 1.
- L 1 , L 2 , L 3 , L 4 , L 5 are leaving groups.
- the term leaving group preferably denotes Cl, Br, I or a reactively modified OH group.
- a reactively modified OH group can be for example, an ester, an imidazolide, an aryloxy or alkylsulfonyloxy having 1 to 6 carbon atoms (preferably methylsulfonyloxy or trifluoromethylsulfonyloxy) or arylsulfonyloxy having 6 to 10 carbon atoms (preferably phenyl- or p tolylsulfonyloxy).
- the term leaving group can denote a reactively modified OH group that can be prepared in situ by reaction of the carboxylic acid with peptide coupling reagents such as HATU, EDC, PyBOP, DCC, TBTU, possibly in the presence of HOBt or N-hydroxysuccinimide.
- L 1 is preferably chloride, bromide, iodide or triflate.
- L 2 is preferably chloride or carboxylate (from anhydride or mixte anhydride).
- L 3 is preferably chloride, bromide, iodide or triflate.
- L 4 is preferably chloride, imidazoyl, trichloromethoxy or para- nitrophenyloxy.
- L 5 is preferably chloride, trichloromethoxy or imidazoyl.
- R denotes independently each other H, Ar, Het, OA or A
- compounds of Formula (I) may be prepared from the corresponding derivatives of Formula (II), by a cross-coupling reaction such as a Suzuki type cross-coupling reaction.
- Preferred conditions consist in the treatment of compounds of Formula (II) with a boronic acid or ester of Formula (RO) 2 B-R b wherein R is a branched or linear alkyl having 1 to 12 C-atoms and R b is as defined above, in presence of a base such as cesium fluoride and a catalyst such as PdCl 2 (PPh 3 ) 2 in a suitable solvent such as a mixture of dioxane and water at temperature between about 80 0 C and about 100 0 C.
- a cross-coupling reaction such as a Suzuki type cross-coupling reaction.
- Preferred conditions consist in the treatment of compounds of Formula (II) with a boronic acid or ester of Formula (RO) 2 B-R b wherein R is a branched or linear alkyl having 1 to 12 C-atom
- Compounds of Formula (II) wherein, X is a carbonyl group and R a is as above defined may be prepared by a coupling reaction between the corresponding derivatives of Formula (III) with L 2 -X-R a wherein X is a carbonyl group, and R a is a group linked to X by a carbon atom.
- Preferred conditions consist in the treatment of compounds of Formula (III) with an acyl chloride or an acyl anhydride in the presence of a base such as pyridine as solvent, with or without an additional suitable solvent such as DCM at temperature between about 0° to about 60 0 C.
- Compounds of Formula (II) wherein X is a carbonyl group and R a is an amino group NR R may be prepared from compounds of Formula (V) wherein X is a carbonyl group, by treatment with an amine of Formula HNR R .
- Compounds of Formula (V) wherein X is a carbonyl group may be prepared from compounds of Formula (III) by treatment with reagents of Formula L 5 -X-L 4 wherein L 4 and L 5 are as defined above.
- An alternative pathway for the synthesis of compounds of Formula (I) from compounds of Formula (II) consists in the preparation of boronic acid derivatives of Formula (IV) wherein R 2 , R 3 are hydrogen or alkyl groups.
- Preferred conditions consist in the treatment of compounds of Formula (II) with bis(pinacolato)diboron in presence of a base such as potassium acetate and a catalyst such as 1 ,1'- bis(diphenylphosphino)ferrocenedichloro palladium(ll) in a suitable solvent such as DMSO at temperature between around 80°C to around 100°C.
- a second step consists of the transformation of compounds of Formula (IV) in compounds of
- Formula (I) by a Suzuki type cross coupling reaction with derivatives of Formula L 3 - R b wherein L 3 and R b are as defined above.
- Preferred conditions consist in the treatment of compounds of Formula (IV) with an aryl or heteroaryl bromide of Formula Br-R b in presence of a base such as cesium fluoride and a catalyst such as PdCI 2 (PPh 3 )2 in a suitable solvent such as a mixture of dioxane and water at temperature between around 80 0 C and around 100 0 C.
- An alternative pathway for the synthesis of compounds of Formula (I) from compounds of Formula (III) consists to start with a cross-coupling reaction to give compounds of Formula (l-l).
- Preferred conditions consist in the treatment of compounds of Formula (III) with a boronic acid or ester of Formula (RO) 2 B-R b wherein R is a branched or linear alkyl having 1 to 12 C-atoms and R b is as defined above, in presence of a base such as cesium fluoride and a catalyst such as PdCI 2 (PPh 3 ) 2 in a suitable solvent such as a mixture of dioxane and water at temperature between around 80 0 C and around 100 0 C.
- a base such as cesium fluoride
- a catalyst such as PdCI 2 (PPh 3 ) 2
- suitable solvent such as a mixture of dioxane and water at temperature between around 80 0 C and around 100 0 C.
- a second step consists in the transformation of compounds of Formula (l-l) in compounds of Formula (I) wherein, X is a carbonyl group and R a is as above defined (with the exception of R a is NR R , for which one the pathway described in the next paragraph is generally preferred), by treatment with a reagent of Formula L 2 -X-R a wherein L 2 is as above defined.
- Preferred conditions consist in the treatment of compounds of Formula (l-l) with an acyl chloride in the presence of a base such as pyridine, with or without an additional suitable solvent such as DCM at temperature between around 0° to around 60°C.
- Compounds of Formula (I) wherein X is a carbonyl group and R a is an amino group NR R may be prepared from compounds of Formula (Vl) wherein X is a carbonyl group and L 4 is as above defined, by treatment with an amine of Formula HNR R .
- Preferred conditions consist in the treatment of compounds of Formula (Vl) with an amine of Formula HNR R in a suitable solvent such as DMF at temperature between RT and around 100°C, in the presence of an additional base such as Et 3 N in case of salified amine of Formula HNR R " .
- Compounds of Formula (Vl) wherein X is a carbonyl group may be prepared from compounds of Formula (l-l) wherein by treatment with reagents of Formula L 5 -X-L 4 wherein L 4 and L 5 are as above defined.
- Preferred conditions consist in the treatment of compounds of Formula (l-l) with 1 ,1 '- carbonyldiimidazole in a suitable solvent such as ACN at temperature between RT to around 60°C.
- Compounds of Formula (III) and reagents of Formulae (RO) 2 B-R b , L 2 -X-R a , L 3 -R b , L 5 -X-L 4 and HNR R may be obtained either from commercial sources or they may be prepared from known compounds using procedures such as those described hereinafter in the examples, or conventional procedures, well known by one skilled in the art.
- Compounds of Formulae (I), (II), (III) and (Vl) may be converted to alternative compounds of Formulae (I), (II), (III) and (Vl) respectively, using suitable interconversion procedures such as those described hereinafter in the examples, or conventional interconversion procedures, well known by one skilled in the art.
- the pharmaceutically acceptable anionic salts of the compounds of Formula (I), which contain a basic center may be prepared in a conventional manner.
- a solution of the free base may be treated with a suitable acid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent.
- the pharmaceutically acceptable cationic salts of the compounds of Formula (I), which contain an acidic center may be prepared in a conventional manner.
- a solution of the free acid may be treated with a suitable base, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent.
- salts can be prepared by mixing a solution of the acid with a solution of an alkali or earth alkali salt (such as sodium ethylhexanoate, magnesium oleate), employing a solvent in which the desired alkali or earth alkali salt of the compounds of formula (I) precipitates, or can be otherwise isolated by concentration and addition of a non- solvent. Both types of salts may be formed or interconverted using ion-exchange resin techniques.
- reaction times are generally between a few minutes and 14 days.
- the reaction temperature is between about -30 0 C and about
- 140 0 C normally between -10°C and 90 0 C, in particular between about 0°C and 70°C.
- Compounds of the formula I and related formulae can furthermore be obtained by liberating compounds of the formula I from one of their functional derivatives by treatment with a solvolysing or hydrogenolysing agent.
- Preferred starting materials for the solvolysis or hydrogenolysis are those which conform to the formula I and related formulae, but contain corresponding protected amino and/or hydroxyl groups instead of one or more free amino and/or hydroxyl groups, preferably those which carry an amino-protecting group instead of an H atom bonded to an N atom, in particular those which carry an R * -N group, in which R * denotes an amino-protecting group, instead of an HN group, and/or those which carry a hydroxyl-protecting group instead of the H atom of a hydroxyl group, for example those which conform to the formula I, but carry a -COOR ** group, in which
- R ** denotes a hydroxyl-protecting group, instead of a -COOH group.
- amino-protecting group is known in general terms and relates to groups which are suitable for protecting (blocking) an amino group against chemical reactions, but which are easy to remove after the desired chemical reaction has been carried out elsewhere in the molecule. Typical of such groups are, in particular, unsubstituted or substituted acyl, aryl, aralkoxymethyl or aralkyl groups. Since the amino-protecting groups are removed after the desired reaction (or reaction sequence), their type and size are furthermore not crucial; however, preference is given to those having 1-20, in particular 1-8, carbon atoms.
- acyl group is to be understood in the broadest sense in connection with the present process.
- acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids, and, in particular, alkoxycarbonyl, aryloxycarbonyl and especially aralkoxycarbonyl groups.
- acyl groups are alkanoyl, such as acetyl, propionyl and butyryl; aralkanoyl, such as phenylacetyl; aroyl, such as benzoyl and tolyl; aryloxyalkanoyl, such as POA; alkoxycarbonyl, such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC (tert-butoxy- carbonyl) and 2-iodoethoxycarbonyl; aralkoxycarbonyl, such as CBZ ("carbobenz- oxy"), 4-methoxybenzyloxycarbonyl and FMOC; and arylsulfonyl, such as Mtr.
- Preferred amino-protecting groups are BOC and Mtr, furthermore CBZ, Fmoc, benzyl and acetyl.
- hydroxyl-protecting group is likewise known in general terms and relates to groups which are suitable for protecting a hydroxyl group against chemical reactions, but are easy to remove after the desired chemical reaction has been carried out elsewhere in the molecule. Typical of such groups are the above- mentioned unsubstituted or substituted aryl, aralkyl or acyl groups, furthermore also alkyl groups.
- the nature and size of the hydroxyl-protecting groups are not crucial since they are removed again after the desired chemical reaction or reaction sequence; preference is given to groups having 1-20, in particular 1-10, carbon atoms.
- hydroxyl-protecting groups are, inter alia, benzyl, 4- methoxybenzyl, p-nitrobenzoyl, p-toluenesulfonyl, tert-butyl and acetyl, where benzyl and tert-butyl are particularly preferred.
- the compounds of the formula I and related formulae are liberated from their functional derivatives - depending on the protecting group used - for example strong inorganic acids, such as hydrochloric acid, perchloric acid or sulfuric acid, strong organic carboxylic acids, such as trichloroacetic acid, TFA or sulfonic acids, such as benzene- or p-toluenesulfonic acid.
- strong inorganic acids such as hydrochloric acid, perchloric acid or sulfuric acid
- strong organic carboxylic acids such as trichloroacetic acid, TFA or sulfonic acids, such as benzene- or p-toluenesulfonic acid.
- Suitable inert solvents are preferably organic, for example carboxylic acids, such as acetic acid, ethers, such as tetrahydrofuran or dioxane, amides, such as DMF, halogenated hydrocarbons, such as dichloromethane, furthermore also alcohols, such as methanol, ethanol or isopropanol, and water. Mixtures of the above-mentioned solvents are furthermore suitable. TFA is preferably used in excess without addition of a further solvent, and perchloric acid is preferably used in the form of a mixture of acetic acid and 70% perchloric acid in the ratio 9:1.
- the reaction temperatures for the cleavage are advantageously between about 0 and about 50 0 C, preferably between 15 and 30 0 C (room temperature).
- the BOC, OtBut and Mtr groups can, for example, preferably be cleaved off using TFA in dichloromethane or using approximately 3 to 5N HCI in dioxane at 15-30°C, and the FMOC group can be cleaved off using an approximately 5 to 50% solution of dimethylamine, diethylamine or piperidine in DMF at 15-30 0 C.
- Protecting groups which can be removed hydrogenolytically can be cleaved off, for example, by treatment with hydrogen in the presence of a catalyst (for example a noble-metal catalyst, such as palladium, advantageously on a support, such as carbon).
- a catalyst for example a noble-metal catalyst, such as palladium, advantageously on a support, such as carbon.
- Suitable solvents are those indicated above, in particular, for example, alcohols, such as methanol or ethanol, or amides, such as DMF.
- the hydrogenolysis is generally carried out at temperatures between about 0 and 100°C and pressures between about 1 and 200 bar, preferably at 20-30°C and 1-10 bar. Hydrogenolysis of the CBZ group succeeds well, for example, on 5 to 10% Pd/C in methanol or using ammonium formate (instead of hydrogen) on Pd/C in methanol/DMF at 20-30 0 C.
- suitable inert solvents are hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1 ,2-dichloroethane, tetrachloromethane, trifluoromethylbenzene, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n- propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether or ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide, N-methylpyrroli
- Esters can be hydrolysed, for example, using HCI, H 2 SO 4 , or using LiOH, NaOH or KOH in water, water/THF, water/THF/ethanol or water/dioxane, at temperatures between 0 and 100 0 C.
- Free amino groups can furthermore be acylated in a conventional manner using an acyl chloride or anhydride or alkylated using an unsubstituted or substituted alkyl halide, advantageously in an inert solvent, such as dichloromethane or THF and/or in the presence of a base, such as triethylamine or pyridine, at temperatures between -60 0 C and +30°C.
- an inert solvent such as dichloromethane or THF
- a base such as triethylamine or pyridine
- the formula I and related formulae also encompasses the optically active forms (stereoisomers), the enantiomers, the racemates, the diastereomers and the hydrates and solvates of these compounds.
- solvates of the compounds is taken to mean adductions of inert solvent molecules onto the compounds which form owing to their mutual attractive force. Solvates are, for example, mono- or dihydrates or alcoholates.
- prodrug is taken to mean, for example, the salts of the compounds of the formula I and so-called prodrug compounds.
- prodrug derivatives is taken to mean compounds of the formula I which have been modified with, for example, alkyl or acyl groups, sugars or oligopeptides and which are rapidly cleaved in the organism to form the active compounds.
- prodrug as of the compounds of formula I, refers to derivative compounds that are rapidly transformed in vivo to yield the parent compound of the formula I, as for example by hydrolysis in blood. T. Higuchi and V.
- the formula I and related formulae also encompasses mixtures of the compounds of the formula I, for example mixtures of two diastereomers, for example in the ratio 1 :1 , 1 :2, 1 :3, 1 :4, 1 :5, 1 :10, 1 :100 or 1 :1000. These are particularly preferably mixtures of stereoisomeric compounds.
- U preferably denotes CR C or S
- V preferably denotes C
- W preferably denotes N or CH
- Y preferably denotes CR 2
- X preferably denote CO
- R 2 and R 3 are preferably simultaneously H.
- R 3 is preferably H or F, more preferably
- R a preferably denotes Alkyl, Ar or Het 1 , and more preferably one of the following groups: H, methyl, ethyl, CF 3 , NH 2 , COOEt, (CH 2 ) 2 CO 2 Et, (CH 2 ) 3 CO 2 Et, (CH 2 ) 2 NHC0 2 tBu , NH(CH 2 ) 2 CO 2 Et, NH(CH 2 ) 3 CO 2 Et, NH(CH 2 ) 2 NHCOMe,
- R a denotes a group -N(H)(CH 2 ) p Het 1 wherein p and Het 1 are as defined above. Most preferably R a is one of the following groups:
- R b preferably denotes Ar or Het, especially substituted or unsubstituted pyridine.
- R b more particularly denotes a group of the following formula:
- R x and R y are each independantly H, Ci-C 8 Alkyl, C 1 -C 8 hydroxyalkyl, Het.
- R x and R y together with the nitrogen atom to which they are attached, can optionally form a 3-8-membered Het ring. More preferably R b denotes one of the following groups.
- R b denotes one of the following group:
- R q denotes A, Het, preferably -CH 3 , -CH 2 CH 3 .
- R c preferably denotes one of the following group:
- Alkyl preferably denotes methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1 ,1-, 1 ,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1 ,1-, 1 ,2-, 1 ,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2- methylpropyl, 1 ,1 ,2- or 1 ,2,2-trimethylpropyl, furthermore preferably, for example, trifluoromethyl, pentafluoroethyl or 1 ,1 ,1 -trifluoroethyl.
- Cycloalkyl groups are cyclic alkyl containing 3 to 12 carbon atoms. Cycloalkyl can optionally be substituted with one or more groups R 1 , COOR 6 or OR 6 , wherein R 1 and
- Cycloalkyl preferably denotes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
- Cycloalkylalkylene preferably denotes cyclopropylmethylene, cyclobutylmethylene, cyclopentylmethylene, cyclohexylmethylene or cycloheptylmethylene.
- Alkylene is preferably methylene, ethylene, propylene, butylene, pentylene or hexylene, furthermore branched alkylene.
- Perfluoroalkyl preferably denotes CF 3 .
- Hal denotes Cl, Br, I, F and preferably F, Cl or Br.
- Alkoxy is branched or linear and preferably denotes a group -O-(CH 2 ) n -CH 3 . Most preferably alkoxy is Methoxy or Ethoxy.
- Carboxy denotes a group -COOH.
- Carboxyalkyl denotes an ester group, preferably an alkyl ester, such as COOMe or COOEt.
- Sulfonyl denotes a group -SO 2 -
- Alkylsulfonyl denotes a group -S ⁇ 2 -alkyl, preferably Methylsulfonyl or Ethylsulfonyl.
- Acyl denotes a group -C(O)R, wherein R can be A, Ar, Het as defined above.
- Acyl denotes acetyl (-C(O)CH 3 ).
- Amino denotes the group -NR'R"where each R', R" is independently hydrogen, alkyl, Ar, Het or A. R and R " , together with the nitrogen atom to which they are attached, can optionally form a 3-8-membered Het ring.
- Amido refers to the group -C(O)NR 1 R" where each R', R" is independently hydrogen, a branched or linear alkyl having 1 to 12 C-atoms, Ar, Het or A, and where R and R " , together with the nitrogen atom to which they are attached, can optionally form a 3-8- membered Het ring.
- Ar denotes a monocyclic or bicyclic, aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by alkyl having 1 to 8 carbon atoms, alkoxy having 1 to 8 carbon atoms, Hal, CF 3 , OCF 3 , NO 2 , CN, perfluoroalkyl, A, OA, OH, amino, CONH 2 ,-NHCOA, -NHSO 2 -N(H) 2-m (A) m , COOA, -SO 2 A, -SO 2 N(H) 2-m (A) m , -SO 2 HeI
- Ar is one of the following groups:
- R 4 , R 5 denote independently each other Ar, Het, OA or A.
- R 4 preferably denotes OA, -SO 2 NHA, -SO 2 N(A) 2 , Or -SO 2 -A and R 5 is preferably OH, Cl or CF 3 .
- Ar is unsubtituted or
- Het, Het 1 and Het 2 are preferably a 6 to 14 membered ring system and denotes, not withstanding further substitutions, for example, 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1 ,2,3-triazol-1-, -4- or -5-yl, 1 ,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1 , 2, 3-oxadiazol-4- or -5-yl, 1 , 2, 4-oxadiazol-3- or -5-yl, 1
- heterocyclic radicals may also be partially or fully hydrogenated.
- Het can thus also denote, for example, 2,3-dihydro-2-, -3-, -A- or -5-furyl, 2,5-dihydro- 2-, -3-, -A- or -5-furyl, tetrahydro-2- or -3-furyl, 1 ,3-dioxolan-4-yl, tetrahydro-2- or -3- thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -A- or -5- pyrrolyl, 1 -, 2- or 3-pyrrolidinyl, tetrahydro-1 -, -2- or -4-imidazolyl, 2,3-dihydro-1 -, -2-,
- 6- or -7-yl furthermore preferably 2,3-dihydrobenzofuranyl or 2,3-dihydro-2-oxo- furanyl.
- Het is substituted or unsubstituted 2-pyridyl.
- Het, Het 1 and Het 2 very particularly denote one of the following groups:
- R 4 and R 5 denote independently from each other Ar, Het, OA or A.
- R 4 preferably denotes OA, -SO 2 NHA, -SO 2 N(A) 2 , NHSO 2 A, Or -SO 2 -A and R 5 is preferably OH, Cl or CF 3 .
- the invention provides compounds of Formula (I')
- U * denotes CR C* , CH, or S
- V* denotes C or N
- W * denotes N or CR 1*
- R a* denotes perfluoroalkyl, A, NH-A, -NH-(CH 2 ) P -A, Ar, Het, Het-alkyl,or if X denotes a bond, also CO-Het, CO-N(H) 2-m (A) m , COOA, CO, CS, or if X denotes CO, SO, SO 2 , CS, also H
- R b* denotes Ar * , Het
- R c* denotes H, alkyl, Ar, Het
- Ar * denotes a monocyclic or bicyclic, aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by, Hal, CF 3 , OCF 3 , NO 2 , CN, perfluoroalkyl, A, OA, OH, NH 2 , COH, CONH 2 ,-NHCOA, -NHSO 2 A, -
- Het denotes a monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms which is unsubstituted or monosubstituted, disubstituted or thsubstituted by alkyl having 1 to 8 carbon atoms, alkoxy having 1 to 8 carbon atoms, Hal, CF 3 , OCF 3 , NO 2 , CN, perfluoroalkyl, A, OA, OH, amino, CONH 2 , - NHCOA, -NHSO 2 -N(H) 2-m (A) m , COOA, -SO 2 A, -SO 2 N(H) 2-m (A) m , - SO 2 Het
- n * denotes O, 1 or 2;
- p* denotes O, 1 , 2, 3, 4;
- R 1* , R 2* are each independently H, Hal, CF 3 , A*; Ar* or Het
- R J is H or Hal
- R , R denote each independently H, Ar*, Het, or A*, and if R'*or R"* is bond to a C atom also OA * .
- R 6* is H, a branched or linear alkyl or hydroxyalkyl having 1 to 12 C-atoms and pharmaceutically acceptable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.
- W * denotes CR 1* .
- the invention provides compounds of formula I' wherein R a* denotes Perfluoroalkyl, A * , -NH-A * , Het, R b* denotes Ar * , Het;
- the invention provides compounds of formula I' wherein R a* denotes A * , -NH-A * , wherein A * is a branched or linear alkyl having 1 to
- the invention provides compounds of formula I' wherein R a* denotes Perfluoroalkyl, A * , -NH-A * wherein A * is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6* , Het, or denotes cycloalkyl, R b* denotes Ar * , Het wherein Ar * and Het may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6* is H or Me;
- the invention provides compounds of formula I' wherein R a* denotes Perfluoroalkyl, A * , -NH-A * wherein A * is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6* , Het, or denotes cycloalkyl, R b* denotes Ar * , Het wherein Ar * and Het may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6* is H, wherein Ar * is phenyl, Het is imidazolyl, pyridinyl, morpholino,wherein n and m are as defined above;
- the invention provides compounds of formula I' wherein R a* denotes Perfluoroalkyl, A * , -N-A * wherein A * is a branched or linear alkyl having 1 to 5 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6* , Het, or denotes cycloalkyl, R b* denotes Ar * , Het wherein Ar * and Het may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6* is H, wherein Ar * is phenyl, Het is imidazolyl, pyridinyl, morpholino, wherein R 4 and/or R 5 are selected from OH, OA * , -SO 2 -N (H ) 2 - m (A)m, -SO 2 -Het or NO 2 ,wherein n and
- the invention provides compounds of formula I' wherein R a* denotes methyl, R b* denotes Ar * , Het wherein Ar * and Het may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H, wherein Ar * is phenyl, Het is imidazolyl, pyridinyl, morpholino, wherein R 4 and/ R 5 are selected from OH, OMe, -SO 2 -NHMe and -SO 2 -NH-CH 2 -CH 2 -OH;
- the invention provides compounds of formula l-a wherein R a denotes Perfluoroalkyl, A, -NHA, Het, R b denotes Ar, Het;
- the invention provides compounds of formula l-a wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het, or denotes cycloalkyl, R b denotes Ar, Het;
- the invention provides compounds of formula l-a wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het, or denotes cycloalkyl, R b denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H or Me;
- the invention provides compounds of formula l-a wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het, or denotes cycloalkyl, R b denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H, wherein Ar is phenyl, Het is imidazolyl, pyridinyl, morpholino,wherein n and m are as defined above;
- the invention provides compounds of formula l-a wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 5 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het, or denotes cycloalkyl, R b denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H, wherein Ar is phenyl, Het is imidazolyl, pyridinyl, morpholino, wherein R 4 and/or R 5 are selected from OH, OA, -SO 2 -N(H) 2 - m (A) m , -SO 2 -Het or NO 2 ,wherein n and m are as defined above;
- the invention provides compounds of formula l-a wherein R a denotes methyl, R b denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H, wherein Ar is phenyl, Het is imidazolyl, pyridinyl, morpholino, wherein R 4 and/or R 5 are selected from OH, OMe, -SO 2 -NHMe and -SO 2 -NH-CH 2 -CH 2 -OH;
- the invention provides compounds of formula l-b wherein R a denotes Perfluoroalkyl, A, -NHA, Het, R b denotes Ar, Het;
- the invention provides compounds of formula l-b wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het, or denotes cycloalkyl, R b denotes Ar, Het;
- the invention provides compounds of formula l-b wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het, or denotes cycloalkyl, R b denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H;
- the invention provides compounds of formula l-b wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het, or denotes cycloalkyl, R b denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H, wherein Ar is phenyl, Het is imidazolyl, pyridinyl, morpholino,wherein n amd m are as defined above; In another specific embodiment the invention provides compounds of formula l-b wherein R a denotes Perfluoroalkyl, A, -NH-A, wherein A is a branched or linear alkyl having 1 to 5
- the invention provides compounds of formula l-b wherein R a denotes methyl, R b denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H, wherein Ar is phenyl, Het is imidazolyl, pyridinyl, morpholino, wherein R 4 and/or R 5 are selected from OH, OMe, -SO 2 -NHMe and -SO 2 -NH-CH 2 -CH 2 -OH;
- the invention provides compounds of formula l-c wherein R a denotes Perfluoroalkyl, A, -NHA, Het, R b denotes Ar, Het;
- the invention provides compounds of formula l-d wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het, or denotes cycloalkyl, R b denotes Ar, Het;
- the invention provides compounds of formula l-c wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het, or denotes cycloalkyl, R b denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H;
- the invention provides compounds of formula l-c wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het, or denotes cycloalkyl, R b denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H, wherein Ar is phenyl, Het is imidazolyl, pyridinyl, morpholino,wherein n amd m are as defined above;
- the invention provides compounds of formula l-c wherein R a denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 5 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR 6 , Het, or denotes cycloalkyl, R b denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H, wherein Ar is phenyl, Het is imidazolyl, pyridinyl, morpholino, wherein R 4 and/or R 5 are selected from OH, OA, -SO 2 -N (H ) 2 - m (A)m, -SO 2 -Het or NO 2 ,wherein n amd m are as defined above;
- the invention provides compounds of formula l-c wherein R a denotes methyl, R b denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R 4 ) n and/or (R 5 ) n , wherein R 6 is H, wherein Ar is phenyl, Het is imidazolyl, pyridinyl, morpholino, wherein R 4 and/or R 5 are selected from OH, OMe, -SO 2 -NHMe and -SO 2 -NH-CH 2 -CH 2 -OH;
- the starting materials can also be formed in situ so that they are not isolated from the reaction mixture, but instead are immediately converted further into the compounds of the formula I.
- the reactions are preferably carried out in an inert solvent.
- suitable inert solvents are hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1 ,2-dichloroethane, tetrachloromethane, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether or ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or
- the invention also relates to the preparation of the compounds of formula (I), (II), (Vl) and (V) and salts thereof, as described in scheme 2.
- the invention relates, in particular, to the use of formula I and related formulae as defined above, as a medicament.
- the invention relates, in particular, to the use of compounds of the formula I and related formulae as defined above, for the preparation of pharmaceutical formulation for the prevention and/or the treatment of multiple sclerosis, cancers and related disorders such as monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, acute myelotic leukaemia, chronic myelotic leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia, glioblastomas and breast carcinoma and colon carcinoma, tumour of the blood and immune system, tumours of the squamous epithelium, of the bladder, of the stomach, of the kidneys, of head and neck, of the oesophagus, of the cervix, of the thyroid, of the intestine, of the liver, of the brain, of the prostate, of the urogenital tract, of the lymphatic system, of the larynx and/or of the lung,
- cancers and related disorders such as monocytic le
- the said compounds of the formula I and related formulae can be used in their final non-salt form.
- the present invention also relates to the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases by procedures known in the art.
- Pharmaceutically acceptable salt forms of the compounds of the formula I are for the most part prepared by conventional methods. If the compound of the formula I and related formulae contains an acidic center, such as a carboxyl group, one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base-addition salt.
- Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; alkaline earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, for example sodium- or potassium methoxide and sodium or potassiumpropoxide, alkalihydrides, such as sodium- or potassiumhydride; and various organic bases, such as piperidine, diethanolamine and N-methyl-glutamine, benzathine, choline, diethanolamine, ethylenediamine, meglumine, benethamine, diethylamine, piperazine and tromethamine.
- the aluminium salts of the compounds of the formula I and related formulae are likewise included.
- acid- addition salts can be formed by treating these compounds with pharmaceutically acceptable organic and inorganic acids, for example hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoaryl-sulfonates, such as ethanesulfonate, toluenesulfonate and benzene-sulfonate, and other organic acids and corresponding salts thereof, such as acetate, trifluoro-acetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like.
- organic and inorganic acids for example hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoaryl-
- pharmaceutically acceptable acid-addition salts of the compounds of the formula I and related formulae include the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzene-sulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphor-sulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclo-pentane-propionate, digluconate, dihydrogen-phosphate, dinitrobenzoate, dodecyl-sulfate, ethanesulfonate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptanoate, gluco-nate, glutamate, glycerophosphate, hemi-succinate, hemisulfate, heptanoate, hexanoate, hippurate, hydro-chloride,
- Both types of salts may be formed or interconverted preferably using ion-exchange resin techniques.
- the base salts of the compounds of the formula I and related formulae include aluminium, ammonium, calcium, copper, iron(lll), iron(ll), lithium, magne-sium, manganese(lll), manganese(ll), potassium, sodium and zink salts, but this is not intended to represent a restriction.
- Salts of the compounds of the formula I which are derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, also including naturally occurring substituted amines, cyclic amines, and basic ion exchanger resins, for example arginine, betaine, caffeine, chloroprocaine, choline, N,N'-dibenzyl-ethylen-ediamine (benzathine), dicyclohexylamine, diethanol-amine, diethyl-amine, 2-diethyl-amino-ethanol, 2-dimethyl-amino-ethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethyl-piperidine, glucamine, glucosamine, histidine, hydrabamine, isopropyl-amine, lido-caine, lysine, meglumine (N-methyl-D- glucamine), morpholine,
- Compounds of the formula I and related formulae of the present invention which contain basic nitrogen-containing groups can be quaternised using agents such as (Ci-C 4 )-alkyl halides, for example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide; di(CrC 4 )alkyl sulfates, for example dimethyl, diethyl and diamyl sulfate; (Ci O -Ci 8 )alkyl halides, for example decyl, do-decyl, lauryl, myristyl and stearyl chloride, bromide and iodide; and aryl-(Ci-C 4 )alkyl halides, for example benzyl chloride and phenethyl bromide. Both water- and oil-soluble compounds of the formula I can be prepared using such salts.
- the above-mentioned pharmaceutical salts which are preferred include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, me-glumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stea-rate, sulfate, subsalicylate, tartrate, thiomalate, tosylate and tro-meth-amine, but this is not intended to represent a restriction.
- the acid-addition salts of basic compounds of the formula I and related formulae are prepared by bringing the free base form into contact with a sufficient amount of the desired acid, causing the formation of the salt in a conventional manner.
- the free base can be regenerated by bringing the salt form into contact with a base and isolating the free base in a conventional manner.
- the free base forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts other-wise correspond to the respective free base forms thereof.
- the pharmaceutically acceptable base-addition salts of the compounds of the formula I are formed with metals or amines, such as alkali metals and alkaline earth metals or organic amines.
- metals are sodium, potassium, magnesium and calcium.
- Preferred organic amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanol-amine, ethylenediamine, N-methyl-D-glucamine and procaine.
- the base-addition salts of acidic compounds of the formula I and related formulae are prepared by bringing the free acid form into contact with a sufficient amount of the desired base, causing the formation of the salt in a conventional manner.
- the free acid can be regenerated by bringing the salt form into contact with an acid and isolating the free acid in a conventional manner.
- the free acid forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts other-wise correspond to the respective free acid forms thereof.
- a compound of the formula I and related formulae contains more than one group which is capable of forming pharmaceutically acceptable salts of this type, the formula I also encompasses multiple salts.
- Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, di-phosphate, disodium and trihydrochloride, but this is not intended to represent a restriction.
- the term "pharmaceutically acceptable salt” in the present connection is taken to mean an active ingredient which comprises a compound of the formula I and related formulae in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active ingredient compared with the free form of the active ingredient or any other salt form of the active ingredient used earlier.
- the pharmaceutically acceptable salt form of the active ingredient can also provide this active ingredient for the first time with a desired pharmacokinetic property which it did not have earlier and can even have a positive influence on the pharmacodynamics of this active ingredient with respect to its therapeutic efficacy in the body.
- the compounds of the formula I and related formulae can be chiral and can accordingly occur in various enantiomeric forms. They can therefore exist in racemic or in optically active form. Since the pharmaceutical activity of the racemates or stereoisomers of the compounds according to the invention may differ, it may be desirable to use the enantiomers. In these cases, the end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art or even employed as such in the synthesis.
- diastereomers are formed from the mixture by reaction with an optically active resolving agent.
- optically active acids such as the R and S forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitable N-protected amino acids (for example N-benzoylproline or N- benzenesulfonylproline), or the various optically active camphorsulfonic acids.
- chromatographic enantiomer resolution with the aid of an optically active resolving agent (for example dinitrobenzoylphenylglycine, cellulose triacetate or other derivatives of carbohydrates or chirally derivatised methacrylate polymers immobilised on silica gel).
- optically active resolving agent for example dinitrobenzoylphenylglycine, cellulose triacetate or other derivatives of carbohydrates or chirally derivatised methacrylate polymers immobilised on silica gel.
- Suitable eluents for this purpose are aqueous or alcoholic solvent mixtures, such as, for example, hexane/isopropanol/ acetonitrile, for example in the ratio 82:15:3.
- the invention furthermore relates to the use of compounds of formula I and related formulae in combination with at least one further medicament active ingredient, preferably medicaments used in the treatment of multiple sclerosis such as cladribine or another co-agent, such as interferon, e.g. pegylated or non-pegylated interferons, preferably interferon beta and/or with compounds improving vascular function or in combination with immunomodulating agents for example Fingolimod; cyclosporins, rapamycins or ascomycins, or their immunosuppressive analogs, e.g.
- multiple sclerosis such as cladribine or another co-agent, such as interferon, e.g. pegylated or non-pegylated interferons, preferably interferon beta and/or with compounds improving vascular function or in combination with immunomodulating agents for example Fingolimod; cyclosporins, rapamycins or ascomycins, or their immunosuppressive analogs,
- cyclosporin A cyclosporin G, FK-506, ABT-281 , ASM981 , rapamycin, 40-O-(2-hydroxy)ethyl- rapamycin etc.
- corticosteroids cyclophosphamide; azathioprene; methotrexate; leflunomide; mizoribine; mycophenolic add; mycophenolate mofetil; 15- deoxyspergualine; diflucortolone valerate; difluprednate; Alclometasone dipropionate; amcinonide; amsacrine; asparaginase; azathioprine; basiliximab; beclometasone dipropionate; betamethasone; betamethasone acetate; betamethasone dipropionate; betamethasone phosphate sodique; betamethasone valerate; budesonide; captopril; chlormethine chlorhydrate; cladribine; clobet
- CTLA41g or other adhesion molecule inhibitors, e.g. mAbs or low molecular weight inhibitors including Selectin antagonists and VLA-4 antagonists.
- a preferred composition is with Cyclosporin A, FK506, rapamycin or 40-(2-hydroxy)ethyl-rapamycin and Fingolimod.
- These further medicaments, such as interferon beta may be administered concomitantly or sequentially, e.g. by subcutaneous, intramuscular or oral routes.
- the invention furthermore relates to the use of compounds of formula I and related formulae in combination with at least one further medicament active ingredient, preferably medicaments used in the treatment of cancer wherein said antitumoral compounds are selected from those well known by the one skilled in the related art.
- These compositions can be used as medicaments in human and veterinary medicine.
- compositions can be administered in the form of dosage units, which comprise a predetermined amount of active ingredient per dosage unit.
- a unit can comprise, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a compound according to the invention, depending on the disease condition treated, the method of administration and the age, weight and condition of the patient, or pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit.
- Preferred dosage unit formulations are those which comprise a daily dose or part-dose, as indicated above, or a corresponding fraction thereof of an active ingredient.
- pharmaceutical formulations of this type can be prepared using a process, which is generally known in the pharmaceutical art.
- compositions can be adapted for administration via any desired suitable method, for example by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) methods.
- oral including buccal or sublingual
- rectal nasal
- topical including buccal, sublingual or transdermal
- vaginal or parenteral including subcutaneous, intramuscular, intravenous or intradermal
- parenteral including subcutaneous, intramuscular, intravenous or intradermal
- compositions adapted for oral administration can be administered as separate units, such as, for example, capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
- the active-ingredient component in the case of oral administration in the form of a tablet or capsule, can be combined with an oral, non-toxic and pharmaceutically acceptable inert excipient, such as, for example, ethanol, glycerol, water and the like.
- an oral, non-toxic and pharmaceutically acceptable inert excipient such as, for example, ethanol, glycerol, water and the like.
- Powders are prepared by comminuting the compound to a suitable fine size and mixing it with a pharmaceutical excipient comminuted in a similar manner, such as, for example, an edible carbohydrate, such as, for example, starch or mannitol.
- a flavour, preservative, dispersant and dye may likewise be present.
- Capsules are produced by preparing a powder mixture as described above and filling shaped gelatine shells therewith.
- Glidants and lubricants such as, for example, highly disperse silicic acid, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form, can be added to the powder mixture before the filling operation.
- a disintegrant or solubiliser such as, for example, agar-agar, calcium carbonate or sodium carbonate, may likewise be added in order to improve the availability of the medica-ment after the capsule has been taken.
- suitable binders include starch, gelatine, natural sugars, such as, for example, glucose or beta-lactose, sweeteners made from maize, natural and synthetic rubber, such as, for example, acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like.
- the lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
- the disintegrants include, without being restricted thereto, starch, methylcellulose, agar, bentonite, xanthan gum and the like.
- the tablets are formulated by, for example, preparing a powder mixture, granulating or dry-pressing the mixture, adding a lubricant and a disintegrant and pressing the entire mixture to give tablets.
- a powder mixture is prepared by mixing the compound comminuted in a suitable manner with a diluent or a base, as described above, and optionally with a binder, such as, for example, carboxymethylcellulose, an alginate, gelatine or polyvinylpyrrolidone, a dissolution retardant, such as, for example, paraffin, an absorption accelerator, such as, for example, a quaternary salt, and/or an absorbant, such as, for example, bentonite, kaolin or dicalcium phosphate.
- a binder such as, for example, carboxymethylcellulose, an alginate, gelatine or polyvinylpyrrolidone
- a dissolution retardant such as, for example, paraffin
- an absorption accelerator such as, for example, a quaternary salt
- an absorbant such as, for example, bentonite, kaolin or dicalcium phosphate.
- the powder mixture can be granulated by wetting it with a binder, such as, for example, syrup, starch paste, acadia mucilage or solutions of cellulose or polymer materials and pressing it through a sieve.
- a binder such as, for example, syrup, starch paste, acadia mucilage or solutions of cellulose or polymer materials
- the powder mixture can be run through a tableting machine, giving lumps of non-uniform shape which are broken up to form granules.
- the granules can be lubricated by addition of stearic acid, a stearate salt, talc or mineral oil in order to prevent sticking to the tablet casting moulds. The lubricated mixture is then pressed to give tablets.
- the active ingredients can also be combined with a free-flowing inert excipient and then pressed directly to give tablets without carrying out the granulation or dry-pressing steps.
- a transparent or opaque protective layer consisting of a shellac sealing layer, a layer of sugar or polymer material and a gloss layer of wax may be present. Dyes can be added to these coatings in order to be able to differentiate between different dosage units.
- Oral liquids such as, for example, solution, syrups and elixirs, can be prepared in the form of dosage units so that a given quantity comprises a pre-specified amount of the compounds.
- Syrups can be prepared by dissolving the compounds in an aqueous solution with a suitable flavour, while elixirs are prepared using a non-toxic alcoholic vehicle.
- Suspensions can be for-mulated by dispersion of the compounds in a nontoxic vehicle.
- Solubilisers and emulsifiers such as, for example, ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavour additives, such as, for example, peppermint oil or natural sweeteners or saccharin, or other artificial sweeteners and the like, can likewise be added.
- the dosage unit formulations for oral administration can, if desired, be encapsulated in microcapsules.
- the formulation can also be prepared in such a way that the release is extended or retarded, such as, for example, by coating or embedding of particulate material in polymers, wax and the like.
- the compounds of the formula I and related formulae and salts, solvates and physiologically functional derivatives thereof and the other active ingredients can also be administered in the form of liposome delivery systems, such as, for exam-pie, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
- Liposomes can be formed from various phospholipids, such as, for example, cholesterol, stearylamine or phosphatidylcholines.
- the compounds of the formula I and related formulae and the salts, solvates and physiologically functional derivatives thereof and the other active ingredients can also be delivered using monoclonal antibodies as individual carriers to which the compound molecules are coupled.
- the compounds can also be coupled to soluble polymers as targeted medicament carriers.
- Such polymers may encompass polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl-methacrylamidophenol, polyhydroxyethylaspartamido-phenol or polyethylene oxide polylysine, substituted by palmitoyl radicals.
- the compounds may furthermore be coupled to a class of biodegradable polymers which are suitable for achieving controlled release of a medicament, for example polylactic acid, poly-epsilon-caprolactone, polyhydroxybutyric acid, poly-orthoesters, polyacetals, polydihydroxypyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
- a class of biodegradable polymers which are suitable for achieving controlled release of a medicament, for example polylactic acid, poly-epsilon-caprolactone, polyhydroxybutyric acid, poly-orthoesters, polyacetals, polydihydroxypyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
- compositions adapted for transdermal administration can be administered as independent plasters for extended, close contact with the epidermis of the recipient.
- the active ingredient can be delivered from the plaster by iontophoresis, as described in general terms in Pharmaceutical Research,
- Pharmaceutical compounds adapted for topical administration can be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
- the formulations are preferably applied as topical ointment or cream.
- the active ingredient can be employed either with a paraffinic or a water-miscible cream base.
- the active ingredient can be formulated to give a cream with an oil-in-water cream base or a water-in-oil base.
- compositions adapted for topical application to the eye include eye drops, in which the active ingredient is dissolved or sus-pended in a suitable carrier, in particular an aqueous solvent.
- compositions adapted for topical application in the mouth encompass lozenges, pastilles and mouthwashes.
- compositions adapted for rectal administration can be administered in the form of suppositories or enemas.
- compositions adapted for nasal administration in which the carrier substance is a solid comprise a coarse powder having a particle size, for example, in the range 20-500 microns, which is administered in the manner in which snuff is taken, i.e. by rapid inhalation via the nasal passages from a container containing the powder held close to the nose.
- suitable formulations for administration as nasal spray or nose drops with a liquid as carrier substance encompass active-ingredient solutions in water or oil.
- compositions adapted for administration by inhalation encompass finely particulate dusts or mists, which can be generated by various types of pressurised dispensers with aerosols, nebulisers or insuf-flators.
- compositions adapted for vaginal administration can be administered as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
- compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions comprising antioxidants, buffers, bacteriostatics and solutes, by means of which the formulation is rendered isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions, which may comprise suspension media and thickeners.
- the formulations can be administered in single-dose or multidose containers, for example sealed ampoules and vials, and stored in freeze-dried (lyophilised) state, so that only the addition of the sterile carrier liquid, for example water for injection purposes, immediately before use is necessary.
- Injection solutions and suspensions prepared in accordance with the recipe can be prepared from sterile powders, granules and tablets.
- formulations may also comprise other agents usual in the art with respect to the particular type of formulation; thus, for example, formulations which are suitable for oral administration may comprise flavours.
- a therapeutically effective amount of a compound of the formula I and related formulae and of the other active ingredient depends on a number of factors, including, for example, the age and weight of the animal, the precise disease condition which requires treatment, and its severity, the nature of the formulation and the method of administration, and is ultimately determined by the treating doctor or vet.
- an effective amount of a compound is generally in the range from 0.1 to 100 mg/kg of body weight of the recipient (mammal) per day and particularly typically in the range from 1 to 10 mg/kg of body weight per day.
- the actual amount per day for an adult mammal weighing 70 kg is usually between 70 and 700 mg, where this amount can be administered as an individual dose per day or usually in a series of part-doses
- An effective amount of a salt or solvate or of a physiologically functional derivative thereof can be determined as the fraction of the effective amount of the compound per se.
- the present invention furthermore relates to a method for treating a subject suffering from a PI3K related disorder, comprising administering to said subject an effective amount of a compound of formula I and related formulae.
- the present invention preferably relates to a method, wherein the PI3K associated disorder is an autoimmune disorder or condition associated with an overactive immune response or cancer.
- the present invention furthermore relates to a method of treating a subject suffering from an immunerogulatory abnomality, comprising administering to said subject a compound of formula I and related formulae in an amount that is effective for treating said immunoregulatory abnormality.
- the present invention preferably relates to a method wherein the immunoregulatory abnormality is an autoimmune or chronic inflammatory disease selected from the group consisting of: amyotrophic lateral sclerosis (ALS), systemic lupus erythematosus, chronic rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, Graves ophthalmopathy and asthma.
- ALS amyotrophic lateral sclerosis
- systemic lupus erythematosus chronic rheumatoid arthritis
- type I diabetes mellitus inflammatory bowel disease
- biliary cirrhosis uveitis
- the present invention furthermore relates to a method wherein the immunoregulatory abnormality is bone marrow or organ transplant rejection or graft-versus-host disease.
- the present invention furthermore relates to a method wherein the immunoregulatory abnormality is selected from the group consisting of: transplantation of organs or tissue, graft-versus-host diseases brought about by transplantation, autoimmune syndromes including rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, posterior uveitis, allergic encephalomyelitis, glomerulonephritis, post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis, inflammatory and hyperproliferative skin diseases, psoriasis, atopic dermatitis, contact dermatitis, eczematous dermatitis, sebor
- cancer diseases are associated with a tumor from the group of tumours of the squamous epithelium, of the bladder, of the stomach, of the kidneys, of head and neck, of the oesophagus, of the cervix, of the thyroid, of the intestine, of the liver, of the brain, of the prostate, of the urogenital tract, of the lymphatic system, of the stomach, of the larynx and/or of the lung.
- tumour originates from the group of monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma and colon carcinoma or of the blood and immune system.
- Preferred compounds of formula I and related formulae exhibit a IC 50 for the binding to PI3K ⁇ of less than about 5 ⁇ M, preferably less than about 1 ⁇ M and even more preferred less than about 0,010 ⁇ M.
- Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by the person skilled in the art, using routine optimisation procedures.
- the synthesis pathways for any individual compound of formula I and related formulae will depend on the specific substitutents of each molecule and upon the ready availability of intermediates necessary; again such factors being appreciated by those of ordinary skill in the art.
- compositions of this invention can be isolated in association with solvent molecules by crystallization from evaporation of an appropriate solvent.
- the pharmaceutically acceptable acid addition salts of the compounds of formula I and related formulae which contain a basic center may be prepared in a conventional manner. For example, a solution of the free base may be treated with a suitable acid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent.
- Pharmaceutically acceptable base addition salts may be obtained in an analogous manner by treating a solution of compound of formula I and related formulae, which contain an acid center, with a suitable base. Both types of salts may be formed or interconverted using ion- exchange resin techniques.
- the compounds of invention have been named according the standards used in the program "ACD/Name Batch” from Advanced Chemistry Development Inc., ACD/Labs (7.00 Release). Product version: 7.10, build: 15 Sep 2003.
- the compounds of invention have been named according to the standards used in the program "ACD/Name Batch” from Advanced Chemistry Development Inc., ACD/Labs (7.00 Release). Product version: 7.10, build: 15 Sep 2003.
- HPLC Waters Alliance 2695, column Waters XBridge C8 3.5 ⁇ m 4.6x50 mm, conditions: solvent A (H 2 O with 0.1% TFA), solvent B (ACN with 0.05% TFA), gradient 5% B to 100% B over 8 min, UV detection with PDA Water 996 (230-400 nm) or Agilent
- Atlantis-1 Column: Atlantis C18 (75X4.6mm, 5 ⁇ ), solvent A (H 2 O with 0.1% TFA), solvent B (ACN)
- Atlantis-2 Column: Atlantis C18 (75X4.6mm, 5 ⁇ ), solvent A (1 OmM NH4OAC), solvent B (ACN)
- Atlantis C18 75X4.6mm, 5 ⁇
- solvent A (1 OmM NH4OAC
- solvent B ACN
- X-Terra XTERRA C18 (30X4.6mm -5 ⁇ m)
- solvent A (1OmM NH4OAC)
- C18 BDS Column: C18 BDS (4.6X250mm), solvent A (H 2 O with 0.1 % TFA), solvent
- ECLIPSED Column: ECLIPSED XDB C18 (250X4.6mm,5 ⁇ ) , solvent A (H 2 O), solvent B (ACN)
- LC/MS Waters Alliance 2795, column Waters XBridge C8 3.5 ⁇ m 2.1x30 mm, conditions: solvent A (1OmM ammonium acetate in water + 5% ACN), solvent B (ACN), gradient 5% B to 100% B over 3 min, Waters Micromass ZMD (positive and negative ESI modes) or for "GENESIS", Column GENESIS C18 50X4.6mm 3U, conditions: solvent A: water, 0.1 %HCOOH, solvent B- ACN or Waters Acquity, column Waters Acquity UPLC BEH C18 1.7 ⁇ m 2.1x50 mm, conditions: solvent A (1 OmM ammonium acetate in water + 5% ACN), solvent B (ACN), gradient 5% B to 100% B over 3 min, UV detection (PDA, 230-400 nm) and MS detection
- the microwave chemistry is performed on a single mode microwave reactor EmrysTM Optimiser from Personal Chemistry.
- Step b) Formation of 6-bromo[1 ,2,4]triazolo[1 ,5-a]pyridin-2-amine A suspension of ethyl ⁇ [(5-bromopyridin-2-yl)amino]carbonothioyl ⁇ carbamate (12.3 g,
- Trifluoroacetic anhydride (24 mL) was added slowly to a stirred suspension of 2-[(2Z)- 5-bromo-2- ⁇ [(4-methylphenyl)sulfonyl]imino ⁇ pyridin-1 (2/-/)-yl]acetamide (4.8 g, 12.5 mmol) in anhydrous DCM (60 mL). After being refluxed for 3 hours, the reaction mixture was concentrated under reduced pressure and the resulting yellow solid was suspended in a saturated aqueous solution of sodium bicarbonate, stirred for 15 min and filtered off.
- Step 2) Formation of 2-[(6Z)-(3-chloro-6- ⁇ [(4- methylphenyl)sulfonyl]imino ⁇ pyridazin-1(6H)-yl]acetamide
- Acetyl chloride (16.65 g, 0.212 mol) was added slowly to a solution of 6- bromoimidazo[1 ,2-a]pyridin-2-amine(45 g, 212 mmol) and triethylamine (64.3 g, 0.636 mol) in DCM (450 mL) over 15 minutes at 0-5 0 C.
- the reaction mixture was warmed to RT and stirred for 12h at the same temperature. It was then poured into ice water (10OmL) and the precipitated solid was filtered, washed with water (75mL) and dried to give the title compound as brown solid.
- HPLC Alignite
- Rt 3.67 min (purity: 95.9%).
- N-bromosuccinimide (22.4 g, 0.126 mol) was added portionwise to a stirred solution of 2-Aminopyrazine (15 g, 157 mmol) in CCI 4 (500 ml.) at O 0 C.
- the reaction mixture was stirred at RT under nitrogen atmosphere. After 3 hours, the reaction mixture was filtered and the filtrate was concentrated under vacuum.
- the crude material was purified by flash chromatography on silica (PE:EtOAc) to give the title compound as a yellow solid. LC/MS (Atlantis), M+(ESI): 173.8.
- 1 H-NMR DMSO-d6, 400 MHz) ⁇ 8.01 (1 H, s), 7.66-7.67 (1 H, s), 6.63 (2H, brs).
- Trifluoroacetic anhydride 45 mL was added dropwise to a stirred solution of 2-[5- Bromo-2- ⁇ [(4-methylphenyl)sulfonyl]imino ⁇ pyrazin-1 (2/-/)-yl] acetamide (9g, 23.3 mmol) in anhydrous DCM (180 mL), The reaction mixture was heated to reflux for 3 hours under nitrogen. The mixture was then concentrated under reduced pressure to afford a solid which was suspended in aqueous sodium bicarbonate (10%, 50ml) solution and stirred for 15 min. The solid was filtered to give the title compound as a light brown solid. HPLC (Atlantis-1 ), Rt: 3.78 min (purity: 95.2%). LC/MS (Atlantis),
- Benzoyl chloride (8.96 g, 63.7 mmol ) was added dropwise over 10 minutes to a solution of ammonium thiocyanate (4.85 g, 63.7 mmol) in acetone (75 ml.) heated at 60 0 C. After 30 min, a solution of 4,6-dichloropyridin-3-ylamine (10 g, 61.3 mmol) in acetone (75 ml.) was added over 10 minutes and the reaction mixture was stirred at 60 0 C.
- Benzoyl chloride (44.84 g, 31.9 mmol) was added dropwise over 10 minutes to a solution of ammonium thiocyanate (24.3g, 31.9 mmol) in acetone (150 mL) heated at 55°C. After 30 min, a solution of 2,6-dichloropyridin-3-amine (50 g, 30.6 mmol) in acetone (150 ml.) was added over 10 minutes and the reaction mixture was stirred at 55°C. After one hour, it was poured to cold water (500 ml.) and the resulting precipitated solid was filtered, washed with water (150 ml.) and dried under reduced pressure to give the title compound as white solid (95g, 95%).
- Cyclopentane carbonyl chloride (8.48 g, 64 mmol) was added to a solution of tert- butyl-3-amino-3-(hydroxyimino)propyl carbamate (10 g, 49.3 mmol) and DIEA (12.7 g, 98.5 mmol) in dry DCM (200 ml_). The reaction mixture was stirred at room temperature for 18h under nitrogen. Solvent was removed under reduced pressure and the solid obtained was slurried in EtOAc:EP (1 :9, 100 ml_), filtered and dried to give the title compound as a whte solid.
- Step 2) Formation of tert-butyl 2-[5-(2-hydroxy-1 , 1-dimethylethyl)-1 ,2,4-oxadiazol-3- yljethylcarbamate
- Step 1) Formation of tert-butyl 2-[5-(2-fluoro- 1, 1 -dimethylethyl)-1 ,2, 4-oxadiazol-3-yl]ethylcarbamate
- Step 3 Formation of tert-butyl [2-(5-ethyl-2H-tetrazol-2-yl)ethyl]carbamate and tert-butyl 2-(5-ethyl- 1 H-tetrazol- 1 -yl)ethylcarbamate
- Step 4) Formation of 2-(5-ethyl-2H-tetrazol-2-yl)ethanamine hydrochloride
- a solution of of te/f-butyl [2-(5-ethyl-2H-tetrazol-2-yl)ethyl]carbamate (2 g, 23.1 mmol) in dry dioxane/HCI (200 ml_, 2N) was stirred at room temperature for 12h. The solvent was removed under reduced pressure. The brown solid obtained was slurried in ACN (30 ml_), filtered and dried to give the titled compound as a pale brown solid.
- the semi-solid obtained was washed with hexane, filtered and dried to give the first regioisomer, te/f-butyl 2-(5- cyclopropyl-1 /-/-tetrazol-1-yl) ethylcarbamate as a white solid.
- the second regioisomer, tert-Butyl 2-(5-cyclopropyl-2H-tetrazol-2-yl)ethylcarbamate was obtained by concentration of the hexane filtrate as a yellow oil.
- Step 1 Formation of benzyl 3-[(3,3-dimethyl-2-oxobutyl)amino]-3- oxopropylcarbamate
- Step 2) Formation of benzyl 3-[(1-formyl-2-methylpropyl)amino]-3- oxopropylcarbamate
- Step 1) Formation of benzyl 3- ⁇ [(1R)-1-(hydroxymethyl)-2,2-dimethylpropyl]amino ⁇ -3- oxo propyl carbarn ate
- Step 2) Formation of benzyl 3- ⁇ [(1 R)-1 -formyl-2,2-dimethylpropyl]amino ⁇ -3- oxopropylcarbamate
- Step 2) Formation of 2-(1 -isobutyl-1 H-imidazol-4-yl)ethanamine Dihydrochloride
- 2-lsobutyl-5-oxo-5,6,7,8-tetrahydroimidazo[1 ,5-c]pyrimidin-2-ium bromide (10 g, 36.6 mmol) was refluxed 6M hydrochloric acid (15 ml_, 132 mmol) of for 5h.
- the reaction mixture was lyophilized to give the title compound as off white solid (9.5 g, 83.5%).
- Step 1) Formation of methyl 4-[(3,3-dimethyl-2-oxobutyl)amino]butanoate
- HCI 65.73 g, 342 mmol
- hydroxy benoztriazole 35.9 g, 264 mmol
- triethyl amine 102.2 ml_, 791 mmol
- 1-amino-3, 3- dimethylbutan-2-one (2 g,13 mmol) was added and stirred for 10h.
- the reaction mixture was quenched with water (500 ml.) and extracted with DCM (2x150 ml_).
- the combined organic phases were dried over sodium sulfate, filtered and concentrated.
- Step 2) Formation of ethyl 4-(5-tert-butyl-1 ,3-oxazol-2-yl)butanoate
- Step 3) Formation of 4-(5-tert-butyl-1 ,3-oxazol-2-yl)butanoic acid
- the reaction mixture was concentrated under reduced pressure and the resulting liquid was azeotroped with toluene (2x100 ml.) to give the titled compound as white solid (8 g, 73%).
- Step 1 Formation of tert-Butyl-2-cyanoethylcarbamate A solution of 3-amino propionitrile (10 g, 142.6 mmol) and BOC-anhydride (37.3 g,
- Step 3 Formation of tert-Butyl [2-(1-isopropyl-1 H-tetrazol-5-yl)ethyl]carbamate and tert-Butyl [2-(2-isopropyl-2H-tetrazol-5-yl)-ethyl]-carbamate.
- 2-lodo propane (1.89 g, 1 1.2 mmol) was added to a solution of tert-butyl-2-(1 H- tetrazol-5-yl) ethylcarbamate (2 g, 9.3 mmol) and TEA (4.7 g; 46.4 mmol) in dry ACN (20 ml_). The reaction mixture was refluxed for 12h under nitrogen.
- Phenylchloroformate (4 mL, 32.7 mmol) was added to a solution of 6-bromo-2- aminobenzothiazole (5 g, 21.8 mmol) and TEA (6.1 mL, 43.6 mmol), in DCM/THF
- Step 2) Formation of N-(6-bromo-1 ,3-benzothiazol-2-yl)-N'-[2-(5-tert-butyl-1 ,2,4- oxadiazol-3-yl)ethyl]urea
- HATU (414 mg, 1.1 mmol) and HOAt (147 mg, 1.1 mmol) were added to a solution of 2-amino-6-bromobenzothiazole (250 mg, 1.1 mmol), 4-(5-tert-butyl-1 ,3-oxazol-2- yl)butanoic acid (276 mg, 1.3 mmol) and N-methyl morpholine (0.6ml, 5.4mmol) in DCM/DMF (1 :1 ) maintained at 0 0 C under nitrogen atmosphere. The reaction mixture was then stirred overnight at RT under nitrogen. After completion, the solvent was removed under reduced pressure and the crude was dissolved in EtOAc. Organic phase was washed with 10% citric acid, sat. sodium bicarbonate, water and brine, then dried over sodium sulphate filtered and concentrated to give the title compound.
- Step 1) Formation of tert-butyl ⁇ 2-[5-(isopropylamino)-1,2,4-oxadiazol-3- yl]ethyl ⁇ carbamate ⁇ /, ⁇ /'-Diisopropylcarbodiimide (0.68 ml_; 4.39 mmol) was added to a solution of tert- butyl [(3£)-3-amino-3-(hydroxyimino)propyl]carbamate (812 mg; 4.00 mmol) in pyridine (4 ml.) and toluene (8 ml.) and the resulting mixture was stirred at reflux for 60 h then concentrated in vacuo.
- Step 1) Formation of tert-butyl 3- ⁇ [(methylsulfonyl)oxy]methyl ⁇ piperidine-1-carboxylate
- Methanesulfonyl chloride (2.93 g; 25.55 mmol) was added dropwise at 0 0 C to a solution of te/f-butyl 3-(hydroxymethyl)tetrahydro-1 (2/-/)-pyridinecarboxylate (5.0 g; 23.22 mmol) and DIEA (6.0 g; 46.45 mmol) in DCM (80 ml.) and the resulting mixture was stirred for 16 h at RT. The solution was washed with sat. aq.
- Step 2 Formation of tert-butyl (2- ⁇ 5-[1-(dimethylamino)-1-methylethyl]-1,2,4- oxadiazol-3-yl ⁇ ethyl)carbamate PyBop (4.42 g; 8.5 mmol) was added at 0 0 C to a solution of ⁇ /, ⁇ /,2-trimethylalanine hydrochloride (1.5 g; 8.95 mmol) and DIEA (3.2 mL; 18.8 mmol) DCM (100 mL) and the resulting mixture was stirred at 0 0 C for 30 min whereupon te/f-butyl [(3£)-3- amino-3-(hydroxyimino)propyl]carbamate (1.82 g; 8.95 mmol) was added.
- Step 3 Formation of 2-[3-(2-aminoethyl)-1,2,4-oxadiazol-5-yl]-N,N-dimethylpropan-2- amine bis trifluoroacetic acid salt
- TFA 2 mL
- te/f-butyl (2- ⁇ 5-[1-(dimethylamino)-1- methylethyl]-1 ,2,4-oxadiazol-3-yl ⁇ ethyl)carbamate 500 mg; 1.68 mmol
- DCM 20 mL
- Concentration in vacuo afforded the title compound (700 mg, 98%) as a yellow oil.
- Methanesulfonyl chloride (2.31 ml_; 29.8 mmol) was added at 0 0 C to a solution of 3- hydroxymethyl-pyrrolidine-1-carboxylic acid te/f-butyl ester (5.0 g; 24.8 mmol) and DIEA (8.56 ml_; 49.7 mmol) in DCM (50 ml.) and the resulting mixture was stirred at RT for 2 h. After concentration in vacuo, the residue was partitioned between DCM and sat. aq. NaHCO 3 and the two phases separated. The aqueous layer was extracted with DCM and the combined organic phase washed with sat. aq.
- Step 2 Formation of tert-butyl 3-(isopropoxymethyl)pyrrolidine-1 -carboxylate Sodium hydride (1.36 g; 57.3 mmol) was added portionwise to a solution of te/f-butyl 3- ⁇ [(methylsulfonyl)oxy]methyl ⁇ pyrrolidine-1 -carboxylate (2.0 g; 7.16 mmol) in isopropanol (20 ml.) and the reaction mixture was stirred at RT for 3 days. The solution was diltuted with EtOAc, washed with sat. aq. NH 4 CI and water, dried over magnesium sulfate and concentrated in vacuo.
- Step 3 Formation of 3-(isopropoxymethyl)pyrrolidine hydrochloride 4M HCI in dioxane (10.3 ml_; 41.1 mmol) was added to a solution of te/f-butyl 3- (isopropoxymethyl)pyrrolidine-i-carboxylate (1.0 g; 4.1 1 mmol) in DCM (8 ml.) and the reaction mixture was stirred at RT for 16 h. The solution was concentrated in vacuo to afford the title compound (0.77 g, quantitative yield) as a yellow oil.
- Step 2) Formation of 2,2-dimethylpropanohydrazide hydrochloride
- fe/f-butyl 2-(2,2-dimethylpropanoyl)hydrazinecarboxylate (30 g, 138.8 mmol) in dry dioxane (150 mL)
- 4M HCI in dioxane (250 mL) at 0 0 C and stirred at RT for 12 h.
- the reaction mixture was evaporated to dryness and the residue was slurried in PE/EtOAc and filtered to afford the title compound (19 g, 90%) as a white solid.
- Step 3 Formation of tert-butyl ⁇ 3-[2-(2,2-dimethylpropanoyl)hydrazino]-3- oxopropyl ⁇ carbamate
- EDC hydrochloride 3.78 g, 19.7 mmol
- HOBt 1.7 g, 13.1 mmol
- T EA 5. 1 m L , 39.4 m m ol
- Step 4) Formation of tert-butyl [2-(5-tert-butyl-1 ,3,4-thiadiazol-2-yl)ethyl]carbamate A mixture of te/f-butyl ⁇ 3-[2-(2,2-dimethylpropanoyl)hydrazino]-3-oxopropyl ⁇ carbamate
- Step 1) Formation of tert-butyl ⁇ 2-[5-(1-hydroxyethyl)-1,2,4-oxadiazol-3- yl]ethyl ⁇ carbamate
- Step 2) Formation of 2,2-dimethylpropanohydrazide hydrochloride
- te/f-butyl 2-(2,2-dimethylpropanoyl)hydrazinecarboxylate (30 g, 138.8 mmol) in dry dioxane (150 mL) was added 4M HCI in dioxane (250 mL) at 0°C and stirred at RT for 12 h.
- the reaction mixture was evaporated to dryness; the residue was slurried in PE/EtOAc and filtered to afford the title compound (19 g, 90%) as a white solid.
- Step 4) Formation of tert-butyl [2-(5-tert-butyl-1 ,3,4-oxadiazol-2-yl)ethyl]carbamate
- triphenylphosphine (2.74 g, 10.4 mmol) in dry DCM (5 mL) was added iodine (2.64 g, 10.4 mmol) portionwise under inert atmosphere and stirred at RT for 10 min.
- Step 5 Formation of 2-(5-tert-butyl-1 ,3,4-oxadiazol-2-yl)ethanamine hydrochloride
- a suspension of [2-(5-te/f-butyl-[1 ,3,4]oxadiazol-2-yl)-ethyl]-carbamic acid te/f-butyl ester (1.18 g; 4.39 mmol) in 4M HCI in dioxane (20 mL; 80 mmol) was stirred at RT for 18 h.
- the white suspension was concentrated under vacuum to give the title compound (1.18 g; quant) as a white solid.
- Step 1) Formation of 3-(dimethylamino)-2,2-dimethylpropanoic acid 2,2-Dimethyl-3-bromopropionic acid (10 g, 55.2 mmol) was mixed with dimethyl amine (2 M in THF, 150 ml.) in a sealed tube and stirred at 65 0 C for 12 h. THF was removed under vacuum and the resulting crude solid was slurried in EtOAc, filtered and dried under vacuum to afford the title compound (6 g, 75%) as a white solid.
- Step 2) Formation of tert-butyl (2- ⁇ 5-[2-(dimethylamino)-1 , 1-dimethylethyl]-1 ,2,4- oxadiazol-3-yl ⁇ ethyl)carbamate
- 3-(dimethylamino)-2,2-dimethylpropanoic acid (6 g, 41.3 mmol)
- te/f-butyl-3-amino-3-(hydroxyimino) propylcarbamate 7 g, 34.4 mmol
- dry dioxane 100 ml.
- Step 2) Formation of tert-butyl 2-(5-tert-butyl-1,2,4-oxadiazol-3- yl)ethyl(methyl)carbamate
- Step 3 Formation of 6-(2-methoxypyridin-3-yl)-1 ,3-benzothiazol-2-amine A mixture of te/f-butyl [6-(2-methoxypyridin-3-yl)-1 ,3-benzothiazol-2-yl]carbamate
- Step 4 Formation of 6-[5 ⁇ (methy!s ⁇ ffonyi)pyridin ⁇ 3-yi]-1 ,3-benzothiazo!-2-amine
- 6 ⁇ (4 > 4,5.5-tetramethyl-1,3-dioxaborolan ⁇ 2-yl ⁇ 1 / 3 ⁇ benzothiazol ⁇ 2 ⁇ amine 5 g, 18 mmol
- 3 ⁇ bromo5 ⁇ (methy!suifonyi)pyridine (4.27 g, 18 mmo!
- cesium fluoride 5.5 g, 36.2 mmol
- PdCi 2 PPh 3 J 2 (0.25 g s 0.4 mmol
- Phenyl chloroformate (11.6 g, 74.2 mmol) was added dropwise at 0 0 C to a solution of 6-bromoimidazo[1 ,2-a]pyridin-2-amine(15 g, 70.7 mmol) and 2,4,6-collidine (12.8 g, 106 mmol) in THF (225 ml.) and the reaction mixture was stirred at RT for 12 h then quenched with water. The precipitate was filtered off, washed with water and dried to afford the title compound as an off- white solid.
- LC/MS Alkyl chloroformate
- Step 1) Formation of tert-butyl (5-chloro[1,3]thiazolo[5,4-b]pyridin-2-yl)carbamate 5-Chloro[1 ,3]thiazolo[5,4-b]pyridin-2-amine (1.50 g; 8.08 mmol) was suspended in
- Step 2) Formation of 5-pyridin-3-yl[1 ,3]thiazolo[5,4-b]pyridin-2-amine te/f-Butyl (5-chloro[1 ,3]thiazolo[5,4-jb]pyridin-2-yl)carbamate (2.03 g; 7.10 mmol), 3- (4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridine (1.89 g; 9.24 mmol), PdCI 2 (PPh 3 ) 2 (498 mg; 0.71 mmol), cesium fluoride (2.69 g; 17.76 mmol) were flushed with argon before addition of degassed dioxane (40 mL) and water (20 mL).
- Reaction mixture was heated at 90 0 C during 3 h after which solvents were removed under vacuum. Solid residue was then triturated in water, filtered then in hot ACN and filtered before addition of 4M HCI in dioxane (25 ml_). Reaction mixture was stirred at RT for 4 h and solvent was evaporated under vacuum. Solid was triturated in sat. aq. Na 2 CO 3 followed by filtration to afford the title compound as a beige solid. LC/MS, M+(ESI): 228.8.
- Step 2) Formation oftert-43utyl[6 ⁇ (4,4,5 ! 5 ⁇ tetrameUi ⁇ 1,3 ! 2 ⁇ dhxaboroian ⁇ 2 ⁇ yi) ⁇ 1,3 ⁇ benzothiazoi ⁇ 2 ⁇ yl]carbamate
- Step 3) Formation oftert-butyi ⁇ 6-[5 ⁇ (2 ⁇ methoxyethoxy)pyridin-3-yl] ⁇ 1,3 ⁇ benzothiazol-2 ⁇ yl ⁇ carbamate
- the titie compound was prepared foiiowing procedure of intermediate 101 step 3 starting from tert-butyi ⁇ -[5-(2-methoxyethoxy)pyridin-3-yi]-1 ,3-benzothiazo!-2- yi ⁇ carbamate.
- Step 1) Formation of N-(6-chloropyridazin-3-yl)-4-methylbenzenesulfonamide p-Toluene sulfonyl chloride (91.8 g, 481 mmol) was added portionwise at 0 0 C to a solution of 3-amino-6-chloropyridazine (52 g, 401 mmol) in pyridine (315 ml.) and the reaction mixture was stirred at 90 0 C for 12 h. After concentration in vacuo, the residue was purified by column chromatography (PE/EtOAc, 90/10) to afford the title compound as a white solid. LC/MS (Atlantis), M+(ESI): 283.8.
- Step 3 Formation of N-(6-chloroimidazo[1,2-b]pyridazin-2-yl)-2,2,2-trifluoroacetamide
- Trifluoroacetic anhydride (175.9 g, 1.54 mol) was slowly added to a solution of 2- [(6Z)-3-chloro-6- ⁇ [(4-methylphenyl)sulfonyl]imino ⁇ pyridazin-1 (6/-/)-yl]acetamide (23 g, 67 mmol) in DCM (290 mL) and the reaction mixture was stirred at 50 0 C for 3 h. After concentration in vacuo, the residue was triturated in 10% aq.
- Step 3) Formation of6-(5-methoxypyridin-3-yl)[1,2,4]triazolo[1,5-a]pyridin-2-amine
- Step 1) Formation of tert-butyl ⁇ 6-[5-(trifluoromethyl)pyridin-3-yl]-1 ,3-benzothiazol-2- yljcarbamate
- Step 2) Formation of 6-[5-(trifluoromethyl)pyridin-3-yl]-1,3-benzothiazol-2-amine 4M HCI in dioxane (15 mL) was added to a solution of te/f-butyl ⁇ 6-[5- (trifluoromethyl)pyridin-3-yl]-1 ,3-benzothiazol-2-yl ⁇ carbamate (340 mg; 0.86 mmol) in MeOH (5 mL) and the resulting mixture was stirred at RT for 18 h. Et 2 O was added and the precipitate filtered off to afford the title compound (280 mg, 98%) as a white solid. HPLC, Rt: 2.98 (purity: 99.2%). LC/MS, M-(ESI): 296.0.
- Step 2) Formation of tert-butyl [6-(5-morpholin-4-ylpyridin-3-yl)-1 ,3-benzothiazol-2- yljcarbamate
- Step 3 Formation of 6-(5-morpholin-4-ylpyridin-3-yl)-1 ,3-benzothiazol-2-amine 4M HCI in dioxane (10 mL, 40 mmol) was added dropwise to te/f-butyl [6-(5- morpholin-4-ylpyridin-3-yl)-1 ,3-benzothiazol-2-yl]carbamate (0.61 g; 1.48 mmol) and the resulting mixture was stirred at RT for 10 h. The solution was poured into sat. aq. NaHCO 3 , extracted with DCM, washed with brine, dried over sodium sulfate and concentrated in vacuo.
- Step 1) Formation of (5-bromopyridin-3-yl)methanol Sodium borohydride (0.4 g; 18.5 mmol) was added to a solution of methyl 5- bromonicotinate (2.0 g; 9.26 mmol) in ethanol (50 ml.) and the resulting mixture was stirred at reflux for 20 h. The solution was diluted with EtOAc, washed with water then brine, dried over sodium sulfate and concentrated in vacuo. Purification by column chromatography on alumina (DCM to DCM/EtOAc, 50/50) afforded the title compound (1.5 g, 86%) as a yellow oil.
- 1 H NMR (DMSOd 6 , 300 MHz) ⁇ 8.58 (d, J 2.3 Hz, 1 H),
- Step 2 Formation of (5-bromopyridin-3-yl) methyl pivalate Pivaloyl chloride (0.81 g; 6.73 mmol) was added dropwise to a solution of (5- bromopyridin-3-yl)methanol (1.15 g; 6.12 mmol) in pyridine (5 ml.) and DCM (45 ml.) and the resulting mixture was stirred at RT for 16 h whereupon pivaloyl chloride (0.81 g; 6.73 mmol) was added. The reaction mixture was stirred for a further 24 h then concentrated in vacuo. The residue was taken up in EtOAc washed with sat. aq.
- Step 4) Formation of [5-(2-amino-1 ,3-benzothiazol-6-yl)pyridin-3-yl]methyl pivalate
- TFA (3 ml.) was added to a solution of (5- ⁇ 2-[(te/f-butoxycarbonyl)amino]-1 ,3- benzothiazol-6-yl ⁇ pyridin-3-yl)methyl pivalate (560 mg; 1.27 mmol) in DCM (10 ml.) and the resulting mixture was stirred at RT for 2 h. The solution was diluted with DCM, washed with sat. aq. NaHCO 3 then brine, dried over sodium sulfate and concentrated in vacuo to afford the title compound as a white solid.
- Step 1) Formation of 3-bromo-5-(methoxymethyl)pyridine
- a solution of (5-bromopyridin-3-yl)methanol 2.2 g, 1 1.7 mmol
- THF 20 ml.
- methyl iodide 2.18 ml_, 35.1 mmol
- Step 1) Formation of tert-butyl [6-(1 -methyl-1 H-imidazol-5-yl)-1 ,3-benzothiazol-2- yl] carbarn ate te/f-Butyl [6-(4,4 ! 5,5-tetramethyl-1 ,3,2-clioxaborolari-2-yl)-1 ,3-benzothiazol-2- yl]carbamate (600 mg; 1.59 mmol) and 5-bromo-1 -methyl-1 /-/-imidazole (308 mg;
- Step 2) Formation of 6-(1 -methyl-1 H-imidazol-5-yl)-1 ,3-benzothiazol-2-amine TFA (20 ml.) was added to a solution of te/f-butyl [6-(1 -methyl-1 /-/-imidazol-5-yl)-1 ,3- benzothiazol-2-yl]carbamate (800 mg) in DCM (50 ml.) and the resulting mixture was stirred at RT for 4 h then concentrated in vacuo. Purification by MD Autoprep afforded the title compound as a white solid. HPLC, Rt: 2.99 (purity 100%). LC/MS, M+(ESI):
- Step 2) Formation of tert-butyl ⁇ 6-[5-(methylthio)pyridin-3-yl]-1 ,3-benzothiazol-2- yljcarbamate
- Step 3 Formation of 6-[5-(methylthio)pyridin-3-yl]-1 ,3-benzothiazol-2-amine hydrochloride 4M HCI in dioxane (30 mL, 120 mmol) was added to te/f-butyl ⁇ 6-[5- (methylthio)pyridin-3-yl]-1 ,3-benzothiazol-2-yl ⁇ carbamate (3.0 g, 8.0 mmol) and the resulting mixture was stirred at RT for 2 h then at 70 0 C for 4 h.
- Step 2 Formation of N-(6-pyridin-3-yl-1 ,3-benzothiazol-2-yl)dodecanamide ( ⁇ /-(6-bromo-1 ,3-benzothiazol-2-yl)dodecanamide (4.15 g; 10.10 mmol) and 3- (4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridine (2.28 g; 1 1.10 mmol) were reacted as described for intermediate 101 step 2. After cooling down to RT, the mixture was filtered through a short plug of Celite® and the two phases were separated. The organic layer was washed with water then brine, dried over magnesium sulfate and concentrated in vacuo.
- Step 2 Formation of 3-(azidomethyl)-5-bromopyridine
- a solution of 3-bromo-5-(chloromethyl)pyridine (2 g, 9.6 mmol) in dry DMF (20 ml_)
- NaN 3 2.5 g, 38.7 mmol
- the reaction mixture was stirred under N 2 for 12 h at RT.
- water was added (100 ml.) and extracted with EtOAc (2 x 100 ml_), the combined organic layer was washed with water (3 x 100 ml_), dried over Na 2 SO 4 and concentrated under vacuum to afford the title compound (1.9 g, 94%) as a brown oil which was used directly in the next step.
- Step 4) Formation N-[(5-bromopyridin-3-yl)methyl]acetamide
- TEA 1.67 mL, 12.0 mmol
- acetyl chloride 0.62 mL, 8.8 mmol
- reaction mixture was quenched with ice water and extracted with DCM (2 x 100 mL); the combined organic layer was washed with NaHCO 3 (10% aq., 100 mL), water (100 mL), brine (100 mL), dried over Na 2 SO 4 and concentrated under vacuum.
- the solid was recrystallised from PE:EtOAc (9:1 , 10 mL), filtered and dried under vacuum to afford the title compound as a brown solid.
- Step 1) Formation ofN-[(5-bromopyridin-3-yl)methyl]methanesulfonamide
- TEA 1.67 mL, 1 1.2 mmol
- methanesulfonyl chloride 0.74 mL, 9.6 mmol
- reaction mixture was quenched with ice water and extracted with DCM (2 x 100 ml_); the combined organic layer was washed with NaHCC>3 (10% aq., 100 ml_), water (100 ml_), brine (100 ml_), dried over Na 2 SO 4 and concentrated under vacuum.
- the crude product was purified by silica gel column chromatography (PE/EtOAc) to afford the title compound as a white solid.
- 1 H NMR (DMSOd 6 , 400 MHz) ⁇ 8.62 (d, J 2.0 Hz,
- Step 2 Formation of4-(5-bromopyridin-3-yl)thiomorpholine 1, 1 -dioxide H 2 O 2 (30%, 500 ⁇ l_) was added at 60 0 C to a solution of 4-(5-bromopyridin-3- yl)thiomorpholine (750 mg; 2.89 mmol) in acetic acid (1 mL) and the resulting mixture was stirred at this temperature for a further 2 h. The solution was diluted with EtOAc, washed successively with sat. aq. NaHCO 3 and brine, dried over sodium sulfate and concentrated in vacuo.
- Step 3 Formation of 6-[5-(1 , 1 -dioxidothiomorpholin-4-yl)pyridin-3-yl]-1 ,3- benzothiazol-2-amine 4-(5-Bromopyridin-3-yl)thiomorpholine 1 ,1 -dioxide (400 mg; 1.37 mmol) and tert-butyl [6-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,3-benzothiazol-2-yl]carbamate (569 mg; 1.51 mmol) were reacted as described for Intermediate 107.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to compounds of formula (I) for the regulation of phosphoinositides 3-kinases activity and related diseases.
Description
FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE
The invention relates to novel compounds of formula I and related formulae, their use as medicament and their use for treating autoimmune diseases, inflammatory disorders, multiple sclerosis and other diseases such as cancers.
The invention relates to compounds of formula I:
Wherein denotes either a single bond or a double bond
U denotes CRC, CH, or S;
V denotes C or N
W denotes N or CR1
X denotes CO, SO, SO2, CS or a bond
Y denotes CR2 or N,
Ra denotes NH-Ab, NA2, -NH-(CH2)P-Ab, -NH-(CH2)P-Ar, -NH-(CH2)P-Het4, -NH- (CH2)pCHOR6-Het1, , -NH-(CH2)pCOAr, -NH-(CH2)pCOHet1, -NH-cycloalkyl, COHet1,
CS, also H, or if V denotes C, also Ar or Het1
or if Rb is Ar, Het3, or one of the following groups:
, Ra also denotes A, -(CH2)S-Ar, -(CH2)S-Het1,
Het1, Het4, or perfluoroalkyl, or if RD denotes Ar, Ra is also -OA or cycloalkyl.
R', R" are independently hydrogen, alkyl, Ar, Het1, Het2 or A. R and R , together with the nitrogen atom to which they are attached, can optionally form a 3-8- membered heterocyclic ring.
Rc denotes H, A, alkyl, Ar, Het1,
Ar denotes a monocyclic or bicyclic, aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by, Hal, CF3, OCF3, NO2, CN, perfluoroalkyl, A, OA, OH, NH2, COH,
CONH21-NHCOA, -NHCO2A, -NHCO2(CH2)sHet1, -(CH2)pHet1, -NHSO2A, -NHSO2- N(H)2-m(A)m, N(H)1-qAqC0A, N(H)1-qASO2-N(H)2-m(A)m, N(H)1-qAqC0N(H)2-m(A)m, COOA, COA, -SO2A, -SO2N(H)2-m(A)m, -SO2Het1, -SO2NHHet1, Het1, - NHSO2NHHet1, or cycloalkyl.
Het1 denotes a monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms and/or 1 CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by alkyl having 1 to
8 carbon atoms, alkoxy having 1 to 8 carbon atoms, Hal, CF3, OCF3, NO2, CN, perfluoroalkyl, A, OA, O(CH2)sAr, O(CH2)sHet1, -(CH2)pHet2, OH, amino, CONH2, - NHCOA, -NHCO2A, -NHCO2(CH2)sAr, -NHSO2-N(H)2-m(A)m, COA, COOA, -SO2A, - SO2N(H)2-m(A)m, -SO2Het2, -SO2NHHet2, -NHSO2NHHet2, Ar, -NHSO2NHAr, - SO2NHAr, SO2Ar, cycloalkyl.
Het2 denotes a monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms and/or 1 CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by alkyl having 1 to 8 carbon atoms, alkoxy having 1 to 8 carbon atoms, Hal, CF3, OCF3, NO2, CN, perfluoroalkyl, A, OA, O(CH2)sAr, O(CH2)sHet1, -(CH2)pHet1, OH, NA2, CONH2, - NHCOA, -NHCO2A, , -NHCO2(CH2)sHet1, -NHCO2(CH2)sAr, -NHSO2-N(H)2-m(A)m, COA, COOA, -SO2A, -SO2N(H)2-m(A)m, -SO2Het1, SO2NHHet2, Ar, SO2Ar, or cycloalkyl.
Het3 denotes a monocyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms and/or 1 CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by NO2, CN, perfluoroalkyl, OH, CONH2, -NHCOA, -NHCO2A, -NHCO2(CH2)sHet1, -NHCO2(CH2)sAr, -NHSO2A, - NHSO2-N(H)2-m(A)m, COA, COOA, -COH, -SO2A, -SO2N(H)2-m(A)m, -SO2Het1, SO2NHHet2, or cycloalkyl or Het3 denotes one of the following groups:
Het4 denotes a monocyclic or bicyclic unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms and/or 1 CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by alkyl having 1 to 8 carbon atoms, alkoxy having 1 to 8 carbon atoms, Hal, CF3, OCF3, NO2, CN, perfluoroalkyl, A, OA, O(CH2)sAr, O(CH2)sHet1, -(CH2)pHet2, OH, amino, CONH2, -NHCOA, -NHCO2A, - NHCO2(CH2)sAr, -NHSO2-N(H)2-m(A)m, COA, COOA, -SO2A, -SO2N(H)2-m(A)m, - SO2Het2, -SO2NHHet2, "NHSO2NHHet2, Ar, -NHSO2NHAr, -SO2NHAr, SO2Ar,
m denotes O, 1 or 2;
n denotes 1 , 2 ,3 or 4;
p denotes O, 1 , 2, 3, 4;
q denotes O or 1
s denotes 1 , 2, 3 , 4
A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by Hal, Ar, Het1, Het2, OR6, CN, NHCO, CONR'R" COOR6 or NR R and wherein one or more, preferably 1 to 7 non-adjacent
CH2-groups may be replaced by O, NR6 or S and/or by -CH=CH- or -C≡C- groups, or denotes cycloalkyl, cycloalken or cycloalkylalkylen having 3-7 ring C atoms wherein the cycloalkylen is optionally substituted by 1 or 2 OH groups;
Ab is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by Hal, Ar, OR6, CN, NHCO, CONR'R" COOR6 or NR R and wherein one or more, preferably 1 to 7 non-adjacent CH2- groups may be replaced by O, NR6 or S and/or by -CH=CH- or -C≡C- groups, or denotes cycloalkyl, cycloalken or cycloalkylalkylen having 3-7 ring C atoms wherein the cycloalkylen is optionally substituted by 1 or 2 OH groups;
R1, R2 are each independently H, Hal, CF3, A; Ar Het1 or Het2
R3 is H or Hal
R , R denote each independently H, Ar, Het1, Het2, or A, and if R'or R" is bond to a C atom also OA.
R6 is H, a branched or linear alkyl or hydroxyalkyl having 1 to 12 C-atoms
and pharmaceutically acceptable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.
In a specific embodiment, the present invention provides compounds of Formula (I) wherein Rb is Ar or a pyridine group optionally substituted by the groups listed in the definitions of Het2, preferably, the group represented by Rb, i.e. Ar or pyridine, is optionally substituted with OA, preferably OCH3, or SO2A, preferably SO2CH3; and wherein Ra is -NH-(CH2)P-Het4.
wherein
Ra and R are as defined above.
and pharmaceutically acceptable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.
In a preferred embodiment, the present invention provides compounds of Formula (I-Z)
Wherein G1 is C or N,
G2 is H, OA, preferably OCH3, SO2A, preferably SO2CH3, G3 is a linear or branched alkyl group optionally substituted with 1 to 3 groups selected from OH, OMe, Hal, preferably F, N(CH3)2, G4 is O or S, G5 is N or C, and pharmaceutically acceptable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.
In another preferred embodiment, the present invention provides compounds of Formula (I-Z*)
Wherein G1 is C or N,
G2 is H, OA, preferably OCH3, SO2A, preferably SO2CH3, G6 is H, Hal, preferably F, and pharmaceutically acceptable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.
In a specific embodiment, Ra also denotes A, perfluoroalkyl, -NH-A, -NH(CH2)P-A, (CH2)sAr, -(CH2)sHet1, -NH(CH2)P-Het1, OA, cycloalkyl, Het1-alkyl, when Rb is not Ar or Het3. In another specific embodiment, Ra also denotes CO-Het1 or COOA when X is a bond.
In another specific embodiment, the invention provides compounds of formula I wherein Ra denotes Perfluoroalkyl, A, -NH-A, Het, Rb denotes Ar, Het2;
In another specific embodiment the invention provides compounds of formula I wherein Ra denotes A, -NH-A, wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, N(R6)2, Het1, Het2, or denotes cycloalkyl, Rb denotes Ar, Het2;
In another specific embodiment the invention provides compounds of formula I wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het1, Het2, or denotes cycloalkyl, Rb denotes Ar, Het2 wherein Ar and Het2 may be unsubstituted or substituted by a group selected from (R4)n and/or
(R5)n, wherein R6 is H or Me;
In another specific embodiment the invention provides compounds of formula I wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het1, Het2, or denotes cycloalkyl, Rb denotes Ar, Het2 wherein Ar and Het2 may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H, wherein Ar is phenyl, Het2 is imidazolyl, pyridinyl, wherein n and m are as defined above;
In another specific embodiment the invention provides compounds of formula I wherein Ra denotes Perfluoroalkyl, A, -N-A wherein A is a branched or linear alkyl having 1 to 5 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het1, Het2, or denotes cycloalkyl, Rb denotes Ar, Het2 wherein Ar and Het2 may be unsubstituted or substituted by a group selected from (R4)n and/or
(R5)n, wherein R6 is H, wherein Ar is phenyl, Het2 is imidazolyl, pyridinyl, wherein R4 and/or R5 are selected from OH, OA, -SO2-N (H )2-m(A)m, -SO2-Het1 or NO2,wherein n and m are as defined above;
In another specific embodiment the invention provides compounds of formula I wherein Ra denotes methyl, Rb denotes Ar, Het2 wherein Ar and Het2 may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H, wherein Ar is phenyl, Het2 is imidazolyl, pyridinyl, wherein R4 and/or R5 are selected from OH, OMe, -SO2-NHMe and -SO2-NH-CH2-CH2-OH;
In another specific embodiment, the invention provides compounds of formula l-a wherein Ra denotes Perfluoroalkyl, A, -NHA, Het, Rb denotes Ar, Het2;
In another specific embodiment the invention provides compounds of formula l-a wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het1, Het2, or denotes cycloalkyl, Rb denotes Ar, Het2;
In another specific embodiment the invention provides compounds of formula l-a wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het1, Het2, or denotes cycloalkyl, Rb denotes Ar, Het2 wherein Ar and Het2 may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H or Me;
In another specific embodiment the invention provides compounds of formula l-a wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het1, Het2, or denotes cycloalkyl, Rb denotes Ar, Het2 wherein Ar and Het2 may be unsubstituted or substituted by a group selected from (R4)n and/or
(R5)n, wherein R6 is H, wherein Ar is phenyl, Het2 is imidazolyl, pyridinyl, wherein n and m are as defined above;
In another specific embodiment the invention provides compounds of formula l-a wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 5 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het1, Het2, or denotes cycloalkyl, Rb denotes Ar, Het2 wherein Ar and Het2 may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H, wherein Ar is phenyl, Het2 is imidazolyl, pyridinyl, wherein R4 and/or R5 are selected from OH, OA, -SO2-N(H)2-m(A)m, -SO2-Het1 or NO2,wherein n and m are as defined above;
In another specific embodiment the invention provides compounds of formula l-a wherein Ra denotes methyl, Rb denotes Ar, Het2 wherein Ar and Het2 may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H, wherein Ar is phenyl, Het2 is imidazolyl, pyridinyl, wherein R4 and/or R5 are selected from OH, OMe, -SO2-NHMe and -SO2-NH-CH2-CH2-OH;
In another specific embodiment, the invention provides compounds of formula l-b wherein Ra denotes Perfluoroalkyl, A, -NHA, Het, Rb denotes Ar, Het2;
In another specific embodiment the invention provides compounds of formula l-b wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het1, Het2, or denotes cycloalkyl, Rb denotes Ar, Het2;
In another specific embodiment the invention provides compounds of formula l-b wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het1, Het2, or denotes cycloalkyl, Rb denotes Ar, Het2 wherein Ar and Het2 may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H;
In another specific embodiment the invention provides compounds of formula l-b wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl
having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het1, Het2, or denotes cycloalkyl, Rb denotes Ar, Het2 wherein Ar and Het2 may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H, wherein Ar is phenyl, Het2 is imidazolyl, pyridinyl, wherein n amd m are as defined above;
In another specific embodiment the invention provides compounds of formula l-b wherein Ra denotes Perfluoroalkyl, A, -NH-A, wherein A is a branched or linear alkyl having 1 to 5 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het1, Het2, or denotes cycloalkyl, Rb denotes Ar, Het2 wherein Ar and Het2 may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H, wherein Ar is phenyl, Het2 is imidazolyl, pyridinyl, morpholino, wherein R4 and/or R5 are selected from OH, OA, -Sθ2-N(H)2-m(A)m, - SO2-Het1 or NO2, wherein n and m are as defined above;
In another specific embodiment the invention provides compounds of formula l-b wherein Ra denotes methyl, Rb denotes Ar, Het2 wherein Ar and Het2 may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H, wherein Ar is phenyl, Het2 is imidazolyl, pyridinyl, morpholino, wherein R4 and/or R5 are selected from OH, OMe, -SO2-NHMe and -SO2-NH-CH2-CH2-OH;
In another specific embodiment, the invention provides compounds of formula l-c wherein Ra denotes Perfluoroalkyl, A, -NHA, Het, Rb denotes Ar, Het2;
In another specific embodiment the invention provides compounds of formula l-d wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het1, Het2, or denotes cycloalkyl, Rb denotes Ar, Het2;
In another specific embodiment the invention provides compounds of formula l-c wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het1, Het2, or denotes cycloalkyl, Rb denotes Ar, Het2 wherein Ar and Het2 may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H;
In another specific embodiment the invention provides compounds of formula l-c wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het1, Het2, or denotes cycloalkyl, Rb denotes Ar, Het2 wherein Ar and Het2 may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H, wherein Ar is phenyl, Het2 is imidazolyl, pyridinyl, wherein n and m are as defined above;
In another specific embodiment the invention provides compounds of formula l-c wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 5 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het1, Het2, or denotes cycloalkyl, Rb denotes Ar, Het2 wherein Ar and Het2 may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H, wherein Ar is phenyl, Het2 is imidazolyl, pyridinyl, wherein R4 and/or R5 are selected from OH, OA, -SO2-N (H )2-m(A)m, -SO2-Het1 or NO2,wherein n and m are as defined above;
In another specific embodiment the invention provides compounds of formula l-c wherein Ra denotes methyl, Rb denotes Ar, Het2 wherein Ar and Het2 may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H, wherein Ar is phenyl, Het2 is imidazolyl, pyridinyl, wherein R4 and/or R5 are selected from OH, OMe, -SO2-NHMe and -SO2-NH-CH2-CH2-OH;
In one embodiment, the compounds of formula I and related formulae modulate activity of Phosphoinositide 3-kinases such as Pi3Kα and Pi3Kγ or other isoforms Phosphoinositide 3-kinases (PI3Ks) have a critical signalling role in cell proliferation, cell survival, vascularization, membrane trafficking, glucose transport, neurite outgrowth, membrane ruffling, superoxide production, actin reorganization and chemotaxis (Cantley, 2000, Science, 296, 1655-1657).
The term PI3K is given to a family of lipid kinases which, in mammals, consists in eight identified PI3Ks that are divided into three sub-families according to their structure and their substrate specificity.
Class I group of PI3Ks consists in two sub-groups, Class IA and Class IB.
Class IA are a family of heterodimeric lipid kinases consisting in a 85 kDa regulatory unit (responsible for protein-protein interactions via the interaction of Src homology 2 (SH2) domain with phosphotyrosine residues of other proteins) and a catalytic sub- unit of 110kDa that generate second messenger signals downstream of tyrosine kinases, thereby controlling cell metabolism, growth, proliferation, differentiation, motility and survival. Three catalytic forms (p110a, p110β and p110δ) and five regulatory isoforms (p85α, p85β, p55γ, p55α and p50α) exist for this class.
Class IB are stimulated by G protein αβ sub-units of heterodimeric G proteins. The only characterized member of Class IB is PI3Kγ (p1 10γ catalytic sub-unit complex with a 101 -kDa regulatory protein, p101 ).
Class 1A PI3Ks comprises α, β and δ isoforms, which are approximately of 170 kDa and characterized by the presence of a C-terminal C2 domain.
Class III PI3Ks includes the phosphatidylinositol specific 3-kinases. The evolutionary conserved isoforms p1 10α and β are ubiquitously expressed, while δ and γ are more specifically expressed in the haematopoetic cell system, smooth muscle cells, myocytes and endothelial cells (Vanhaesebroeck et al., 2001 , Annu. Rev. Biochem., 70, 535-602). Their expression might also be regulated in an inducible manner depending on the cellular-, tissue type and stimuli as well as disease context.
PI3Ks are enzymes involved in phospholipid signalling and are activated in response to a variety of extra-cellular signals such as growth factors, mitogens, integrins (cell-cell interactions) hormones, cytokines, viruses and neurotransmitters and also by intra-cellular cross regulation by other signalling molecules (cross-talk, where the original signal can activate some parallel pathways that in a second step transmit signals to PI3Ks by intra-cellular signalling events), such as small GTPases, kinases or phosphatases for example.
Phosphatidylinositol (Ptdlns) is the basic building block for the intracellular inositol lipids in eukaryotic cells, consisting of D-myo-inositol-1 -phosphate (Insi P) linked via its phosphate group to diacylglycerol. The inositol head group of Ptdlns has five free
hydroxy groups and three of these are found to be phosphorylated in cells in different combinations. Ptdlns and its phosphorylated derivatives are collectively referred as inositol phospholipids or phosphoinositides (PIs). Eight Pl species have been documented in eukaryotic cells (Vanhaesebroeck et al., 2001 , above). PIs all reside in membranes and are substrates for kinases, phosphatases and lipases. In vitro, PI3Ks phosphorylate the 3-hydroxyl group of the inositol ring in three different substrates: phosphatidylinositol (Ptdlns), phosphatidylinositol-4-phosphate (PI(4)P) and phosphatidylinositol-4,5-biphosphate (PI(4,5)P2), respectively generating three lipid products, namely phosphatidylinositol 3-monophosphate (PI(3)P), phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2) and phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3 (see Scheme A below).
S ch em e A
The preferred substrate for Class I PI3Ks is PI(4,5)P2. Class Il PIKs have a strong prefererence for Ptdlns as substrate over PI(4)P and PI(4,5)P2 Class III PI3Ks can only use Ptdlns as substrate in vivo and are likely to be responsible for the generation of most PI(3)P in cells (Vanhaesebroeck et al., 2001 , above).
The phosphoinositides intracellular signalling pathway begins with the binding of a signalling molecule (extracellular ligands, stimuli, receptor dimidiation,
transactivation by heterologous receptor (e.g. receptor tyrosine kinase)) to a G- protein linked transmembrane receptor integrated into the plasma membrane resulting in the activation of PI3Ks.
Once activated, PI3Ks convert the membrane phospholipid PI(4,5)P2 into PI(3,4,5)P3 which in turn can be further converted into another 3' phosphorylated form of phosphoinositides by 5'-specific phosphoinositide phosphatases, thus PI3K enzymatic activity results either directly or indirectly in the generation of two 3'- phosphoinositide sub-types that function as second messengers in intra-cellular signal transduction (Toker et al., 2002, Cell MoI. Life Sci. 59(5) 761-79).
The role as second messengers of phosphorylated products of Ptdlns act is involved in a variety of signal transduction pathways, including those essential to cell proliferation, cell differentiation, cell growth, cell size, cell survival, apoptosis, adhesion, cell motility, cell migration, chemotaxis, invasion, cytoskeletal rearrangement, cell shape changes, vesicle trafficking and metabolic pathway (Stein, 2000, MoI. Med. Today 6(9) 347-57). Chemotaxis - the directed movement of cells toward a concentration gradient of chemical attractants, also called chemokines is involved in many important diseases such as inflammation/auto- immunity, neurodegeneration, angiogenesis, invasion/metastasis and wound healing
(Wyman et al., 2000, Immunol Today 21 (6) 260-4 and Gerard et al., 2001 , Nat Immunol. 2(2) 108-15).
PI3-kinase activation, is therefore believed to be involved in a range of cellular responses including cell growth, differentiation, migration and apoptosis (Parker et al., 1995, Current Biology, 5, 577-99; Yao et al., 1995, Science, 267, 2003-05).
PI3Ks appear to be involved in a number of aspects of leukocyte activation. A p85- associated PI3-kinase activity has been shown to physically associate with the cytoplasmic domain of CD28, which is an important co-stimulatory molecule for the activation of T-cells in response to antigen. These effects are linked to increases in the transcription of a number of genes including interleukin-2 (IL-2), an important T cell growth factor (Fraser et al., 1991 , Science, 251 , 313-16). Mutation of CD28 such that it can longer interact with PI3-kinase leads to a failure to initiate IL-2 production, suggesting a critical role for PI3-kinase in T cell activation.
Cellular processes in which PI3Ks play an essential role include suppression of apoptosis, reorganization of the actin skeleton, cardiac myocyte growth, glycogen synthase stimulation by insulin, TNFα-mediated neutrophil priming and superoxide generation, and leukocyte migration and adhesion to endothelial cells.
Recent biochemical studies revealed that, Class I PI3Ks (e.g. Class IB isoform PI3Kγ) are dual-specific kinase enzymes, i.e. they display both lipid kinase activity (phosphorylation of phospho-inositides) as well as protein kinase activity, as they are able to induce the phosphorylation of other protein as substrates, including auto- phosphorylation as intra-molecular regulatory mechanism.
Recently, it has been described that PI3Kγ relays inflammatory signals through various G(i)-coupled receptors (Laffargue et al., 2002, Immunity 16(3) 441-51 ) and its central to mast cell function, stimuli in context of leukocytes, immunology includes cytokines, chemokines, adenosines, antibodies, integrins, aggregation factors, growth factors, viruses or hormones for example (Lawlor et al., 2001 , J. Cell. ScL, 1 14 (Pt 16) 2903-10). It has been described that it exist a resistance to thromboembolism in Pi3Kγ- deficient mice, thromboembolism is a major cause of a variety of pathological processes such as artherosclerosis, occlusion of vascular grafts, or acute restenosis after angioplasty Emilio Hirsch et al.The FASEB journal vol.15 September 2001 2019-2021 ). Also the severity of Secretagogue-lnduced Acute pancreatitis is reduced in Mice lacking PI3Kγ.pancreatic damage and neutrophil infiltration resulted significantly reduced in PI3Kγ"'" compared to wild-type mice. This protective effect was associated with preserved exocrine secretion from isolated pancreatic acini, increased apoptosis of acinar cells, and decreased neutrophil infiltration withinthe pancreatic tissue (Goffi A et al. J Prancreas 2004; 5(5 suppl): 414-415.). It has been also shown that tissue mast cells are key regulators in allergy and inflammation and release histamine upon clustering of their IgE receptors.
Researchers have demonstrated that murine mast cell responses are exacerbated in vitro and in vivo by autocrine signals, and require functional PI3K gamma. Adenosine, acting through the A(3) adenosine receptor, as well as other agonists of G(alpha i)-coupled receptors, transiently increased Ptdlns(3,4,5) P (3) exclusively via PI3Kγ (Wymann MP et al. Biochem Soc Trans. 2003 Feb;31 (Pt 1 ):275-80.).
PI3Kγ KO mice challenged with PLY responded with lung edema and neutrophilic alveolitis, but showed a drop in alveolar macrophages and failed to recruit exudate macrophages when compared with wild-type mice. S. pneumoniae-infected PI3Kγ KO mice and wild-type mice pretreated with the pharmacologic inhibitor of PI3Kγ recruited similar numbers of neutrophils but substantially fewer exudate macrophages into their lungs than control animals. They also displayed a significantly reduced lung pneumococcal clearance and showed an impaired resolution/repair process, leading to progressive pneumococcal pneumonia. PI3Kγ gene deletion or pharmacologic inhibition of PI3Kγ leads to perturbations of critical innate immune responses of the lung to challenge with S. pneumoniae.
These data are of clinical relevance for the treatment of chronic inflammatory diseases where pharmacologic inhibition of PI3Kγ signaling to attenuate effector cell recruitment may have implications for innate immune surveillance of remote organ systems. (Ulrich A. Maus et al. American Journal of Respiratory and Critical Care Medicine VoI 175. pp. 958-966, (2007)).
Also PI3Kγ Gene Knockout Impairs Postischemic Neovascularization and Endothelial Progenitor Cell Functions. Capillarization and arteriogenesis were reduced in PI3Kγ ("Λ) ischemic muscles resulting in delayed reperfusion compared with WT, whereas reparative neovascularization was preserved in PI3Kγ (kDa/kDa). In PI3Kγ ("Λ) muscles, endothelial cell proliferation was reduced, apoptosis was increased, and interstitial space was infiltrated with leukocytes but lacked cKit(+) progenitor cells that in WT muscles typically surrounded arterioles. PI3Kgamma is constitutively expressed by WT EPCs, with expression levels being upregulated by hypoxia. PI3Kgamma(-/-) EPCs showed a defect in proliferation, survival, integration into endothelial networks, and migration toward SDF-1. The dysfunctional phenotype was associated with nuclear constraining of FOXO1 , reduced Akt and eNOS phosphorylation, and decreased nitric oxide (NO) production. Pretreatment with an NO donor corrected the migratory defect of PI3Kγ ("Λ) EPCs. PI3Kγ (kDa/kDa) EPCs showed reduced Akt phosphorylation, but constitutive activation of eNOS and preserved proliferation, survival, and migration consequently PI3Kγ modulates angiogenesis, arteriogenesis, and vasculogenesis by mechanisms independent from its kinase activity (Paolo Madeddu et al. Arterioscler Thromb Vase Biol. 2007 Oct 25).
Two compounds, LY294002 and Wortmannin (cf.hereinafter), have been widely used as PI3-kinase inhibitors. These compounds are non-specific PI3K inhibitors, as they do not distinguish among the four members of Class I PI3-kinases.
IC50 values of Wortmannin against each of the various Class I PI3-kinases are in the range of 1-10 nM and IC5O values for LY294002 against each of these PI3-kinases are about 15-20 μM (Fruman et al., 1998, Ann. Rev. Biochem., 67, 481-507), also 5- 10 mM on CK2 protein kinase and some inhibitory activity on phospholipases. Wortmannin is a fungal metabolite which irreversibly inhibits PI3K activity by binding covalently to the catalytic domain of this enzyme. Inhibition of PI3K activity by Wortmannin eliminates the subsequent cellular response to the extracellular factor (Thelen et al., 1994, Proc. Natl. Acad. Sci. USA, 91 , 4960-64). Experiments with wortmannin, show that PI3K activity in cells of hematopoietic lineage, particularly neutrophils, monocytes, and other types of leukocytes, is involved in many of the non-memory immune response associated with acute and chronic inflammation. Based on studies using Wortmannin, there is evidence that PI3-kinase function is also required for some aspects of leukocyte signalling through G-protein coupled receptors (Thelen et al., 1994, above). Moreover, it has been shown that Wortmannin and LY294002 block neutrophil migration and superoxide release. Some results have indicated that PI3K inhibitors, for example, LY294002, can increase the in vivo antitumor activity of certain cytotoxic agents (e.g. paclitaxel) (Grant, 2003, Current Drugs, 6(10), 946-948).
Recently, PI3K inhibitors in general have been developed: thiazole derivatives (WO 2005/021519; and WO 04/078754), thiazolidine derivatives (WO 2004/007491 and WO 2004/056820) and quinazolinones derivatives (WO 03 /035075) and more recently imidazolopyridine or benzothiazole derivatives (WO2007/095588).
Immunosuppressive agents are further useful in a wide variety of autoimmune and chronic inflammatory diseases, including systemic lupus erythematosus, chronic rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel diseases, biliary cirrhosis, uveitis and other disorders such as Crohn's diseases, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, Graves ophthalmopathy, atopic dermatitis and asthma. They are also useful as part of chemotherapeutic regimens for the treatment of cancers, lymphomas and leukemias.
It has been found that the compounds of the present invention are modulating PI3K inhibitor with improved pharmacological and/ or other properties.
Thus, the present invention preferably comprises compounds which are inhibitors of the PI3K receptor, especially having selectivity for the PI3Kγ receptor. A PI3Kγ receptor selective inhibitor has advantages over current therapies and extends the therapeutic window of lymphocyte sequestration agents, allowing better tolerability with higher dosing and thus improving efficacy.
The inventions further relates to the use of compounds according to formula I in combination with immunomodulating agents for example Fingolimod; cyclosporins, rapamycins or ascomycins, or their immunosuppressive analogs, e.g. cyclosporin A, cyclosporin G, FK-506, ABT-281 , ASM981 , rapamycin, 40-O-(2-hydroxy)ethyl- rapamycin etc.; corticosteroids; cyclophosphamide; azathioprene; methotrexate; leflunomide; mizoribine; mycophenolic add; mycophenolate mofetil; 15- deoxyspergualine; diflucortolone valerate; difluprednate; Alclometasone dipropionate; amcinonide; amsacrine; asparaginase; azathioprine; basiliximab; beclometasone dipropionate; betamethasone; betamethasone acetate; betamethasone dipropionate; betamethasone phosphate sodique; betamethasone valerate; budesonide; captopril; chlormethine chlorhydrate; cladribine; clobetasol propionate; cortisone acetate; cortivazol; cyclophosphamide; cytarabine; daclizumab; dactinomycine; desonide; desoximetasone; dexamethasone; dexamethasone acetate; dexamethasone isonicotinate; dexamethasone metasulfobenzoate sodique; dexamethasone phosphate;dexamethasone tebutate;dichlorisone acetate; doxorubicine chlorhydrate; epirubicine chlorhydrate; fluclorolone acetonide; fludrocortisone acetate; fludroxycortide; flumetasone
pivalate; flunisolide; fluocinolone acetonide; fluocinonide; fluocortolone; fluocortolone hexanoate; fluocortolone pivalate; fluorometholone; fluprednidene acetate; fluticasone propionate; gemcitabine chlorhydrate; halcinonide; hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone hemisuccinate; melphalan; meprednisone; mercaptopurine; methylprednisolone; methylprednisolone acetate; methylprednisolone hemisuccinate; misoprostol; muromonab-cd3; mycophenolate mofetil; paramethasone acetate; prednazoline, prednisolone; prednisolone acetate; prednisolone caproate; prednisolone metasulfobenzoate sodique; prednisolone phosphate sodique; prednisone; prednylidene; rifampicine; rifampicine sodique; tacrolimus; thalidomide; thiotepa; tixocortol pivalate; triamcinolone; triamcinolone acetonide hemisuccinate; triamcinolone benetonide; triamcinolone diacetate; triamcinolone hexacetonide; immunosuppressive monoclonal antibodies, e.g., monoclonal antibodies to leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD40, CD45 or CD58 or their ligands; or other immunomodulatory compounds, e.g.
CTLA41g, or other adhesion molecule inhibitors, e.g. mAbs or low molecular weight inhibitors including Selectin antagonists and VLA-4 antagonists. A preferred composition is with Cyclosporin A, FK506, rapamycin or 40-(2-hydroxy)ethyl- rapamycin and Fingolimod.
The compounds according to formula I and related formulae may be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred experimental conditions (i.e. reaction temperatures, time, stoechiometry of reagents, solvents etc.) are given, other experimental conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by the person skilled in the art, using routine optimisation procedures.
The following abbreviations refer respectively to the definitions below: aq (aqueous), h (hour), g (gram), L (liter), mg (milligram), MHz (Megahertz), μM (micormolar) min. (minute), mm (millimeter), mmol (millimole), mM (millimolar), m.p. (melting point), eq (equivalent), ml. (milliliter), μl_ (microliter), ACN (acetonitrile), BINAP (2,2'-bis(disphenylphosphino)-1 ,1 '-binaphthalene, BOC (tert- butoxy-carbonyl), CBZ (carbobenzoxy), CDCI3 (deuterated chloroform), CD3OD
(deuterated methanol), CH3CN (acetonitrile), c-hex (cyclohexane), DCC (dicyclohexyl carbodiimide), DCM (dichloromethane), DIC (diisopropyl carbodiimide), DIEA (diisopropylethyl-amine), DMF (dimethylformamide), DMSO (dimethylsulfoxide), DMSO-dβ (deuterated dimethylsulfoxide), EDC (1-(3-dimethyl- amino-propyl)-3-ethylcarbodiimide), ESI (Electro-spray ionization), EtOAc (ethyl acetate), Et2O (diethyl ether), EtOH (ethanol), FMOC (fluorenylmethyloxycarbonyl), HATU (dimethylamino-([1 ,2,3]triazolo[4,5-b]pyridin-3-yloxy)-methylene]-dimethyl- ammonium hexafluorophosphate), HPLC (High Performance Liquid Chromatography), i-PrOH (2-propanol), K2CO3 (potassium carbonate), LC (Liquid Chromatography), MeCN (Acetonitrile), MeOH (methanol), MgSO4 (magnesium sulfate), MS (mass spectrometry), MTBE (Methyl tert-butyl ether), Mtr. ( 4-Methoxy- 2, 3, 6-trimethylbenzensulfonyl), MW(microwave), NaHCO3 (sodium bicarbonate), NaBH4 (sodium borohydride), NMM (N-methyl morpholine), NMR (Nuclear Magnetic Resonance), POA (phenoxyacetate), PyBOP (benzotriazole-1-yl-oxy-tris-pyrrolidino- phosphonium hexafluorophosphate), RT (room temperature), Rt (retention time),
SPE (solid phase extraction), TBTU (2-(1-H-benzotriazole-1-yl)-1 , 1 ,3,3- tetramethyluromium tetrafluoro borate), tBu (tert-butyl), TEA (triethylamine), TFA (trifluoroacetic acid), THF (tetrahydrofuran), TLC (Thin Layer Chromatography), UV (Ultraviolet).
In general, the compounds according to formula I and related formulae of this invention may be prepared from readily available starting materials. If such starting materials are not commercially available they may be prepared by standard synthetic techniques. The following general methods and procedures described hereinafter in the examples may be employed to prepare compounds of formula I and related formulae.
In general, the synthesis pathways for any individual compound of formula I and related formulae will depend on the specific substitutents of each molecule and upon the availability of intermediates; again such factors being appreciated by those of ordinary skill in the art. For all the protection and deprotection methods, see Philip J. Kocienski, in "Protecting Groups", Georg Thieme Verlag Stuttgart, New York, 1994 and, Theodora W. Greene and Peter G. M. Wuts in "Protective Groups in Organic Synthesis", Wiley Interscience, 3rd Edition 1999.
Synthesis of compounds of the invention
The compounds according to Formula (I) may be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred experimental conditions (i.e. reaction temperatures, time, stoechiometry of reagents, solvents, etc.) are given, other experimental conditions can also be used unless otherwise stated. Generally, the compounds according to the general Formula (I) may be obtained by several processes using both solution-phase and/or solid-phase chemistry protocols.
Examples of synthetic pathways for the preparation of compounds according to the general Formula (I) will be described. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by the person skilled in the art, using routine optimization procedures.
Above and below, all substituents, such as Ra, Rb, Rc, R1, R2, R3, R6, A, U, V, W, X, Y, Het, Ar, m, p and q have the meaning indicated under the formula I, unless expressly stated otherwise.
Depending on the nature of Ra, Rb, Rc, R1, R2, R3, R6, U, V, W, Y and X, different synthetic strategies may be selected for the synthesis of compounds of Formula (I). In general, the synthesis pathways for any individual compound of Formula (I) will depend on the specific substitutents of each molecule and upon the availability of intermediates; again such factors being appreciated by those of ordinary skill in the art. For all the protection and deprotection methods, see Philip J. Kocienski, in
"Protecting Groups", Georg Thieme Verlag Stuttgart, New York, 1994 and, Theodora W. Greene and Peter G. M. Wuts in "Protective Groups in Organic Synthesis", Wiley Interscience, 3rd Edition 1999.
The compounds according to Formula (I) may be prepared following the synthetic pathways described in the general scheme 1. In the process illustrated in the following scheme L1, L2, L3, L4, L5 are leaving groups. Throughout the specification, the term leaving group preferably denotes Cl, Br, I or a reactively modified OH group. A reactively modified OH group can be for example, an ester, an imidazolide, an aryloxy or alkylsulfonyloxy having 1 to 6 carbon atoms (preferably
methylsulfonyloxy or trifluoromethylsulfonyloxy) or arylsulfonyloxy having 6 to 10 carbon atoms (preferably phenyl- or p tolylsulfonyloxy). When the leaving groups L1 to L5 are linked to X when X is CO, the term leaving group can denote a reactively modified OH group that can be prepared in situ by reaction of the carboxylic acid with peptide coupling reagents such as HATU, EDC, PyBOP, DCC, TBTU, possibly in the presence of HOBt or N-hydroxysuccinimide.
L1 is preferably chloride, bromide, iodide or triflate. L2 is preferably chloride or carboxylate (from anhydride or mixte anhydride). L3 is preferably chloride, bromide, iodide or triflate. L4 is preferably chloride, imidazoyl, trichloromethoxy or para- nitrophenyloxy. L5 is preferably chloride, trichloromethoxy or imidazoyl. In the following R , R denotes independently each other H, Ar, Het, OA or A
Scheme 1
According to a preferred synthetic pathway, compounds of Formula (I), may be prepared from the corresponding derivatives of Formula (II), by a cross-coupling reaction such as a Suzuki type cross-coupling reaction. Preferred conditions consist
in the treatment of compounds of Formula (II) with a boronic acid or ester of Formula (RO)2B-Rb wherein R is a branched or linear alkyl having 1 to 12 C-atoms and Rb is as defined above, in presence of a base such as cesium fluoride and a catalyst such as PdCl2(PPh3)2 in a suitable solvent such as a mixture of dioxane and water at temperature between about 800C and about 1000C.
Compounds of Formula (II) wherein, X is a carbonyl group and Ra is as above defined (with the exception of Ra is NHR6, for which one of the pathway described in the next paragraph is generally preferred), may be prepared by a coupling reaction between the corresponding derivatives of Formula (III) with L2-X-Ra wherein X is a carbonyl group, and Ra is a group linked to X by a carbon atom. Preferred conditions consist in the treatment of compounds of Formula (III) with an acyl chloride or an acyl anhydride in the presence of a base such as pyridine as solvent, with or without an additional suitable solvent such as DCM at temperature between about 0° to about 600C.
Compounds of Formula (II) wherein X is a carbonyl group and Ra is an amino group NR R may be prepared from compounds of Formula (V) wherein X is a carbonyl group, by treatment with an amine of Formula HNR R . Compounds of Formula (V) wherein X is a carbonyl group may be prepared from compounds of Formula (III) by treatment with reagents of Formula L5-X-L4 wherein L4 and L5 are as defined above.
An alternative pathway for the synthesis of compounds of Formula (I) from compounds of Formula (II) consists in the preparation of boronic acid derivatives of Formula (IV) wherein R2, R3 are hydrogen or alkyl groups. Preferred conditions consist in the treatment of compounds of Formula (II) with bis(pinacolato)diboron in presence of a base such as potassium acetate and a catalyst such as 1 ,1'- bis(diphenylphosphino)ferrocenedichloro palladium(ll) in a suitable solvent such as DMSO at temperature between around 80°C to around 100°C. A second step consists of the transformation of compounds of Formula (IV) in compounds of
Formula (I) by a Suzuki type cross coupling reaction with derivatives of Formula L3- Rb wherein L3 and Rb are as defined above. Preferred conditions consist in the treatment of compounds of Formula (IV) with an aryl or heteroaryl bromide of Formula Br-Rb in presence of a base such as cesium fluoride and a catalyst such as
PdCI2(PPh3)2 in a suitable solvent such as a mixture of dioxane and water at temperature between around 800C and around 1000C.
An alternative pathway for the synthesis of compounds of Formula (I) from compounds of Formula (III) consists to start with a cross-coupling reaction to give compounds of Formula (l-l). Preferred conditions consist in the treatment of compounds of Formula (III) with a boronic acid or ester of Formula (RO)2B-Rb wherein R is a branched or linear alkyl having 1 to 12 C-atoms and Rb is as defined above, in presence of a base such as cesium fluoride and a catalyst such as PdCI2(PPh3)2 in a suitable solvent such as a mixture of dioxane and water at temperature between around 800C and around 1000C. A second step consists in the transformation of compounds of Formula (l-l) in compounds of Formula (I) wherein, X is a carbonyl group and Ra is as above defined (with the exception of Ra is NR R , for which one the pathway described in the next paragraph is generally preferred), by treatment with a reagent of Formula L2-X-Ra wherein L2 is as above defined.
Preferred conditions consist in the treatment of compounds of Formula (l-l) with an acyl chloride in the presence of a base such as pyridine, with or without an additional suitable solvent such as DCM at temperature between around 0° to around 60°C.
Compounds of Formula (I) wherein X is a carbonyl group and Ra is an amino group NR R may be prepared from compounds of Formula (Vl) wherein X is a carbonyl group and L4 is as above defined, by treatment with an amine of Formula HNR R . Preferred conditions consist in the treatment of compounds of Formula (Vl) with an amine of Formula HNR R in a suitable solvent such as DMF at temperature between RT and around 100°C, in the presence of an additional base such as Et3N in case of salified amine of Formula HNR R ". Compounds of Formula (Vl) wherein X is a carbonyl group may be prepared from compounds of Formula (l-l) wherein by treatment with reagents of Formula L5-X-L4 wherein L4 and L5 are as above defined. Preferred conditions consist in the treatment of compounds of Formula (l-l) with 1 ,1 '- carbonyldiimidazole in a suitable solvent such as ACN at temperature between RT to around 60°C.
Compounds of Formula (III) and reagents of Formulae (RO)2B-Rb, L2-X-Ra, L3-Rb, L5-X-L4 and HNR R may be obtained either from commercial sources or they may
be prepared from known compounds using procedures such as those described hereinafter in the examples, or conventional procedures, well known by one skilled in the art.
Compounds of Formulae (I), (II), (III) and (Vl) may be converted to alternative compounds of Formulae (I), (II), (III) and (Vl) respectively, using suitable interconversion procedures such as those described hereinafter in the examples, or conventional interconversion procedures, well known by one skilled in the art.
If the above set of general synthetic methods is not applicable to obtain compounds according to Formula (I) and/or necessary intermediates for the synthesis of compounds of Formula (I), suitable methods of preparation known by a person skilled in the art should be used.
Compounds of this invention can be isolated in association with solvent molecules by crystallization from an appropriate solvent or by evaporation of an appropriate solvent.
The pharmaceutically acceptable anionic salts of the compounds of Formula (I), which contain a basic center, may be prepared in a conventional manner. For example, a solution of the free base may be treated with a suitable acid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent.
The pharmaceutically acceptable cationic salts of the compounds of Formula (I), which contain an acidic center, may be prepared in a conventional manner. For example, a solution of the free acid may be treated with a suitable base, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent. In some cases, salts can be prepared by mixing a solution of the acid with a solution of an alkali or earth alkali salt (such as sodium ethylhexanoate, magnesium oleate), employing a solvent in which the desired alkali or earth alkali salt of the compounds of formula (I) precipitates, or can be otherwise isolated by concentration and addition of a non- solvent.
Both types of salts may be formed or interconverted using ion-exchange resin techniques.
Depending on the conditions used, the reaction times are generally between a few minutes and 14 days. The reaction temperature is between about -300C and about
1400C, normally between -10°C and 900C, in particular between about 0°C and 70°C.
Compounds of the formula I and related formulae can furthermore be obtained by liberating compounds of the formula I from one of their functional derivatives by treatment with a solvolysing or hydrogenolysing agent.
Preferred starting materials for the solvolysis or hydrogenolysis are those which conform to the formula I and related formulae, but contain corresponding protected amino and/or hydroxyl groups instead of one or more free amino and/or hydroxyl groups, preferably those which carry an amino-protecting group instead of an H atom bonded to an N atom, in particular those which carry an R*-N group, in which R* denotes an amino-protecting group, instead of an HN group, and/or those which carry a hydroxyl-protecting group instead of the H atom of a hydroxyl group, for example those which conform to the formula I, but carry a -COOR** group, in which
R** denotes a hydroxyl-protecting group, instead of a -COOH group.
It is also possible for a plurality of - identical or different - protected amino and/or hydroxyl groups to be present in the molecule of the starting material. If the protecting groups present are different from one another, they can in many cases be cleaved off selectively.
The term "amino-protecting group" is known in general terms and relates to groups which are suitable for protecting (blocking) an amino group against chemical reactions, but which are easy to remove after the desired chemical reaction has been carried out elsewhere in the molecule. Typical of such groups are, in particular, unsubstituted or substituted acyl, aryl, aralkoxymethyl or aralkyl groups. Since the amino-protecting groups are removed after the desired reaction (or reaction sequence), their type and size are furthermore not crucial; however, preference is given to those having 1-20, in particular 1-8, carbon atoms. The term "acyl group" is
to be understood in the broadest sense in connection with the present process. It includes acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids, and, in particular, alkoxycarbonyl, aryloxycarbonyl and especially aralkoxycarbonyl groups. Examples of such acyl groups are alkanoyl, such as acetyl, propionyl and butyryl; aralkanoyl, such as phenylacetyl; aroyl, such as benzoyl and tolyl; aryloxyalkanoyl, such as POA; alkoxycarbonyl, such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC (tert-butoxy- carbonyl) and 2-iodoethoxycarbonyl; aralkoxycarbonyl, such as CBZ ("carbobenz- oxy"), 4-methoxybenzyloxycarbonyl and FMOC; and arylsulfonyl, such as Mtr. Preferred amino-protecting groups are BOC and Mtr, furthermore CBZ, Fmoc, benzyl and acetyl.
The term "hydroxyl-protecting group" is likewise known in general terms and relates to groups which are suitable for protecting a hydroxyl group against chemical reactions, but are easy to remove after the desired chemical reaction has been carried out elsewhere in the molecule. Typical of such groups are the above- mentioned unsubstituted or substituted aryl, aralkyl or acyl groups, furthermore also alkyl groups. The nature and size of the hydroxyl-protecting groups are not crucial since they are removed again after the desired chemical reaction or reaction sequence; preference is given to groups having 1-20, in particular 1-10, carbon atoms. Examples of hydroxyl-protecting groups are, inter alia, benzyl, 4- methoxybenzyl, p-nitrobenzoyl, p-toluenesulfonyl, tert-butyl and acetyl, where benzyl and tert-butyl are particularly preferred.
The compounds of the formula I and related formulae are liberated from their functional derivatives - depending on the protecting group used - for example strong inorganic acids, such as hydrochloric acid, perchloric acid or sulfuric acid, strong organic carboxylic acids, such as trichloroacetic acid, TFA or sulfonic acids, such as benzene- or p-toluenesulfonic acid. The presence of an additional inert solvent is possible, but is not always necessary. Suitable inert solvents are preferably organic, for example carboxylic acids, such as acetic acid, ethers, such as tetrahydrofuran or dioxane, amides, such as DMF, halogenated hydrocarbons, such as dichloromethane, furthermore also alcohols, such as methanol, ethanol or isopropanol, and water. Mixtures of the above-mentioned solvents are furthermore suitable. TFA is preferably used in excess without addition of a further solvent, and
perchloric acid is preferably used in the form of a mixture of acetic acid and 70% perchloric acid in the ratio 9:1. The reaction temperatures for the cleavage are advantageously between about 0 and about 500C, preferably between 15 and 300C (room temperature).
The BOC, OtBut and Mtr groups can, for example, preferably be cleaved off using TFA in dichloromethane or using approximately 3 to 5N HCI in dioxane at 15-30°C, and the FMOC group can be cleaved off using an approximately 5 to 50% solution of dimethylamine, diethylamine or piperidine in DMF at 15-300C.
Protecting groups which can be removed hydrogenolytically (for example CBZ, benzyl or the liberation of the amidino group from the oxadiazole derivative thereof) can be cleaved off, for example, by treatment with hydrogen in the presence of a catalyst (for example a noble-metal catalyst, such as palladium, advantageously on a support, such as carbon). Suitable solvents here are those indicated above, in particular, for example, alcohols, such as methanol or ethanol, or amides, such as DMF. The hydrogenolysis is generally carried out at temperatures between about 0 and 100°C and pressures between about 1 and 200 bar, preferably at 20-30°C and 1-10 bar. Hydrogenolysis of the CBZ group succeeds well, for example, on 5 to 10% Pd/C in methanol or using ammonium formate (instead of hydrogen) on Pd/C in methanol/DMF at 20-300C.
Examples of suitable inert solvents are hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1 ,2-dichloroethane, tetrachloromethane, trifluoromethylbenzene, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n- propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether or ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide, N-methylpyrrolidone (NMP) or dimethylformamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids, such as formic acid or acetic acid; nitro compounds, such as nitromethane or nitrobenzene; esters, such as ethyl acetate, or mixtures of the said solvents.
Esters can be hydrolysed, for example, using HCI, H2SO4, or using LiOH, NaOH or KOH in water, water/THF, water/THF/ethanol or water/dioxane, at temperatures between 0 and 1000C.
Free amino groups can furthermore be acylated in a conventional manner using an acyl chloride or anhydride or alkylated using an unsubstituted or substituted alkyl halide, advantageously in an inert solvent, such as dichloromethane or THF and/or in the presence of a base, such as triethylamine or pyridine, at temperatures between -600C and +30°C.
The formula I and related formulae also encompasses the optically active forms (stereoisomers), the enantiomers, the racemates, the diastereomers and the hydrates and solvates of these compounds. The term "solvates of the compounds" is taken to mean adductions of inert solvent molecules onto the compounds which form owing to their mutual attractive force. Solvates are, for example, mono- or dihydrates or alcoholates.
The term "pharmaceutically usable derivatives" is taken to mean, for example, the salts of the compounds of the formula I and so-called prodrug compounds. The term "prodrug derivatives" is taken to mean compounds of the formula I which have been modified with, for example, alkyl or acyl groups, sugars or oligopeptides and which are rapidly cleaved in the organism to form the active compounds. Preferably "prodrug", as of the compounds of formula I, refers to derivative compounds that are rapidly transformed in vivo to yield the parent compound of the formula I, as for example by hydrolysis in blood. T. Higuchi and V. Stella provide a thorough discussion of the prodrug concept in "Pro-drugs as Novel Delivery Systems", VoI 14 of the A.C.S. Symposium Series, American Chemical Society (1975). Examples of esters useful as prodrugs for compounds containing carboxyl groups can be found on pages 14-21 of "Bioreversible Carriers in Drug Design: Theory and Application", edited by E. B. Roche, Pergamon Press: New York (1987). It is intended that these references, and any others cited throughout this specification, are incorporated herein by reference.
These also include biodegradable polymer derivatives of the compounds according to the invention, as described, for example, in Int. J. Pharm. 1 15, 61-67 (1995). As an example, compound 383 may be considered as a prodrug of the compound 133:
The formula I and related formulae also encompasses mixtures of the compounds of the formula I, for example mixtures of two diastereomers, for example in the ratio 1 :1 , 1 :2, 1 :3, 1 :4, 1 :5, 1 :10, 1 :100 or 1 :1000. These are particularly preferably mixtures of stereoisomeric compounds.
Very particularly, compounds of formula I are the more preferred, the more preferred substiutents they carry.
U preferably denotes CRC or S
V preferably denotes C;
W preferably denotes N or CH
Y preferably denotes CR2
X preferably denote CO,
R2 and R3 are preferably simultaneously H. R3 is preferably H or F, more preferably
H.
Ra preferably denotes Alkyl, Ar or Het1, and more preferably one of the following groups: H, methyl, ethyl, CF3, NH2, COOEt, (CH2)2CO2Et, (CH2)3CO2Et, (CH2)2NHC02tBu , NH(CH2)2CO2Et, NH(CH2)3CO2Et, NH(CH2)2NHCOMe,
NH(CH2)CONMe2, NH(CH2)2COOtBu, NH(CH2)2CO2Me, NH(CH2)3OtBu,
NH(CH2)2NHCOMe, NH(CH2)2NHCθ2tBu, N((CH2)2θH)2!
More preferably, Ra denotes a group -N(H)(CH2)pHet1 wherein p and Het1 are as defined above. Most preferably Ra is one of the following groups:
Rb preferably denotes Ar or Het, especially substituted or unsubstituted pyridine. Rb more particularly denotes a group of the following formula:
Wherein Rx and Ry are each independantly H, Ci-C8 Alkyl, C1-C8 hydroxyalkyl, Het. Rx and Ry, together with the nitrogen atom to which they are attached, can optionally form a 3-8-membered Het ring. More preferably Rb denotes one of the following groups.
Most preferably, Rb denotes one of the following group:
Wherein Rq denotes A, Het, preferably -CH3, -CH2CH3.
Rc preferably denotes one of the following group:
A very preferably denotes alkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms.
Alkyl preferably denotes methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1 ,1-, 1 ,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1 ,1-, 1 ,2-, 1 ,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2- methylpropyl, 1 ,1 ,2- or 1 ,2,2-trimethylpropyl, furthermore preferably, for example, trifluoromethyl, pentafluoroethyl or 1 ,1 ,1 -trifluoroethyl.
Cycloalkyl groups are cyclic alkyl containing 3 to 12 carbon atoms. Cycloalkyl can optionally be substituted with one or more groups R1, COOR6 or OR6, wherein R1 and
R6 are as defined above.
Cycloalkyl preferably denotes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
Cycloalkylalkylene preferably denotes cyclopropylmethylene, cyclobutylmethylene, cyclopentylmethylene, cyclohexylmethylene or cycloheptylmethylene.
Alkylene is preferably methylene, ethylene, propylene, butylene, pentylene or hexylene, furthermore branched alkylene.
Perfluoroalkyl preferably denotes CF3.
Hal denotes Cl, Br, I, F and preferably F, Cl or Br.
Alkoxy is branched or linear and preferably denotes a group -O-(CH2)n-CH3. Most preferably alkoxy is Methoxy or Ethoxy.
Carboxy denotes a group -COOH.
Carboxyalkyl denotes an ester group, preferably an alkyl ester, such as COOMe or COOEt.
Sulfonyl denotes a group -SO2-
Alkylsulfonyl denotes a group -Sθ2-alkyl, preferably Methylsulfonyl or Ethylsulfonyl.
Acyl denotes a group -C(O)R, wherein R can be A, Ar, Het as defined above.
Preferably Acyl denotes acetyl (-C(O)CH3).
Amino denotes the group -NR'R"where each R', R" is independently hydrogen, alkyl, Ar, Het or A. R and R", together with the nitrogen atom to which they are attached, can optionally form a 3-8-membered Het ring.
Amido refers to the group -C(O)NR1R" where each R', R" is independently hydrogen, a branched or linear alkyl having 1 to 12 C-atoms, Ar, Het or A, and where R and R", together with the nitrogen atom to which they are attached, can optionally form a 3-8- membered Het ring.
Ar denotes a monocyclic or bicyclic, aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by alkyl having 1 to 8 carbon atoms, alkoxy having 1 to 8 carbon atoms, Hal, CF3, OCF3, NO2, CN, perfluoroalkyl, A, OA, OH, amino, CONH2,-NHCOA, -NHSO2-N(H)2-m(A)m, COOA, -SO2A, -SO2N(H)2-m(A)m, -SO2HeI
More particulary, Ar is one of the following groups:
wherein R4, R5 denote independently each other Ar, Het, OA or A. R4 preferably denotes OA, -SO2NHA, -SO2N(A)2, Or -SO2-A and R5 is preferably OH, Cl or CF3.
Most preferably, Ar is unsubtituted or
Het, Het1 and Het2 are preferably a 6 to 14 membered ring system and denotes, not withstanding further substitutions, for example, 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1 ,2,3-triazol-1-, -4- or -5-yl, 1 ,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1 , 2, 3-oxadiazol-4- or -5-yl, 1 , 2, 4-oxadiazol-3- or -5-yl, 1 ,3,4- thiadiazol-2- or -5-yl, 1 ,2,4-thiadiazol-3- or -5-yl, 1 ,2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, indazolyl, 4- or 5-isoindolyl,
1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7- benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-,
A-, 5-, 6- or 7-benzisothiazolyl, A-, 5-, 6- or 7-benz-2,1 ,3-oxadiazolyl, 2-, 3-, A-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, A-, 5-, 6-, 7- or 8-isoquinolyl, 3-, A-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1 ,A- oxazinyl, furthermore preferably 1 ,3-benzodioxol-5-yl, 1 ,4-benzodioxane-6-yl, 2,1 ,3- benzothiadiazol-4- or -5-yl or 2,1 ,3-benzoxadiazol-5-yl.
The heterocyclic radicals may also be partially or fully hydrogenated. Het can thus also denote, for example, 2,3-dihydro-2-, -3-, -A- or -5-furyl, 2,5-dihydro- 2-, -3-, -A- or -5-furyl, tetrahydro-2- or -3-furyl, 1 ,3-dioxolan-4-yl, tetrahydro-2- or -3- thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -A- or -5- pyrrolyl, 1 -, 2- or 3-pyrrolidinyl, tetrahydro-1 -, -2- or -4-imidazolyl, 2,3-dihydro-1 -, -2-,
-3-, -A- or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1 ,4-dihydro-1-, -2-, -3- or -4- pyridyl, 1 ,2,3,4-tetrahydro-1-, -2-, -3-, -A-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, tetrahydro-2-, -3- or -4-pyranyl, 1 ,4-dioxaneyl, 1 ,3-dioxane-2-, -A- or -5-yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -A- or -5-pyrimidinyl, 1-, 2- or 3-piperazinyl, 1 ,2,3,4-tetrahydro-1-, -2-, -3-, -A-, -5-, -6-, -7- or -8-quinolyl,
1 ,2,3,4-tetrahydro-1-, -2-, -3-, -A-, -5-, -6-, -7- or -8-isoquinolyl, 2-, 3-, 5-, 6-, 7- or 8-3,4-dihydro-2H-benzo-1 ,4-oxazinyl, furthermore preferably 2,3- methylenedioxyphenyl, 3,4-methylenedioxyphenyl, 2,3-ethylenedioxyphenyl, 3,4- ethylenedioxyphenyl, 3,4-(difluoromethylenedioxy)phenyl, 2,3-dihydrobenzofuran-5- or -6-yl, 2,3-(2-oxomethylenedioxy)phenyl or also 3,4-dihydro-2H-1 ,5-benzodioxepin-
6- or -7-yl, furthermore preferably 2,3-dihydrobenzofuranyl or 2,3-dihydro-2-oxo- furanyl. Very preferably, Het is substituted or unsubstituted 2-pyridyl.
Het, Het1 and Het2 very particularly denote one of the following groups:
Wherein R4 and R5 denote independently from each other Ar, Het, OA or A. R4 preferably denotes OA, -SO2NHA, -SO2N(A)2, NHSO2A, Or -SO2-A and R5 is preferably OH, Cl or CF3.
In another embodiment, the invention provides compounds of Formula (I')
Wherein denotes either a single bond or a double bond
U* denotes CRC*, CH, or S;
V* denotes C or N
W* denotes N or CR1*
Ra* denotes perfluoroalkyl, A, NH-A, -NH-(CH2)P-A, Ar, Het, Het-alkyl,or if X denotes a bond, also CO-Het, CO-N(H)2-m(A)m, COOA, CO, CS, or if X denotes CO, SO, SO2, CS, also H
Rb* denotes Ar*, Het
Rc* denotes H, alkyl, Ar, Het
Ar* denotes a monocyclic or bicyclic, aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by, Hal, CF3, OCF3, NO2, CN, perfluoroalkyl, A, OA, OH, NH2, COH, CONH2,-NHCOA, -NHSO2A, -
NHSO2-N(H)2-m(A)m, N(H)1-qAqCOA, N(H)1-qASO2-N(H)2-m(A)m, N(H)1- qAqCON(H)2-m(A)m, COOA, -SO2A, -SO2N(H)2-m(A)m, -SO2Het
X* denotes CO, SO, SO2, CS or a bond
Het denotes a monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms which is unsubstituted or monosubstituted, disubstituted or thsubstituted by alkyl having 1 to 8 carbon atoms, alkoxy having 1 to 8 carbon atoms, Hal, CF3, OCF3, NO2, CN, perfluoroalkyl, A, OA, OH, amino, CONH2, - NHCOA, -NHSO2-N(H)2-m(A)m, COOA, -SO2A, -SO2N(H)2-m(A)m, - SO2Het
m* denotes O, 1 or 2;
p* denotes O, 1 , 2, 3, 4;
q* denotes O or 1
A* is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by Hal, Ar, Het, OR6, CN, CONR'R" COOR6 or NR R" and wherein one or more, preferably 1 to 7 non- adjacent CH2-groups may be replaced by O, NR6 or S and/or by -CH=CH- or C≡C- groups, or denotes cycloalkyl or cycloalkylalkylen having 3-7 ring C atoms;
R1*, R2* are each independently H, Hal, CF3, A*; Ar* or Het
RJ is H or Hal
R , R denote each independently H, Ar*, Het, or A*, and if R'*or R"* is bond to a C atom also OA*.
R6* is H, a branched or linear alkyl or hydroxyalkyl having 1 to 12 C-atoms
and pharmaceutically acceptable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.
In another preferred embodiment, W* denotes CR1*.
In another specific embodiment, the invention provides compounds of formula I' wherein Ra* denotes Perfluoroalkyl, A*, -NH-A*, Het, Rb* denotes Ar*, Het;
In another specific embodiment the invention provides compounds of formula I' wherein Ra* denotes A*, -NH-A*, wherein A* is a branched or linear alkyl having 1 to
12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6*, N(R6*)2, Het, or denotes cycloalkyl, Rb* denotes Ar*, Het;
In another specific embodiment the invention provides compounds of formula I' wherein Ra* denotes Perfluoroalkyl, A*, -NH-A* wherein A* is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6*, Het, or denotes cycloalkyl, Rb* denotes Ar*, Het wherein Ar* and Het may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6* is H or Me;
In another specific embodiment the invention provides compounds of formula I' wherein Ra* denotes Perfluoroalkyl, A*, -NH-A* wherein A* is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6*, Het, or denotes cycloalkyl, Rb* denotes Ar*, Het wherein Ar* and Het may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6* is H, wherein Ar* is phenyl, Het is imidazolyl, pyridinyl, morpholino,wherein n and m are as defined above;
In another specific embodiment the invention provides compounds of formula I' wherein Ra* denotes Perfluoroalkyl, A*, -N-A* wherein A* is a branched or linear alkyl having 1 to 5 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6*, Het, or denotes cycloalkyl, Rb* denotes Ar*, Het wherein Ar* and Het may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6* is H, wherein Ar* is phenyl, Het is imidazolyl, pyridinyl, morpholino,
wherein R4 and/or R5 are selected from OH, OA*, -SO2-N (H )2-m(A)m, -SO2-Het or NO2,wherein n and m are as defined above;
In another specific embodiment the invention provides compounds of formula I' wherein Ra* denotes methyl, Rb* denotes Ar*, Het wherein Ar* and Het may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H, wherein Ar* is phenyl, Het is imidazolyl, pyridinyl, morpholino, wherein R4 and/ R5 are selected from OH, OMe, -SO2-NHMe and -SO2-NH-CH2-CH2-OH;
In another specific embodiment, the invention provides compounds of formula l-a wherein Ra denotes Perfluoroalkyl, A, -NHA, Het, Rb denotes Ar, Het;
In another specific embodiment the invention provides compounds of formula l-a wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het, or denotes cycloalkyl, Rb denotes Ar, Het;
In another specific embodiment the invention provides compounds of formula l-a wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het, or denotes cycloalkyl, Rb denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H or Me;
In another specific embodiment the invention provides compounds of formula l-a wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het, or denotes cycloalkyl, Rb denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H, wherein Ar is phenyl, Het is imidazolyl, pyridinyl, morpholino,wherein n and m are as defined above;
In another specific embodiment the invention provides compounds of formula l-a wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 5 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be
replaced by OR6, Het, or denotes cycloalkyl, Rb denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H, wherein Ar is phenyl, Het is imidazolyl, pyridinyl, morpholino, wherein R4 and/or R5 are selected from OH, OA, -SO2-N(H)2-m(A)m, -SO2-Het or NO2,wherein n and m are as defined above;
In another specific embodiment the invention provides compounds of formula l-a wherein Ra denotes methyl, Rb denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H, wherein Ar is phenyl, Het is imidazolyl, pyridinyl, morpholino, wherein R4 and/or R5 are selected from OH, OMe, -SO2-NHMe and -SO2-NH-CH2-CH2-OH;
In another specific embodiment, the invention provides compounds of formula l-b wherein Ra denotes Perfluoroalkyl, A, -NHA, Het, Rb denotes Ar, Het;
In another specific embodiment the invention provides compounds of formula l-b wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het, or denotes cycloalkyl, Rb denotes Ar, Het;
In another specific embodiment the invention provides compounds of formula l-b wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het, or denotes cycloalkyl, Rb denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H;
In another specific embodiment the invention provides compounds of formula l-b wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het, or denotes cycloalkyl, Rb denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H, wherein Ar is phenyl, Het is imidazolyl, pyridinyl, morpholino,wherein n amd m are as defined above;
In another specific embodiment the invention provides compounds of formula l-b wherein Ra denotes Perfluoroalkyl, A, -NH-A, wherein A is a branched or linear alkyl having 1 to 5 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het, or denotes cycloalkyl, Rb denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H, wherein Ar is phenyl, Het is imidazolyl, pyridinyl, morpholino, wherein R4 and/or R5 are selected from OH, OA, -SO2-N (H )2-m(A)m, -SO2-Het or NO2,wherein n and m are as defined above;
In another specific embodiment the invention provides compounds of formula l-b wherein Ra denotes methyl, Rb denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H, wherein Ar is phenyl, Het is imidazolyl, pyridinyl, morpholino, wherein R4 and/or R5 are selected from OH, OMe, -SO2-NHMe and -SO2-NH-CH2-CH2-OH;
In another specific embodiment, the invention provides compounds of formula l-c wherein Ra denotes Perfluoroalkyl, A, -NHA, Het, Rb denotes Ar, Het;
In another specific embodiment the invention provides compounds of formula l-d wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het, or denotes cycloalkyl, Rb denotes Ar, Het;
In another specific embodiment the invention provides compounds of formula l-c wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het, or denotes cycloalkyl, Rb denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H;
In another specific embodiment the invention provides compounds of formula l-c wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het, or denotes cycloalkyl, Rb denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n,
wherein R6 is H, wherein Ar is phenyl, Het is imidazolyl, pyridinyl, morpholino,wherein n amd m are as defined above;
In another specific embodiment the invention provides compounds of formula l-c wherein Ra denotes Perfluoroalkyl, A, -NH-A wherein A is a branched or linear alkyl having 1 to 5 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR6, Het, or denotes cycloalkyl, Rb denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H, wherein Ar is phenyl, Het is imidazolyl, pyridinyl, morpholino, wherein R4 and/or R5 are selected from OH, OA, -SO2-N (H )2-m(A)m, -SO2-Het or NO2,wherein n amd m are as defined above;
In another specific embodiment the invention provides compounds of formula l-c wherein Ra denotes methyl, Rb denotes Ar, Het wherein Ar and Het may be unsubstituted or substituted by a group selected from (R4)n and/or (R5)n, wherein R6 is H, wherein Ar is phenyl, Het is imidazolyl, pyridinyl, morpholino, wherein R4 and/or R5 are selected from OH, OMe, -SO2-NHMe and -SO2-NH-CH2-CH2-OH;
Compounds wherein V and W are both not simultaneously N are prefered. Further prefered compounds of Formula I are those wherein Rb does not denotes 4-amino-3- pyridinyl group. Further prefered compounds of formula I are those wherein Ra does not denotes Chloroalkyles such as CH2CI. Compounds where X denotes a bond and Ra is H are not prefered.
Preference is given to the compounds of the present invention selected from the following formulae 1 to 395:
and pharmaceutically acceptable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.
The compounds of the formula I and related formulae and also the starting materials for the preparation thereof are, in addition, prepared by methods known per se, as described in the literature (for example in the standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme- Verlag, Stuttgart), under reaction conditions which are known and suitable for the said reactions. For all the protection and deprotection methods, see Philip J. Kocienski, in "Protecting Groups", Georg Thieme Verlag Stuttgart, New York, 1994 and, Theodora W. Greene and Peter G. M. Wuts in "Protective Groups in Organic Synthesis", Wiley Interscience, 3rd Edition 1999.
Use can also be made here of variants which are known per se, but are not mentioned here in greater detail.
If desired, the starting materials can also be formed in situ so that they are not isolated from the reaction mixture, but instead are immediately converted further into the compounds of the formula I.
The starting compounds for the preparation of compounds of formula I and related formulae are generally known. If they are novel, they can, however, be prepared by methods known per se.
The reactions are preferably carried out in an inert solvent. Examples of suitable inert solvents are hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1 ,2-dichloroethane, tetrachloromethane, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether or ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethyl- formamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids, such as formic acid or acetic acid; nitro compounds, such as nitromethane or nitrobenzene; esters, such as ethyl acetate, or mixtures of the said solvents.
Therefore, the invention also relates to the preparation of the compounds of formula (I), (II), (Vl) and (V) and salts thereof, as described in scheme 2.
Scheme 2
The process for the preparation of compounds of Formulae (I), (II), (Vl) and (V) wherein G is Rb or L1, wherein R2, R3, X, W, V, Y, U, Ra and Rb are as defined above, comprises:
A) the step of reacting a compound of Formula (l-l) or (III) with L5-X-L4 where L4 is preferably a chloride, imidazoyl or para-nitrophenoxy and L5 is preferably chloride, imidazoyl or trichloromethoxy to form compounds of Formulae (Vl) or (V), respectively;
B) the step of reacting a compound of Formula (l-l) or (III) with L2-X-Ra where L2 is preferably a chloride, a carboxylate, or OH in the presence of coupling reagent(s), preferably DCC, DIC, EDC, HOBt or N-hydroxysuccinimide, to form compounds of Formulae (I) or (II), respectively;
Accordingly, the invention relates, in particular, to the use of formula I and related formulae as defined above, as a medicament.
Accordingly, the invention relates, in particular, to the use of compounds of the formula I and related formulae as defined above, for the preparation of pharmaceutical formulation for the prevention and/or the treatment of multiple sclerosis, cancers and related disorders such as monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, acute myelotic leukaemia, chronic myelotic leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia, glioblastomas and breast carcinoma and colon carcinoma, tumour of the blood and immune system, tumours of the squamous epithelium, of the bladder, of the stomach, of the kidneys, of head and neck, of the oesophagus, of the cervix, of the thyroid, of the intestine, of the liver, of the brain, of the prostate, of the urogenital tract, of the lymphatic system, of the larynx and/or of the lung,
The said compounds of the formula I and related formulae can be used in their final non-salt form. On the other hand, the present invention also relates to the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases by procedures known in the art. Pharmaceutically acceptable salt forms of the compounds of the formula I are
for the most part prepared by conventional methods. If the compound of the formula I and related formulae contains an acidic center, such as a carboxyl group, one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base-addition salt. Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; alkaline earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, for example sodium- or potassium methoxide and sodium or potassiumpropoxide, alkalihydrides, such as sodium- or potassiumhydride; and various organic bases, such as piperidine, diethanolamine and N-methyl-glutamine, benzathine, choline, diethanolamine, ethylenediamine, meglumine, benethamine, diethylamine, piperazine and tromethamine. The aluminium salts of the compounds of the formula I and related formulae are likewise included. In the case of certain compounds of the formula I and related formulae, which contain a basic center, acid- addition salts can be formed by treating these compounds with pharmaceutically acceptable organic and inorganic acids, for example hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoaryl-sulfonates, such as ethanesulfonate, toluenesulfonate and benzene-sulfonate, and other organic acids and corresponding salts thereof, such as acetate, trifluoro-acetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like. Accordingly, pharmaceutically acceptable acid-addition salts of the compounds of the formula I and related formulae include the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzene-sulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphor-sulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclo-pentane-propionate, digluconate, dihydrogen-phosphate, dinitrobenzoate, dodecyl-sulfate, ethanesulfonate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptanoate, gluco-nate, glutamate, glycerophosphate, hemi-succinate, hemisulfate, heptanoate, hexanoate, hippurate, hydro-chloride, hydrobromide, hydroiodide, 2-hydroxy-ethane-sulfonate, iodide, isethionate, isobutyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, mono-hydrogen-phosphate, 2- naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, palmo-ate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate, phthalate, but this does not represent a restriction. Both types of salts may be formed or interconverted preferably using ion-exchange resin techniques.
Furthermore, the base salts of the compounds of the formula I and related formulae include aluminium, ammonium, calcium, copper, iron(lll), iron(ll), lithium, magne-sium, manganese(lll), manganese(ll), potassium, sodium and zink salts, but this is not intended to represent a restriction. Of the above-mentioned salts, preference is given to ammonium; the alkali metal salts sodium and potassium, and the alkaline earth metal salts calcium and magnesium. Salts of the compounds of the formula I which are derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, also including naturally occurring substituted amines, cyclic amines, and basic ion exchanger resins, for example arginine, betaine, caffeine, chloroprocaine, choline, N,N'-dibenzyl-ethylen-ediamine (benzathine), dicyclohexylamine, diethanol-amine, diethyl-amine, 2-diethyl-amino-ethanol, 2-dimethyl-amino-ethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethyl-piperidine, glucamine, glucosamine, histidine, hydrabamine, isopropyl-amine, lido-caine, lysine, meglumine (N-methyl-D- glucamine), morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanol-amine, triethylamine, trimethylamine, tripropyl-amine and tris(hydroxy-methyl)-methylamine (tromethamine), but this is not intended to represent a restriction. Compounds of the formula I and related formulae of the present invention which contain basic nitrogen-containing groups can be quaternised using agents such as (Ci-C4)-alkyl halides, for example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide; di(CrC4)alkyl sulfates, for example dimethyl, diethyl and diamyl sulfate; (CiO-Ci8)alkyl halides, for example decyl, do-decyl, lauryl, myristyl and stearyl chloride, bromide and iodide; and aryl-(Ci-C4)alkyl halides, for example benzyl chloride and phenethyl bromide. Both water- and oil-soluble compounds of the formula I can be prepared using such salts.
The above-mentioned pharmaceutical salts which are preferred include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, me-glumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stea-rate, sulfate, subsalicylate, tartrate, thiomalate, tosylate and tro-meth-amine, but this is not intended to represent a restriction.
The acid-addition salts of basic compounds of the formula I and related formulae are prepared by bringing the free base form into contact with a sufficient amount of the desired acid, causing the formation of the salt in a conventional manner. The free base can be regenerated by bringing the salt form into contact with a base and isolating the free base in a conventional manner. The free base forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts other-wise correspond to the respective free base forms thereof.
As mentioned, the pharmaceutically acceptable base-addition salts of the compounds of the formula I are formed with metals or amines, such as alkali metals and alkaline earth metals or organic amines. Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanol-amine, ethylenediamine, N-methyl-D-glucamine and procaine.
The base-addition salts of acidic compounds of the formula I and related formulae are prepared by bringing the free acid form into contact with a sufficient amount of the desired base, causing the formation of the salt in a conventional manner. The free acid can be regenerated by bringing the salt form into contact with an acid and isolating the free acid in a conventional manner. The free acid forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts other-wise correspond to the respective free acid forms thereof.
If a compound of the formula I and related formulae contains more than one group which is capable of forming pharmaceutically acceptable salts of this type, the formula I also encompasses multiple salts. Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, di-phosphate, disodium and trihydrochloride, but this is not intended to represent a restriction.
With regard to that stated above, it can be seen that the term "pharmaceutically acceptable salt" in the present connection is taken to mean an active ingredient which comprises a compound of the formula I and related formulae in the form of one of its
salts, in particular if this salt form imparts improved pharmacokinetic properties on the active ingredient compared with the free form of the active ingredient or any other salt form of the active ingredient used earlier. The pharmaceutically acceptable salt form of the active ingredient can also provide this active ingredient for the first time with a desired pharmacokinetic property which it did not have earlier and can even have a positive influence on the pharmacodynamics of this active ingredient with respect to its therapeutic efficacy in the body.
Owing to their molecular structure, the compounds of the formula I and related formulae can be chiral and can accordingly occur in various enantiomeric forms. They can therefore exist in racemic or in optically active form. Since the pharmaceutical activity of the racemates or stereoisomers of the compounds according to the invention may differ, it may be desirable to use the enantiomers. In these cases, the end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art or even employed as such in the synthesis.
In the case of racemic amines, diastereomers are formed from the mixture by reaction with an optically active resolving agent. Examples of suitable resolving agents are optically active acids, such as the R and S forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitable N-protected amino acids (for example N-benzoylproline or N- benzenesulfonylproline), or the various optically active camphorsulfonic acids. Also advantageous is chromatographic enantiomer resolution with the aid of an optically active resolving agent (for example dinitrobenzoylphenylglycine, cellulose triacetate or other derivatives of carbohydrates or chirally derivatised methacrylate polymers immobilised on silica gel). Suitable eluents for this purpose are aqueous or alcoholic solvent mixtures, such as, for example, hexane/isopropanol/ acetonitrile, for example in the ratio 82:15:3.
The invention furthermore relates to the use of compounds of formula I and related formulae in combination with at least one further medicament active ingredient, preferably medicaments used in the treatment of multiple sclerosis such as cladribine or another co-agent, such as interferon, e.g. pegylated or non-pegylated interferons, preferably interferon beta and/or with compounds improving vascular function or in
combination with immunomodulating agents for example Fingolimod; cyclosporins, rapamycins or ascomycins, or their immunosuppressive analogs, e.g. cyclosporin A, cyclosporin G, FK-506, ABT-281 , ASM981 , rapamycin, 40-O-(2-hydroxy)ethyl- rapamycin etc.; corticosteroids; cyclophosphamide; azathioprene; methotrexate; leflunomide; mizoribine; mycophenolic add; mycophenolate mofetil; 15- deoxyspergualine; diflucortolone valerate; difluprednate; Alclometasone dipropionate; amcinonide; amsacrine; asparaginase; azathioprine; basiliximab; beclometasone dipropionate; betamethasone; betamethasone acetate; betamethasone dipropionate; betamethasone phosphate sodique; betamethasone valerate; budesonide; captopril; chlormethine chlorhydrate; cladribine; clobetasol propionate; cortisone acetate; cortivazol; cyclophosphamide; cytarabine; daclizumab; dactinomycine; desonide; desoximetasone; dexamethasone; dexamethasone acetate; dexamethasone isonicotinate; dexamethasone metasulfobenzoate sodique; dexamethasone phosphate;dexamethasone tebutate;dichlorisone acetate; doxorubicine chlorhydrate; epirubicine chlorhydrate; fluclorolone acetonide; fludrocortisone acetate; fludroxycortide; flumetasone pivalate; flunisolide; fluocinolone acetonide; fluocinonide; fluocortolone; fluocortolone hexanoate; fluocortolone pivalate; fluorometholone; fluprednidene acetate; fluticasone propionate; gemcitabine chlorhydrate; halcinonide; hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone hemisuccinate; melphalan; meprednisone; mercaptopurine; methylprednisolone; methylprednisolone acetate; methylprednisolone hemisuccinate; misoprostol; muromonab-cd3; mycophenolate mofetil; paramethasone acetate; prednazoline, prednisolone; prednisolone acetate; prednisolone caproate; prednisolone metasulfobenzoate sodique; prednisolone phosphate sodique; prednisone; prednylidene; rifampicine; rifampicine sodique; tacrolimus; thalidomide; thiotepa; tixocortol pivalate; triamcinolone; triamcinolone acetonide hemisuccinate; triamcinolone benetonide; triamcinolone diacetate; triamcinolone hexacetonide; immunosuppressive monoclonal antibodies, e.g., monoclonal antibodies to leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD40, CD45 or CD58 or their ligands; or other immunomodulatory compounds, e.g. CTLA41g, or other adhesion molecule inhibitors, e.g. mAbs or low molecular weight inhibitors including Selectin antagonists and VLA-4 antagonists. A preferred composition is with Cyclosporin A, FK506, rapamycin or 40-(2-hydroxy)ethyl-rapamycin and Fingolimod. These further medicaments, such as interferon beta, may be administered concomitantly or sequentially, e.g. by subcutaneous, intramuscular or oral routes.
The invention furthermore relates to the use of compounds of formula I and related formulae in combination with at least one further medicament active ingredient, preferably medicaments used in the treatment of cancer wherein said antitumoral compounds are selected from those well known by the one skilled in the related art. These compositions can be used as medicaments in human and veterinary medicine.
Pharmaceutical formulations can be administered in the form of dosage units, which comprise a predetermined amount of active ingredient per dosage unit. Such a unit can comprise, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a compound according to the invention, depending on the disease condition treated, the method of administration and the age, weight and condition of the patient, or pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit. Preferred dosage unit formulations are those which comprise a daily dose or part-dose, as indicated above, or a corresponding fraction thereof of an active ingredient. Furthermore, pharmaceutical formulations of this type can be prepared using a process, which is generally known in the pharmaceutical art.
Pharmaceutical formulations can be adapted for administration via any desired suitable method, for example by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) methods. Such formulations can be prepared using all processes known in the pharmaceutical art by, for example, combining the active ingredient with the excipient(s) or adjuvant(s).
Pharmaceutical formulations adapted for oral administration can be administered as separate units, such as, for example, capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
Thus, for example, in the case of oral administration in the form of a tablet or capsule, the active-ingredient component can be combined with an oral, non-toxic and pharmaceutically acceptable inert excipient, such as, for example, ethanol, glycerol, water and the like. Powders are prepared by comminuting the compound to a suitable fine size and mixing it with a pharmaceutical excipient comminuted in a similar
manner, such as, for example, an edible carbohydrate, such as, for example, starch or mannitol. A flavour, preservative, dispersant and dye may likewise be present.
Capsules are produced by preparing a powder mixture as described above and filling shaped gelatine shells therewith. Glidants and lubricants, such as, for example, highly disperse silicic acid, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form, can be added to the powder mixture before the filling operation. A disintegrant or solubiliser, such as, for example, agar-agar, calcium carbonate or sodium carbonate, may likewise be added in order to improve the availability of the medica-ment after the capsule has been taken.
In addition, if desired or necessary, suitable binders, lubricants and disintegrants as well as dyes can likewise be incorporated into the mixture. Suitable binders include starch, gelatine, natural sugars, such as, for example, glucose or beta-lactose, sweeteners made from maize, natural and synthetic rubber, such as, for example, acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. The lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. The disintegrants include, without being restricted thereto, starch, methylcellulose, agar, bentonite, xanthan gum and the like. The tablets are formulated by, for example, preparing a powder mixture, granulating or dry-pressing the mixture, adding a lubricant and a disintegrant and pressing the entire mixture to give tablets. A powder mixture is prepared by mixing the compound comminuted in a suitable manner with a diluent or a base, as described above, and optionally with a binder, such as, for example, carboxymethylcellulose, an alginate, gelatine or polyvinylpyrrolidone, a dissolution retardant, such as, for example, paraffin, an absorption accelerator, such as, for example, a quaternary salt, and/or an absorbant, such as, for example, bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting it with a binder, such as, for example, syrup, starch paste, acadia mucilage or solutions of cellulose or polymer materials and pressing it through a sieve. As an alternative to granulation, the powder mixture can be run through a tableting machine, giving lumps of non-uniform shape which are broken up to form granules. The granules can be lubricated by addition of stearic acid, a stearate salt, talc or mineral oil in order to prevent sticking to the tablet casting moulds. The lubricated mixture is then pressed to give tablets. The active ingredients
can also be combined with a free-flowing inert excipient and then pressed directly to give tablets without carrying out the granulation or dry-pressing steps. A transparent or opaque protective layer consisting of a shellac sealing layer, a layer of sugar or polymer material and a gloss layer of wax may be present. Dyes can be added to these coatings in order to be able to differentiate between different dosage units.
Oral liquids, such as, for example, solution, syrups and elixirs, can be prepared in the form of dosage units so that a given quantity comprises a pre-specified amount of the compounds. Syrups can be prepared by dissolving the compounds in an aqueous solution with a suitable flavour, while elixirs are prepared using a non-toxic alcoholic vehicle. Suspensions can be for-mulated by dispersion of the compounds in a nontoxic vehicle. Solubilisers and emulsifiers, such as, for example, ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavour additives, such as, for example, peppermint oil or natural sweeteners or saccharin, or other artificial sweeteners and the like, can likewise be added.
The dosage unit formulations for oral administration can, if desired, be encapsulated in microcapsules. The formulation can also be prepared in such a way that the release is extended or retarded, such as, for example, by coating or embedding of particulate material in polymers, wax and the like.
The compounds of the formula I and related formulae and salts, solvates and physiologically functional derivatives thereof and the other active ingredients can also be administered in the form of liposome delivery systems, such as, for exam-pie, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
Liposomes can be formed from various phospholipids, such as, for example, cholesterol, stearylamine or phosphatidylcholines.
The compounds of the formula I and related formulae and the salts, solvates and physiologically functional derivatives thereof and the other active ingredients can also be delivered using monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds can also be coupled to soluble polymers as targeted medicament carriers. Such polymers may encompass polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl-methacrylamidophenol, polyhydroxyethylaspartamido-phenol or polyethylene oxide polylysine, substituted by
palmitoyl radicals. The compounds may furthermore be coupled to a class of biodegradable polymers which are suitable for achieving controlled release of a medicament, for example polylactic acid, poly-epsilon-caprolactone, polyhydroxybutyric acid, poly-orthoesters, polyacetals, polydihydroxypyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
Pharmaceutical formulations adapted for transdermal administration can be administered as independent plasters for extended, close contact with the epidermis of the recipient. Thus, for example, the active ingredient can be delivered from the plaster by iontophoresis, as described in general terms in Pharmaceutical Research,
3(6), 318 (1986).
Pharmaceutical compounds adapted for topical administration can be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
For the treatment of the eye or other external tissue, for example mouth and skin, the formulations are preferably applied as topical ointment or cream. In the case of formulation to give an ointment, the active ingredient can be employed either with a paraffinic or a water-miscible cream base. Alternatively, the active ingredient can be formulated to give a cream with an oil-in-water cream base or a water-in-oil base.
Pharmaceutical formulations adapted for topical application to the eye include eye drops, in which the active ingredient is dissolved or sus-pended in a suitable carrier, in particular an aqueous solvent.
Pharmaceutical formulations adapted for topical application in the mouth encompass lozenges, pastilles and mouthwashes.
Pharmaceutical formulations adapted for rectal administration can be administered in the form of suppositories or enemas.
Pharmaceutical formulations adapted for nasal administration in which the carrier substance is a solid comprise a coarse powder having a particle size, for example, in the range 20-500 microns, which is administered in the manner in which snuff is
taken, i.e. by rapid inhalation via the nasal passages from a container containing the powder held close to the nose. Suitable formulations for administration as nasal spray or nose drops with a liquid as carrier substance encompass active-ingredient solutions in water or oil.
Pharmaceutical formulations adapted for administration by inhalation encompass finely particulate dusts or mists, which can be generated by various types of pressurised dispensers with aerosols, nebulisers or insuf-flators.
Pharmaceutical formulations adapted for vaginal administration can be administered as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions comprising antioxidants, buffers, bacteriostatics and solutes, by means of which the formulation is rendered isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions, which may comprise suspension media and thickeners. The formulations can be administered in single-dose or multidose containers, for example sealed ampoules and vials, and stored in freeze-dried (lyophilised) state, so that only the addition of the sterile carrier liquid, for example water for injection purposes, immediately before use is necessary.
Injection solutions and suspensions prepared in accordance with the recipe can be prepared from sterile powders, granules and tablets.
It goes without saying that, in addition to the above particularly mentioned constituents, the formulations may also comprise other agents usual in the art with respect to the particular type of formulation; thus, for example, formulations which are suitable for oral administration may comprise flavours.
A therapeutically effective amount of a compound of the formula I and related formulae and of the other active ingredient depends on a number of factors, including, for example, the age and weight of the animal, the precise disease condition which requires treatment, and its severity, the nature of the formulation and the method of administration, and is ultimately determined by the treating doctor or vet. However, an
effective amount of a compound is generally in the range from 0.1 to 100 mg/kg of body weight of the recipient (mammal) per day and particularly typically in the range from 1 to 10 mg/kg of body weight per day. Thus, the actual amount per day for an adult mammal weighing 70 kg is usually between 70 and 700 mg, where this amount can be administered as an individual dose per day or usually in a series of part-doses
(such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same. An effective amount of a salt or solvate or of a physiologically functional derivative thereof can be determined as the fraction of the effective amount of the compound per se.
The present invention furthermore relates to a method for treating a subject suffering from a PI3K related disorder, comprising administering to said subject an effective amount of a compound of formula I and related formulae. The present invention preferably relates to a method, wherein the PI3K associated disorder is an autoimmune disorder or condition associated with an overactive immune response or cancer. The present invention furthermore relates to a method of treating a subject suffering from an immunerogulatory abnomality, comprising administering to said subject a compound of formula I and related formulae in an amount that is effective for treating said immunoregulatory abnormality. The present invention preferably relates to a method wherein the immunoregulatory abnormality is an autoimmune or chronic inflammatory disease selected from the group consisting of: amyotrophic lateral sclerosis (ALS), systemic lupus erythematosus, chronic rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, Graves ophthalmopathy and asthma. The present invention furthermore relates to a method wherein the immunoregulatory abnormality is bone marrow or organ transplant rejection or graft-versus-host disease. The present invention furthermore relates to a method wherein the immunoregulatory abnormality is selected from the group consisting of: transplantation of organs or tissue, graft-versus-host diseases brought about by transplantation, autoimmune syndromes including rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, posterior uveitis, allergic encephalomyelitis, glomerulonephritis, post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis, inflammatory and hyperproliferative skin
diseases, psoriasis, atopic dermatitis, contact dermatitis, eczematous dermatitis, seborrhoeic dermatitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa, urticaria, angioedemas, vasculitis, erythema, cutaneous eosinophilia, lupus erythematosus, acne, alopecia areata, keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical cornea, dystrophia epithelialis corneae, corneal leukoma, ocular pemphigus, Mooren's ulcer, scleritis, Graves' opthalmopathy, Vogt-Koyanagi-Harada syndrome, sarcoidosis, pollen allergies, reversible obstructive airway disease, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dust asthma, chronic or inveterate asthma, late asthma and airway hyper-responsiveness, bronchitis, gastric ulcers, vascular damage caused by ischemic diseases and thrombosis, ischemic bowel diseases, inflammatory bowel diseases, necrotizing enterocolitis, intestinal lesions associated with thermal burns, coeliac diseases, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease, ulcerative colitis, migraine, rhinitis, eczema, interstitial nephritis, Goodpasture's syndrome, hemolytic-uremic syndrome, diabetic nephropathy, multiple myositis, Guillain-Barre syndrome, Meniere's disease, polyneuritis, multiple neuritis, mononeuritis, radiculopathy, hyperthyroidism, Basedow's disease, pure red cell aplasia, aplastic anemia, hypoplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, agranulocytosis, pernicious anemia, megaloblastic anemia, anerythroplasia, osteoporosis, sarcoidosis, fibroid lung, idiopathic interstitial pneumonia, dermatomyositis, leukoderma vulgaris, ichthyosis vulgaris, photoallergy sensitivity, cutaneous T cell lymphoma, chronic lymphocytic leukemia, arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritis nodosa, myocardosis, scleroderma, Wegener's granuloma, Sjogren's syndrome, adiposis, eosinophilic fascitis, lesions of gingiva, periodontium, alveolar bone, substantia ossea dentis, glomerulonephritis, male pattern alopecia or alopecia senilis by preventing epilation or providing hair germination and/or promoting hair generation and hair growth, muscular dystrophy, pyoderma and Sezary's syndrome, Addison's disease, ischemia-reperfusion injury of organs which occurs upon preservation, transplantation or ischemic disease, endotoxin-shock, pseudomembranous colitis, colitis caused by drug or radiation, ischemic acute renal insufficiency, chronic renal insufficiency, toxinosis caused by lung-oxygen or drugs, lung cancer, pulmonary emphysema, cataracta, siderosis, retinitis pigmentosa, senile macular degeneration, vitreal scarring, corneal alkali burn, dermatitis erythema multiforme, linear IgA ballous dermatitis and cement dermatitis,
gingivitis, periodontitis, sepsis, pancreatitis, diseases caused by environmental pollution, aging, carcinogenesis, metastasis of carcinoma and hypobaropathy, disease caused by histamine or Ieukotriene-C4 release, Behcet's disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, partial liver resection, acute liver necrosis, necrosis caused by toxin, viral hepatitis, shock, or anoxia, B-virus hepatitis, non-A/non-B hepatitis, cirrhosis, alcoholic cirrhosis, hepatic failure, fulminant hepatic failure, late-onset hepatic failure, "acute-on-chronic" liver failure, augmentation of chemotherapeutic effect, cytomegalovirus infection, HCMV infection, AIDS, cancer, senile dementia, parkison diseases, trauma, and chronic bacterial infection.
In the following preferred embodiments are disclosed:
Use of a compound of formula I for the preparation of a medicament for the treatment and prophylaxis of cancer diseases.
Use of a compound of formula I for the preparation of a medicament for the treatment and prophylaxis of cancer diseases, where the cancer diseases are associated with a tumor from the group of tumours of the squamous epithelium, of the bladder, of the stomach, of the kidneys, of head and neck, of the oesophagus, of the cervix, of the thyroid, of the intestine, of the liver, of the brain, of the prostate, of the urogenital tract, of the lymphatic system, of the stomach, of the larynx and/or of the lung.
Use of a compound of formula I for the preparation of a medicament for the treatment and prophylaxis of tumors, where the tumour originates from the group of monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma and colon carcinoma or of the blood and immune system.
Use of compounds of formula I and pharmaceutically usable derivatives, salts, tautomers, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and/or prophylaxis of diseases in which the inhibition, activation, regulation, and/or modulation of PI3Kγ receptor signal transduction plays a role and for treatment of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases,
bacterial or viral infections, allergy, asthma, pancreatitis, multi-organe failure, kidney diseases, platelet aggregation, cancer, transplantation, sperm motility, erythrocyte deficiency, graft rejection or lung injuries.
Use of compounds of formula I and pharmaceutically usable derivatives, salts, tautomers, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosis, inflammatory bowel disease, lung inflammation, thrombosis or brain infection/inflammation such as meningitis or encephalitis, Alzheimer's disease, Huntington's disease, CNS trauma, stroke or ischemic conditions atherosclerosis, heart hypertrophy, cardiac myocyte dysfunction, elevated blood pressure or vasoconstriction, chronic obstructive pulmonary disease, anaphylactic shock fibrosis, psoriasis, allergic diseases, asthma, stroke or ischemic conditions, ischemia-reperfusion, platelets aggregation/activation, skeletal muscle atrophy/hypertrophy, leukocyte recruitment in cancer tissue, angiogenesis, invasion metastisis, melanoma, Karposi's sarcoma, acute and chronic bacterial and viral infections, sepsis, graft rejection, glomerulo sclerosis, glomerulo nephritis, progressive renal fibrosis, endothelial and epithelial injuries in the lung or in general lung airways inflammation.
Preferred compounds of formula I and related formulae exhibit a IC50 for the binding to PI3Kγ of less than about 5 μM, preferably less than about 1 μM and even more preferred less than about 0,010 μM.
Compounds according to formula formula I and related formulae may be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred experimental conditions (i.e. reaction temperatures, time, moles of reagents, solvents etc.) are given, other experimental conditions can also be used unless otherwise stated.
Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by the person skilled in the art, using routine optimisation procedures.
In general, the synthesis pathways for any individual compound of formula I and related formulae will depend on the specific substitutents of each molecule and upon the ready availability of intermediates necessary; again such factors being appreciated by those of ordinary skill in the art.
Compounds of this invention can be isolated in association with solvent molecules by crystallization from evaporation of an appropriate solvent. The pharmaceutically acceptable acid addition salts of the compounds of formula I and related formulae which contain a basic center, may be prepared in a conventional manner. For example, a solution of the free base may be treated with a suitable acid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent. Pharmaceutically acceptable base addition salts may be obtained in an analogous manner by treating a solution of compound of formula I and related formulae, which contain an acid center, with a suitable base. Both types of salts may be formed or interconverted using ion- exchange resin techniques.
The compounds of invention have been named according the standards used in the program "ACD/Name Batch" from Advanced Chemistry Development Inc., ACD/Labs (7.00 Release). Product version: 7.10, build: 15 Sep 2003.
In the following the present invention shall be illustrated by means of some examples, which are not construed to be viewed as limiting the scope of the invention.
EXPERIMENTAL PART
The compounds of invention have been named according to the standards used in the program "ACD/Name Batch" from Advanced Chemistry Development Inc., ACD/Labs (7.00 Release). Product version: 7.10, build: 15 Sep 2003.
Ac (acetyl), ACN (acetonitrile), aq (aqueous), Boc (tert-butoxycarbonyl), cHex (cyclohexane), DCE (dichloroethane), DCM (dichloromethane), DIEA (diisopropylethylamine), DMA (dimethylacetamide), DMF (dimethylformamide), DMSO (dimethylsulfoxide), dppf (1 ,1'-bis(diphenylphosphino)ferrocene), EDC (1-
Ethyl-3-(3-dimethyllaminopropyl)carbodiimide), eq (equivalent), ESI (electro-spray ionization), Et (ethyl), Et2O (diethyl ether), EtOAc (ethyl acetate), h (hour), HOBt (N- hydroxybenzotriazole), HPLC (high performance liquid chromatography), iPr (isopropyl), L (liter), LC (liquid chromatography), m (meter), MD Autoprep (mass directed preparative HPLC), Me (methyl), MeOH (methanol), mg (milligram), min
(minute), mL (milliliter), μL (microliter), m.p. (melting point), mm (millimeter), μm (micrometer), mmol (millimole), MS (mass spectrometry), NMP (N- methylpyrrolydinone), NMM (N-methylmorpholine), NMR (nuclear magnetic resonance), PE (petroleum ether), Ph (phenyl), Rt (retention time), RT (room temperature), sat. (saturated), TBD (1 ,5,7-triazabicyclo[4.4.0]dec-5-ene), TEA
(triethylamine), TFA (trifluoroacetic acid), THF (tetrahydrofuran), UPLC (ultra performance liquid chromatography), UV (ultraviolet).
The commercially available starting materials used in the following experimental description were purchased from Sigma-Aldrich-Fluka unless otherwise reported.
However, specific reagents were purchased from another suppliers: 1-(2-aminoethyl)- 4-methyl-piperazine (Apollo), 2-amino-1-morpholin-4-yl-ethanone (Fluorochem), 3- aminocarbonylphenylboronic acid (ABCR), benzenesulfonamide-3-boronic acid pinacol ester (Frontier), beta-alanine tert-butyl ester hydrochloride (Bachem), 1 ,1 '- bis(diphenylphosphino)ferrocenedichloro palladium(ll) (Avocado), 4-bromo-1-fluoro-2-
(methylsulfonyl)benzene (Apollo), 4-bromo-1 -methyl-2-(methylsulfonyl)benzene (Peakdale), 5-bromopyridine-3-sulfonamide (Combi-Blocks), 6-chloropyridazin-3- amine (APOLLO), 4,5-dibromothiophene-2-sulfonyl chloride (ABCR), [3-(N, N- dimethylsulfamoylamino)phenyl]boronic acid (Combi-Blocks), N,N-dimethyl-3- boronobenzenesulfonamide (Combi-Blocks), ethyl 3-boronobenzenesulfonamide
(Combi-Blocks), (3-fluoro-4-hydroxyphenyl)boronic acid (Combi-Blocks), (3-fluoro-5- hydroxyphenyl)boronic acid (Combi-Blocks), 5-formylthiophen-3-boronic acid (Combi-Blocks), glycine dimethylamide acetate (Chem-lmpex), N-(2-hydroxyethyl)-3- boronobenzenesulfonamide (Combi-Blocks), 2-(3-isopropyl-1 ,2,4-oxadiazol-5- yl)ethanamine (Anichem), (3-methylsulfonylphenyl)boronic acid (Combi-Blocks), [4- methoxy-3-(morpholinosulfonyl)phenyl]boronic acid (Combi-Blocks), 3- (methylsulfonyl)aminobenzeneboronic acid (ABCR), N-morpholinyl 3- boronobenzenesulfonamide (Combi-Blocks), 5-pyrimidinylboronic acid (Combi- Blocks), 2-(1 ,2,4-triazole-1-yl)-ethylamine (ABCR), 2,2,2-trifluoroethyl formate (Synquest). methoxyacetic acid (Acros), 3-aminopropanenitrile (ABCR), 1-Λ/-boc-3-
cyano-pyrrolidine (ABCR), fe/f-butyl carbazate (Chem Impex International), propionyl chloride (Alfa Aesar), ethyl L-lactate (VWR International), 2-methyl-4,4,4- trifluorobutyric acid (Appolo Scientific), 2,2-difluorocyclobutane carboxylic acid (VWR International), 2-fluoroisobutyric acid (Fluorochem), 2-fluoropropionic acid (Fluorochem), 1-Boc-3-aminopyrrolidine (CHN Technologies Inc.), 5- bromonicotinonitrile (Alfa Aesar), 2-(5-methylisoxazol-3-yl)ethanamine (Otava), 1 ,3- dimethyl-1 /-/-pyrazole-4-boronic acid pinacol ester (Boron Molecular Inc), 1 ,3,5- trimethyl-4-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-1 /-/-pyrazole (ABCR), (2,5- dimethyl-3-thienyl)boronic acid (Borochem), 2-methoxypyridine-3-boronic acid (Focus Synthesis LLC), 3-hydroxymethyl-pyrrolidine-1 -carboxylic acid te/f-butyl ester (Tyger
Scientific Inc.), 3-amino-6-chloropyridazine (Appolo), methyl 5-bromonicotinate (Avocado), 4-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-1 H-indazole (J & W Pharma Lab LLC), 6-bromo-3/-/-imidazo[4,5-b]pyridine (Focus Synthesis LLC), 6- bromo-2-methyl-3/-/-imidazo[4,5-t)]pyridine (Focus Synthesis LLC), thiomorpholine (Chemie Brunschwig AG).
m.p., NMR, HPLC and MS data provided in the examples described below are registered on: NMR: Bruker DPX-300, using residual signal of deuterated solvent as internal reference.
HPLC: Waters Alliance 2695, column Waters XBridge C8 3.5 μm 4.6x50 mm, conditions: solvent A (H2O with 0.1% TFA), solvent B (ACN with 0.05% TFA), gradient 5% B to 100% B over 8 min, UV detection with PDA Water 996 (230-400 nm) or Agilent
Atlantis-1 : Column: Atlantis C18 (75X4.6mm, 5μ ), solvent A (H2O with 0.1% TFA), solvent B (ACN)
Atlantis-2 : Column: Atlantis C18 (75X4.6mm, 5μ ), solvent A (1 OmM NH4OAC), solvent B (ACN) X-Terra : XTERRA C18 (30X4.6mm -5μm), solvent A (1OmM NH4OAC), solvent B
(ACN)
C18 BDS: Column: C18 BDS (4.6X250mm), solvent A (H2O with 0.1 % TFA), solvent
B (ACN)
ECLIPSED: Column: ECLIPSED XDB C18 (250X4.6mm,5μ) , solvent A (H2O), solvent B (ACN)
LC/MS: Waters Alliance 2795, column Waters XBridge C8 3.5 μm 2.1x30 mm, conditions: solvent A (1OmM ammonium acetate in water + 5% ACN), solvent B (ACN), gradient 5% B to 100% B over 3 min, Waters Micromass ZMD (positive and negative ESI modes) or for "GENESIS", Column GENESIS C18 50X4.6mm 3U, conditions: solvent A: water, 0.1 %HCOOH, solvent B- ACN or Waters Acquity, column Waters Acquity UPLC BEH C18 1.7 μm 2.1x50 mm, conditions: solvent A (1 OmM ammonium acetate in water + 5% ACN), solvent B (ACN), gradient 5% B to 100% B over 3 min, UV detection (PDA, 230-400 nm) and MS detection (SQ detector, positive and negative ESI modes, cone voltage 30V).
m.p. were recorded on a MPA100 from Standford Research Systems and are uncorrected.
The microwave chemistry is performed on a single mode microwave reactor Emrys™ Optimiser from Personal Chemistry.
MD Autoprep purification: preparative HPLC purifications are performed with a mass directed autopurification Fractionlynx from Waters equipped with a Sunfire Prep C18 OBD column 19x100 mm 5 μm, unless otherwise reported. All HPLC purifications were performed with a gradient of ACN/H2O or ACN/H2O/HCOOH (0.1 %).
Intermediate 1 : Formation of Λ/-(6-bromo-1 ,3-benzothiazol-2-yl)acetamide
Acetic anhydride (4.95 mL, 52.4 mmol) was added to a solution of 2-amino-6- bromobenzothiazole (3.00 g, 13.2 mmol) in anhydrous pyridine (30 ml) at 00C. The resulting mixture was stirred at RT for 48 hours. The reaction mixture was poured into water (300 mL) and stirred for 30 minutes. Then the precipitate was washed with water (5x) and dried under reduced pressure to give the title compound as a white powder (3.44 g, 97%). HPLC, Rt: 3.3 min (purity: 99.1 %). UPLC/MS, M+(ESI): 270.1 and 272.1 , M-(ESI): 269.1 and 271.1.
Intermediate 2: Formation of Λ/-[6-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)- 1 ,3-benzothiazol-2-yl]acetamide
A mixture of Λ/-(6-bromo-1 ,3-benzothiazol-2-yl)acetamide (2.0 g, 7.38 mmol), bis(pinacolato)diboron (3.75 g, 14.75 mmol), 1 ,1'- bis(diphenylphosphino)ferrocenedichloro palladium(ll) (325 mg, 0.44 mmol) and potassium acetate (3.62 g, 36.88 mmol) in DMSO (24 ml) was prepared and the resulting mixture was heated at 800C for 5 hours. The reaction mixture was cooled at RT and poured into water (80 ml_), then extracted with EtOAc (2x50 ml_). The organic layers were combined, dried (MgSO4) and the solvents were concentrated under reduced pressure to give a brown oil. Purification by precipitation from methanol gave the title compound as an off-white powder (1.75 g, 75%). UPLC/MS, M+(ESI): 319.2,
M-(ESI): 317.3. 1 H-NMR (DMSO-d6): δ 12.44 (s, 1 H), 8.26 (brs, 1 H), 7.71 (brs, 2H), 2.21 (s, 3H), 1.31 (s, 12H).
Intermediate 3: Formation of 6-bromo[1 ,2,4]triazolo[1 ,5-a]pyridin-2-amine Step a) Formation of ethyl {[(5-bromopyridin-2-yl)amino]carbonothioyl}carbamate
A solution of 2-amino-5-bromopyridine (8.9 g, 51.2 mmol) and ethoxycarbonyl isothiocyanate (7.7 g, 58.9 mmol) in dioxane (100 ml.) was stirred at RT overnight. The resulting precipitate was filtered off and washed with cyclohexane to give the title compound as a pale yellow powder (12.3 g, 79%). HPLC, Rt: 4.1 min (purity 99.9%).
LC/MS, M+(ESI): 305.9.
Step b) Formation of 6-bromo[1 ,2,4]triazolo[1 ,5-a]pyridin-2-amine
A suspension of ethyl {[(5-bromopyridin-2-yl)amino]carbonothioyl}carbamate (12.3 g,
40.4 mmol), hydroxylamine hydrochloride (14.1 g, 202 mmol) and DIEA (15.7 g, 122 mmol) in a mixture of MeOH and EtOH (ratio 1 :1 , 200 ml.) was stirred at RT for 2 hours and then at 700C for 3 hours. The solvents were removed under reduced pressure. The residue was taken up in dioxane/water (1 :1 ) and filtered to give the title
compound as an off-white powder (42.6 g, 99%). HPLC, Rt: 1.1 min (purity 99.8%). LC/MS, M+(ESI): 215.3.
Intermediate 4: Λ/-(6-Bromoimidazo[1 ,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide
Step 1) Formation of N-(5-bromopyridin-2-yl)-4-methylbenzenesulfonamide
To a solution of 2-amino-5-bromopyridine (40 g, 0.23 mol) in anhydrous pyridine (240 ml_), was slowly added tosyl chloride (53 g, 0.28 mol) at 00C. The reaction mixture was then heated at 900C for 16 hours. Pyridine was removed under reduced pressure and water (500 ml.) was added. The resulting mixture was stirred for 30 min at RT and filtered off to give the title compound as an off-white solid (77.0 g, quantitative). 1H-NMR (DMSO-d6, 400 MHz) δ 1 1.24 (brs, 1 H), 8.26 (d, 1 H), 7.89 (m, 1 H), 7.74 (m, 2H), 7.35 (m, 2H), 7.02 (d, 1 H), 2.36 (s, 3H).
Step 2) Formation of
2-[(2Z)-5-bromo-2-{[(4-methylphenyl)sulfonyl]imino}pyridin-1(2H)-yl]acetamide
Λ/-Ethyldiisopropyl amine (3 ml_, 16.8 mmol) and 2-chloroacetamide (1.6 g, 16.8 mmol) were added to a suspension of Λ/-(5-bromopyridin-2-yl)-4- methylbenzenesulfonamide (5.0 g, 15.3 mmol) in anhydrous DMF (30 ml_). The reaction mixture was heated at 80°C for 48 hours. It was then poured into water (70 ml.) and the resulting mixture was stirred for 1 hour. The precipitate was filtered off, washed with water and dried under reduced pressure to give the title compound as an off-white solid (4.8 g, 82%). 1H-NMR (DMSO-d6, 400 MHz) δ 8.37 (d, 1 H), 7.88 (m, 1 H), 7.80 (s, 1 H), 7.64 (d, 2H), 7.40 (d, 1 H), 7.29 (m, 3H), 4.76 (brs, 2H), 2.32 (s,
3H).
Trifluoroacetic anhydride (24 mL) was added slowly to a stirred suspension of 2-[(2Z)- 5-bromo-2-{[(4-methylphenyl)sulfonyl]imino}pyridin-1 (2/-/)-yl]acetamide (4.8 g, 12.5 mmol) in anhydrous DCM (60 mL). After being refluxed for 3 hours, the reaction mixture was concentrated under reduced pressure and the resulting yellow solid was suspended in a saturated aqueous solution of sodium bicarbonate, stirred for 15 min and filtered off. The crude was purified by flash chromatography on silica (PE:EtOAc, 90:10) to give the title compound as a pale yellow solid .HPLC, Rt: 3.4 min (purity: 97%). UPLC/MS, M+(ESI): 308.1 , 310.1 , M-(ESI): 306.1 , 308.1. 1 H-NMR (DMSO-d6, 400 MHz) δ 12.53 (brs, 1 H), 8.94 (m, 1 H), 8.23 (s, 1 H), 7.49 (m, 1 H), 7.39
(m, 1 H).
Intermediate 5: Λ/-(6-chloroimidazo[1 ,2-b]pyridazin-2-yl)-2,2,2-trifluoroacetamide Step 1) Formation of N-(6-chloropyridazin-3-yl)-4-methylbenzenesulfonamide
The title compound was prepared according to procedure described for Intermediate 4 step 1 ), but starting from 6-chloropyridazin-3-amine. The title compound was obtained as a white solid .1H-NMR (DMSO-d6, 400 MHz) δ 7.78 (m, 4H), 7.56 (brs, 1 H), 7.38 (m, 2H), 2.49 (s, 3H).
Step 2) Formation of 2-[(6Z)-(3-chloro-6-{[(4- methylphenyl)sulfonyl]imino}pyridazin-1(6H)-yl]acetamide
The title compound was prepared according to procedure described for Intermediate 4, step 2), but starting from Λ/-(6-chloropyridazin-3-yl)-4-methylbenzenesulfonamide.
The title compound was obtained as beige solid (17.5 g, 97%). 1H-NMR (DMSO-d6, 400 MHz) δ 7.98 (d, 1 H), 7.79 (d, 1 H), 7.69 (m, 3H), 7.39 (s, 1 H), 7.31 (m, 2H), 4.82 (s, 2H), 2.34 (s, 3H).
Step 3) Formation of N-(6-chloroimidazo[1,2-b]pyridazin-2-yl)-2,2,2- trifluoroacetamide
The title compound was prepared according to procedure described for Intermediate
4, step 3), but starting from 2-[(6Z)(3-chloro-6-{[(4- methylphenyl)sulfonyl]imino}pyridazin-1 (6/-/)-yl]acetamide. The title compound was obtained as an off-white solid (12 g, 88%). HPLC, Rt: 3.7 min (purity: 98.8%). UPLC/MS, M+(ESI): 265.0, M-(ESI): 263.1. 1H-NMR (DMSO-d6, 400 MHz) δ 12.70 (s, 1 H), 8.40 (s, 1 H), 8.18 (d, J=9.6 Hz, 1 H), 7.43 (d, J=9.6 Hz, 1 H).
Intermediate 6: 6-bromoimidazo[1 ,2-a]pyridin-2 -amine
A solution of Λ/-(6-bromoimidazo[1 ,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide (5.5 g, 18.2 mmol) and lithium hydroxide (1.2 g, 27.3 mmol) in THF/Water (5OmL, 7:3) was stirred at room temperature for 24h. THF was then removed under reduced pressure and the aqueous layer was extracted with DCM. Combined organic layers were then washed with brine, dried over sodium sulphate and concentrated under reduced pressure to give the titled compound as a pale brown solid (2.9 g, 77%). HPLC (X-Terra), Rt: 3.07 min (purity: 97.0%). LC/MS (Atlantis), M+(ESI): 214.1.1H-
NMR (DMSO-d6, 400 MHz) δ 8.58-8.59 (1 H, s), 7.11-7.13 (1 H, d), 7.05-7.07 (1 H, d), 6.98 (1 H1 S), 5.19 (2H, s).
Acetyl chloride (16.65 g, 0.212 mol) was added slowly to a solution of 6- bromoimidazo[1 ,2-a]pyridin-2-amine(45 g, 212 mmol) and triethylamine (64.3 g, 0.636 mol) in DCM (450 mL) over 15 minutes at 0-50C. The reaction mixture was warmed to RT and stirred for 12h at the same temperature. It was then poured into ice water (10OmL) and the precipitated solid was filtered, washed with water (75mL) and dried to give the title compound as brown solid. HPLC (Atlantis- 1 ), Rt: 3.67 min
(purity: 95.9%). LC/MS (Atlantis), M+(ESI): 253.9 .1H-NMR (DMSO-dθ, 400 MHz) δ 10.74 (1 H, s), 8.86 (1 H, d), 8.09 (1 H, s), 7.40-7.37 (1 H, m), 7.30-7.28 (1 H, m), 2.05 (3H, s).
Intermediate 8: N-(6-bromoimidazo[1 ,2-a]pyrazin-2-yl)-2,2,2-trifluoroacetamide
N-bromosuccinimide (22.4 g, 0.126 mol) was added portionwise to a stirred solution of 2-Aminopyrazine (15 g, 157 mmol) in CCI4 (500 ml.) at O0C. The reaction mixture was stirred at RT under nitrogen atmosphere. After 3 hours, the reaction mixture was filtered and the filtrate was concentrated under vacuum. The crude material was purified by flash chromatography on silica (PE:EtOAc) to give the title compound as a yellow solid. LC/MS (Atlantis), M+(ESI): 173.8.1H-NMR (DMSO-d6, 400 MHz) δ 8.01 (1 H, s), 7.66-7.67 (1 H, s), 6.63 (2H, brs).
Step 2) Formation of N-(5-Bromopyrazin-2-yl)-4-methylbenzenesulfonamide
Tosyl chloride (26.3 g, 0.137 mol) was added portionwise to a stirred solution of 5- Bromopyrazin-2-amine (20 g, 28.7 mmol) in dry pyridine (120 ml.) at O0C. The reaction mixture was heated at 900C for 16 hours. Pyridine was removed under reduced pressure and the crude was slurried in water (250 ml.) and stirred for 30 min. The solid obtained was filtered, washed with water and dried under reduced pressure to give the titled compound as a white solid. HPLC (Atlantis-1 ), Rt: 4.51 min (purity: 90.7%). LC/MS (Atlantis), M+(ESI): 327.8. 1H-NMR (DMSO-d6, 400 MHz) δ 1 1.8 (1 H, brs), 8.43-8.42 (1 H, s), 8.17-8.16 (1 H, s), 7.82-7.80 (2H, m), 7.39-7.37 (2H, m), 2.49-
2.48 (3H, s).
A solution of of Λ/-(5-Bromopyrazin-2-yl)-4-methylbenzenesulfonamide (2g, mmol), DIEA (1.3 ml_, 6.7 mmol) and 2-bromoacetamide (0.9 g, 6 mmol) in dry DMF (5 mL) was stirred at RT for 72 hours. The reaction mixture was then poured into water (25 mL) and stirred for another 1 hour. The solid obtained was collected by filtration, washed with water (2OmL) and dried under vacuum to give the title compound as a brown solid. HPLC (Atlantis-1 ), Rt: 3.89 min (purity: 99.6%). LC/MS (Atlantis), M+(ESI): 387.0. 1H-NMR (DMSO-d6, 400 MHz) δ 8.67 (1 H, s), 8.43 (1 H, s), 7.8 (1 H, s), 7.71-7.69 (2H, m), 7.47 (1 H, s), 7.32-7.30 (2H, m), 4.70 (2H, s), 2.34 (3H, s).
Trifluoroacetic anhydride (45 mL) was added dropwise to a stirred solution of 2-[5- Bromo-2-{[(4-methylphenyl)sulfonyl]imino}pyrazin-1 (2/-/)-yl] acetamide (9g, 23.3 mmol) in anhydrous DCM (180 mL), The reaction mixture was heated to reflux for 3 hours under nitrogen. The mixture was then concentrated under reduced pressure to afford a solid which was suspended in aqueous sodium bicarbonate (10%, 50ml) solution and stirred for 15 min. The solid was filtered to give the title compound as a light brown solid. HPLC (Atlantis-1 ), Rt: 3.78 min (purity: 95.2%). LC/MS (Atlantis),
M+(ESI): 31 1.0. 1H-NMR (DMSO-d6, 400 MHz) δ 13.0 (1 H, brs), 8.93 (1 H, s), 8.78 (1 H, s), 8.38 (1 H, s).
The title compound was prepared following procedure described for intermediate 6, but starting from N-(6-Bromoimidazo[1,2-a]pyrazin-2-yl)-2,2,2-trifluoroacetamide.
Intermediate 9: 6-Chloro[1 ,3]thiazolo[4,5-c]pyridin-2 -amine
Step 1) Formation of N-(6-Chloro[1 ,3]thiazolo[4,5-c]pyridin-2-yl)benzamide
Benzoyl chloride (8.96 g, 63.7 mmol ) was added dropwise over 10 minutes to a solution of ammonium thiocyanate (4.85 g, 63.7 mmol) in acetone (75 ml.) heated at 600C. After 30 min, a solution of 4,6-dichloropyridin-3-ylamine (10 g, 61.3 mmol) in acetone (75 ml.) was added over 10 minutes and the reaction mixture was stirred at 600C. After one hour, it was poured to cold water (500 ml.) and the resulting precipitated solid was filtered, washed with water (150 ml.) and dried under reduced pressure to give the title compound as white solid (16 g, 90.4 %). HPLC (Atlantis-1 ), Rt: 5.44 min (purity: 97.2%). LC/MS (Atlantis), M+(ESI): 291.8. 1H-NMR (DMSO-d6,
400 MHz) δ 13.22 (1 H, brs), 8.86(1 H, s), 8.26 (1 H, s), 8.14-8.12 (2H, m), 7.68-7.66 (1 H, m), 7.60-7.56 (2H, m).
Λ/-(6-chloro[1 ,3]thiazolo[4,5-c]pyridin-2-yl)benzamide (16 g, 54.8 mmol) was dissolved in concentrated sulphuric acid (100 ml.) under nitrogen atmosphere. The reaction mixture was stirred for 2h at 1100C then cooled down to 0-50C. It was neutralized to pH 7 by addition of sodium hydroxide (50% solution) while maintaining temperature at 0-50C. The precipitated solid was filtered, washed with water (1 L) and dried under reduced pressure to give the title compound as a white solid (10g, 98%). HPLC (Atlantis-2), Rt: 4.33 min (purity: 97.2%). LC/MS (Atlantis), M+(ESI): 186.1. 1H-NMR (DMSO-d6, 400 MHz) δ 8.31 (1 H, s), 7.94 (2H, brs), 7.86 (1 H, s).
Intermediate 10: 5-chloro[1 ,3]thiazolo[5,4-b]pyridin-2 -amine
Step 1) Formation of N-{[(2,6-Dichloropyridin-3-yl)amino]carbonothioyl}benzamide
Benzoyl chloride (44.84 g, 31.9 mmol) was added dropwise over 10 minutes to a solution of ammonium thiocyanate (24.3g, 31.9 mmol) in acetone (150 mL) heated at 55°C. After 30 min, a solution of 2,6-dichloropyridin-3-amine (50 g, 30.6 mmol) in
acetone (150 ml.) was added over 10 minutes and the reaction mixture was stirred at 55°C. After one hour, it was poured to cold water (500 ml.) and the resulting precipitated solid was filtered, washed with water (150 ml.) and dried under reduced pressure to give the title compound as white solid (95g, 95%). HPLC (Atlantis-1 ), Rt: 5.49 min (purity: 98.1 %). LC/MS (Atlantis), M+(ESI): 326.0. 1H-NMR (DMSO-d6, 400 MHz) δ 12.61 (1 H, brs), 1 1.99 (1 H, brs),8.47 (1 H, m), 8.00-7.98 (2H, m), 7.69-7.65 (2H, m), 7.56-7.52 (2H, m).
Freshly prepared sodium methoxide (31.6 g, 584 mmol) was added to a solution of N-
{[(2,6-dichloropyridin-3-yl)amino]carbonothioyl}benzamide (95 g, 29.2 mmol) in NMP (550 ml.) at RT. Reaction mixture was stirred at 1200C for 4h, then cooled down to RT and poured to cold water (1 L). Precipitated solid was filtered, washed with water (1 L) and dried to give the title compound as a pale yellow solid (80 g, 95%). LC/MS
(Atlantis), M+(ESI): 290.0. 1H-NMR (DMSO-d6, 400 MHz) δ 13.13 (1 H, brs), 8.20-8.18 (1 H, m), 8.13-8.1 1 (2H, m), 7.69-7.66 (1 H, m), 7.60-7.55 (3H, m).
Λ/-(5-Chloro[1 ,3]thiazolo[5,4-b]pyridin-2-yl)benzamide (60 g, 20.6 mmol) was dissolved in concentrated sulphuric acid (300 mL) under nitrogen atmosphere. The reaction mixture was stirred for 2h at 1000C then cooled down to 0-5°C. It was neutralized to pH 7 by addition of sodium hydroxide (50% solution) while maintaining temperature at 0-50C. The precipitated solid was filtered, washed with water (1 L) and dried under reduced pressure to give the title compound as a white solid (32g, 84%). HPLC (Atlantis-2), Rt: 4.69 min (purity: 99.0%). LC/MS (Atlantis), M+(ESI): 186.1. 1H- NMR (DMSO-d6, 400 MHz) δ 7.92 (2H, brs), 7.65-7.63 (1 H, d), 7.30-7.28 (1 H, d).
Intermediate 11 : [2-(3-tert-butyl-1 ,2,4-oxadiazol-5-yl)ethyl]amine hydrochloride
To a stirred solution of trimethylacetonitrile (30.8 g, 372 mmol) in absolute ethanol (250 mL) was added hydroxylamine hydrochloride (25.9 g, 372 mmol) followed by potassium carbonate (51.5 g, 372 mmol). The mixture was stirred at room temperature for 2Oh and filtered. The filtrate was removed under vacuum to give the title compound as a a viscous liquid (34 g, 92%). 1H-NMR (DMSO-dθ, 400 MHz) δ 1.25 (9H, s), 4.6 (2H, bs), 8.65 (1 H, brs).
DIC (1 1 g, 87 mmol) was added dropwise to a solution of Λ/-hydroxy-2,2- dimethylpropanamidamide (10 g, 86 mmmol) and 3-[(tert- butoxycarbonyl)amino]propanoic acid (18 g, 90 mmol) in dry DCM (15OmL). The reaction mixture was stirred at room temperature for 11 h. It was then filtered and concentrated under reduced pressure. The residue obtained was suspended in pyridine (100 mL) and refluxed for 5h. The pyridine was removed under reduced pressure and the residue was diluted with ethyl acetate (150 mL). The organic phase was washed with water, brine, dried over magnesium sulfate, filtered and concentrated. The crude was purified by flash chromatography on silica (chloroform: MeO H, 90:10) to give the titled compound as a thick liquid. LC/MS
(Atlantis), M+(ESI): 269.9. 1H-NMR (CDCI3-d6, 400 MHz) δ 1.27 (9H, s), 1.35 (9H, s), 2.91-2.94 (2H, m), 3.22-3.26 (2H, m), 7.03 (1 H, brs). Step 3) Formation of [2-(3-tert-Butyl-1 ,2,4-oxadiazol-5-yl)ethyl]amine hydrochloride
A solution of te/f-butyl [2-(3-te/f-butyl-1 ,2,4-oxadiazol-5-yl)ethyl]carbamate (10 g, 49 mmol) in dioxane /HCI (150 mL, 2M) was stirred at room temperature for 5h. The solvent was removed under reduced pressure to give the titled compound as a solid (7g, 92%). HPLC (Atlantis-1 ), Rt: 4.41 min (purity: 99.5%). LC/MS (Genesis), M+(ESI): 170.3. 1H-NMR (CDCI3-d6, 400 MHz) δ 1.28 (9H, s), 3.21-3.23 (2H, m), 3.29-3.32 (2H, m), 8.47 (3H, brs).
Intermediate 12: [2-(5-cyclopentyl-1 ,2,4-oxadiazol-3-yl)ethyl]amine
Step 1) Formation of tert-Butyl 2-cyanoethylcarbamate
Di-tert-Butyldicarboxylate (186.5 g, 856 mmol) was added to a solution of 3- aminopropanenitrile (50 g, 713 mmol) and TEA (72.1 g, 0713 mmol) in dry DCM (500 ml.) at O0C. The reaction mixture was then stirred at room temperature for 14h. It was washed with 10% citric acid (2x500mL), water (2x200ml_) and brine (50OmL), dried over sodium sulfate, filtrated and concentrated. The crude was purified by flash chromatography on silica (chloroform: MeOH, 9:1 ) to give the title compound as a white solid. 1H NMR (CDCI3, 400MHz): δ 5.1 (1 H, bs), 3.41-3.36 (2H, m), 2.60-2.57 (2H, t),1.43 (9H, s),
Step 2) Formation of tert-Butyl -3-amino-3-(hydroxyimino)propylcarbamate
Hydroxylamine (29.2 g, 882 mmol) was added dropwise to a solution of te/f-butyl 2- cyanoethylcarbamate (5Og, 294 mmol) in absolute Ethanol (1 L) at room temperature. Reaction mixture was then refluxed for 16 h and concentrated under reduced pressure. The solid was slurried in ethyl acetate (500 mL), filtered, washed with PE (100 mL) and dried to give the title compound as a white solid. LC/MS (Genesis),
M+(ESI): 203.9. 1H-NMR (CDCI3, 400 MHz) δ 5.18 (1 H, brs), 4.91 (2H, brs), 3.38-3.35 (2H, m), 2.38-2.35 (2H, t),1.36 (9H, s).
Step 3) Formation of tert-Butyl -3-amino-3-{[(cyclopentylcarbonyl)oxy] iminojpropylcarbamate
Cyclopentane carbonyl chloride (8.48 g, 64 mmol) was added to a solution of tert- butyl-3-amino-3-(hydroxyimino)propyl carbamate (10 g, 49.3 mmol) and DIEA (12.7 g,
98.5 mmol) in dry DCM (200 ml_). The reaction mixture was stirred at room temperature for 18h under nitrogen. Solvent was removed under reduced pressure and the solid obtained was slurried in EtOAc:EP (1 :9, 100 ml_), filtered and dried to give the title compound as a whte solid. 1H NMR (CDCI3, 400MHz): 810.9 (1 H, brs), 5.55 (1 H, brs), 3.68-3.62 (2H, m), 3.40-3.37 (1 H, m), 3.12-3.05 (2H, m), 2.48-2.45
(1 H, m), 2.35-2.26 (2H, m), 1.93-1.85 (2H, m), 1.74-1.62 (1 H, m), 1.58-1.41 (3H, m), 1.42 (9H, m).
A solution of fe/f-butyl -3-amino-3-{[(cyclopentylcarbonyl)oxy]imino}propylcarbamate (10 g, 33.4 mmol) in pyridine (30 ml.) was refluxed for 16h. The pyridine was removed under reduced pressure and the residue was dissolved in EtOAc (200 ml_), washed with water (2x200 ml_), brine (200 ml_), dried over sodium sulfate, filtered and concentrated to give the title compound as a white solid (7 g, 75%). 1H NMR (CDCI3,
400MHz) δ5.01 (1 H, brs), 3.55-3.51 (2H, m), 3.34-3.30 (1 H, m), 2.92-2.89 (2H, t), 2.15-2.10 (2H, m), 1.94-1.87 (2H, m),1.85-1.83 (2H, m), 1.82-1.64 (2H, m),1.41 (9H, s).
A solution of te/f-butyl 2-(5-cyclopentyl-1 ,2,4-oxadiazol-3-yl)ethylcarbamate (7 g, 24.9 mmol) in dry dioxane/Hcl (100 ml_, 2N) was stirred at room temperature for 5h. The solvent was removed under reduced pressure to give the titled compound as a pale yellow solid (4.7 g, 86%). HPLC (C18 BDS), Rt: 3.84 min (purity: 99.7%). LC/MS
(Genesis), M+(ESI): 181.9. 1H-NMR (DMSO-d6, 400 MHz) δ 8.31 (3H, brs), 3.43-3.35 (1 H, m), 3.12-2.90 (4H, m), 2.10-2.05 (2H, m), 1.85-1.79 (2H, m), 1.78-1.52 (4H, m).
Intermediate 13: 2-[3-(2-aminoethyl)-1 ,2,4-oxadiazol-5-yl]-2-methylpropan-1 -ol Step 1) Formation of tert-butyl (3Z)-3-amino-3-{[(3-hydroxy-2,2-dimethylpropanoyl)oxy]imino} propylcarbamate
A solution of 2,2-Dimethyl-3-hydroxy propionic acid (1 1.6 g, 93.8 mmol), EDCHCI (18.85 g, 98.3 mmol) and 1-hydroxybenzo-triazole (6.6 g, 49.1 mmol) in dry DCM (125 ml.) was stirred at RT under nitrogen for 30minut.es. te/f-Butyl (3Z)-3-amino-3- (hydroxyimino)propylcarbamate (10 g, 49.1 mmol) was then added and the reaction mixture was stirred for 12h at RT. Then reaction mixture was quenched with water and extracted with DCM (2x250ml_). Combined organic layers were washed with 10% sodium bicarbonate (250 ml_), water (250 ml.) and brine (250 ml_), dried over sodium sulfate, filtered and concentrated The crude was purified by flash chromatography on silica (PE. EtOAc) to give the title compound as an orange-yellow liquid (1 1 g, 77%).
1H NMR (DMSO-de, 400MHz): δ 6.76-6.79 (1 H, t), 6.23 (2H, brs), 5.05-5.08 (1 H, t), 3.32-3.42 (2H, m), 3.1-3.15 (2H,q, J1 6.92, J2 14.56), 1.36 (9H, s), 1.04 (6H, s).
Step 2) Formation of tert-butyl 2-[5-(2-hydroxy-1 , 1-dimethylethyl)-1 ,2,4-oxadiazol-3- yljethylcarbamate
Tertiary butyl ammonium fluoride trihydrate (22.3 g79.1 mmol) was added to a solution of te/f-butyl (3Z)-3-amino-3-{[(3-hydroxy-2,2- dimethylpropanoyl)oxy]imino}propylcarbamate (12 g, 39.5 mmol) in THF(125 ml_). Reaction mixture was then stirred at RT for 12h. It was then quenched with water and extracted with EtOAc (2X250 ml_). Combined organic layers were washed with water
(250 ml.) and brine (250 ml_), dried over sodium sulfate, filtered and concentrated.
The crude was purified by flash chromatography on silica (HCCI3:MeOH) to give the title compound as a white solid (9g, 76%). 1H NMR (DMSO-d6, 400MHz): δ 6.90-6.93 (1 H, t), 4.99-5.01 (1 H, brs), 3.52-3.53 (2H, d, J = 5.7 Hz), 3.21-3.26 (2H, m), 2.73-2.77
(2H, t), 1.36 (9H, s).1.24 (6H, s).
Step 3) Formation of
HCI in dioxane (4N, 150 ml.) was added to a solution of te/f-butyl 2-[5-(2-hydroxy- 1 ,1-dimethylethyl)-1 ,2,4-oxadiazol-3-yl]ethylcarbamate (12 g, 41.9 mmol) in dioxane (75 ml.) maintained at O0C. The reaction mixture was stirred for 12h at RT and concentrated under reduced pressure to give the title compound as colorless liquid
(8.5 g, 91%). HPLC (Eclipse), Rt: 3.57 min (purity: 98.7%). 1H-NMR (DMSO-dθ, 400 MHz) δ 8.21 (3H, brs), 5.08 (1 H, brs), 3.53-3.55 (2H, d), 3.12 (2H, m) 3.02-3.06 (2H, m) 1.29 (6H, s).
Intermediate 14: {2-[5-(2-fluoro-1 ,1 -dimethylethyl)-1 ,2,4-oxadiazol-3- yl]ethyl}amine
Step 1) Formation of tert-butyl 2-[5-(2-fluoro- 1, 1 -dimethylethyl)-1 ,2, 4-oxadiazol-3-yl]ethylcarbamate
Diethyl amino sulphur trifluride (1.16 g, 6.9 mmol) was added slowly to a stirred solution of te/f-butyl 2-[5-(2-hydroxy-1 ,1-dimethylethyl)-1 ,2,4-oxadiazol-3- yl]ethylcarbamate (2 g, 5.7 mmol) in dry DCM (20 ml_)maintained at -600C under nitrogen atmosphere. Reaction mixture was then warmed RT and stirred for 12hrs It was quenched with water and extracted with EtOAc (2X250 ml_). Combined organic layers were washed with water (250 ml.) and brine (25OmL), dried over sodium sulfate, filtered and concentrated. The crude was purified by flash chromatography on silica (EP:EtOAc) to give the title compound as a pale yellow liquid.1H NMR (DMSO- d6, 400MHz): δ 4.98 (1 H, bs), 4.59( 1 H, s), 4.48 (1 H, s), 3.54-3.58 (2H, q, J1-2.2J2- 8.4), 2,921-2.953 (2H, t),1.47 (6H, s)1.42 (9H, s).
Step 2) formation of
2-[5-(2-fluoro-1 , 1 -dimethylethyl)-1 ,2,4-oxadiazol-3-yl]ethanamine hydrochloride
The title compound was prepared following procedure described for intermediate 13, step 3), but starting from te/f-butyl 2-[5-(2-fluoro-1 ,1-dimethylethyl)-1 ,2,4-oxadiazol-3- yl]ethylcarbamate (3.5 g, 12.1 mmol). The title compound was obtained as a colorless liquid (2.5g, 95%). HPLC (Eclipsed), Rt: 3.57 min (purity: 96.32. 1H NMR (CDCI3-d6, 400MHz) δ 8.29 (3H, brs), 4.56 (1 H, s), 4.44 (1 H, s), 3.50 (2H, brs.), 3.29-3.33 (2H, t),
1.42 (6H, s).
Intermediate 15: [2-(5-ethyl-2H-tetrazol-2-yl)ethyl]amine
Step 1) Formation of 5-Ethyl-1H-tetrazole
A solution of propionitrile (25 g, 45.4 mmol), trimethylsilylazide (104.5 g, 90.8 mmol) and dibutyltinoxide (1 1.0 g, 45.4 mmol) in dry toluene (300 ml.) was heated at 980C under nitrogen for 24h. The reaction mixture was cooled down to RT and poured into water (90 ml_). The mixture was stirred for 1 h at RT, then the aqueous phase was washed with EtOAc (2x100 ml.) and acidified to pH 2 by addition of concentrated HCI.
The precipitate thus obtained was filtered and dried under reduced pressure to give the title compound as a white solid. 1H NMR (DMSOd6, 400MHz) δ 16.02 (1 H, s), 2.79-2.81 (2H, m), 1.20-1.24 (3H, t).
Di-tert-butyl dicarboxylate (39.24 g, 180 mmol) was added to a solution of 2- bromoethylamine hydrobromide (25 g, 122 mmol)and TEA (60 g, 61.4 mmol) in dry MeOH (100 ml_). The reaction mixture was stirred at 750C for 24h. Solvent was removed under reduced pressure and the residue was dissolved in EtOAc (150 ml_).
The solution was washed with brine, dried over sodium sulfate, filtered and concentrated. The crude was purified by flash chromatography (Hex:EtOAc) to give the title compound as a solid. 1H NMR (DMSO-d6 400MHz) δ 7.10 (1 H, brs), 3.39-
3.43 (2H, m), 3.25-3.23 (2H, m), 1.38 (9H, s).
Step 3) Formation of tert-butyl [2-(5-ethyl-2H-tetrazol-2-yl)ethyl]carbamate and tert-butyl 2-(5-ethyl- 1 H-tetrazol- 1 -yl)ethylcarbamate
A solution of 5-ethyl-1 /-/-tetrazole (2 g, 20.3 mmol), TEA (2 g, 102 mmol) and tert- butyl 2-bromoethylcarbamate (4.5 g, 20.3 mmol) in dry ACN (25 ml.) was stirred under nitrogen atmosphere at 700C for 18h. The solvent was removed under reduced pressure and the residue was purified by flash chromatography on silica (PE:EtOAc) to give the title compounds as pale-yellow liquids of fe/f-butyl [2-(5-ethyl-2/-/-tetrazol- 2-yl)ethyl]carbamate along with 0.8 g of te/f-butyl 2-(5-ethyl-1 H-tetrazol-1- yl)ethylcarbamate. Major isomer: 1H NMR (DMSOd6 400MHz) δ 6.97 (1 H, s), 4.58- 4.61 (2H, t), 3.37-3.47 (2H, m), 2.78-2.83 (2H, m), 1.32(12H, s); Minor isomer: 1H NMR (DMSO-d6 400MHz) δ 6.97 (1 H, s), 4.33-4.36 (2H, t), 3.28-3.33 (2H, t), 2.78-
2.83 (2H, m), 1.32 (12H, s).
Step 4) Formation of 2-(5-ethyl-2H-tetrazol-2-yl)ethanamine hydrochloride
A solution of of te/f-butyl [2-(5-ethyl-2H-tetrazol-2-yl)ethyl]carbamate (2 g, 23.1 mmol) in dry dioxane/HCI (200 ml_, 2N) was stirred at room temperature for 12h. The solvent was removed under reduced pressure. The brown solid obtained was slurried in ACN (30 ml_), filtered and dried to give the titled compound as a pale brown solid. 1H NMR (DMSO-d6, 400MHz) δ 8.31 (3H, s), 4.88-4.91 (2H, t), 3.36-3.38 (2H, t), 2.82- 2.87 (2H, m), 1.25-1.31 (3H, t).
Intermediate 16: [2-(5-cyclopropyl-2H-tetrazol-2-yl)ethyl]amine
Step 1) Formation of 5-Cyclopropyl-2H-tetrazole
A solution of cyclopropanecarbonitrile (20 g, 298 mmol), sodium azide (58 g, 894 mmol) and TEA.HCI (122 g, 894 mmol) in toluene (300 mL) was heated to 11 O0C under nitrogen atmosphere for 24h. Reaction mixture was cooled down to RT and
water (90 mL) was added. The two phases were separated and aqueous phase was acidified with concentrated HCI to pH (1-2). The precipitated solid was filtered and dried to give the title compound as a white solid (14 g, 80%). LC/MS (Atlantis), M+(ESI): 102.2. 1H-NMR (DMSO-dθ, 400 MHz) δ 2.23-2.16 (1 H, m),1.19-1.16 (2H,m),1.13-1.09 (2H, m). Step 2) Formation of tert-Butyl 2-(5-cyclopropyl-2H-tetrazol-2-yl)ethylcarbamate
A solution of te/f-Butyl-2-bromoethylcarbamate (10.2 g, 45 mmol) and TEA (22.7 mL, 225 mmol) in ACN (30 mL) was added dropwise to a solution of 5-cyclopropyl-2H- tetrazole (5 g, 45 mmol) in ACN (80 mL). The reaction mixture was then stirred under nitrogen atmosphere at 7O0C for 18h. Acetonitrile was removed under reduced pressure and ethyl acetate was added to the residue. The semi-solid obtained was washed with hexane, filtered and dried to give the first regioisomer, te/f-butyl 2-(5- cyclopropyl-1 /-/-tetrazol-1-yl) ethylcarbamate as a white solid. The second regioisomer, tert-Butyl 2-(5-cyclopropyl-2H-tetrazol-2-yl)ethylcarbamate was obtained by concentration of the hexane filtrate as a yellow oil. First regioisomer: te/f-butyl 2- (5-cyclopropyl-1 H-tetrazol-1-yl) ethylcarbamate. LC/MS (Atlantis), M+(ESI): 254.3. 1H- NMR (DMSO-d6, 400 MHz) δ 1H NMR (DMSO-d6 400MHz) d 7.0 (1 H, bs), 4.47-4.44 (2H, m), 3.37-3.32 (2H, m), 2.13-2.09 (1 H, m), 1.31 (9H, s), 1.14-1.12 (2H, m), 1.1 1- 1.0.99 (2H, m). Second regioisomer: tert-Butyl 2-(5-cyclopropyl-2H-tetrazol-2- yl)ethylcarbamate. LC/MS (Atlantis), M+(ESI): 254.3. 1H-NMR (DMSO-d6, 400 MHz) δ 1H NMR (DMSO-d6 400MHz) d 6.890 (1 H, bs), 4.5765-4.5476(2H, m), 3.401- 3.2088 (2H, m), 2.1713-2.1384 (1 H, m), 1.3230(9H, s), 1.0689-1.0583(2H, m), 1.057- 1.0374 (2H, m).
Step 3) Formation of [2-(5-cyclopropyl-2H-tetrazol-2-yl)ethyl]amine hydrochloride
The title compound was prepared following procedure described for intermediate 13, step 3), but starting from tert-Butyl 2-(5-cyclopropyl-2H-tetrazol-2-yl)ethylcarbamate.
Intermediate 17: [2-(5-tert-butyl-1 ,3-oxazol-2-yl)ethyl]amine hydrochloride
Step 1 ) Formation of benzyl 3-[(3,3-dimethyl-2-oxobutyl)amino]-3- oxopropylcarbamate
A mixture of Z-Beta-Ala-OH (3.6 g, 016.5 mmol), EDCI. HCI (4.12 g, 21.5 mmol) hydroxybenzotriazole (2.25 g, 16.5 mmol), TEA (2.9 mL, 21.5 mmol), in dry DCM (75 ml.) was stirred at O0C under nitrogen for 30 min. 1-Amino-3,3-dimethylbutan-2-one (2.5 g, 16.5 mmol) was added and the reaction mixture was stirred for 1 h at RT. Water was added, the phases swere separated and the aqueous phase was extracted with DCM (2x150 mL). Combined organic phases were dried over sodium sulfate, filtered and concentrated. The crude was purified by flash chromatography on silica (PE: ETOAC) to give the titled compound as a orange-yellow liquid (3.4g, 80%). 1H NMR (DMSOd6, 400MHz) δ (1 H, s), 7.35-7.29 (5H, m), 7.20 (1 H, s), 4.99 (2H, s), 4.10 (2H, d), 3.18 (2H, d), 2.32 (2H, t), 1.09 (9H, s).
Iodine (3.55 g, 14 mmol) was added portionwise to a solution of triphenylphosphine (3.68 g, 14 mmol) in dry DCM (50 mL) over a period of 30 minutes. Reaction mixture was stirred under nitrogen at RT for 30 min before the addition of a solution of TEA (2.8 g, 28.2 mmol) and benzyl 3-[(3,3-dimethyl-2-oxobutyl)amino]-3- oxopropylcarbamate (3 g, 9.36 mmol) in dry DCM (30 mL). Reaction mixture was stirred again at RT for 12h. Solvent was removed under reduced pressure and the crude was purified by flash chromatography on silica (PE:EtOAc) to give the title compound as pale yellow liquid. 1H NMR (DMSOd6, 400MHz) δ 7.39-7.29 (5H, m), 6.66 (1 H, s), 4.99 (2H, s), 3.34 (2H, m), 2.83-2.79 (2H, m), 1.20 (9H, s).
Palladium on carbon (1.5 g) was added to a solution of 4-methoxy-1-[(1 E)-3- (methylthio)prop-1-enyl]-2-nitrobenzene(3.5 g) in dry ethanol (300 ml_).The mixture was hydrogenated under a pressure of 7 bars of hydrogen for 12h. The catalyst was removed by filtration and the filtrate was concentrated under reduced pressure. The crude was purified by flash chromatography on silica (PE: EtOAc) to give the title compound as brown thick liquid (1.5g, 78%). Hydrochloride salt was prepared by addition of HCI/dioxane. HPLC (Atlantis-1 ), Rt: 3.85 min (purity: 98.2%). LC/MS (Atlantis), M+(ESI): 169.3. 1H-NMR (DMSO-dθ, 400 MHz) δ 6.75 (1 H, s), 5.2-5.4 (3H, brs), 3.16-3.13 (2H, t), 3.06-3.02 (2H, t), 1.23 (9H, s).
Intermediate 18: [2-(5-ethyl-1 ,3-oxazol-2-yl)ethyl]amine
Step 1 ) Formation of Benzyl 3-[(2-hydroxybutyl)amino]-3-oxopropylcarbamate
The title compound was prepared according to procedure described for Intermediate
17 step 1 ), but starting from 1-Amino-2-butanol (4.2 ml_, 44.3 mmol). The title compound was obtained as a a orange-yellow liquid (10.5 g, 81%). 1H-NMR (CDCI3, 400MHz) δ 7.34-7.26 (5H, m)6.34 (1 H, s), 5.58 (1 H, s), 5.08 (1 H, s), 3.61-3.58 (1 H, t), 3.49-3.43 (3H, m), 3.1 1-3.07 (1 H, m),2.46-2.43 (3H, d),1.50-1.43 (2H m), .096-.093 (3H, t).
Step 2) Formation of Benzyl 3-oxo-3-[(2-oxobutyl)amino]propylcarbamate
DMSO (4 ml_, 057.1 mmol) was added dropwise to a solution of oxalyl chloride (3.8 ml_, 42.8 mmol) in dry DCM maintained at-78°C under nitrogen. After 15 minutes, a solution of benzyl 3-[(2-hydroxybutyl)amino]-3-oxopropylcarbamate (10.5 g, 35.7 mmol) in dry DCM (75 ml.) was added. TEA (21 ml.) was added to the solution maintained at -78°C after one hour. The reaction mixture was then stirred one more hour at this temperature and then warmed up to RT. It was then diluted with DCM (100 ml_), washed with HCI (1.5N, 200 ml_), saturated sodium bicarbonate solution
(200 ml_), water (200 ml_), and brine solution (200 ml_), dried over sodium sulfate, filtered and concentrated to give the title compound as a white solid (8.5 g, 85%). 1H NMR (CDCI3, 400MHz) δ 7.34-7.26 (5H, m), 6.34 (1 H, s), 546 (1 H, s), 5.08 (1 H, s), 4.13-4.12 (2H, d),3.50-3.49 (2H,d),2.50-2.45(5H,m),1.141.10(3H,t).
The title compound was prepared according to procedure described for Intermediate 17B step 2), but starting from benzyl 3-oxo-3-[(2-oxobutyl)amino]propylcarbamate). The title compound was obtained as pale yellow liquid. 1H NMR (DMSO-dβ, 400MHz) δ 7.4-7.29 (5H, m), 6.69(1 H, s)4.99 (2H, s),3.34 -3.32(2H, m), 2.83-2.79(2H,t),2.5- 2.48(2H,m)1.16-1.1 1 (3H, m).
The title compound was prepared according to procedure described for Intermediate 17 step 3), but starting from benzyl 2-(5-ethyl-1 ,3-oxazol-2-yl)ethylcarbamate (7g). The title compound was obtained as an off white solid. HPLC, Rt: 2.89 min (purity: 86.0%). LC/MS (Atlantis), M+(ESI): 141.1. 1H-NMR (DMSO-d6, 400 MHz) δ 6.69-6.67 (1 H, s), 2.91-2.86(2H, m), 2.77-2.72 (2H, m),2.62-2.58(2H, m), 1.16-1.12(3H,t).
Intermediate 19: [2-(4-isopropyl-1 ,3-oxazol-2-yl)ethyl]amine
Stepi) Formation of benzyl 3-{[1 -(hydroxymethyl)-2-methylpropyl] amino}-3- oxopropylcarbamate
The title compound was prepared according to procedure described for Intermediate 17 step 1 ), but starting from 2- Amino- 3 -methyl -1 - butanol (DL- Valinol) (30gm, 0.2916mol). The title compound was obtained as a white solid (40 g, 91%). LC/MS (Atlantis), M-(ESI): 306.0. 1H-NMR (DMSO-d6, 400 MHz) δ 7.50 (1 H, bs), 7.35-7.40
(5H, m), 7.20 (1 H, bs), 5.21 , (2H, s), 3.54-3.62 (1 H, m), 3.25-3.31 (2H, m), 3.15-3.20 (2H, m), 3.11-3.19 (1 H,m), 2.25-2.30 ( 2H, m), 0.78-0.90 (6H, m).
The title compound was prepared according to procedure described for Intermediate 18 step 2), but starting benzyl 3-{[1-(hydroxymethyl)-2-methylpropyl] amino}-3- oxopropylcarbamate (40 g, 129 mmol). The title compound was obtained as a liquid (40 g, 90%). 1H NMR (DMSOd6, 400MHz) δ 9.40 (1 H, s), 8.20 (1 H, bs), 7.38 (1 H, bs), 7.35-7.40 (5H, m) 5.21 (2H, s), 3.25-3.31 (2H, m), 3.1 1-3.20 (1 H, m), 2.25-2.30 (2H, m), 2.13-2.1 1 (1 H, m) 0.78-0.90 (6H, m).
The title compound was prepared according to procedure described for Intermediate 17 step 2), but starting from benzyl 3-[(1-formyl-2-methylpropyl)amino]-3- oxopropylcarbamate (40 g, 130 mmol). The title compound was obtained as a yellow liquid. HPLC (Atlantis-1 ), Rt: 4.48 min (purity: 84.3%). LC/MS (Atlantis), M-(ESI): 289.0. 1H-NMR (DMSO-d6, 400 MHz) δ 7.67-7.77 (1 H, m), 7.30-7.40 (6H, m), 5.10
(2H, s), 3.30-3.41 (2H, m), 2.80-2.90 (2H, m), 2.65-2.71 (1 H, m), 1.12-1.24 (6H, m).
Step 4) Formation of 2-(4-lsopropyl-1 ,3-oxazol-2-yl)ethanamine
17 step 3), but starting from benzyl 2-(4-isopropyl-1 ,3-oxazol-2-yl)ethylcarbamate (12 g, 41 mmol). The title compound was obtained as a yellow liquid. HPLC (Atlantis-2), Rt: 3.51 min (purity: 98.7%). LC/MS (Atlantis), M-(ESI): 155.0. 1H-NMR (DMSO-d6, 400 MHz) δ 7.61 (1 H, s), 2.90-2.95 (2H, m), 2.65-2.82 (3H, m), 1.12 (6H, d).
Intermediate 20: [2-(4-tert-butyl-1 ,3-oxazol-2-yl)ethyl]amine
Step 1) Formation of benzyl 3-{[(1R)-1-(hydroxymethyl)-2,2-dimethylpropyl]amino}-3- oxo propyl carbarn ate
The title compound was prepared according to procedure described for Intermediate 17 step 1 ), but starting from L-Tert-Leucinol (5 g, 42 mmol). The title compound was obtained as a colorless liquid (14 g, 95%). LC/MS (Atlantis), M-(ESI): 323.3. 1H-NMR (DMSO-d6, 400 MHz) δ 7.42 (1 H, brs), 7.33-7.35 (5H, m), 7.16 (1 H, brs), 4.99 (2H, s),
3.56-3.60 (2H, m), 3.25-3.27 (2H, m), 3.15-3.20 (1 H, m), 2.32-2.42 (2H, m), 0.818 (9H, m).
Step 2) Formation of benzyl 3-{[(1 R)-1 -formyl-2,2-dimethylpropyl]amino}-3- oxopropylcarbamate
The title compound was prepared according to procedure described for Intermediate 18, step 2), but starting from Benzyl 3-{[(1 R)-1-(hydroxymethyl)-2, 2- dimethylpropyl]amino}-3-oxopropylcarbamate (14 g, 46.4 mmol). The title compound was obtained as a colorless liquid (14 g, 95%). 1HNMR (DMSOd6, 400MHz) δ 9.56
(1 H, s), 7.45 (1 H, brs), 7.33 -7.35 (5H, m) 7.20(1 H, brs), 4.99 (2H,s), 3.56-3.62 (2H, m), 3.25-3.27 (2H, m), 3.20-3.35 (1 H, m), 0.81 (9H, m).
Step 3) Formation of benzyl 2-(4-tert-butyl-1,3-oxazol-2-yl)ethylcarbamate
The title compound was prepared according to procedure described for Intermediate 17, step 2), but starting from benzyl 3-{[(1 R)-1-formyl-2,2-dimethylpropyl] amino}-3- oxopropylcarbamate (14 g, 43 mmol). The title compound was obtained as a yellow
liquid. LC/MS (Atlantis), M-(ESI): 303.0. 1H NMR (DMSO-d6, 400MHz) δ 7.60 (1 H, brs), 7.45-7.51 (7H, m), 5.10 (2H, s), 3.30-3.32 (2H, m), 3.31-3.32 (2H, m), 2.75-2.85 (2H, m), 1.15 (9H, s).
The title compound was prepared according to procedure described for Intermediate 17, step 3), but starting from benzyl 2-(4-fe/f-butyl-1 ,3-oxazol-2-yl)ethylcarbamate (3 g, 9 mmol). The title compound was obtained as a yellow liquid. LC/MS (Atlantis), M- (ESI): 168.9. 1H NMR (DMSOd6, 400MHz) δ 7.59 (1 H, s), 2.85-2.90 (2H, m), 2.75-
2.82 (2H, m), 1.17 (9H, s).
Intermediate 21 : 1 -[4-(2-aminoethyl)-1 H-imidazol-1 -yl]-2-methylpropan-2-ol
Step 1 ) Formation of 7,8-Dihydroimidazo[1 ,5-c]pyrimidin-5(6H)-one
To a solution of histamine (25 g, 225 mmol) in dry DMF, 1 ,1 '-carbonyl diimidazole (36.5 g, 225 mmol) was added. The reaction mixture was stirred for 5h at 70° C and for 16h at RT. It was then concentrated under reduced pressure and the residue was extracted from ACN to afford the title compound as off white solid (25g, 81 %). 1H
NMR: (DMSO-d6, 400MHz), δ 8.2 (s, 1 H), 8.02 (s, 1 H), 6.78 (s, 1 H), 3.35 (m, 2H), 2.82 (t, 2H).
Step 2) Formation of 2-(2-Methylprop-2-enyl)-5-oxo-5,6, 7,8-tetrahydroimidazo[1 ,5- c]pyrimidin-2-ium Bromide
A solution of 7,8-dihydroimidazo[1 ,5-c]pyrimidin-5(6H)-one (25 g, 182 mmol) and 3- bromo 2-methyl propene (74 g, 547 mmol) in dry ACN was refluxed at 95° C for 15h under nitrogen atmosphere. The solvent was removed under reduced pressure to
give the title compound as brown liquid (50 g, 100%). LC/MS (Atlantis), M+(ESI): 193.3. 1H NMR: (DMSO-d6, 400MHz), δ 9.76 (s, 1 H), 9.0.3 (s, 1 H), 7.57 (s, 1 H), 5.05 (s, 1 H), 4.91 (s, 1 H), 4.8 (s, 2H), 3.4 (m, 2H), 3.0 (t, 2H), 1.69 (s, 3H).
2-(2-Methylprop-2-enyl)-5-oxo-5,6,7,8-tetrahydroimidazo[1 ,5-c]pyrimidin-2-ium bromide (12 g, 44 mmol) was refluxed in 25 ml. (132 mmol) of 6M hydrochloric acid for 5h. The reaction mixture was lyophilized to afford the title compound as an off white solid (10 g, 90%). 1H NMR (DMSO-d6, 400MHz), δ 14.96 (s, 1 H), 9.0.3 (s, 1 H), 8.27 (s, 3H), 7.52 (s, 1 H), 4.0 (s, 2H), 3.18 (d, 2H), 3.04 (t, 2H), 1.08 (s, 6H).
Intermediate 22: [2-(1 -isobutyl-1 H-imidazol-4-yl)ethyl]amine Step 1) Formation of 2-lsobutyl-5-oxo-5, 6, 7, 8-tetrahydroimidazo[1 , 5-c]pyrimidin-2-ium
Bromide
Pd/C (10%, 150 mg) was added to a solution of 2-(2-Methylprop-2-enyl)-5-oxo- 5,6,7,8-tetrahydroimidazo[1 ,5-c]pyrimidin-2-ium bromide (12 g, 44 mmol) in MeOH (150 ml_). The reaction mixture was hydrogenated under a pressure of 5 bars of hydrogen for 3h. It was then filtered and the filtrate was concentrated under reduced pressure. The crude was purified by flash chromatography on silica (HCCI3:MeOH, 93:7) to give the title compound as off white solid (10 g, 83%). 1H NMR :(DMSO-d6, 400MHz),δ 9.76 (s, 1 H), 9.0.3 (s, 1 H), 7.67 (s, 1 H), 4.05 (d, 2H), 3.45 (m, 2H), 3.0 (t, 2 H), 2.1 (t, 1 H), 0.8 (q, 6H).
Step 2) Formation of 2-(1 -isobutyl-1 H-imidazol-4-yl)ethanamine Dihydrochloride
2-lsobutyl-5-oxo-5,6,7,8-tetrahydroimidazo[1 ,5-c]pyrimidin-2-ium bromide (10 g, 36.6 mmol) was refluxed 6M hydrochloric acid (15 ml_, 132 mmol) of for 5h. The reaction mixture was lyophilized to give the title compound as off white solid (9.5 g, 83.5%). 1H NMR (DMSO-d6, 400MHz), δ 14.88 (s,1 H), 9.25 (s, 1 H), 8.34 (s, 3H), 7.66 (s, 1 H), 3.98 (d, 2H), 3.13 (d, 2H), 3.04 (t, 2H), 2.0 (m, 1 H), 0.8 (s, 6H).
Intermediate 23: 4-(5-tert-butyl-1 ,3-oxazol-2-yl)butanoic acid
Step 1) Formation of methyl 4-[(3,3-dimethyl-2-oxobutyl)amino]butanoate
A mixture of monomethylglutarate (40 g, 264 mmol), EDCI. HCI (65.73 g, 342 mmol) hydroxy benoztriazole (35.9 g, 264 mmol) and triethyl amine (102.2 ml_, 791 mmol) in dry DCM (300 ml.) was stirred at O0C under nitrogen for 30 min. 1-amino-3, 3- dimethylbutan-2-one (2 g,13 mmol) was added and stirred for 10h. The reaction mixture was quenched with water (500 ml.) and extracted with DCM (2x150 ml_). The combined organic phases were dried over sodium sulfate, filtered and concentrated.
The crude was purified by flash chromatography on silica (PE:EtOAc) to give the titled compound as an orange liquid. 1H NMR (CDCI3, 400MHz) δ 7.98-8.01 (1 H, t), 4.10-4.1 1 (2H, d), 3.57 (3H, s), 2.67-2.71 (2H, t), 2.36-2.40 (2H,m), 1.84-1.92 (2H, m), 1.21 (9H, s).
The title compound was prepared according to procedure described for Intermediate 17 step 2), but starting from methyl 4-[(3,3-dimethyl-2-oxobutyl)amino]butanoate (40 g, 73 mmol). The title compound was obtained as a yellow liquid. 1H NMR (DMSO-dβ,
400MHz) δ 6.64 (1 H, s), 3.57 (3H, s), 2.67-2.71 (2H, t), 2.36-2.40 (2H, m), 1.84-1.92 (2H, m), 1.21 (9H, s).
Step 3) Formation of 4-(5-tert-butyl-1 ,3-oxazol-2-yl)butanoic acid
A mixture of methyl 4-(5-te/f-butyl-1 ,3-oxazol-2-yl)butanoate (10 g, 44 mmol) and 6N aqueous HCI solution (200 ml.) was heated at 1050C under nitrogen for 4h. The reaction mixture was concentrated under reduced pressure and the resulting liquid was azeotroped with toluene (2x100 ml.) to give the titled compound as white solid (8 g, 73%). HPLC (Atlantis-1 ), Rt: 4.52 min (purity: 97.1%). LC/MS (Atlantis), M+(ESI):
211.9. 1H-NMR (DMSO-dθ, 400 MHz) δ 10.2-10.5 (1 H, bs), 6.80 (1 H, s), 2.72-2.76 (2H, t), 2.28-2.31 (2H, t), 1.84-1.88 (2H, t), 1.22 (9H,s).
Intermediate 24: 3-(5-tert-butyl-1 ,3-oxazol-2-yl)propanoic acid Step 1 ) Formation of ethyl 3-[(3,3-dimethyl-2-oxobutyl)amino]-3-oxopropanoate
The title compound was prepared according to procedure described for Intermediate 23 step 1 ), but starting 1-amino-3, 3-dimethylbutan-2-one (2 g, 13.1 mmol). The title compound was obtained as a yellow liquid. 1H NMR (CDCI3, 400MHz) δ 7.91-8.01 (1 H, t), 4.10-4.11 (2H, d), 3.55 (3H, s), 2.07-2.43 (4H, m), 1.09 (9H, s).
The title compound was prepared according to procedure described for intermediate 17 step 2), but starting from methyl 3-[(3,3-dimethyl-2-oxobutyl)amino]-3- oxopropanoate (9 g, 41.8 mmol). The title compound was obtained as a yellow liquid. 1H NMR (DMSOd6, 400MHz) δ 6.63 (1 H, s), 3.58 (3H, s), 2.90-2.94 (2H, t), 2.70-2.73 (2H, t), 1.20 (9H, s).
A solution of methyl 3-(5-tert-butyl-1 ,3-oxazol-2-yl) propanoate (2.5 g, 18 mmol) and Lithium hydroxide (60 mg, 23.6 mmol) in THF: water (20 mL:5 mLI) was stirred at RT for 4h. The solvent was removed under reduced pressure and the resulting residue was acidified with 1.5N HCI. The precipitated solid was filtered and dried
under vacuum to give the titled compound as a white solid (1.5g, 73%). HPLC (Atlantis-1 ), Rt: 3.20 min (purity: 98.9%). LC/MS (Atlantis), M+(ESI): 198.1. 1H-NMR (DMSO-dθ, 400 MHz) δ 12-13 (1 H, brs), 6.62 (1 H, s), 2.85-2.88 (2H, t), 2.59-2.62 (2H1 1), 1.21 (9H, s).
Intermediate 25: [2-(2-isopropyl-2H-tetrazol-5-yl)ethyl]amine
Step 1 ) Formation of tert-Butyl-2-cyanoethylcarbamate
A solution of 3-amino propionitrile (10 g, 142.6 mmol) and BOC-anhydride (37.3 g,
171 mmol) in dry DCM and TEA (43.31 g, 428 mmol) was stirred at RT for 10h. The reaction mixture was washed with water, brine, dried over magnesium sulfate, filtered and concentrated to give the title compound as a liquid. 1H NMR (DMSO: 400MHz) 1.35 (9H, s) 2.57-2.60 (2H, t) 3.12-3.16 (2H, m), 7.16(1 H, s).
A solution of tert-butyl-2-cyanoethylcarbamate (10 g, 58.7 mmol), Sodium azide (1 1.5 g, 176 mmol) and TEA.HCI (32.8 g, 176 mmol) in dry Toluene (200 ml.) was refluxed for 15h under nitrogen. The reaction mixture was cooled down to RT and water (70 ml.) was added. The aqueous phase was separated and acidified to pH = 2 with 6N HCI. The precipitated solid was filtered, washed with cold water and to give the title compound as a solid (10 g, 80%). 1H NMR (DMSO: 400MHz) 1.34 (9H,s) 2.97-2.98 (2H,t) 3.25-3.28 (2H,m) 6.98 (1 H, s).
Step 3) Formation of tert-Butyl [2-(1-isopropyl-1 H-tetrazol-5-yl)ethyl]carbamate and tert-Butyl [2-(2-isopropyl-2H-tetrazol-5-yl)-ethyl]-carbamate.
2-lodo propane (1.89 g, 1 1.2 mmol) was added to a solution of tert-butyl-2-(1 H- tetrazol-5-yl) ethylcarbamate (2 g, 9.3 mmol) and TEA (4.7 g; 46.4 mmol) in dry ACN
(20 ml_). The reaction mixture was refluxed for 12h under nitrogen. The solvent was removed under reduced pressure and the residue was purified by flash chromatography on silica (PE: EtOAc) to give tert-Butyl [2-(1-isopropyl-1 H-tetrazol- 5-yl)ethyl]carbamate (0.8 g 35%, minor isomer), LC/MS (Atlantis), M+(ESI): 257.4. δ 1 HNMR (DMSO- 400MHz) 1.33 (9H, s) 1.46-1.48 (6H, d) 2.98-3.02 (2H, t), 3.26 -
3.32 (2H, p), 4.7-4.73 (1 H, m), 6.98 (1 H, s) along with tert-Butyl [2-(2-isopropyl-2H- tetrazol-5-yl)-ethyl]-carbamate. Major isomer LC/MS (Atlantis), M+(ESI): 256.1. 1H- NMR (DMSO-d6, 400 MHz) δ 6.92 (1 H, brs), 5.05-5.02 (1 H, m), 3.28-3.23 (2H, t), 2.93-2.89 (2H, t), 1.53-1.51 (6H, d), 1.34 (9H, s).
The title compound was prepared following procedure described for intermediate 13, step 3), but starting from tert-Butyl [2-(2-isopropyl-2H-tetrazol-5-yl)-ethyl]-carbamate.
Intermediate 26: 1 -[(5-bromopyridin-3-yl)sulfonyl]pyrrolidin-3-ol
TEA (0.32 ml_, 2.29 mmol) was added to a suspension of 5-bromo pyridine-3- sulfonyl chloride (370 mg, 1.26 mmol) in dichloromethane at O0C. The reaction mixture was stirred for 10 min at 00C before the addition of a solution of 3- pyrrolidinol (100 mg, 1.147 mmol) in DCM. Reaction mixture was then stirred at RT overnight under nitrogen atmosphere. It was then washed successively with saturated sodium bicarbonate, water and brine. Organic layer was separated and dried over sodium sulfate, filtered and concentrated. The crude was purified by flash chromatography on basic alumina (HCC^MeOH) to give the title compound.
Following intermediates 27-36 have been prepared according to procedure described above:
Intermediate 37: 3-[2-azabicyclo[2.2.1]hept-2-yl]-3-oxopropan-1 -amine
TEA (4eq.) and T3P (2 eq.) were added to a solution of boc-β-ala-OH (1 eq.) and 2- aza-bicyclo(2,2,1 )heptane in DCM at 00C. Reaction mixture was then stirred at RT overnight. It was washed with HCI solution (1.5 N), NaHCO3 (10% solution) and water. Organic layer was dried over sodium sulfate, filtered and concentrated. The crude was purified by flash chromatography on silica to give the title compound
The title compound was prepared following procedure described for intermediate 13, step 3), but starting from Tert-butyl [3-(2-azabicyclo[2.2.1]hept-2-yl)-3- oxopropyl]carbamate.
Intermediate 47: N-[6-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)imidazo[1 ,2- a]pyridin-2-yl]acetamide
The title compound was prepared following procedure described for intermediate 2), but starting from N-(6-bromoimidazo[1 ,2-a]pyridin-2-yl)acetamide.
Intermediate 48: N-(6-bromo-1 ,3-benzothiazol-2-yl)-N'-[2-(5-tert-butyl-1 ,2,4- oxadiazol-3-yl)ethyl]urea
Step 1) Formation of phenyl (6-bromo-1,3-benzothiazol-2-yl)carbamate
Phenylchloroformate (4 mL, 32.7 mmol) was added to a solution of 6-bromo-2- aminobenzothiazole (5 g, 21.8 mmol) and TEA (6.1 mL, 43.6 mmol), in DCM/THF
(1 :1 , 500 mL) at 00C. The reaction mixture was then stirred at RT overnight. The solvent was removed under reduced pressure and the crude was triturated with methanol, filtered and dried to give the title compound (7g, Yield 92%).
Step 2) Formation of N-(6-bromo-1 ,3-benzothiazol-2-yl)-N'-[2-(5-tert-butyl-1 ,2,4- oxadiazol-3-yl)ethyl]urea
A solution of phenyl phenyl (6-bromo-1 ,3-benzothiazol-2-yl)carbamate (1 g, 3.01 mmol), 2-(5-tert-butyl-1 ,2,4-oxadiazol-3-yl)ethanamine (0.61 g, 3.62 mmol), TEA (0.5 mL, 3.62 mmol) in NMP was heated in MW at 55°C for 15 min. Water was added and the reaction mixture was stirred at RT for 1 h. The precipitate obtained was filtered and dried to give the title compound as a white solid. HPLC (Atlantis-1 ), Rt: 5.09 min (purity: 99.6%). LC/MS (Atlantis), M+(ESI): 423.7.
Intermediate 49: N-[2-(5-tert-butyl-1 ,2,4-oxadiazol-3-yl)ethyl]-N'-[6-(4,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,3-benzothiazol-2-yl]urea
The title compound was prepared following procedure described for intermediate 2 but starting from N-(6-bromo-1 ,3-benzothiazol-2-yl)-N'-[2-(5-tert-butyl-1 ,2,4-oxadiazol- 3-yl)ethyl]urea and using dioxane as solvent instead of DMSO.
Intermediate 50: N-(6-bromoimidazo[1 ,2-a]pyridin-2-yl)-N'-[2-(5-tert-butyl-1 ,2,4- oxadiazol-3-yl)ethyl]urea
The title compound was prepared following procedure described for intermediate 48 but starting from 6-bromoimidazo[1 ,2-a]pyridin-2-amine. The title compound was obtained as a yellow solid, HPLC (Atlantis-1 ), Rt: 3.27 min (purity: 96.8%). LC/MS
(Atlantis), M+(ESI): 406.9.
Intermediate 51 : N-[2-(5-tert-butyl-1 ,2,4-oxadiazol-3-yl)ethyl]-N'-[6-(4,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyridin-2-yl]urea
The title compound was prepared following procedure described for intermediate 49 but starting from N-(6-bromoimidazo[1 ,2-a]pyridin-2-yl)-N'-[2-(5-tert-butyl-1 ,2,4- oxadiazol-3-yl)ethyl]urea.
Intermediate 52: N-(6-bromo-1 ,3-benzothiazol-2-yl)-N'-[2-(5-tert-butyl-1 ,3-oxazol-
The title compound was prepared following procedure described for intermediate 48, but starting from [2-(5-tert-butyl-1 ,3-oxazol-2-yl)ethyl]amine. The title compound was obtained as an off white solid (47 mg, 72%), HPLC (Atlantis-1 ), Rt: 5.09 min (purity:
96.4%). LC/MS (Atlantis), M+(ESI): 423.0.
Intermediate 53: N-[2-(5-tert-butyl-1 ,3-oxazol-2-yl)ethyl]-N'-[6-(4,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,3-benzothiazol-2-yl]urea
The title compound was prepared following procedure described for intermediate 49, but starting from N-(6-bromo-1 ,3-benzothiazol-2-yl)-N'-[2-(5-tert-butyl-1 ,3-oxazol-2- yl)ethyl]urea.
Intermediate 54: N-(6-bromoimidazo[1 ,2-a]pyridin-2-yl)-N'-[2-(5-tert-butyl-1 ,3- oxazol-2-yl)ethyl]urea
The title compound was prepared following procedure described for intermediate 48 but starting from 6-bromo-1 ,3-benzothiazol-2-amine and 2-[3-(2-aminoethyl)-1 ,2,4- oxadiazol-5-yl]-2-methylpropan-1-ol. The title compound was obtained as an off white solid, HPLC (Atlantis-1 ), Rt: 3.39 min (purity: 99.5%). LC/MS (Atlantis), M+(ESI): 405.9.
Intermediate 55: N-[2-(5-tert-butyl-1.S-oxazol^-yOethyll-N'-IΘ-^AS.S- tetramethyl-1 ,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyridin-2-yl]urea
The title compound was prepared following procedure described for intermediate 49, but starting from [N-(6-bromoimidazo[1 ,2-a]pyridin-2-yl)-N'-[2-(5-tert-butyl-1 ,3-oxazol- 2-yl)ethyl]urea.
Intermediate 56: N-(6-bromo-1 ,3-benzothiazol-2-yl)-N'-{2-[5-(2-hydroxy-1 ,1 - dimethylethyl)-1 ,2,4-oxadiazol-3-yl]ethyl}urea
The title compound was prepared following procedure described for intermediate 48 but starting from 6-bromo-1 ,3-benzothiazol-2-amine and 2-[3-(2-aminoethyl)-1 ,2,4- oxadiazol-5-yl]-2-methylpropan-1-ol.
Intermediate 57: N-(6-bromo-1 ,3-benzothiazol-2-yl)-N'-{2-[5-(2-fluoro-1 ,1 - dimethylethyl)-1 ,2,4-oxadiazol-3-yl]ethyl}urea
The title compound was prepared following procedure described for intermediate 48 but starting from 6-bromo-1 ,3-benzothiazol-2-amine and {2-[5-(2-fluoro-1 ,1- dimethylethyl)-1 ,2,4-oxadiazol-3-yl]ethyl}amine.
Intermediate 58: N-[3-(3,3-difluoroazetidin-1 -yl)-3-oxopropyl]-N-{6-bromo-1 ,3- benzothiazol-2-yl}urea
\
The title compound was prepared following procedure described for intermediate 48 but 3-(3,3-difluoroazetidin-1 -yl)-3-oxopropan-1 -amine.
Intermediate 59: N-(6-bromoimidazo[1,2-a]pyridin-2-yl)-N'-[2-(5-phenyl-1 ,2,4- oxadiazol-3-yl)ethyl]urea
The title compound was prepared following procedure described for intermediate 48 but starting from 6-bromo-1 ,3-benzothiazol-2-amine and 2-(5-phenyl-1 ,2,4-oxadiazol- 3-yl (Journal of Chemical Research, Synopses (1979), (2), 64-5.). The title compound was obtained as an yellow solid, HPLC (Atlantis-1 ), Rt: 3.56 min (purity:
96.3%). LC/MS (Atlantis), M+(ESI): 426.9.
HATU (414 mg, 1.1 mmol) and HOAt (147 mg, 1.1 mmol) were added to a solution of 2-amino-6-bromobenzothiazole (250 mg, 1.1 mmol), 4-(5-tert-butyl-1 ,3-oxazol-2- yl)butanoic acid (276 mg, 1.3 mmol) and N-methyl morpholine (0.6ml, 5.4mmol) in DCM/DMF (1 :1 ) maintained at 00C under nitrogen atmosphere. The reaction mixture was then stirred overnight at RT under nitrogen. After completion, the solvent was removed under reduced pressure and the crude was dissolved in EtOAc. Organic phase was washed with 10% citric acid, sat. sodium bicarbonate, water and brine, then dried over sodium sulphate filtered and concentrated to give the title compound.
Intermediate 61 : 3-(methylsulfonyl)-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)pyridine
A mixture of 3-bromo-5-methanesulfonylpyridine (2 g, 8.47 mmol), bis(pinacolato)diboron (2.36 g, 9.31 mmol), potassium acetate (1.25 g, 12.7 mmol),
Pd2dba3 (0.38 g, 0.42 mmol) and tricyclohexylphosphine (0.52 g, 1.86 mmol) in degassed dioxane was heated at 1000C for 5h. The reaction mixture was then diluted with EtOAc and washed with brine. Organic layer was dried over sodium sulfate, filtered and concentrated. The residue obtained was triturated in ether, ether layer was carefully removed and the solid was dried to give the title compound (1.82 g,
75%). 1H NMR (DMSO-d6, 400MHz) δ 9.16(1 H, s), 9.01 (1 H, s), 8.39-8.40 (1 H, s), 3.34 (3H, s), 1.32 (12H, s).
Intermediate 62: 5-[3-(methylsulfonyl)phenyl][1 ,3]thiazolo[5,4-b]pyridin-2 -amine
A mixture of 5-chloro[1 ,3]thiazolo[5,4-b]pyridin-2-amine (2 g, 11 mmol), 3- methylsulfonylphenylboronic acid (4.32 g, 21.62 mmol), cesium fluoride (6.56 g, 43.24mmol) and bis(triphenylphosphine)palladium(ll) chloride (1.52 g, 2.16 mmol) in degassed dioxane/water (30mL/15mL) was heated at 1030C under nitrogen overnight. Hence, the solvent was removed, washed with pet.ether and diethylether. Then dichloromethane slurry was given and the solid precipitated was filtered through vacuum and dried to yield the pure compound.
Intermediate 63: 6-[3-(methylsulfonyl)phenyl][1,3]thiazolo[4,5-c]pyridin-2 -amine
The title compound was prepared following procedure described for intermediate 63, but starting from 6-chloro[1 ,3]thiazolo[4,5-c]pyridin-2-amine.
Intermediate 64: 6-[3-(methylsulfonyl)phenyl]imidazo[1 ,2-a]pyrazin-2 -amine
The title compound was prepared following procedure described for intermediate 63, but starting from 6-bromoimidazo[1 ,2-a]pyrazin-2-amine.
Intermediate 65: 6-(5-methoxypyridin-3-yl)-1 ,3-benzothiazol-2 -amine
A mixture of 2-amino-6-bromo benzothiazole (1 g, 4.4 mmol), 5-methoxy-3-pyridine boronic acid pinacol ester (1.54 g, 6.55 mmol) and cesium fluoride (1.98 g, 13.1 mmol) and bis(triphenylphosphine)palladium(ll) chloride (0.46 g, 0.655 mmol) in dioxane/water (30 ml_:15 ml.) was heated in a sealed tube at 1050C for 4h under nitrogen. Solvent was removed under reduced pressure and the residue was dissolved in EtOAc. Organic phase was
washed with water, brine, dried over sodium sulfate, filtered and concentrated. The solid crude was washed with PE and diethyl ether. It was finally slurred with dichloromethane and the precipitate was filtered and dried to give the title compound.
Intermediate 66: 5-(5-methoxypyridin-3-yl)[1 ,3]thiazolo[5,4-b]pyridin-2 -amine
The title compound was prepared following procedure described for intermediate 65, but starting from 5-chloro[1 ,3]thiazolo[5,4-b]pyridin-2-amine.
Intermediate 67: 5-[5-(methylsulfonyl)pyridin-3-yl][1,3]thiazolo[5,4-b]pyridin-2- amine
The title compound was prepared following procedure described for intermediate 65, but starting from 5-chloro[1 ,3]thiazolo[5,4-b]pyridin-2-amine and 3-(methylsulfonyl)-5- (4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridine.
Intermediate 68: tert-butyl (5-bromopyridin-3-yl)methylcarbamate
Step 1) Formation of tert-butyl (5-bromopyridin-3-yl)carbamate
A solution of 5-bromonicotinic acid (5 g, 24.75 mmol), diphenylphosphonylazide (8 ml_, 37.13 mmol) and TEA (10.3 ml_l, 74.3 mmol) in tert-butanol, was heated at 650C for 45 min under nitrogen. Temperature was then increased slowly to1000C and maintained overnight under nitrogen. Solvent was removed under reduced pressure and the crude was purified by flash chromatography on (PE:EtOAC, 8:2) to give the title compound.
Step 2) Formation of tert-butyl (5-bromopyridin-3-yl)methylcarbamate
A solution of tert-butyl (5-bromopyridin-3-yl)carbamate (1.2 g, 4.41 mmol) in THF was slowly added to a suspension of sodium hydride
(60%, 221 mg, 5.29 mmol) in THF maintained at 00C under nitrogen atmosphere. A solution of methyl iodide (0.83 ml_, 13.24 mmol) in THF was then added slowly at 00C. reaction mixture was then stirred at RT for 3h. Ice cooled water was added and reaction mixture was extracted with EtOAc (twice). Combined organic phases were washed with brine, dried over sodium sulfate, filtered and concentrated to give the title compound.
Intermediate 69: 6-bromo-2-tert-butyl-2,3-dihydro-1 ,2-benzisothiazole 1 ,1 - dioxide Step 1) Formation of 5-Bromo-N-(tert-butyl)-2-methylbenzenesulfonamide
Tert-butylamine (16.25 g, 222.6 mmol) was added in dropwise to a solution of 5- Bromo-2-methylbenzenesulfonyl chloride (Tetrahedron, 2006, 62(33), 7902-7910, 30 g, 1 11.3 mmol) in dry HCCI3 (300 ml.) at O0C. The reaction mixture was stirred RT for 16 h. It was then concentrated under reduced pressure, diluted with water (500 ml.) and stirred for 15 min. The precipitate obtained was filtered, washed with water (200 ml.) and dried to give the title compound as a white solid (25 g, 73%). 1H NMR :(CDCI3, 400MHz) δ 8.17 (1 H, s), 7.56-7.55 (1 H, d), 7.19-7.18 (1 H, d),4.61 (1 H, brs), 2.60 (3H, s),1.27 (9H, s).
To a solution of 5-Bromo-Λ/-(te/f-butyl)-2-methylbenzenesulfonamide (10 g, 32.6 mmol) in CCI4 (200 ml.) was added benzoyl peroxide (1 g, 10%w/w) followed by NBS (5.8 g, 32.6 mmol) portionwiseThe reaction mixture was refluxed for 16 h, then cooled to RT and filtered. The filtrate was concentrated under reduced pressure and the crude was purified by flash chromatography on silica (PE, EtOAc) to give the title compound as a white solid. LC/MS (Atlantis), M+(ESI): 329.8. 1H NMR :(CDCI3, 400MHz) δ 8.20 (1 H, s),7.67-7.66 (1 H, d) ,7.44-7.42 (1 H, d), 4.92 (2H, s),4.85 (1 H, brs),1.27 (9H, s).
Sodium bicarbonate (3.27 g, 40 mmol) was added to a solution of 5-bromo-2- (bromomethyl)-Λ/-(te/f-butyl)benzenesulfonamide (5 g, 13 mmol) in dry ACN (100 ml.) at room temperature. Reaction mixture was refluxed for 20 h then cooled to RT.
Precipitate was filtered and washed with ACN. Filtrate was concentrated under reduced pressure and the crude was purified by flash chromatography on silica
(PE/EtOAc) to give the title compound as white solid. LC/MS (Atlantis), M+(ESI): 247.0. 1H NMR :(DMSO, 400MHz) δ 8.05 (1 H, d),7.88-7.87 (1 H, d) ,7.53-7.51 (1 H, s),4.51 (2H, s) 1.45 (9H, s).
Intermediate 75 : 3-(2-aminoethyl)-Λ/-isopropyl-1 ,2,4-oxadiazol-5-amine hydrochloride
Step 1) Formation of tert-butyl {2-[5-(isopropylamino)-1,2,4-oxadiazol-3- yl]ethyl}carbamate
Λ/,Λ/'-Diisopropylcarbodiimide (0.68 ml_; 4.39 mmol) was added to a solution of tert- butyl [(3£)-3-amino-3-(hydroxyimino)propyl]carbamate (812 mg; 4.00 mmol) in pyridine (4 ml.) and toluene (8 ml.) and the resulting mixture was stirred at reflux for 60 h then concentrated in vacuo. The residue was taken up in DCM, washed successively with sat. aq. NaHCO3 then brine dried over magnesium sulfate and concentrated in vacuo. Purification by column chromatography (c-hexane/EtOAc, 50/50) afforded the title compound as colourless oil. 1H NMR (DMSOd6, 300 MHz) δ 6.14 (s, 1 H), 5.10 (s, 1 H), 3.98-3.94 (m, 1 H), 3.52 (bs, 2H), 2.81 (t, J = 6.0 Hz, 2H), 1.45 (s, 9H), 1.33 (d, J = 6.4 Hz, 6H). Step 2) Formation of 3-(2-aminoethyl)-N-isopropyl-1 ,2,4-oxadiazol-5-amine hydrochloride
4M HCI in dioxane (17.5 ml_; 70 mmol) was added to te/f-butyl {2-[5-(isopropylamino)- 1 ,2,4-oxadiazol-3-yl]ethyl}carbamate (474 mg; 1.75 mmol) and the resulting mixture was stirred at RT for 16 h then concentrated in vacuo to afford the title compound (415 mg, 97%) as an off-white solid. 1H NMR (DMSOd6, 300 MHz) δ 8.30 (d, J = 7.5
Hz, 1 H), 8.15 (bs, 3H), 4.73 (bs, 2H), 3.07 (hept, J = 7.4 Hz, 2H), 2.82 (t, J = 7.4 Hz, 2H), 1.16 (d, J = 6.4 Hz, 6H)
Intermediate 76 : 2-[5-(Methoxymethyl)-1 ,2,4-oxadiazol-3-yl]ethanamine trifluoroacetic acid salt
Step 1) Formation of tert-butyl {2-[5-(methoxymethyl)-1,2,4-oxadiazol-3- yl]ethyl}carbamate
PyBop (2.22 g; 4.27 mmol) was added at 00C to a solution of methoxyacetic acid (0.35 ml_; 4.50 mmol) and DIEA (0.84 ml_; 4.95 mmol) in DCM (50 mL) and the resulting mixture was stirred at 00C for 30 min whereupon te/f-butyl [(3E)-3-amino-3- (hydroxyimino)propyl]carbamate (0.91 g; 4.50 mmol) was added. The reaction mixture was stirred at 00C for one hour then at RT for 72 h. The solvent was evaporated and the residue was taken up in pyridine (25 mL) and toluene (25 mL) and was stirred at reflux for 12 h. The solvent was evaporated and the residue partitioned between EtOAc and water. The two phases were separated; the organic
layer was washed with sat.aq. NaHCO3 then brine, dried over sodium sulfate and concentrated in vacuo. Purification by column chromatography (DCM then DCIWMeOH, 99/1 ) afforded the title compound as yellow oil. 1H NMR (DMSO-d6, 300 MHz) δ 6.93 (bs, 1 H), 4.70 (s, 2H), 3.37 (s, 3H), 3.26 (q, J = 6.8 Hz, 2H), 2.81 (t, J = 6.8 Hz, 2H), 1.35 (s, 9H)
Step 2) Formation of 2-[5-(methoxymethyl)-1 ,2,4-oxadiazol-3-yl]ethanamine trifluoroacetic acid salt
TFA (2.5 ml.) was added to a solution of fe/f-butyl {2-[5-(methoxymethyl)-1 ,2,4- oxadiazol-3-yl]ethyl}carbamate (560 mg; 2.18 mmol) in DCM (20 ml.) and the resulting mixture was stirred at RT for 60 h. Concentration in vacuo afforded the title compound (550 mg, 93%) as a yellow oil. 1H NMR (DMSO-d6, 300 MHz) δ 7.89 (s, 3H), 4.74 (s, 2H), 3.39 (s, 3H), 3.15-3.1 1 (m, 4H).
Intermediate 77 : 2-[5-(Trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]ethanamine hydrochloride
The title compound was prepared following procedure of intermediate 70 starting from trifluoroaceticanhydride and 3-aminopropanenitrile. LC/MS, M+(ESI): 182.0, HPLC, Rt: 3.66 min (purity: 98.7%), 1H NMR (CD3OD, 400 MHz) δ 3.45-3.41 (m, 2H), 3.32- 3.29 (m, 2H).
Intermediate 78 : 3-(lsopropoxymethyl)piperidine hydrochloride
Step 1) Formation of tert-butyl 3-{[(methylsulfonyl)oxy]methyl}piperidine-1-carboxylate Methanesulfonyl chloride (2.93 g; 25.55 mmol) was added dropwise at 00C to a solution of te/f-butyl 3-(hydroxymethyl)tetrahydro-1 (2/-/)-pyridinecarboxylate (5.0 g;
23.22 mmol) and DIEA (6.0 g; 46.45 mmol) in DCM (80 ml.) and the resulting mixture was stirred for 16 h at RT. The solution was washed with sat. aq. NH4CI (2x) then brine (2x), dried over magnesium sulfate and concentrated in vacuo. Purification by filtration through a short plug of silica (DCM) followed by crystallization from DCM/n- pentane afforded the title compound (6.48 g, 95%) as an off-white solid. 1H NMR
(CDCI3, 300 MHz) δ 4.17-4.05 (m, 2H), 3.95 (dd, J = 3.8, 13.2 Hz, 1 H), 3.82 (dt, J = 4.2, 13.2 Hz, 1 H), 3.04 (s, 3H), 2.99-2.88 (m, 1 H), 2.81 (dd, J = 9.3, 13.1 Hz, 1 H), 2.03-1.78 (m, 2H), 1.74-1.62 (m, 1 H), 1.56-1.24 (m, 1 1 H). Step 2) Formation of tert-butyl 3-(isopropoxymethyl)piperidine-1-carboxylate Sodium hydride (0.25 g; 10.2 mmol) was added portionwise to a solution of fe/f-butyl
3-{[(methylsulfonyl)oxy]methyl}piperidine-1-carboxylate (1.5 g; 5.11 mmol) in isopropanol (20 ml.) and the resulting mixture was stirred at RT for 3 days. The solution was diltued with EtOAc, washed with sat. aq. NH4CI and water, dried over magnesium sulfate and concentrated in vacuo. Purification by filtration through a short plug of silica (EtOAc/c-hexane, 1/1 ) afforded the title compound (1.4 g, quantitative yield) as yellow oil. 1H NMR (DMSOd6, 300 MHz) δ 4.13 - 3.61 (m, 2H), 3.54 - 3.42 (m, 1 H), 3.26 - 3.12 (m, 2H), 2.84 - 2.713 (m, 1 H), 1.72 - 1.48 (m, 3H), 1.38 (s, 9H), 1.35 - 1.1 1 (m, 3H), 1.07 (d, J = 5.9 Hz, 6H). Step 3) Formation of 3-(isopropoxymethyl)piperidine hydrochloride 4M HCI in dioxane (14.6 ml_; 58.3 mmol) was added to a solution of te/f-butyl 3-
(isopropoxymethyl)piperidine-i-carboxylate (1.5 g; 5.83 mmol) in DCM (10 ml.) and the reaction mixture was stirred at RT overnight. The solution was concentrated in vacuo to afford the title compound (1.5 g, quantitative yield) as a white solid. 1H NMR (DMSOd6, 300 MHz) δ 8.91 - 8-6 (m, 2H), 3.53 - 3.45 (m, 1 H), 3.24 - 3.14 (m, 3H), 2.80 - 2.53 (m, 2H), 2.01 - 1.85 (m, 1 H), 1.81 - 1.54 (m, 3H), 1.29 - 1.10 (m, 2H), 1.07
(d, J = 6.2 Hz, 6H).
Intermediate 79 : 2-[3-(2-Aminoethyl)-1 ,2,4-oxadiazol-5-yl]-Λ/,Λ/-dimethylpropan- 2 -amine bis trifluoroacetic acid salt
A solution of 2-aminoisobutyric acid (5.2 g; 50.2 mmol), formaldehyde (10 mL) and formic acid (13 mL) was stirred at reflux for 2 h. 5M aq. HCI (6 mL) was added and the solution was concentrated in vacuo. Purification by recrystallization from acetic acid afforded the title compound (7.12 g, 85%) as a white solid. 1H NMR (DMSOd6,
300 MHz) δ 14.20 (bs, 1 H). 10.89 (bs, 1 H), 2.72 (s, 6H), 1.51 (s, 6H), Step 2) Formation of tert-butyl (2-{5-[1-(dimethylamino)-1-methylethyl]-1,2,4- oxadiazol-3-yl}ethyl)carbamate PyBop (4.42 g; 8.5 mmol) was added at 00C to a solution of Λ/,Λ/,2-trimethylalanine hydrochloride (1.5 g; 8.95 mmol) and DIEA (3.2 mL; 18.8 mmol) DCM (100 mL) and the resulting mixture was stirred at 00C for 30 min whereupon te/f-butyl [(3£)-3- amino-3-(hydroxyimino)propyl]carbamate (1.82 g; 8.95 mmol) was added. The reaction mixture was stirred at 00C for one hour and then at RT for 72 h. The solvent was evaporated, the residue, taken up in pyridine (60 mL) and toluene (60 mL) and stirred at reflux for 24 h. The solvent was evaporated and the residue partitioned between EtOAc and water. The two phases were separated; the organic layer was washed with sat. aq. NaHCO3 then brine, dried over sodium sulfate and concentrated in vacuo. Purification by column chromatography (DCM/MeOH/Et3N, 99/1/0.1 to 98/2/0.1 ) afforded the title compound as a colourless oil. 1H NMR (DMSO-d6, 300 MHz) δ 6.93 (s, 1 H), 3.25 (q, J = 6.9 Hz, 2H), 2.79 (t, J = 6.9
Hz, 2H), 2.13 (s, 6H) 1.46 (s, 6H), 1.35 (s, 9H).
Step 3) Formation of 2-[3-(2-aminoethyl)-1,2,4-oxadiazol-5-yl]-N,N-dimethylpropan-2- amine bis trifluoroacetic acid salt TFA (2 mL) was added to a solution of te/f-butyl (2-{5-[1-(dimethylamino)-1- methylethyl]-1 ,2,4-oxadiazol-3-yl}ethyl)carbamate (500 mg; 1.68 mmol) in DCM (20 mL) and the resulting mixture was stirred at RT for 60 h. Concentration in vacuo afforded the title compound (700 mg, 98%) as a yellow oil. 1H NMR (DMSO-d6, 300 MHz) δ 8.03 (bs, 3H), 3.24-3.20 (m, 2H), 3.13-3.09 (m, 3H), 2.78 (s, 6H), 1.78 (s, 6H).
Intermediate 80 : 2-[5-(Tetrahydrofuran-3-yl)-1 ,2,4-oxadiazol-3-yl]ethanamine hydrochloride
The title compound was prepared following procedure of intermediate 70 starting from tetrahydro-3-furoic acid, PyBop and 3-aminopropanenitrile. 1H NMR (DMSOd6, 300 MHz) δ 8.11 (s, 3H), 4.03 (m, 1 H), 3.85 (m, 4H), 3.10 (m, 4H), 2.37 (m, 1 H), 2.17 (m, 1 H).
Intermediate 81 : 3-(lsopropoxymethyl)pyrrolidine hydrochloride
Step 1) Formation of tert-butyl 3-{[(methylsulfonyl)oxy]methyl}pyrrolidine-1- carboxylate
Methanesulfonyl chloride (2.31 ml_; 29.8 mmol) was added at 00C to a solution of 3- hydroxymethyl-pyrrolidine-1-carboxylic acid te/f-butyl ester (5.0 g; 24.8 mmol) and DIEA (8.56 ml_; 49.7 mmol) in DCM (50 ml.) and the resulting mixture was stirred at RT for 2 h. After concentration in vacuo, the residue was partitioned between DCM and sat. aq. NaHCO3 and the two phases separated. The aqueous layer was extracted with DCM and the combined organic phase washed with sat. aq. NH4CI then brine, dried over magnesium sulfate and concentrated in vacuo to afford the title compound (6.5 g, 94%) as a brown oil. 1H NMR (DMSOd6, 300 MHz) δ 4.25-4.11 (m, 2H), 3.46-3.31 (m, 2H), 3.27-3.18 (m, 1 H), 3.19 (s, 3H), 3.06-2.95 (m, 1 H), 2.62-2.52 (m, 1 H), 2.02-1.88 (m, 1 H), 1.72-1.55 (m, 1 H), 1.40 (s, 9H).
Step 2) Formation of tert-butyl 3-(isopropoxymethyl)pyrrolidine-1 -carboxylate Sodium hydride (1.36 g; 57.3 mmol) was added portionwise to a solution of te/f-butyl 3-{[(methylsulfonyl)oxy]methyl}pyrrolidine-1 -carboxylate (2.0 g; 7.16 mmol) in isopropanol (20 ml.) and the reaction mixture was stirred at RT for 3 days. The solution was diltuted with EtOAc, washed with sat. aq. NH4CI and water, dried over magnesium sulfate and concentrated in vacuo. Purification by column chromatography (DCM to DCM/MeOH, 98/2) afforded the title compound as a yellow oil. 1H NMR (DMSO-d6, 300 MHz) δ 3.55-3.47 (m, 1 H), 3.37-3.10 (m, 5H), 2.99-2.88 (m, 1 H), 2.39-2.24 (m, 1 H), 1.93-1.79 (m, 1 H), 1.63-1.47 (m, 1 H), 1.39 (s, 9H), 1.07 (d, J = 6.1 Hz, 6H).
Step 3) Formation of 3-(isopropoxymethyl)pyrrolidine hydrochloride
4M HCI in dioxane (10.3 ml_; 41.1 mmol) was added to a solution of te/f-butyl 3- (isopropoxymethyl)pyrrolidine-i-carboxylate (1.0 g; 4.1 1 mmol) in DCM (8 ml.) and the reaction mixture was stirred at RT for 16 h. The solution was concentrated in vacuo to afford the title compound (0.77 g, quantitative yield) as a yellow oil. 1H NMR (DMSOd6, 300 MHz) δ 9.45 9.03 (m, 2H), 3.59-3.49 (m, 1 H), 3.41-3.29 (m, 3H), 3.26-
3.01 (m, 2H), 2.95-2.77 (m, 1 H), 2.48-2.36 (m, 1 H), 2.1 1-1.90 (m, 1 H), 1.74-1.54 (m, 1 H), 1.08 (d, J = 6.1 Hz, 6H).
Intermediate 82 : 5-terf-Butyl-3-pyrrolidin-3-yl-1 ,2,4-oxadiazole hydrochloride
The title compound was prepared following procedure of intermediate 70 starting from pivaloyl chloride and 1-Λ/-boc-3-cyano-pyrrolidine. 1H NMR (DMSOd6, 300 MHz) δ 9.75-9.65 (m, 2H), 4.03 (m, 1 H), 3.85 (m, 4H), 3.10 (m, 4H), 2.37 (m, 1 H), 2.17 (m,
1 H), 2.95 (m, 1 H)
Intermediate 83 : 2-(5-ferf-Butyl-1 ,3,4-thiadiazol-2-yl)ethanamine hydrochloride
To a solution of te/f-butyl carbazate (25 g, 189.6 mmol) in dry DCM (350 ml.) was added TEA (52.6 ml_, 378.3 mmol) at 00C under inert atmosphere. After 10 min, pivaloyl chloride (25 g, 208.0 mmol) was slowly added and the reaction mixture was stirred at RT for 1 h. The reaction mixture was washed with water (2 x 300 ml_), brine (100 ml_), dried over Na2SC>4, evaporated under vacuum and slurried in a PE:EtOAc mixture (4:1 , 200 ml.) then filtered to afford the title compound (30 g, 70%) as a white solid. 1H NMR (DMSOd6, 400 MHz) δ 9.22 (s, 1 H), 8.55 (s, 1 H), 1.33 (s, 9H), 1.09 (s, 9H). Step 2) Formation of 2,2-dimethylpropanohydrazide hydrochloride
To a stirred solution of fe/f-butyl 2-(2,2-dimethylpropanoyl)hydrazinecarboxylate (30 g, 138.8 mmol) in dry dioxane (150 mL) was added 4M HCI in dioxane (250 mL) at 00C and stirred at RT for 12 h. The reaction mixture was evaporated to dryness and the residue was slurried in PE/EtOAc and filtered to afford the title compound (19 g, 90%) as a white solid. 1H NMR (DMSOd6, 400 MHz) δ 10.84 (s, 1 H), 10.32 (bs, 3H),
1.14 (s, 9H).
Step 3) Formation of tert-butyl {3-[2-(2,2-dimethylpropanoyl)hydrazino]-3- oxopropyl}carbamate To a solution of Boc-β-Ala-OH (3.9 g, 19.7 mmol) in dry DCM (30 mL) were added EDC hydrochloride (3.78 g, 19.7 mmol) and HOBt (1.7 g, 13.1 mmol) at 00C followed by T EA (5. 1 m L , 39.4 m m ol ) . Afte r 30 m i n , 2 , 2-dimethylpropanohydrazide hydrochloride (2 g, 13.1 mmol) was added in portions to the reaction mixture which was further stirred for 12 h at RT. Reaction mixture was washed with NaHCO3 (10% aq., 50 mL), water (2 x 50 mL) and brine (50 mL). The organic layer was dried over Na2SO4, evaporated under vacuum and purified by silica gel column chromatography
(chloroform/MeOH) to afford the title compound as a colorless liquid. 1H NMR (DMSO-de, 400 MHz) δ 9.65 (s, 1 H), 9.31 (s, 1 H), 6.74 (t, J = 10.9 Hz, 1 H), 3.14-3.09 (m, 2H), 2.27-2.23 (m, 2H), 1.34 (s, 9H), 1.12 (s, 9H). Step 4) Formation of tert-butyl [2-(5-tert-butyl-1 ,3,4-thiadiazol-2-yl)ethyl]carbamate A mixture of te/f-butyl {3-[2-(2,2-dimethylpropanoyl)hydrazino]-3-oxopropyl}carbamate
(0.5 g, 1.8 mmol) and Lawesson's reagent (0.45 g, 1.1 mmol) in THF (12 mL) was heated at 120 C for 20 min (microwave heating). Solvents were removed under vacuum before addition of water (10 mL) and extraction with Et2O (2 x 10 mL). Organic layer was washed with water, brine, dried over Na2SO4 and purified by silica gel column chromatography (PE/EtOAc) to afford the title compound as a white solid.
LC/MS, M+(ESI): 286.3. HPLC, Rt: 3.99 min (purity: 97.8%). 1H NMR (DMSO-d6, 400 MHz) δ 7.02 (t, J = 5.5 Hz, 1 H), 3.32-3.26 (m, 2H), 3.14-3,11 (m, 2H), 1.38 (s, 9H), 1.35 (s, 9H). Step 5) 2-(5-tert-butyl-1,3,4-thiadiazol-2-yl)ethanamine hydrochloride [2-(5-te/f-Butyl-[1 ,3,4]thiadiazol-2-yl)-ethyl]-carbamic acid te/f-butyl ester (300 mg;
1.05 mmol) was dissolved in DCM (10 mL) to which was added 4M HCI in dioxane (4 mL). After 10 minutes solvents were evaporated to give the title compound (200 mg, quant.) as a white solid. LC/MS, M+(ESI): 186.0. HPLC, Rt: 1.24 min (purity: 99.7%).
The title compound was prepared following procedure of Intermediate 70 starting from isobutyryl chloride and 3-aminopropanenitrile. 1H NMR (DMSOd6, 300 MHz) δ 8.30 (bs, 3H), 3.25 (hept, J = 7.0 Hz, 1 H), 3.12-3.07 (m, 4H), 1.31 (d, J = 7.0 Hz, 6H).
Intermediate 85 : 2-(5-Ethyl-1 ,2,4-oxadiazol-3-yl)ethanamine hydrochloride
The title compound was prepared following procedure of Intermediate 70 starting from propionyl chloride and 3-aminopropanenitrile. 1H NMR (DMSO-dβ, 300 MHz) δ 8.12 (bs, 3H), 3.18-3.13 (m, 2H), 3.07-3.01 (m, 2H), 2.92 (q, J = 7.6 Hz, 2H), 1.28 (t, J = 7.6 Hz, 3H).
Intermediate 86 : 1 -[3-(2-Aminoethyl)-1 ,2,4-oxadiazol-5-yl]ethanol trifluoroacetic acid salt
Ethyl L-lactate (0.69 g; 5.83 mmol) and te/f-butyl [(3£)-3-amino-3- (hydroxyimino)propyl]carbamate (1.18 g; 5.83 mmol) were solubilised in toluene (22 ml.) to which K2CO3 (1.61 g; 11.66 mmol) was added. The mixture was stirred at reflux for 12 h after which time solvents were evaporated. The crude was taken up in water, extracted with DCM, dried over Na2SO4 and concentrated to give the title compound as a colorless oil. 1H NMR (DMSO-d6, 300 MHz) δ 6.95 (t, J = 5.0 Hz, 1 H), 6.06 (d, J = 5.4 Hz, 1 H), 4.93 (q, J = 6.2 Hz, 1 H), 3.25 (q, J = 6.8 Hz, 2H), 2.79 (t, J = 6.8 Hz, 2H), 1.45 (d, J = 6.6 Hz, 3H), 1.36 (s, 9H).
Step 2) Formation of 1-[3-(2-aminoethyl)-1,2,4-oxadiazol-5-yl]ethanol trifluoroacetic acid salt
TFA (2 ml_; 25.96 mmol) was added was added to a solution of ferf-butyl {2-[5-(1- hydroxyethyl)-1 ,2,4-oxadiazol-3-yl]ethyl}carbamate (997 mg; 3.88 mmol) in DCM (20 mL) and the mixture was stirred for 12 h at RT. Solvents were removed under vacuum to give the title compound (1.05 g; quant.) as a yellow oil. 1H NMR (DMSO- d6, 300 MHz) δ 7.89 (bs, 3H), 6.10 (bs, 1 H), 4.97 (q, J = 6.6 Hz, 1 H), 3.19 (q, J = 6.5 Hz, 2H), 3.03 (t, J = 6.5 Hz, 2H), 1.47 (d, J = 6.6 Hz, 3H).
Intermediate 87 : 2-(5-teιt-Butyl-1,3,4-oxadiazol-2-yl)ethanamine hydrochloride
Step 1) Formaϋon oftert-butyl 2-(2,2-dimethylpropanoyl)hydrazinecarboxylate
To a solution of terf-buty! hydrazinecarboxyiate (25 g, 189.6 mmol) in dry DCM (350 mL) was added TEΞA (52.6 mL, 378.3 mmol) at 00C under inert atmosphere. After 10 min, pivaloyl chloride (25 g, 208.0 mmol) was slowly added and the reaction mixture was stirred at RT for 1 h. The reaction mixture was washed with water (2 x 300 mL), brine (100 mL), dried over Na2SO4, evaporated under vacuum, slurried in a PE/EtOAc mixture (4:1, 200 mL) and filtered to afford the title compound (30 g, 70%) as a white solid. 1H NMR (DMSO-Cl6, 400 MHz) δ 9.22 (s, 1 H), 8.55 (s, 1 H), 1.33 (s, 9H), 1.09 (s, 9H).
Step 2) Formation of 2,2-dimethylpropanohydrazide hydrochloride To a stirred solution of te/f-butyl 2-(2,2-dimethylpropanoyl)hydrazinecarboxylate (30 g, 138.8 mmol) in dry dioxane (150 mL) was added 4M HCI in dioxane (250 mL) at 0°C and stirred at RT for 12 h. The reaction mixture was evaporated to dryness; the residue was slurried in PE/EtOAc and filtered to afford the title compound (19 g, 90%) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.84 (s, 1 H), 10.32 (bs, 3H), 1.14 (S, 9H).
Step 3) Formation oftert-butyl {3-[2-(2,2-dimethylpropanoyl)hydrazino]-3- oxopropyljcarbamate To a solution of Boc-β-Ala-OH (3.9 g, 19.7 mmol) in dry DCM (30 mL) were added
EDC hydrochloride (3.78 g, 19.7 mmol) and HOBt (1.7 g, 13.1 mmol) at 00C followed by TEA (5.1 m L, 39.4 mmol). After 30 min , 2,2-dimethylpropanohydrazide hydrochloride (2 g, 13.1 mmol) was added in portions to the reaction mixture which
was further stirred for 12 h at RT. Reaction mixture was washed with NaHCO3 (10% aq., 50 ml_), water (2 x 50 mL) and brine (50 ml_). The organic layer was dried over Na2SO4, evaporated under vacuum and purified by silica gel column chromatography (chloroform/MeOH) to afford the title compound as a colorless liquid. 1H NMR (DMSO-de, 400 MHz) δ 9.65 (s, 1 H), 9.31 (s, 1 H), 6.74 (t, J = 10.9 Hz, 1 H), 3.14-3.09
(m, 2H), 2.27-2.23 (m, 2H), 1.34 (s, 9H), 1.12 (s, 9H).
Step 4) Formation of tert-butyl [2-(5-tert-butyl-1 ,3,4-oxadiazol-2-yl)ethyl]carbamate To a solution of triphenylphosphine (2.74 g, 10.4 mmol) in dry DCM (5 mL) was added iodine (2.64 g, 10.4 mmol) portionwise under inert atmosphere and stirred at RT for 10 min. TEA (2.7 mL, 20.9 mmol) followed by solution of tert-butyl {3-[2-(2,2- dimethylpropanoyl)hydrazino]-3-oxopropyl}carbamate (2 g, 6.9 mmol) in DCM (10 mL). After 12 h, solvents were removed under vacuum and purified by silica gel column chromatography (PE/EtOAc) to afford the title compound as a white solid. LC/MS, M+(ESI): 270.2. HPLC, Rt: 7.37 min (purity: 98.8%). 1H NMR (DMSO-d6, 400 MHz) δ 6.95 (t, J = 5.7 Hz, 1 H), 3.32-3.24 (m, 2H), 2.91-2.87 (m, 2H), 1.33 (s, 9H),
1.31 (s, 9H).
Step 5) Formation of 2-(5-tert-butyl-1 ,3,4-oxadiazol-2-yl)ethanamine hydrochloride A suspension of [2-(5-te/f-butyl-[1 ,3,4]oxadiazol-2-yl)-ethyl]-carbamic acid te/f-butyl ester (1.18 g; 4.39 mmol) in 4M HCI in dioxane (20 mL; 80 mmol) was stirred at RT for 18 h. The white suspension was concentrated under vacuum to give the title compound (1.18 g; quant) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.23 (bs, 2H), 3.23-3.19 (m, 4H), 1.35 (s, 9H).
Intermediate 88 : 2-[5-(3,3,3-Trifluoro-1 -methylpropyl)-1 ,2,4-oxadiazol-3- yljethanamine hydrochloride
The title compound was prepared following procedure of Intermediate 70 starting from 2-methyl-4,4,4-trifluorobutyric acid, PyBop and 3-aminopropanenitrile. 1H NMR (DMSO-de, 300 MHz) δ 8.31 (bs, 3H), 3.61-3.50 (m, 1 H), 3.17-3.07 (m, 4H), 2.89-2.76 (m, 2H), 1.40 (s, J = 7.0 Hz, 3H).
Intermediate 89 : 2-[5-(3,3-Difluorocyclobutyl)-1 ,2,4-oxadiazol-3-yl]ethanamine hydrochloride
The title compound was prepared following procedure of Intermediate 70 starting from 2,2-difluorocyclobutanecarboxylic acid, PyBop and 3-aminopropanenitrile. 1H
NMR (DMSOd6, 300 MHz) δ 8.24 (bs, 3H), 3.85-3.75 (m, 1 H), 3.18-2.92 (m, 8H).
Intermediate 90 : 2-[5-(2,2,2-Trifluoro-1 ,1 -dimethylethyl)-1 ,2,4-oxadiazol-3- yljethanamine hydrochloride
The title compound was prepared following procedure of Intermediate 70 starting from 3,3,3-trifluoro-2,2-dimethylpropionic acid, PyBop and 3-aminopropanenitrile. 1H NMR (DMSOd6, 300 MHz) δ 8.28 (bs, 3H), 3.17-3.14 (m, 4H), 1.64 (s, 6H).
Intermediate 91 : 2-[5-(1 -Fluoro-1 -methylethyl)-1 ,2,4-oxadiazol-3-yl]ethanamine hydrochloride
The title compound was prepared following procedure of Intermediate 70 starting from 2-fluoroisobutyric acid, PyBop and 3-aminopropanenitrile. 1H NMR (DMSOd6, 300 MHz) δ 8.27 (bs, 3H), 3.18-3.13 (m, 4H), 1.84 (s, 3H), 1.77 (s, 3H).
Intermediate 92 : 2-[5-(1 -Fluoroethyl)-1 ,2,4-oxadiazol-3-yl]ethanamine hydrochloride
The title compound was prepared following procedure of Intermediate 70 starting from 2-fluoropropionic acid, PyBop and 3-aminopropanenitrile. 1H NMR (DMSO-dβ, 300 MHz) δ 8.18 (bs, 3H), 6.09 (dq, J = 6.7, 46.4 Hz, 1 H), 3.19-3.10 (m, 4H), 1.73 (dd, J = 6.7, 24.8 Hz, 3H).
Intermediate 93 : [2-(5-lsobutyl-1 ,2,4-oxadiazol-3-yl)ethyl]amine hydrochloride
The title compound was prepared following procedure of Intermediate 70 starting from 2-isovaleryl chloride and 3-aminopropanenitrile. 1H NMR (DMSO-dβ, 400 MHz) δ 8.43 (bs, 3H), 3.12-3.01 (m, 4H), 2.77-2.75 (m, 2H), 2.10-2.03 (m, 1 H), 0.91 (d, J = 6.7 Hz, 6H).
Intermediate 94 : [2-(5-sec-Butyl-1 ,2,4-oxadiazol-3-yl)ethyl]amine hydrochloride
The title compound was prepared following procedure of Intermediate 70 starting from 2-methylbutyryl chloride and 3-aminopropanenitrile. LC/MS, M+(ESI): 170.0. HPLC, Rt: 3.61 min (Purity 96.9%).
Intermediate 95 : Λ/-(2-Aminoethyl)-2,2-dimethylpropanamide hydrochloride
The title compound was prepared following procedure of intermediate 37 starting from te/f-butyl Λ/-(2-aminoethyl)carbamate and pivaloyl chloride. 1H NMR (DMSOd6, 300
MHz) δ 8.03 (bs, 3H), 7.80-7.76 (m, 1 H), 3.32-3.26 (m, 2H), 3.85-3.80 (m, 2H), 1.10 (bs, 9H).
Intermediate 96 : Λ/-{2-[3-(2-Aminoethyl)-1 ,2,4-oxadiazol-5-yl]-2-methylpropyl}- N,N-dimethylamine bis hydrochloride
Step 1) Formation of 3-(dimethylamino)-2,2-dimethylpropanoic acid 2,2-Dimethyl-3-bromopropionic acid (10 g, 55.2 mmol) was mixed with dimethyl amine (2 M in THF, 150 ml.) in a sealed tube and stirred at 650C for 12 h. THF was removed under vacuum and the resulting crude solid was slurried in EtOAc, filtered and dried under vacuum to afford the title compound (6 g, 75%) as a white solid. 1H NMR (DMSOd6, 400 MHz) δ 9.47 (bs, 1 H), 3.28 (s, 2H), 2.77 (s, 6H), 1.22 (s, 6H). Step 2) Formation of tert-butyl (2-{5-[2-(dimethylamino)-1 , 1-dimethylethyl]-1 ,2,4- oxadiazol-3-yl}ethyl)carbamate To a mixture of 3-(dimethylamino)-2,2-dimethylpropanoic acid (6 g, 41.3 mmol) and te/f-butyl-3-amino-3-(hydroxyimino) propylcarbamate (7 g, 34.4 mmol) in dry dioxane (100 ml.) was added DCC (8.5 g, 43.1 mmol) at once and the reaction mixture was stirred at RT for 1 h. After this time, the reaction mixture was heated to 1000C for 12 h
then cooled to RT and filtered. The filtrate was concentrated in vacuo and the residue filtered through a short plug of silica. Purification by preparative HPLC afforded the title compound as colourless liquid which was used as such in next step. Step 3) Formation of N-{2-[3-(2-aminoethyl)-1,2,4-oxadiazol-5-yl]-2-methylpropyl}- N,N-dimethylamine dihydrochloride
To a solution fe/f-butyl 2-{5-[2-(dimethylamino)-1 ,1-dimethylethyl]-1 ,2,4-oxadiazol-3- yl}ethylcarbamate (2 g, 6.4 mmol) in 1 ,4 dioxane (15 ml_), was added 4M HCI in dioxane (15 mL) at 00C and stirred for 12 h at RT. After completion, the reaction mixture was concentrated under vacuum to get the title compound (1.4 g, 77%) as a white solid. LC/MS, M+(ESI): 213.0. HPLC, Rt: 3.43 min (purity: 99.7%).
Intermediate 97 : Λ/-[2-(5-tert-Butyl-1 ,2,4-oxadiazol-3-yl)ethyl]-Λ/-methylamine hydrochloride
Step 1) Formation of tert-butyl 2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)ethylcarbamate te/f-Butyl-3-amino-3-(hydroxyimino) propylcarbamate (12 g, 59.11 mmol) was taken in pyridine (150 mL) and cooled to 00C under nitrogen atmosphere to which was slowly added te/f-butyl carbonyl chloride (7.84 g, 65.0 mmol). After 2 h, the reaction mixture was heated to reflux for 12 h. After this time, pyridine was removed under reduced pressure and the residue was taken up in EtOAc (200 mL) and washed with water (250 mL) then brine (100 mL). The organic layer was dried over Na2SO4, filtered and concentrated under vacuum. The crude product was purified by silica gel column chromatography (PE/EtOAc) to afford the title compound as a colorless liquid. 1H NMR (DMSO-de, 400 MHz) δ 5.00 (bs, 1 H), 3.28-3.22 (m, 2H), 2.91 (t, J = 7.0 Hz, 2H), 1.43 (s, 18H).
Step 2) Formation of tert-butyl 2-(5-tert-butyl-1,2,4-oxadiazol-3- yl)ethyl(methyl)carbamate
To a solution of te/f-butyl 2-(5-te/f-butyl-1 ,2,4-oxadiazol-3-yl)ethylcarbamate (3 g,
1 1.1 mmol), in dry DMF (50 mL) was added sodium hydride (60% suspension in mineral oil, 0.8 g, 33.4 mmol) at 00C and stirred for 30 min at this temperature. After this time, methyl iodide (4.75 g, 33.4 mmol) was added in a dropwise fashion and the reaction mixture was stirred for 12 h at 400C. The reaction mixture was poured onto ice and extracted with EtOAc (3 x 100 mL). The organic layer was washed with water
(2 x 200 ml_), brine (200 ml_), dried over Na2SO4 and evaporated under reduced pressure to afford the title compound (2.5 g, 80%) as pale yellow liquid which was used as such for the next step.
Step 3) Formation of N-[2-(5-tert-butyl-1 ,2,4-oxadiazol-3-yl)ethyl]-N-methylamine hydrochloride
To a solution te/f-butyl 2-(5-fe/f-butyl-1 ,2,4-oxadiazol-3-l)ethyl(methyl)carbamate (2.5 g, 8.80 mmol) in dry dioxane (25 ml.) was added 4M HCI in dioxane (20 ml.) at 00C and stirred at RT for 5 h. The reaction mixture was evaporated to dryness to afford the title compound (1.4 g, 73%) as a pale brown solid. LC/MS, M+(ESI): 185.2. HPLC, Rt: 2.76 min (purity 93.67%). 1H NMR (DMSOd6, 400 MHz) δ 9.34 (bs, 2H),
3.21-3.14 (m, 4H), 2.55 (s, 3H), 1.36 (s, 9H).
Intermediate 98 : 2-[5-(2,2,2-Trifluoroethyl)-1 ,2,4-oxadiazol-3-yl]ethanamine hydrochloride
The title compound was prepared following procedure of Intermediate 70 starting from 3,3,3-trifluoropropionic acid, DCC and 3-aminopropanenitrile. LC/MS, M+(ESI): 196.0. HPLC, Rt: 2.57 min (purity 99.1 %). 1H NMR (DMSOd6, 400 MHz) δ 8.35 (bs, 3H), 4.49-4.41 (m, 2H), 3.14 (s, 4H).
Intermediate 99 : 2-(5-Ethyl-1 ,3,4-thiadiazol-2-yl)ethanamine hydrochloride
The title compound was prepared following procedure of Intermediate 83 starting from propionic acid and Boc-beta-alanine. 1H NMR (DMSOd6, 400 MHz) δ 8.42 (bs, 3H), 3.43-3.39 (m, 2H), 3.22-3.16 (m, 2H), 3.07-3.01 (m, 2H), 1.27 (t, J = 7.5 Hz, 3H).
Intermediate 100 : 4-Methyl-Λ/-pyrrolidin-3-ylpentanamide hydrochloride
The title compound was prepared following procedure of Intermediate 37 starting from 1-Booc-3-aminopyrrolidine and γ-methylvaleroyl chloride. 1H NMR (DMSOd6, 300 MHz) δ 8.87 (bs, 1 H), 8.55 (bs, 1 H), 7.51-7.48 (m, 1 H), 4.63-4.56 (m, 1 H), 3.72- 3.37 (m, 3H), 2.52-2.41 (m, 1 H), 2.30-2.15 (m, 3H), 1.58-1.45 (m, 3H), 0.90 (d, J =
6.2 Hz, 6H).
Intermediate 101 : 6-(2-Methoxypyridin-3-yl)-1 ,3-benzothiazol-2 -amine
Step 1) Formation of tert-butyl (6-bromo-1 ,3-benzothiazol-2-yl) carbamate
2-Amino-6-bromobenzothiazole (2.0 g; 8.7 mmol) was suspended in DCM (40 ml.) to which were added di-te/f-butyl dicarbonate (2.86 g; 13.1 mmol) and DMAP (4 mg; 0.03 mmol). The resulting mixture was stirred at RT for 16 h then concentrated in vacuo. The residue was suspended in 2M NH3 in MeOH and stirred at RT for 2 h then concentrated in vacuo. The residue was triturated in water and filtered to afford the title compound (2.64 g, 92%) as a white solid. 1H NMR (DMSOd6, 300 MHz) δ 1 1.86 (s, 1 H), 8.19 (d, J = 2.0 Hz, 1 H), 7.60 (d, J = 8.5 Hz, 1 H), 7.52 (dd, J = 2.0, 8.5 Hz, 1 H), 1.51 (s, 9H).
Step 2) Formation of tert-butyl [6-(2-methoxypyridin-3-yl)-1 ,3-benzothiazol-2- yljcarbamate
A mixture of fe/f-butyl (6-bromo-1 ,3-benzothiazol-2-yl)carbamate (1.0 g; 3.04 mmol), 2-methoxypyridine-3-boronic acid (0.56 g; 3.65 mmol), PdCI2(PPh3)2 (0.1 1 g; 0.15 mmol) and cesium fluoride (1.38 g; 9.11 mmol) in dioxane (12 ml.) and water (6 ml.) was stirred at 900C for 3 h. The solution was diluted with DCM, washed successively with sat. aq. NaHCO3 and brine, dried over sodium sulfate and concentrated in vacuo. The residue was taken up in DCM and filtered through a short plug of alumina. After concentration in vacuo, the residue was triturated in MeOH and filtered to afford the title compound as a pale grey solid. 1H NMR (DMSO-d6, 300 MHz) δ 1 1.80 (s, 1 H),
8.18 (dd, J = 1.8, 4.9 Hz, 1 H), 8.09 (d, J = 1.6 Hz, 1 H), 7.79 (dd, J = 1.8, 7.2 Hz, 1 H), 7.71 (d, J = 8.5, 1 H), 7.57 (dd, J = 1.8, 8.4 Hz, 1 H), 7.10 (dd, J = 4.9, 7.3 Hz, 1 H), 3.89 (s, 3H), 1.52 (s, 9H). Step 3) Formation of 6-(2-methoxypyridin-3-yl)-1 ,3-benzothiazol-2-amine A mixture of te/f-butyl [6-(2-methoxypyridin-3-yl)-1 ,3-benzothiazol-2-yl]carbamate
(615 mg; 1.72 mmol) and 4M HCI in dioxane (20 ml_; 80 mmol) was stirred at RT for 5 h then concentrated in vacuo. The residue was taken up in 2M NH3 in MeOH (10 ml.) and the mixture stirred for 10 min then concentrated in vacuo. The residue was triturated in water to afford the title compound (402 mg, 91 %) as a pale grey solid. 1H NMR (DMSO-d6, 300 MHz) δ 8.14 (dd, J = 1.9, 4.9 Hz, 1 H), 7.84 (d, J = 1.4 Hz, 1 H),
7.73 (dd, J = 1.8, 7.3 Hz, 1 H), 7.57 (bs, 2H), 7.40-7.36 (m, 2H), 7.07 (dd, J = 4.9, 7.4 Hz, 1 H), 3.88 (s, 3H). HPLC, Rt 2.07 min (purity: 92.6%). LC/MS, M+(ESI): 257.9.
Intermediate 102 : 6-(5-Methoxypyridin-3-yl)imidazo[1 ,2-ϋ]pyridazin-2 -amine
A mixture of 6-chloro-imidazo[1 ,2-b]pyridazin-2-ylamine (375 mg; 2.22 mmol), 5- methoxy-3-pyridineboronic acid pinacol ester (784 mg; 3.34 mmol), PdCI2(PPh3)2 (156 mg; 0.22 mmol), cesium fluoride (1.0 g; 6.67 mmol) in dioxane (5 ml.) and water
(1.5 ml.) was stirred at 1500C for one hour (microwave heating). After concentration in vacuo, the residue was partitioned between DCM and water. The two phases were separated, the organic layer washed with water, dried over magnesium sulfate, filtered through a short plug of Celite® and concentrated in vacuo. Purification by column chromatography on alumina (DCM to DCM/MeOH, 95/5) afforded the title compound as a yellow solid. 1H NMR (DMSOd6, 300 MHz) δ 8.78 (d, J = 1.8 Hz, 1 H), 8.38 (d, J = 2.8 Hz, 1 H), 7.91-7.86 (m, 1 H), 7.76 (d, J = 9.2 Hz, 1 H), 7.63 (d, J = 9.2 Hz, 1 H), 7.41 (s, 1 H), 5.63 (s, 2H), 3.93 (s, 3H). HPLC, Rt: 1.34 min (purity 96.2%).
Intermediate 103 : 6-[5-(Methylsulfonyl)pyridin-3-yl]-1 ,3-benzothiazol-2 -amine
Step 1) Formation of 3-bromo-5-(methylthio)pyridine
To a solution of 3,5-dibromopyridine (5 g, 21.1 mmol) in dry DMF (50 ml.) was added in portions sodium thiomethoxide (1.63 g, 23.0 mmol) at 00C under nitrogen and stirred at RT for 14 h. The mixture was quenched with sat. aq. ammonium chloride solution and extracted with EtOAc. The organic layer was washed with water, dried over Na2SC>4 and concentrated under vacuum to afford the title compound (4 g, 93%) as a yellow liquid. LC/MS, M+(ESI): 205.8. HPLC, Rt: 3.04 min (purity: 99.0%). 1H NMR (CDCI3, 400 MHz) δ 8.43-8.40 (m, 2H), 7.68 (s, 1 H), 2.52 (s, 3H). Step 2) Formation of 3-bromo-5-(methylsulfonyl)pyridine
To a solution of 2-bromo-6-(methylthio)pyridine (10 g, 49.0 mmol) in THF (125 mL) was added oxone® (30 g, 98.0 mmol) in water in a dropwise fashion at 00C and stirred at RT for 3 h. The mixture was extracted with EtOAc washed with water, brine, dried over Na2SO4, evaporated and purified by silica gel column chromatography (PE/EtOAc) to afford the title compound as a white solid. LC/MS, M+(ESI): 237.8.
HPLC, Rt: 5.45 min (purity: 99.6%). 1H NMR (DMSO-d6, 400 MHz) δ 9.07-9.04 (m, 2H), 8.58 (s, 1 H), 3.39 (s, 3H).
Step 3) Formation of6-(4,4,5,δ-tetramethyl-1,3-dioxaborolan-2-yl)-1,3-henzoϋi!azol-2- amine
To a solution of 6-bromo~1 ,3-benzothiazoi-2~amine (10 g, 43.6 mmoi) in dioxane (50 mL) was added bispinacoiotodiboron (16.6 g, 65.4 mmol), potassium acetate (12.8 g, 130.8 mmol) and PdCI2dppf.DCM (3.55 g, 43.6 mmol) and the resulting mixture was stirred at 100&C for 12 h. After cooiing to RT the reaction mixture was filtered through a plug of Celite which was further washed with EA. The combined filtrate was evaporated to dryness and the residue purified by column chromatography (PBEA1 85/15) to afford the title compound (5.1 g, 42%) as a white solid. 1H NMR (DMSO-dt, 400 MHz) δ 7.92 (s, 1 H)1 7.65 (bs, 2H)1 7.50 (d, J= 8.7 Hz1 1 H)1 7.29 (d, J = 8.2 Hz,
1 H), 1.27 (s, 12H).
Step 4} Formation of 6-[5~(methy!sυffonyi)pyridin~3-yi]-1 ,3-benzothiazo!-2-amine A mixture of 6~(4>4,5.5-tetramethyl-1,3-dioxaborolan~2-yl}~1/3~benzothiazol~2~amine (5 g, 18 mmol), 3~bromo5~(methy!suifonyi)pyridine (4.27 g, 18 mmo!), cesium fluoride (5.5 g, 36.2 mmol) and PdCi2 (PPh3J2 (0.25 gs 0.4 mmol) in DMF (25 mL) stirred at
800C for 12 h. The reaction mixture was cooied RT. poured into ice water and the product was extracted with ethyl acetate (2x10OmL). The combined organic layer was dried over Na2SO4 and evaporated under vacuum. The crude product was purified by column chromatography (CHCi3ZMeOH) to afford the titie compound (3.5 g, 64%) as paie yellow solid.
LC/MS, M+(ESi): 305.9. HPLC1 Rt: 5.45 min (purity 99.6%).
Intermediate 104 : 6-(6-Methoxypyridin-3-yl)-1,3-benzothiazol-2 -amine
The title compound was prepared following procedure of Intermediate 101 starting from 2-amino-6-bromobenzothiazole and 2-methoxypyridine-5-boronic acid pinacol ester. 1H NMR (DMSO-d6, 300 MHz) δ 8.93 (bs, 3H), 8.47-8.46 (m, 1 H), 8.10 (d, J = 1.7 Hz, 1 H), 8.02-7.97 (m, 1 H), 7.64 (dd, J = 1.9, 8.4 Hz, 1 H), 7.48 (d, J = 8.4 Hz,
1 H), 6.91 (m, J = 8.6 Hz, 1 H), 3.89 (s, 3H).
Intermediate 105 : 2-[(Benzoyloxy)amino]-6-bromoimidazo[1 ,2-a]pyridine
Phenyl chloroformate (11.6 g, 74.2 mmol) was added dropwise at 00C to a solution of 6-bromoimidazo[1 ,2-a]pyridin-2-amine(15 g, 70.7 mmol) and 2,4,6-collidine (12.8 g, 106 mmol) in THF (225 ml.) and the reaction mixture was stirred at RT for 12 h then quenched with water. The precipitate was filtered off, washed with water and dried to afford the title compound as an off- white solid. LC/MS (Atlantis), M+(ESI): 334.1. HPLC, Rt: 3.86 (purity: 94.1 %). 1H NMR (DMSOd6, 400 MHz) δ 10.95 (bs, 1 H), 8.89 (s, 1 H), 7.88 (s, 1 H), 7.44-7.40 (m, 3H), 7.35-7.31 (m, 1 H), 7.31-7.30 (m, 1 H), 7.28- 7.20 (m, 2H).
Intermediate 106 : 5-Pyridin-3-yl[1 ,3]thiazolo[5,4-b]pyridin-2 -amine
Step 1) Formation of tert-butyl (5-chloro[1,3]thiazolo[5,4-b]pyridin-2-yl)carbamate 5-Chloro[1 ,3]thiazolo[5,4-b]pyridin-2-amine (1.50 g; 8.08 mmol) was suspended in
DCM (30 ml.) to which were added di-te/f-butyl dicarbonate (2.64 g; 12.12 mmol) and 4-dimethylaminopyridine (2 mg; 0.02 mmol). The suspension was stirred at RT during 4 h after which it was filtered and washed with DCM to give the title compound (2.03 g; 88%) as a white solid. LC/MS, M-(ESI): 283.8. HPLC, Rt: 3.56 min (purity: 97.5%). Step 2) Formation of 5-pyridin-3-yl[1 ,3]thiazolo[5,4-b]pyridin-2-amine te/f-Butyl (5-chloro[1 ,3]thiazolo[5,4-jb]pyridin-2-yl)carbamate (2.03 g; 7.10 mmol), 3- (4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridine (1.89 g; 9.24 mmol), PdCI2(PPh3)2 (498 mg; 0.71 mmol), cesium fluoride (2.69 g; 17.76 mmol) were flushed with argon before addition of degassed dioxane (40 mL) and water (20 mL).
Reaction mixture was heated at 900C during 3 h after which solvents were removed under vacuum. Solid residue was then triturated in water, filtered then in hot ACN and filtered before addition of 4M HCI in dioxane (25 ml_). Reaction mixture was stirred at RT for 4 h and solvent was evaporated under vacuum. Solid was triturated in sat. aq. Na2CO3 followed by filtration to afford the title compound as a beige solid. LC/MS, M+(ESI): 228.8.
Intermediate 107 : 6-[5-(2-Methoxyethoxy)pyridin-3-yl]-1,3-benzothiazol-2 -amine
To a solution of 3-bromo-5-hydroxypyridine (2 g, 11.4 mmol) in dry DMF (10 mL) was added potassium carbonate (2.3 g, 17.2 mmol) at once and stirred for 20 min under inert atmosphere at RT before dropwise addition of 2-bromomethyl ethyl ether. After 4 h the reaction mixture was filtered and water (100 mL) was added to the filtrate which was extracted with EtOAc (2 x 15 mL). The organic layer was washed with aq. sodium hydroxide (10% solution, 15 mL), water, brine then dried over Na2SO4 and concentrated under vacuum to afford the title compound (2 g, 75%) as a brown liquid. LC/MS, M+(ESI): 234.0. HPLC, Rt: 2.33 min (purity: 96.3%). 1H NMR (CDCI3, 400 MHz) δ 8.25 (S, 2H), 7.37 (t, J = 2.4 Hz, 1 H), 4.13-4.11 (m, 2H), 3.73-3.71 (m, 2H), 3.41 (S, 3H).
Step 2) Formation oftert-43utyl[6~(4,4,5!5~tetrameUi^~1,3!2~dhxaboroian~2~yi)~1,3~ benzothiazoi~2~yl]carbamate
A mixture of tert-buty! {6-bromo-1 ,3-benzothiazo!-2-yi)carbamate (8.0 g; 24.3 mmol), bis(pinacolato)diboron (18.9 g; 72.9 mmoi), PdC!2dppf (1.07 g; 1.46 mmoi) and potassium acetate (21.7 g; 219 mmoi) in dioxane (80 mL) was stirred at 80°C for 4 h.
After cooling down to RT, the solution was filtered through a short piug of Celite. The filtrated was poured into water and extracted with EtOAc. The combined organic layer was washed with brine, dried over magnesium sulfate and concentrated in vacuo. Purification by column chromatography (cHex/EtOAc) afforded the title compound
contaminated with bis(pinacoiato)diboron (6.84 g) as a pale orange solid which was used without further purification. LC/MS, M-(ESi): 375.2.
Step 3) ) Formation oftert-butyi {6-[5~(2~methoxyethoxy)pyridin-3-yl]~1,3~ benzothiazol-2~yl}carbamate
A mixture of ferf-butyi [6-(4,4,5,5-tetrameihyi-1 ,3,2-dioxaboroian-2-yi)-1 ,3- benzothiazoi-2-y!]carbamate (500 mg; 1 ,33 mmoi), 3-bromo-5-(2-methoxy-ethoxy)- pyridine (206 mg; 0.89 mmoi), cesium fluoride (407 mg; 2.68 mmoi) and PdCi2(PPh5)J
(39 mg; 0.06 mmoi) in dioxane (4 mi_) and water (2 mi.) was stirred at SO0C for 16 h.
After dilution with ethy! acetate, the soiution was washed with sat. aq. NH4Ci then brine, dried over magnesium suifale and concentrated in vacuo. Purification by coiumn chromatography (DCM/MeOH) afforded the titie compound (188 mg, 53%) as a white soiid.
LC/MS, M+(ESi): 402.1.
Step 4) Formation of 6-[5~(2~methoxyethoxy)pyridin-3-yl]~1,3~henzothiazol~2~amine
The titie compound was prepared foiiowing procedure of intermediate 101 step 3 starting from tert-butyi {δ-[5-(2-methoxyethoxy)pyridin-3-yi]-1 ,3-benzothiazo!-2- yi}carbamate. LC/MS, M+(ESi): 302,0. 1H NMR (DMSO-ds> 300 MHz) δ 8.48 {6, J ^
1.5 Hz1 1 H), 8.23 (d, J = 2.6 Hz, 1 H)1 8.10 (d, J = 1.5 Hz, 1 H), 7.63-7.59 (m, 4H), 7.40
(d, J = 8,3 Hz, 1 H), 4.29-4.26 (m, 2H)5 3.71-3.68 (m, 2H), 3.32 (s, 3H),
Intermediate 108 : 5-(2-Amino-1,3-benzothiazol-6-yl)nicotinonitrile
The title compound was prepared following procedure of Intermediate 101 starting from tert-butyi [6~(4s4,5!5~tetramethyi-1 ,3,2~dioxaboroian-2~yi>-1 ,3-benzothiazoi-2~ yijcarbamate and 5-bromonicotinonitrile. LC/MS, M+(ESI): 252.9.
Intermediate 109 : 6-Chloroimidazo[1 ,2-fe]pyridazin-2 -amine
Step 1) Formation of N-(6-chloropyridazin-3-yl)-4-methylbenzenesulfonamide p-Toluene sulfonyl chloride (91.8 g, 481 mmol) was added portionwise at 00C to a solution of 3-amino-6-chloropyridazine (52 g, 401 mmol) in pyridine (315 ml.) and the reaction mixture was stirred at 900C for 12 h. After concentration in vacuo, the residue was purified by column chromatography (PE/EtOAc, 90/10) to afford the title compound as a white solid. LC/MS (Atlantis), M+(ESI): 283.8. HPLC, Rt: 3.06 (purity: 98.0%). 1H NMR (DMSOd6, 300 MHz) δ 7.80-7.75 (m, 4H), 7.56 (bs, 1 H), 7.39-7.37 (m, 2H), 2.49 (s, 3H).
Step 2) Formation of 2-[(6Z)-3-Chloro-6-{[(4-methylphenyl)sulfonyl]imino}pyridazin- 1 (6H)-yl]acetamide
2-Bromoacetamide (10.6 g, 77 mmol) was added to a solution of Λ/-(6- chloropyridazin-3-yl)-4-methylbenzenesulfonamide (20 g, 70 mmol) and DIEA (10.6 g, 77 mmol) in DMF (100 ml.) and the reaction mixture was stirred at room temperature for 3 h then quenched with water. The precipitate was washed with water and dried to afford the title compound (23.3 g, 98%) as a beige solid. LC/MS (Atlantis), M+(ESI): 340.8. HPLC, Rt: 2.35 (purity: 97.2%). 1H NMR (DMSOd6, 300 MHz) δ 7.99-7.97 (m, 1 H), 7.80-7.78 (m, 1 H), 7.70-7.68 (m, 3H), 7.39 (s, 1 H), 7.32-7.30 (m, 2H), 4.82 (s, 2H), 2.34 (s, 3H).
Step 3) Formation of N-(6-chloroimidazo[1,2-b]pyridazin-2-yl)-2,2,2-trifluoroacetamide Trifluoroacetic anhydride (175.9 g, 1.54 mol) was slowly added to a solution of 2- [(6Z)-3-chloro-6-{[(4-methylphenyl)sulfonyl]imino}pyridazin-1 (6/-/)-yl]acetamide (23 g, 67 mmol) in DCM (290 mL) and the reaction mixture was stirred at 500C for 3 h. After concentration in vacuo, the residue was triturated in 10% aq. NaHCC>3, filtered washed with water and dried to afford the title compound (15.7 g, 88%) as an off- white solid. LC/MS (Atlantis), M+(ESI): 265.0. HPLC, Rt: 3.73 (purity: 97.8%). 1H NMR (DMSOd6, 400 MHz) δ 12.70 (s, 1 H), 8.40 (s, 1 H), 8.19-8.17(m, 1 H), 7.44-7.41 (s, 1 H). Step 4) Formation of 6-chloroimidazo[1 ,2-b]pyridazin-2-amine
Potassium phosphate (42.36 g 0.2 mol) in water (60 mL) was added to a solution of Λ/-(6-chloroimidazo[1 ,2-t)]pyridazin-2-yl)-2,2,2-trifluoroacetamide (15 g, 56 mmol) in 1 ,2-dimethoxyethane (102 mL) and the reaction mixture was stirred at 900C for 12 h.
The two phases were separated and the aqueous layer extracted with EtOAc (2x10OmL). The combined organic phase was washed with brine (50 ml_), dried over sodium sulfate and concentrated in vacuo. The residue was triturated in PE and the precipitate filtered off, washed with PE and dried to afford the title compound (8.5 g, 89%) as a brown solid. LC/MS (Atlantis), M+(ESI): 169.1. HPLC, Rt: 1.39 (purity: 96.7%). 1H NMR (DMSOd6, 400 MHz) δ 7.68-7.66 (d, 1 H), 7.35 (s, 1 H), 7.04-7.01 (m, 1 H), 5.67 (s, 2H).
Intermediate 110 : 6-(5-Methoxypyridin-3-yl)[1 ,2,4]triazolo[1 ,5-a]pyridin-2-amine
Step 1) Formation of ethyl {[(5-bromopyridin-2-yl)amino]carbonothioyl}carbamate
Ethoxycarbonyl isothiocyanate (3.6 mL; 31.8 mmol) was added to a solution of 2- amino-5-bromo-pyridine (5 g; 28.9 mmol) in dioxane (55 mL) and the resulting mixture was stirred at RT for 16 h then concentrated in vacuo. The residue was triturated in c-hexane, the precipitate filtered off, washed with c-hexane and dried to afford the title compound (8 g, 91%) as an off-white solid. 1H NMR (DMSOd6, 300 MHz) δ 12.20 (s, 1 H), 1 1.82-1 1.64 (m, 1 H), 8.70-8.56 (m, 1 H), 8.54 (dd, J = 0.6, 2.5 Hz, 1 H), 8.13 (dd, J = 2.5, 8.9 Hz, 1 H), 4.23 (q, J = 7.1 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H). Step 2) Formation of 6-bromo[1, 2, 4]triazolo[1 , 5-a]pyridin-2-amine
Hydroxylamine hydrochloride (9.20 g; 132 mmol) was added to a solution of ethyl {[(5-bromopyridin-2-yl)amino]carbonothioyl}carbamate (8 g; 26.3 mmol) and DIEA (13.5 mL; 79 mmol) in EtOH (65 mL) and MeOH (65 mL) and the resulting mixture was stirred at RT for 3 h. The solvents were removed in vacuo and the residue taken up in dioxane. Water was added until precipitation started. The solids were collected by filtration, washed with water and dried to afford the title compound (5.26 g, 94%) as a pale pink solid. 1H NMR (DMSO-d6, 300 MHz) δ 9.80 (s, 1 H), 7.75 (d, J = 9.0 Hz, 1 H), 7.15 (d, J = 9.0 Hz, 1 H), 6.13-6.08 (m, 2H). LC/MS, M+(ESI): 212.9.
Step 3) Formation of6-(5-methoxypyridin-3-yl)[1,2,4]triazolo[1,5-a]pyridin-2-amine A mixture of 6-bromo[1 ,2,4]triazolo[1 ,5-a]pyridin-2-amine (200 mg; 0.94 mmol), 3- methoxypyridine-5-boronic acid pinacol ester (287 mg; 1.22 mmol), PdCI2(PPh3J2 (66 mg; 0.09 mmol), cesium fluoride (357 mg; 2.35 mmol) in dioxane (4 ml_) and water (2 mL) was stirred at 85°C for 2 days. After concentration in vacuo, the residue was triturated in water, filtered and dried to afford the title compound (235 mg, quantitative yield) as a brown solid. LC/MS, M+(ESI): 242.1.
Intermediate 111 : 6-(5-Ethoxypyridin-3-yl)-1,3-benzothiazol-2-amine trifluoroacetic acid salt
Step 1) Formation oftert~bυtyl[6~(5~eϋioxypyήdin~3~yl}~1,3~benzothiazol~2~ yijcarbamate
A mixture of 3~bromo~5-ethoxypyridine (prepared according to WO 2006/023630, 510 mg; 2.52 mmol), terf-butyl [6-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,3- benzothiazol-2-yl]carbamate (950 mg; 2.52 mmol), PdCI2(PPh3J2 (266 mg; 0.38 mmol) and cesium fluoride (1.15 g; 7.57 mmol) in dioxane (6 mL) and water (2 mL) was stirred at 1000C for 1 hour (microwave heating). After concentration in vacuo, the residue was taken up in EtOAc, washed with water then sat. aq. NaHCO3, dried over magnesium sulfate, filtered through a short plug of Celite® and concentrated in vacuo. Crystallization from hot MeOH afforded the title compound (450 mg, 48%) as a white solid. 1H NMR (DMSO-d6l 300 MHz) δ 11.86 (s, 1 H), 8.52 (d, J = 1.9 Hz, 1 H), 8.35 (bs, 1 H), 8.25 (d, J = 2.7 Hz, 1 H), 7.77-7.71 (m, 2H), 7.68-7.65 (m, 1 H), 4.21 (q, J = 7.0 Hz, 2H), 1.52 (s, 9H), 1.38 (t, J = 7.0 Hz, 3H). LC/MS, M+(ESI): 372.1. Step 2) Formation of 6-(5-ethQxypyndin~3~yi)~1,3~benzQthiazal~2~amine trifiuoroacetic acid salt
TFA (12 mL) was added to a solution of ferf-butyl [6-(5-ethoxypyridin-3-yl)-1 ,3- benzothiazol-2-yl]carbamate (400 mg; 1.01 mmol) in DCM (12 mL) and the resulting mixture was stirred at RT for 2 h then concentrated in vacuo. The solid was triturated in a mixture of DCM and MeOH, filtered. The mother liquor was concentrated in
vacuo to afford the title compound (350 mg, quantitative yieid) as a white solid. LC/MS, M+(ESI): 272,0,
Intermediate 112 : 6-[5-(Trifluoromethyl)pyridin-3-yl]-1 ,3-benzothiazol-2 -amine
Step 1) Formation of tert-butyl {6-[5-(trifluoromethyl)pyridin-3-yl]-1 ,3-benzothiazol-2- yljcarbamate
A mixture of fe/f-butyl [6-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,3- benzothiazol-2-yl]carbamate (400 mg; 1.06 mmol), PdCI2(PPh3)2 (45 mg; 0.06 mmol), 3-bromo-5-(trifluoromethyl)pyridine (336 mg; 1.49 mmol) and cesium fluoride (565 mg; 3.72 mmol) in dioxane (10 mL) and water (5 ml.) was stirred at 100°C for 1 hour. After cooling down to RT, the precipitate was filtered off to afford the title compound (220 mg, 86%) as a beige solid. 1H NMR (DMSOd6, 300 MHz) δ 1 1.93 (s, 1 H), 9.28 (d, J = 2.0 Hz, 1 H), 8.96 (bs, 1 H), 8.53 (bs, 1 H), 8.50 (d, J = 1.7 Hz, 1 H), 7.90 (dd, J = 1.9, 8.5 Hz, 1 H), 7.80 (d, J = 8.5 Hz, 1 H), 1.53 (s, 9H). LC/MS, M-(ESI): 394.1.
Step 2) Formation of 6-[5-(trifluoromethyl)pyridin-3-yl]-1,3-benzothiazol-2-amine 4M HCI in dioxane (15 mL) was added to a solution of te/f-butyl {6-[5- (trifluoromethyl)pyridin-3-yl]-1 ,3-benzothiazol-2-yl}carbamate (340 mg; 0.86 mmol) in MeOH (5 mL) and the resulting mixture was stirred at RT for 18 h. Et2O was added and the precipitate filtered off to afford the title compound (280 mg, 98%) as a white solid. HPLC, Rt: 2.98 (purity: 99.2%). LC/MS, M-(ESI): 296.0.
Intermediate 113 : 6-(5-Morpholin-4-ylpyridin-3-yl)-1 ,3-benzothiazol-2 -amine
Step 1) Formation of4-(5-bromopyridin-3-yl)morpholine
A mixture of 3,5-dibromopyridine (2.0 g; 8.44 mmol), morpholine (0.81 g; 9.29 mmol) and TEA (1.71 g; 16.89 mmol) in DMA (10 mL) was stirred for 2 h at 2000C (microwave heating). The solution was poured onto a mixture of ice and sat. aq.
NaHCO3 and extracted with EtOAc (2x). The combined organic phase was washed with brine (2x), dried over sodium sulfate and concentrated in vacuo to give a yellow oil which crystallized from n-pentane to afford the title compound as a beige solid. 1H NMR (DMSO-d6! 300 MHz) δ 8.30 (bs, 1 H), 8.07 (bs, 1 H), 7.55 (bs, 1 H), 3.73 (t, J = 4.6 Hz, 4H), 3.22 (t, J = 4.6 Hz, 4H).
Step 2) Formation of tert-butyl [6-(5-morpholin-4-ylpyridin-3-yl)-1 ,3-benzothiazol-2- yljcarbamate
A mixture of 4-(5-bromopyridin-3-yl)morpholine (0.68 g; 2.80 mmol), te/f-butyl [6-
(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,3-benzothiazol-2-yl]carbamate (1.05 g; 2.80 mmol), cesium fluoride (1.70 g; 1 1.19 mmol) and PdCI2(PPh3)4 (0.24 g; 0.34 mmol) in dioxane (12 mL) and water (6 mL) was stirred at 1000C for 2 h (microwave heating). The reaction mixture was partitionned between DCM and sat. aq. NaHCO3. The aqueous phase was extracted with DCM and the combined organic layer washed with brine, dried over sodium sulfate and concentrated in vacuo. Crystallization from EtOAc and washing with n-pentane afforded the title compound as an off-white solid.
1H NMR (DMSO-d6, 300 MHz) δ 1 1.86 (s, 1 H), 8.38 (d, J = 1.5 Hz, 1 H), 8.34 (bs, 1 H), 8.30 (d, J = 2.7 Hz, 1 H), 7.76 (bs, 2H), 7.59 (t, J = 2.3 Hz, 1 H), 3.78 (t, J = 4.8 Hz, 4H), 3.28 (t, J = 4.8 Hz, 4H), 1.53 (s, 9H). LC/MS, M+(ESI): 413.2. Step 3) Formation of 6-(5-morpholin-4-ylpyridin-3-yl)-1 ,3-benzothiazol-2-amine 4M HCI in dioxane (10 mL, 40 mmol) was added dropwise to te/f-butyl [6-(5- morpholin-4-ylpyridin-3-yl)-1 ,3-benzothiazol-2-yl]carbamate (0.61 g; 1.48 mmol) and the resulting mixture was stirred at RT for 10 h. The solution was poured into sat. aq. NaHCO3, extracted with DCM, washed with brine, dried over sodium sulfate and
concentrated in vacuo. Trituration in DCM and filtration afforded the title compound as an off-white solid. 1H NMR (DMSOd6, 300 MHz) δ 8.33 (d, J = 1.5 Hz, 1 H), 8.25 (d, J = 2.6 Hz, 1 H), 8.07 (d, J = 1.8 Hz, 1 H), 7.63-7.55 (m, 3H), 7.53 (t, J = 2.3 Hz, 1 H), 7.40 (d, J = 8.3 Hz, 1 H), 3.78 (t, J = 4.8 Hz, 4H), 3.26 (t, J = 4.8 Hz, 4H). LC/MS, M+(ESI): 313.1.
Intermediate 114 : [5-(2-Amino-1 ,3-benzothiazol-6-yl)pyridin-3-yl]methyl pivalate
Step 1) Formation of (5-bromopyridin-3-yl)methanol Sodium borohydride (0.4 g; 18.5 mmol) was added to a solution of methyl 5- bromonicotinate (2.0 g; 9.26 mmol) in ethanol (50 ml.) and the resulting mixture was stirred at reflux for 20 h. The solution was diluted with EtOAc, washed with water then brine, dried over sodium sulfate and concentrated in vacuo. Purification by column chromatography on alumina (DCM to DCM/EtOAc, 50/50) afforded the title compound (1.5 g, 86%) as a yellow oil. 1H NMR (DMSOd6, 300 MHz) δ 8.58 (d, J = 2.3 Hz, 1 H),
8.51 (d, J = 1.6 Hz, 1 H), 7.97-7.95 (m, 1 H), 5.45 (t, J = 5.8 Hz, 1 H), 4.54 (d, J = 5.8 Hz, 2H).
Step 2) Formation of (5-bromopyridin-3-yl) methyl pivalate Pivaloyl chloride (0.81 g; 6.73 mmol) was added dropwise to a solution of (5- bromopyridin-3-yl)methanol (1.15 g; 6.12 mmol) in pyridine (5 ml.) and DCM (45 ml.) and the resulting mixture was stirred at RT for 16 h whereupon pivaloyl chloride (0.81 g; 6.73 mmol) was added. The reaction mixture was stirred for a further 24 h then concentrated in vacuo. The residue was taken up in EtOAc washed with sat. aq. NaHCOβ, dried over magnesium sulfate and concentrated in vacuo. Filtration through a short plug of alumina (DCM) afforded the title compound (1.35 mg, 81%) as a colourless oil. 1H NMR (DMSO-d6, 300 MHz) δ 8.68 (d, J = 2.3 Hz, 1 H), 8.58 (d, J = 1.6 Hz, 1 H), 8.05 (t, J = 2.1 Hz, 1 H), 5.13 (s, 2H), 1.17 (s, 9H).
Step 3) Formation of (5-{2-[(tert-butoxycarbonyl)amino]-1,3-benzothiazol-6-yl}pyridin- 3-yl)methyl pivalate
A mixture of (5-bromopyridin-3-yl)methyl pivalate (500 mg; 1.84 mmol), te/f-butyl [6- (4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,3-benzothiazol-2-yl]carbamate (691 mg; 1.84 mmol), cesium fluoride (1.12 g; 7.35 mmol) and PdCI2(PPh3)2 (155 mg; 0.22 mmol) in dioxane (8 ml.) and water (4 ml.) was stirred at 1000C for 2 h then concentrated in vacuo. The residue was taken up in DCM, washed with sat. aq. NaHCC>3 then brine, dried over magnesium sulfate and concentrated in vacuo. Trituration in EtOAc and filtration afforded the title compound (580 mg, 71%) as a white solid. 1H NMR (DMSOd6, 300 MHz) δ 1 1.88 (s, 1 H), 8.92 (d, J = 2.2 Hz, 1 H),
8.57 (d, J = 1.9 Hz, 1 H), 8.35 (s, 1 H), 8.1 1 (t, J = 2.1 Hz, 1 H), 7.81 - 7.72 (m, 2H), 5.22 (s, 2H), 1.53 (s, 9H), 1.19 (s, 9H). HPLC, Rt: 3.86 (purity 86.3%). Step 4) Formation of [5-(2-amino-1 ,3-benzothiazol-6-yl)pyridin-3-yl]methyl pivalate TFA (3 ml.) was added to a solution of (5-{2-[(te/f-butoxycarbonyl)amino]-1 ,3- benzothiazol-6-yl}pyridin-3-yl)methyl pivalate (560 mg; 1.27 mmol) in DCM (10 ml.) and the resulting mixture was stirred at RT for 2 h. The solution was diluted with DCM, washed with sat. aq. NaHCO3 then brine, dried over sodium sulfate and concentrated in vacuo to afford the title compound as a white solid. 1H NMR (DMSO-de, 300 MHz) δ 8.86 (d, J = 2.2 Hz, 1 H), 8.52 (d, J = 1.8 Hz, 1 H), 8.08 (d, J = 1.8 Hz, 1 H), 8.04 (t, J = 2.1 Hz, 1 H), 7.63 (bs, 2H), 7.58 (dd, J = 1.9, 8.4
Hz, 1 H), 7.44 (d, J = 8.4 Hz, 1 H), 5.19 (s, 2H), 1.18 (s, 9H). HPLC, Rt: 2.10 (purity 95.6%).
Intermediate 115 : 6-(1H-lndazol-5-yl)-1 ,3-benzothiazol-2 -amine
A mixture of 2-amino-6-bromobenzothiazole (350 mg; 1.53 mmol), 1 /-/-indazole-5- boronic acid pinacol ester (485 mg; 1.99 mmol), PdCI2(PPh3^ (129 mg; 0.18 mmol) and cesium fluoride (0.93 g; 6.11 mmol) in dioxane (9 mL) and water (4.5 mL) was
stirred at 900C for 24 h then concentrated in vacuo. The residue was taken up in DCM, washed with sat. aq. NaHCC>3 then brine, dried over magnesium sulfate and concentrated in vacuo. Purification by trituration in DCM and filtration afforded the title compound as a beige solid. LC/MS, M+(ESI): 267.0.
Intermediate 116 : 6-(1H-lndazol-4-yl)-1 ,3-benzothiazol-2 -amine
2-Amino-6-bromobenzothiazole (400 mg; 1.75 mmol) and 4-(4,4,5,5-tetramethyl- [1 ,3,2]dioxaborolan-2-yl)-1 /-/-indazole (554 mg; 2.27 mmol) were reacted as described for Intermediate 115. Purification by trituration in ACN and filtration afforded the title compound as a beige solid. LC/MS, M+(ESI): 267.0.
Intermediate 117 : 6-(3H-lmidazo[4,5-fe]pyridin-6-yl)-1 ,3-benzothiazol-2 -amine
A mixture of 6-bromo-3/-/-imidazo[4,5-b]pyridine (300 mg; 1.51 mmol), te/f-butyl [6-
(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,3-benzothiazol-2-yl]carbamate (570 mg; 1.51 mmol), cesium fluoride (921 mg; 6.06 mmol) and PdCI2(PPh3)2 (128 mg; 0.18 mmol) in dioxane (8 ml.) and water (4 ml.) was stirred at 125°C for 3 h (microwave heating) then concentrated in vacuo. The residue was triturated in water then in ACN to afford the crude title compound as an orange oil which was used without further purification. LC/MS, M+(ESI): 268.0.
Intermediate 118 : 6-[5-(Methoxymethyl)pyridin-3-yl]-1 ,3-benzothiazol-2 -amine
Step 1) Formation of 3-bromo-5-(methoxymethyl)pyridine To a slurry of NaH (60%, 1.6 g, 17.5 mmol) in dry THF (20 ml.) under N2, was added a solution of (5-bromopyridin-3-yl)methanol (2.2 g, 1 1.7 mmol) in THF (20 ml.) in a dropwise fashion at 00C. After stirring at RT for 10 min, was added methyl iodide (2.18 ml_, 35.1 mmol) in drops at 00C and further stirred at RT for 1 h. After this time, ice cold water (10 ml.) was added followed by evaporation under vacuum. Residue was dissolved with EtOAc, washed with water, brine then dried over Na2SO4, concentrated under vacuum and purified by silica gel column chromatography (PE/EtOAc) to afford the title compound as a pale yellow liquid. LC/MS, M+(ESI) 204.0. HPLC, Rt: 1.96 min (purity: 99.9%). 1H NMR (CDCI3, 400 MHz) δ 8.61 (s, 1 H), 8.48 (s, 1 H), 7.86 (s, 1 H), 4.46 (s, 2H), 3.42 (s, 3H). Step 2) Formation of 6-[5-(methoxymethyl)pyridin-3-yl]-1 ,3-benzothiazol-2-amine
3-Bromo-5-methoxymethyl-pyridine (750 mg; 3.71 mmol), 6-(4,4,5,5-tetramethyl- [1 ,3,2]dioxaborolan-2-yl)-benzothiazol-2-ylamine (1.13 g; 4.08 mmol) were reacted as described for Intermediate 115. After cooling to RT, the reaction mixture was filtered to afford the title compound as a white solid. LC/MS, M+(ESI): 272.0. 1H NMR (DMSO-de, 300 MHz) δ 8.82 (d, J = 2.3 Hz, 1 H), 8.47 (d, J = 1.9 Hz, 1 H),
8.08 (d, J = 1.8 Hz, 1 H), 7.99 (t, J = 2.1 Hz, 1 H), 7.63-7.56 (m, 3H), 7.41 (d, J = 8.3 Hz, 1 H), 4.52 (s, 2H), 3.35 (s, 3H).
Step 1) Formation of tert-butyl [6-(1 -methyl-1 H-imidazol-5-yl)-1 ,3-benzothiazol-2- yl] carbarn ate te/f-Butyl [6-(4,4!5,5-tetramethyl-1 ,3,2-clioxaborolari-2-yl)-1 ,3-benzothiazol-2- yl]carbamate (600 mg; 1.59 mmol) and 5-bromo-1 -methyl-1 /-/-imidazole (308 mg;
1.91 mmol) were reacted as described for intermediate 114 step 3. After concentration in vacuo, the residue was taken up in DCM, washed with sat. aq. NaHCC>3 then brine, dried over magnesium sulfate and concentrated in vacuo to afford the crude title compound (800 mg) as a brown solid which was used without further purification.
Step 2) Formation of 6-(1 -methyl-1 H-imidazol-5-yl)-1 ,3-benzothiazol-2-amine TFA (20 ml.) was added to a solution of te/f-butyl [6-(1 -methyl-1 /-/-imidazol-5-yl)-1 ,3- benzothiazol-2-yl]carbamate (800 mg) in DCM (50 ml.) and the resulting mixture was stirred at RT for 4 h then concentrated in vacuo. Purification by MD Autoprep afforded the title compound as a white solid. HPLC, Rt: 2.99 (purity 100%). LC/MS, M+(ESI):
231.0.
Intermediate 120 : 6-(2-Methyl-3H-imidazo[4,5-b]pyridin-6-yl)-1 ,3-benzothiazol-2- amine
6-Bromo-2-methyl-3/-/-imidazo[4,5-b]pyridine (300 mg; 1.41 mmol) and 6-(4,4,5,5- tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-benzothiazol-2-ylamine (430 mg; 1.56 mmol)
were reacted as described for Intermediate 115. After cooling to RT, the reaction mixture was filtered to afford the title compound as a pink solid. LC/MS, M+(ESI): 282.0.
Intermediate 121 : 6-[5-(Methylthio)pyridin-3-yl]-1 ,3-benzothiazol-2 -amine hydrochloride
Step 1) Formation of 3-bromo-5-methylsulfanyl-pyridine
To a solution of 3,5-dibromopyridine (5 g, 21.1 mmol) in dry DMF (50 ml.) was added in portions sodium thiomethoxide (1.63 g, 23.0 mmol) at 00C under nitrogen and stirred at RT for 14 h. The mixture was quenched with sat. aq. ammonium chloride and extracted with EtOAc. The organic layer was washed with water, dried over Na2SO4 and concentrated under vacuum to afford title compound (4 g, 93%) as a yellow liquid. LC/MS, M+(ESI) 205.8. HPLC: Rt 3.04 min (purity: 99.0%). 1H NMR (CDCI3, 400 MHz) δ 8.40-8.43 (m, 2H), 7.68 (s, 1 H), 2.52 (s, 3H).
Step 2) Formation of tert-butyl {6-[5-(methylthio)pyridin-3-yl]-1 ,3-benzothiazol-2- yljcarbamate
3-Bromo-5-methylsulfanyl-pyridine (3.0 g; 14.7 mmol) and [6-(4,4,5,5-tetramethyl-
[1 ,3,2]dioxaborolan-2-yl)-benzothiazol-2-yl]-carbamic acid fe/f-butyl ester (5.53 g; 14.7 mmol) were reacted as described for Intermediate 114 step 3. The reaction mixture was cooled down to 700C, diluted with water and stirred at this temperature for a further hour. After cooling to RT, the precipitate was filtered off and washed thoroughly with water. Trituration in hot dioxane and filtration afforded the title compound as a white solid. 1H NMR (DMSO-d6, 300 MHz) δ 1 1.87 (s, 1 H), 8.70 (d, J = 2.1 Hz, 1 H), 8.45 (d, J = 2.2 Hz, 1 H), 8.38 (bs, 1 H), 7.98 (t, J = 2.2 Hz, 1 H), 7.82-
7.73 (m, 2H), 2.61 (s, 3H), 1.53 (s, 9H). LC/MS, M+(ESI): 374.0. Step 3) Formation of 6-[5-(methylthio)pyridin-3-yl]-1 ,3-benzothiazol-2-amine hydrochloride 4M HCI in dioxane (30 mL, 120 mmol) was added to te/f-butyl {6-[5- (methylthio)pyridin-3-yl]-1 ,3-benzothiazol-2-yl}carbamate (3.0 g, 8.0 mmol) and the resulting mixture was stirred at RT for 2 h then at 700C for 4 h. After cooling to RT, the precipitate was filtered off and washed with dioxane to afford the title compound
(2.45 g, 99%) as an off-white solid. 1H NMR (DMSO-d6, 300 MHz) δ 8.86 (d, J = 1.9 Hz, 1 H), 8.66 (d, J = 2.1 Hz, 1 H), 8.43-8.39 (m, 2H), 7.92 (dd, J = 1.8, 8.4 Hz, 1 H), 7.64 (d, J = 8.5 Hz, 1 H), 2.70 (s, 3H). LC/MS, M+(ESI): 273.8.
Intermediate 122 : 6-Pyridin-3-yl-1 ,3-benzothiazol-2 -amine
Step 1) Formation of N-(6-bromo-1 ,3-benzothiazol-2-yl)dodecanamide
Laurie acid chloride (3.43 ml_; 14.43 mmol) was added to a suspension of 2-amino-6- bromobenzothiazole (3.00 g; 13.09 mmol) and pyridine (1.6 ml_; 19.7 mmol) in DCM (30 ml.) and the resulting mixture was stirred at RT for for 4 h. The precipitate was filtered off and washed successively with DCM, water, sat. aq. NaHCC>3, water and ACN. Recrystallization from MeOH (200 mL) afforded the title compound as a white solid. 1H NMR (DMSOd6, 300 MHz) δ 12.40 (s, 1 H), 8.24 (d, J = 2.0 Hz, 1 H), 7.66 (d, J = 8.6 Hz, 1 H), 7.56 (dd, J = 2.1 , 8.6 Hz, 1 H), 2.50-2.43 (m, 2H), 1.65-1.55 (m, 2H), 1.34-1.15 (m, 16H), 0.84 (t, J = 6.6 Hz, 3H). LC/MS, M+(ESI): 413.1.
Step 2) Formation of N-(6-pyridin-3-yl-1 ,3-benzothiazol-2-yl)dodecanamide (Λ/-(6-bromo-1 ,3-benzothiazol-2-yl)dodecanamide (4.15 g; 10.10 mmol) and 3- (4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridine (2.28 g; 1 1.10 mmol) were reacted as described for intermediate 101 step 2. After cooling down to RT, the mixture was filtered through a short plug of Celite® and the two phases were separated. The organic layer was washed with water then brine, dried over magnesium sulfate and concentrated in vacuo. Purification by column chromatography on alumina (DCM/MeOH, 98/2) afforded the title compound as a brown solid. LC/MS, M+(ESI): 409.9. Step 3) Formation of 6-pyridin-3-yl-1 ,3-benzothiazol-2-amine
A mixture of Λ/-(6-pyridin-3-yl-1 ,3-benzothiazol-2-yl)dodecanamide (917 mg; 2.24 mmol) in dioxane (30 mL) and 5M NaOH (20 mL) was stirred at reflux for 16 h. The two phases were separated and the organic layer was concentrated in vacuo. The
residue was taken up in 1 M HCI and the solution was washed with DCM (3x). The aq. phase was neutralized with 1 M NaOH and extracted with EtOAc (3x). The combined organic phase was washed with brine and concentrated in vacuo to afford the title compound as a yellow solid. 1H NMR (DMSO-d6, 300 MHz) δ 8.89 (bs, 1 H), 8.52 (bs, 1 H), 8.09-8.02 (m, 2H), 7.66-7.54 (m, 3H), 7.50-7.37 (m, 2H). LC/MS, M+(ESI): 227.9.
Intermediate 123 : Λ/-{[5-(2-Amino-1 ,3-benzothiazol-6-yl)pyridin-3- yl]methyl}acetamide
Step 1) Formation of 3-bromo-5-(chloromethyl)pyridine
To a solution of (5-bromopyridin-3-yl) methanol (3 g, 15.9 mmol) in DCM (100 ml_), was added thionyl chloride (1.7 ml_, 23.9 mmol) in a dropwise fashion at O0C followed by 30 min at RT. After this time, reaction mixture was quenched with ice water and extracted with DCM (2 x 100 ml_), washed with NaHCO3 (10% aq., 100 ml_), water
(100 ml_), brine (100 ml_), dried over Na2SO4 and concentrated under vacuum to afford the title compound (2.9 g, 88%) as a yellow oil. 1H NMR (DMSO-d6, 400 MHz) δ 8.68 (d, J = 2.2 Hz, 1 H), 8.64 (d, J = 1.7 Hz, 1 H), 8.16 (bs, 1 H), 4.80 (s, 2H). Step 2) Formation of 3-(azidomethyl)-5-bromopyridine To a solution of 3-bromo-5-(chloromethyl)pyridine (2 g, 9.6 mmol) in dry DMF (20 ml_), was added NaN3 (2.5 g, 38.7 mmol) after which the reaction mixture was stirred under N2 for 12 h at RT. After this time, water was added (100 ml.) and extracted with EtOAc (2 x 100 ml_), the combined organic layer was washed with water (3 x 100 ml_), dried over Na2SO4 and concentrated under vacuum to afford the title compound (1.9 g, 94%) as a brown oil which was used directly in the next step.
Step 3) Formation of (5-bromopyridin-3-yl)methylamine
To a solution of 3-(azidomethyl)-5-bromopyridine (1.9 g; 8.9 mmol) in THF (50 ml.) and water (2 ml.) was added triphenylphosphine (9.2 g, 35.1 mmol) after which it was heated to 7O0C under N2for 1 h. After this time, reaction mixture was concentrated under vacuum and the residue was purified by silica gel column chromatography
(chloroform/MeOH) to afford the title compound (1.5 g, 85%) as a brown oil. 1H NMR (DMSOd6, 400 MHz) δ 8.52 (d, J = 2.2 Hz, 1 H), 8.48 (bs, 1 H), 8.01 (bs, 1 H), 3.71 (s, 2H).
Step 4) Formation N-[(5-bromopyridin-3-yl)methyl]acetamide To a solution of (5-bromopyridin-3-yl)methylamine (1.5 g, 8.0 mmol), in DCM (50 mL) were added TEA (1.67 mL, 12.0 mmol) and acetyl chloride (0.62 mL, 8.8 mmol) dropwise at 00C after which it was stirred under N2 for 1 h at RT. After this time, reaction mixture was quenched with ice water and extracted with DCM (2 x 100 mL); the combined organic layer was washed with NaHCO3 (10% aq., 100 mL), water (100 mL), brine (100 mL), dried over Na2SO4 and concentrated under vacuum. The solid was recrystallised from PE:EtOAc (9:1 , 10 mL), filtered and dried under vacuum to afford the title compound as a brown solid. 1H NMR (DMSO d6, 400 MHz) δ 8.58 (d, J = 2.2 Hz, 1 H), 8.45 (d, J = 1.4 Hz, 1 H), 8.42 (s, 1 H), 7.89 (s, 1 H) 4.26 (d, J = 5.9 Hz, 2H), 1.86 (s, 3H). LC/MS, M+(ESI) 229.0. HPLC: Rt 3.06 min (purity 96.0%). Step 5) Formation of N-{[5-(2-amino-1 ,3-benzothiazol-6-yl)pyridin-3- yl]methyl}acetamide
Λ/-(5-Bromo-pyridin-3-ylmethyl)-acetamide (500 mg; 2.18 mmol) and 6-(4,4,5,5- tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-benzothiazol-2-ylamine (663 mg; 2.40 mmol) were reacted as described for Intermediate 107. After cooloing down to RT, the two phases were separated and the organic layer concentrated in vacuo. The residue was triturated in ACN and DCM to afford the title compound as a brown solid. LC/MS, M+(ESI): 298.8.
Intermediate 124 : Λ/-{[5-(2-Amino-1 ,3-benzothiazol-6-yl)pyridin-3- yl]methyl}methanesulfonamide
Step 1) Formation ofN-[(5-bromopyridin-3-yl)methyl]methanesulfonamide To a solution of (5-bromopyridin-3-yl)methylamine (1.5 g, 8.0 mmol), in DCM (50 mL), was added TEA (1.67 mL, 1 1.2 mmol) and methanesulfonyl chloride (0.74 mL, 9.6 mmol) in drops at 00C after which it was stirred under N2 for 1 h at RT. After this time,
reaction mixture was quenched with ice water and extracted with DCM (2 x 100 ml_); the combined organic layer was washed with NaHCC>3 (10% aq., 100 ml_), water (100 ml_), brine (100 ml_), dried over Na2SO4 and concentrated under vacuum. The crude product was purified by silica gel column chromatography (PE/EtOAc) to afford the title compound as a white solid. 1H NMR (DMSOd6, 400 MHz) δ 8.62 (d, J = 2.0 Hz,
1 H), 8.53 (s, 1 H), 7.99 (s, 1 H), 7.66 (t, J = 6.2 Hz, 1 H) 4.21 (d, J = 6.2 Hz, 2H), 2.93 (s, 3H). LC/MS, M+(ESI) 265.0. HPLC: Rt 1.66 min (purity: 94.5%). Step 2) Formation of N-{[5-(2-amino-1 ,3-benzothiazol-6-yl)pyridin-3- yl]methyl}methanesulfonamide Λ/-(5-Bromo-pyridin-3-ylmethyl)-methanesulfonamide (500 mg; 1.89 mmol) and 6-
(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-benzothiazol-2-ylamine (573 mg; 2.07 mmol) were reacted as described for Intermediate 107. After cooloing down to RT, the two phases were separated and the organic layer concentrated in vacuo to afford the crude title compound (800 mg) as an orange solid which was used without further purification. LC/MS, M+(ESI): 335.0.
Intermediate 125 : 6-[5-(1 ,1 -Dioxidothiomorpholin-4-yl)pyridin-3-yl]-1 ,3- benzothiazol-2 -amine
A mixture of 3,5-dibromopyridine (2.0 g; 8.44 mmol), thiomorpholine (2.61 g; 25.33 mmol) and DIEA (3.27 g; 25.33 mmol) in NMP (5 mL) was stirred at 2500C for 1 hour (microwave heating). The solution was diluted with EtOAc, washed several times with brine, dried over magnesium sulfate and concentrated in vacuo. Purification by column chromatography (c-hexane/EtOAc, 80/20) afforded the title compound (1.56 g, 71 %) as a yellow oil. 1H NMR (DMSO-d6, 300 MHz) δ 8.27 (d, J = 2.6 Hz, 1 H), 8.00 (d, J = 1.9 Hz, 1 H), 7.55-7.52 (m, 1 H), 3.69-3.62 (m, 4H), 2.66-2.61 (m, 4H). Step 2) Formation of4-(5-bromopyridin-3-yl)thiomorpholine 1, 1 -dioxide H2O2 (30%, 500 μl_) was added at 600C to a solution of 4-(5-bromopyridin-3- yl)thiomorpholine (750 mg; 2.89 mmol) in acetic acid (1 mL) and the resulting mixture was stirred at this temperature for a further 2 h. The solution was diluted with EtOAc,
washed successively with sat. aq. NaHCO3 and brine, dried over sodium sulfate and concentrated in vacuo. Purification by column chromatography (increasing amount of MeOH in DCM) followed by crystallization from Et2O afforded the title compound as an off-white solid. 1H NMR (DMSO-d6, 300 MHz) δ 8.37 (d, J = 2.5 Hz, 1 H), 8.08 (d, J = 1.7 Hz, 1 H), 7.71-7.67 (m, 1 H), 3.90-3.84 (m, 4H), 3.18-3.11 (m, 4H). LC/MS,
M+(ESI): 290.9.
Step 3) Formation of 6-[5-(1 , 1 -dioxidothiomorpholin-4-yl)pyridin-3-yl]-1 ,3- benzothiazol-2-amine 4-(5-Bromopyridin-3-yl)thiomorpholine 1 ,1 -dioxide (400 mg; 1.37 mmol) and tert-butyl [6-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,3-benzothiazol-2-yl]carbamate (569 mg; 1.51 mmol) were reacted as described for Intermediate 107. After cooling down to RT, the reaction mixture was diluted with DCM, washed with brine, dried over magnesium sulfate and concentrated in vacuo. Purification by column chromatography (DCM to DCM/MeOH, 90/10) followed by trituration in ACN and filtration afforded the title compound as an off-white solid. 1H NMR (DMSO-d6, 300
MHz) δ 8.36-8.31 (m, 2H), 8.09 (d, J = 1.8 Hz, 1 H), 7.64-7.56 (m, 4H), 7.40 (d, J = 8.3 Hz, 1 H), 3.92 (bs, 4H), 3.18 (bs, 4H). LC/MS, M+(ESI): 361.0.
Intermediate 126 : 6-(5-r(Methylsulfonyl)methyllpyridin-3-yl)-1 ,3-benzothiazol-2- amine
Step 1) Formation of 3-bromo-5-[(methylthio)methyl]pyridine
To a solution of sodium thiomethoxide (1.1 g, 16.8 mmol) in ethanol (20 ml.) under nitrogen was added 3-bromo-5-(chloromethyl)pyridine (2.9 g, 14.0 mmol) in ethanol (20 ml.) at 00C in a dropwise fashion and then allowed to stir for 1 h at RT.
The reaction mixture was concentrated under vacuum before addition of ice water and extracted with EtOAc (2 x 100 ml_), water (100 ml.) and organics was dried over Na2SO4 and concentrated under vacuum to afford the title compound (2.7 g, 88%) as a brown oil. 1H NMR (DMSO-d6, 400 MHz) δ 8.58 (d, J = 2.2 Hz, 1 H), 8.48 (d, J = 1.7 Hz, 1 H), 8.01 (t, J = 3.9 Hz, 1 H), 3.71 (s, 2H), 1.95 (s, 3H).
Step 2) Formation of 3-bromo-5-[(methylsulfonyl)methyl]pyridine
To a solution of 3-bromo-5-[(methylthio)methyl]pyridine (2.5 g, 11.4 mmol) in DCM (30 ml.) was added m-CPBA (5.9 g, 34.3 mmol) in DCM (20 ml.) in a dropwise fashion at 00C and then was allowed to stir for 30 min at RT. The reaction mixture was filtered, precipitate was washed with cold DCM then filtrate was washed with K2CO3 (20 % aqueous, 2 x 100 ml_), water (100 ml_), brine (100 ml_), dried over
Na2SO4 and concentrated under vacuum. The solid was recrystallised from Et2O (5 ml_), filtered and dried under vacuum to afford the title compound as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.73 (d, J = 2.2 Hz, 1 H), 8.57 (d, J = 1.5 Hz, 1 H), 8.08 (t, J = 1.8 Hz, 1 H), 4.50 (s, 2H), 2.97 (s, 3H). LC/MS, M+(ESI) 252.0. HPLC: Rt 1.86 min (Purity 96.4%).
Step 3) Formation of 6-{5-[(methylsulfonyl)methyl]pyridin-3-yl}-1,3-benzothiazol-2- amine
3-Bromo-5-methanesulfonylmethyl-pyridine (500 mg; 2.00 mmol) and 6-(4,4,5,5- tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-benzothiazol-2-ylamine (607 mg; 2.20 mmol) were reacted as described for Intermediate 107. After cooling down to RT, the mixture was diluted with DCM, washed with water then brine, dried over magnesium sulfate and concentrated in vacuo. Purification by trituration in ACN and filtration afforded the title compound as a beige solid. LC/MS, M+(ESI): 319.8.
Method A: Suzuki cross-coupling reaction (Conditions A)
A mixture of Λ/-(6-bromo-1 ,3-benzothiazol-2-yl)acetamide (1 eq), boronic acid or ester (1.5 to 2 eq), cesium fluoride (3 to 5 eq) and bis(triphenylphosphine)palladium(ll) chloride (0.05 to 0.15 eq) was prepared in dioxane/water (ratio 2:1 to 3:1 , typical concentration from 0.05 to 0.5M). The resulting mixture was heated at 900C for 30 min to 15 hours typically. Depending of the solubility of the final product, different work-ups could be applied.
Work-up A: for final compounds soluble in reaction mixture at RT. The reaction mixture was cooled at RT and filtered, and then diluted with EtOAc (4-10 volumes compare to dioxane). The aqueous layer was removed. The organic layer was washed with brine and dried (MgSO4), optionally treated with activated charcoal, and then the solvents were removed under reduced pressure. The residue was purified by precipitation from an adequate solvent mixture (usually MeOH with or without additional amount of DCM, Et2O or dioxane) or by flash chromatography on silica (using an adequate solvent mixture (such as cHex/EtOAc or DCM/MeOH) or by
reverse chromatography (such as using AutoPrep system) to give the expected compound.
Work-up B: for final compounds soluble in reaction mixture at RT. The reaction mixture was cooled at RT, filtered and diluted with MeOH. The resulting solution was stored at 4°C until precipitation. The solid was filtered off, washed and dried under reduced pressure to give the expected compound.
Work-up C: for final compounds soluble in hot reaction mixture only. The hot reaction mixture was filtered through a syringe filter (0.45 Dm). The resulting solution was cooled at RT and a solid precipitated out. The solid was filtered off, washed with MeOH (2x), Et2O (2x) and pentane (2x), and then dried under reduced pressure to give the expected compound.
Work-up D: for final compounds insoluble in hot reaction mixture. The reaction mixture was cooled at RT. The precipitate appeared during the reaction was filtered off and washed with dioxane. Purification by precipitation from an adequate solvent mixture (such as DCM/MeOH with or without an additional amount of DMSO), optionally preceded by a treatment with activated charcoal, gave the expected compound.
Method B: Suzuki cross-coupling reaction (Conditions B) A mixture of Λ/-[6-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,3-benzothiazol-2- yl]acetamide (1 eq), the halogenated derivative (1.5 to 2 eq), cesium fluoride (3 to 5 eq) and bis(triphenylphosphine)palladium(ll) chloride (0.05 to 0.15 eq) was prepared in dioxane/water (ratio 2:1 to 3:1 , typical concentration from 0.05 to 0.5M). The resulting mixture was heated at 900C for 30 min to 15 hours typically. Depending of the solubility of the final product, the same work-ups as described in Method A were applied.
Example 1 : Formation of Λ/-(6-{3-[(ethylamino)sulfonyl]phenyl}-1 ,3- benzothiazol-2-yl)acetamide (1)
The title compound was prepared following procedure described in Method A (workup A) starting from ethyl 3-boronobenzenesulfonamide. The title compound (1 ) was obtained as a pale orange powder. HPLC, Rt: 3.4 min (purity: 100%). UPLC/MS,
M+(ESI): 376.2, M-(ESI): 374.3. 1H-NMR (DMSO-d6): δ 12.43 (s, 1 H), 8.36 (d, J=1.6 Hz, 1 H), 8.09 (brs, 1 H), 8.00 (brd, J=7.7 Hz, 1 H), 7.85 (d, J=8.5 Hz, 1 H), 7.77 (m, 2H), 7.70 (dd, J=7.7, 7.8 Hz, 1 H), 7.61 (t, J=5.7 Hz, 1 H), 2.82 (dq, J=5.7, 7.2 Hz, 2H), 2.22 (s, 3H), 0.99 (t, J=7.2 Hz, 3H).
Example 2: Formation of Λ/-{6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2- yl}acetamide (2)
The title compound was prepared following procedure described in Method A (work- up A) starting from (3-methylsulfonylphenyl)boronic acid. The title compound (2) was obtained as a pale beige powder. HPLC, Rt: 3.1 min (purity: 99.4%). UPLC/MS,
M+(ESI): 347.2, M-(ESI): 345.2. 1H-NMR (DMSOd6): δ 12.45 (s, 1 H), 8.43 (brs, 1 H),
8.23 (m, 1 H), 8.10 (dm, J=8.0 Hz, 1 H), 7.91 (dm, J=7.9 Hz, 1 H), 7.84 (m, 2H), 7.76
(dd, J=7.9, 8.0 Hz, 1 H), 3.31 (s, 3H), 2.22 (s, 3H).
Example 3: Formation of Λ/-(6-{3-[(methylsulfonyl)amino]phenyl}-1 ,3- benzothiazol-2-yl)acetamide (3)
The title compound was prepared following procedure described in Method A (work- up A) starting from 3-(methylsulfonyl)aminobenzeneboronic acid. The title compound
(3) was obtained as an orange powder. HPLC, Rt: 3.1 min (purity: 98.9%). UPLC/MS,
M+(ESI): 362.2, M-(ESI): 360.3. 1H-NMR (DMSOd6): δ 12.40 (s, 1 H), 9.84 (s, 1 H),
8.23 (d, J=1.8 Hz, 1 H), 7.81 (d, J=8.4 Hz, 1 H), 7.66 (dd, J=1.8, 8.4 Hz, 1 H), 7.51 (brs,
1 H), 7.44 (m, 2H), 7.21 (m, 1 H), 3.05 (s, 3H), 2.22 (s, 3H).
Example 4: Formation of Λ/-[6-(3-{[(2-hydroxyethyl)amino]sulfonyl}phenyl)-1 ,3- benzothiazol-2-yl]acetamide (4)
The title compound was prepared following procedure described in Method A (workup D) starting from Λ/-(2-hydroxyethyl)-3-boronobenzenesulfonamide. The title compound (4) was obtained as a white powder. HPLC, Rt: 2.8 min (purity: 99.9%). UPLC/MS, M+(ESI): 392.2, M-(ESI): 390.3. 1H-NMR (DMSOd6): δ 12.44 (s, 1 H), 8.36 (brs, 1 H), 8.12 (brs, 1 H), 8.00 (brd, J=7.8 Hz, 1 H), 7.85 (d, J=8.5 Hz, 1 H), 7.78 (m, 2H), 7.70 (m, 2H), 4.72 (t, J=5.3 Hz, 1 H), 3.39 (m, 2H), 2.84 (m, 2H), 2.22 (s, 3H).
Example 5: Formation of Λ/-[6-(3-{[(dimethylamino)sulfonyl]amino}phenyl)-1 ,3- benzothiazol-2-yl]acetamide (5)
The title compound was prepared following procedure described in Method A (workup C) starting from [3-(Λ/,Λ/-dimethylsulfamoylamino)phenyl]boronic acid. The title compound (5) was obtained as an off-white powder. HPLC, Rt: 3.3 min (purity: 98.9%). UPLC/MS, M+(ESI): 391.3, M-(ESI): 389.3. 1H-NMR (DMSOd6): δ 12.37 (s, 1 H), 10.00 (s, 1 H), 8.20 (d, J=1.6 Hz, 1 H), 7.81 (d, J=8.4 Hz, 1 H), 7.63 (dd, J=1.6, 8.4
Hz, 1 H), 7.50 (brs, 1 H), 7.39 (m, 2H), 7.20 (m, 1 H), 2.74 (s, 6H), 2.22 (s, 3H).
Example 6: Formation of 3-[2-(acetylamino)-1 ,3-benzothiazol-6-yl]benzamide (6)
The title compound was prepared following procedure described in Method A (workup D) starting from 3-aminocarbonylphenylboronic acid. The title compound (6) was obtained as a pale beige powder. HPLC, Rt: 2.8 min (purity: 99.3%). UPLC/MS, M+(ESI): 312.2, M-(ESI): 310.3. 1H-NMR (DMSOd6): δ 12.41 (s, 1 H), 8.35 (brs, 1 H), 8.23 (brs, 1 H), 8.12 (brs, 1 H), 7.87 (m, 2H), 7.82 (m, 2H), 7.56 (dd, J=7.7, 7.8 Hz, 1 H), 7.45 (brs, 1 H), 2.22 (s, 3H).
The title compound was prepared following procedure described in Method A (workup C) starting from 2-methoxy-4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)phenol. The title compound (7) was obtained as an off-white powder. HPLC, Rt: 3 min (purity: 99.5%). UPLC/MS, M+(ESI): 315.2, M-(ESI): 313.2. 1H-NMR (DMSOd6): δ 12.33 (s,
1 H), 9.10 (s, 1 H), 8.21 (d, J=1.7 Hz, 1 H), 7.74 (d, J=8.4 Hz, 1 H), 7.67 (dd, J=1.7, 8.4 Hz, 1 H), 7.25 (d, J=2.0 Hz, 1 H), 7.12 (dd, J=2.0, 8.2 Hz, 1 H), 6.86 (d, J=8.2 Hz, 1 H), 3.87 (s, 3H), 2.21 (s, 3H).
Example 8: Formation of Λ/-(6-{3-[(dimethylamino)sulfonyl]phenyl}-1 ,3- benzothiazol-2-yl)acetamide (8)
The title compound was prepared following procedure described in Method A (workup B) starting from Λ/,Λ/-dimethyl-3-boronobenzenesulfonamide. The title compound (8) was obtained as an off-white powder. HPLC, Rt: 3.5 min (purity: 96.7%).
UPLC/MS, M+(ESI): 376.2, M-(ESI): 374.3. 1H-NMR (DMSOd6): δ 12.43 (s, 1 H), 8.41 (d, J=1.9 Hz, 1 H), 8.08 (ddd, J=1.8, 2.0, 6.8 Hz, 1 H), 7.98 (m, 1 H), 7.84 (d, J=8.4 Hz, 1 H), 7.79 (dd, J=1.9, 8.4 Hz, 1 H), 7.75 (m, 2H), 2.67 (s, 6H), 2.22 (s, 3H).
Example 9: Formation of Λ/-{6-[4-methoxy-3-(morpholin-4-ylsulfonyl)phenyl]-1 ,3- benzothiazol-2-yl}acetamide (9)
The title compound was prepared following procedure described in Method A (workup B) starting from [4-methoxy-3-(morpholinosulfonyl)phenyl]boronic acid. The title compound (9) was obtained as a pale yellow powder (210 mg, 85%). HPLC, Rt: 3.4 min (purity: 96.5%). UPLC/MS, M+(ESI): 448.3, M-(ESI): 446.4. 1H-NMR (DMSOd6): δ 12.40 (s, 1 H), 8.29 (d, J=1.9 Hz, 1 H), 8.01 (m, 2H), 7.81 (d, J=8.5 Hz, 1 H), 7.70 (dd,
J=1.9, 8.5 Hz, 1 H), 7.40 (d, J=9.4 Hz, 1 H), 3.96 (s, 3H), 3.61 (m, 4H), 3.12 (m, 4H), 2.22 (s, 3H).
Example 10: Formation of Λ/-(6-pyridin-3-yl-1 ,3-benzothiazol-2-yl)acetamide (10)
The title compound was prepared following procedure described in Method A (workup D) starting from 3-pyridineboronic acid. The title compound (10) was obtained as an off-white powder (107 mg, 72%). HPLC, Rt: 2.8 min (purity: 93%). UPLC/MS, M+(ESI): 270.2, M-(ESI): 268.3. 1H-NMR (DMSOd6): δ 12.43 (s, 1 H), 8.96 (brd, J=2.4 Hz, 1 H), 8.57 (dd, J=1.6, 4.8 Hz, 1 H), 8.38 (d, J=1.8 Hz, 1 H), 8.13 (ddd, J=1.6, 2.4,
8.0 Hz, 1 H), 7.84 (d, J=8.5 Hz, 1 H), 7.79 (dd, J=1.8, 8.5 Hz, 1 H), 7.50 (ddd, J=0.7, 4.8, 8.0 Hz, 1 H), 2.22 (s, 3H).
Example 11 : Formation of Λ/-{6-[3-(morpholin-4-ylsulfonyl)phenyl]-1 ,3- benzothiazol-2-yl}acetamide (11 )
The title compound was prepared following procedure described in Method A (workup B) starting from N-morpholinyl 3-boronobenzenesulfonamide. The title compound (11 ) was obtained as an off-white powder. HPLC, Rt: 3.6 min (purity: 98.1 %). LC/MS, M+(ESI): 418.2, M-(ESI): 416.2. 1H-NMR (DMSOd6): δ12.44 (s, 1 H), 8.41 (d, J=1.2
Hz, 1 H), 8.1 1 (dm, J=7.6 Hz, 1 H), 7.97 (m, 1 H), 7.85 (d, J=8.4 Hz, 1 H), 7.79 (m, 2H), 7.73 (dm, J=7.8 Hz, 1 H), 3.65 (m, 4H), 2.93 (m, 4H), 2.23 (s, 3H).
Example 12: Formation of Λ/-(6-pyridin-4-yl-1 ,3-benzothiazol-2-yl)acetamide (12)
The title compound was prepared following procedure described in Method A (workup D) starting from 4-pyridineboronic acid. The title compound (12) was obtained as a yellow powder. LC/MS, M+(ESI): 270.2, M-(ESI): 268.2. 1H-NMR (DMSOd6): δ 12.47
(s, 1 H), 8.64 (m, 2H), 8.48 (d, J=1.7 Hz, 1 H), 7.88 (dd, J=1.7, 8.5 Hz, 1 H), 7.84 (d, J=8.5 Hz, 1 H), 7.77 (m, 2H), 2.23 (s, 3H).
Example 13: Formation of Λ/-{6-[3-(aminosulfonyl)phenyl]-1 ,3-benzothiazol-2- yl}acetamide (13)
The title compound was prepared following procedure described in Method A (workup B) starting from benzenesulfonamide-3-boronic acid pinacol ester. The title compound (13) was obtained as a grey powder. HPLC, Rt: 3.0 min (purity: 98%). LC/MS, M+(ESI): 348.0, M-(ESI): 346.0. 1H-NMR (DMSOd6): δ 12.45 (s, 1 H), 8.35 (d,
J=1.8 Hz, 1 H), 8.17 (m, 1 H), 7.96 (dm, J=7.9 Hz, 1 H), 7.86 (d, J=8.5 Hz, 1 H), 7.81 (dm, J=7.7 Hz, 1 H), 7.77 (dd, J=1.8, 8.5 Hz, 1 H), 7.68 (dd, J=7.7, 7.9 Hz, 1 H), 7.42 (s, 2H), 2.22 (s, 3H).
Example 14: Formation of Λ/-{6-[4-methyl-3-(methylsulfonyl)phenyl]-1 ,3- benzothiazol-2-yl}acetamide (14)
The title compound was prepared following procedure described in Method B (workup C) starting from 4-bromo-1-methyl-2-(methylsulfonyl)benzene. The title compound (14) was obtained as a pale orange powder. HPLC, Rt: 3.7 min (purity: 95.3%).
UPLC/MS, M+(ESI): 361.2, M-(ESI): 359.2. 1H-NMR (DMSOd6): δ 12.43 (s, 1 H), 8.36 (d, J=1.7 Hz, 1 H), 8.18 (d, J=1.9 Hz, 1 H), 7.97 (dd, J=1.9, 8.0 Hz, 1 H), 7.84 (d, J=8.5 Hz, 1 H), 7.76 (dd, J=1.7, 8.5 Hz, 1 H), 7.57 (d, J=8.0 Hz, 1 H), 3.29 (s, 3H), 2.68 (s, 3H), 2.22 (s, 3H).
Example 15: Formation of 6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2- amine (15)
The title compound was prepared following procedure described in Method A starting from 2-amino-6-bromobenzothiazole and (3-methylsulfonylphenyl)boronic acid. The reaction mixture was diluted with water and extracted with EtOAc (2x). The organic layers were combined and the solvents were removed under reduced pressure. The crude was taken up with EtOAc and extracted with a 1 N aqueous solution of HCI (2x).
The acidic aqueous layers were combined, basified until pH 12 with a 5N aqueous solution of NaOH and extracted with EtOAc (2x). The organic layers were combined, dried (MgSO4) and the solvent was removed under reduced pressure. The residue was taken up with a small amount of EtOAc and a precipitation occurred after a few minutes. The solid was filtered off, washed with pentane and dried under reduced pressure to give the title compound (15) as a white powder. HPLC, Rt: 2.1 min (purity: 99.8%). UPLC/MS, M+(ESI): 305.2, M-(ESI): 303.2.
Example 16: Formation of Λ/-{6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2- yl}propanamide (16)
Propionyl chloride (105 mg, 1.15 mmol) was added to a solution of 6-[3- (methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-amine (70 mg, 0.23 mmol) and pyridine (56 μl_, 0.69 mmol) in anhydrous DCM (1.5 ml_). The reaction mixture was stirred at RT for 15 hours. The reaction mixture was diluted with water. The precipitate was filtered off, washed with water and EtOAc, and then dried under reduced pressure to give the title compound (16) as a white powder. HPLC, Rt: 3.3 min (purity: 97.8%). UPLC/MS, M+(ESI): 361.2, M-(ESI): 359.2. 1H-NMR (DMSO-d6): δ 12.41 (s, 1 H), 8.44 (m, 1 H), 8.24 (m, 1 H), 8.10 (dm, J=7.7 Hz, 1 H), 7.91 (dm, J=7.8 Hz, 1 H), 7.84 (m, 2H), 7.76 (dd, J=7.7, 7.8 Hz, 1 H), 3.32 (s, 3H), 2.53 (q, J=7.4 Hz, 2H), 1.13 (t, J=7.4
Hz, 3H).
Example 17: Formation of Λ/-{3-[2-(acetylamino)-1 ,3-benzothiazol-6- yl]phenyl}acetamide (17)
The title compound was prepared following procedure described in Method A (workup A) starting from 3-acetamidobenzeneboronic acid. The title compound (17) was obtained as a beige powder. HPLC, Rt: 2.8 min (purity: 97.1 %). UPLC/MS, M+(ESI): 326.2, M-(ESI): 324.3.
Example 18: Formation of ethyl ({6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol- 2-yl}amino)(oxo)acetate (18)
Ethyl chlorooxoacetate (81 μl_, 0.72 mmol) was added to a suspension of 6-[3- (methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-amine (200 mg, 0.66 mmol) and DIEA
(240 μl_, 1.45 mmol) in anhydrous DCM (4 ml_). The reaction mixture was stirred at RT for 1 hour. The reaction mixture was diluted with water and cyclohexane. The precipitate was filtered off, washed with water (2x) and dried under reduced pressure to give the title compound (18) as a yellow powder. HPLC, Rt: 3.4 min (purity: 86.9%). UPLC/MS, M+(ESI): 405.2, M-(ESI): 403.3.
Example 19: Formation of Λ/-[6-(3-methylphenyl)-1 ,3-benzothiazol-2- yl]acetamide (19)
The title compound was prepared following procedure described in Method A (workup A) starting from m-tolylboronic acid. The title compound (19) was obtained as an off-white powder. HPLC, Rt: 3.9 min (purity: 98.9%). UPLC/MS, M+(ESI): 283.2, M- (ESI): 281.3.
Example 20: Formation of Λ/-{6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2- yl}nicotinamide (20)
Nicotinoyl chloride hydrochloride (178 mg, 1.00 mmol) was added to a solution of 6- [3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-amine (60 mg, 0.20 mmol) and pyridine (80 μl_, 1.00 mmol) in anhydrous DCM (2 ml_). The reaction mixture was stirred at RT for one hour. The reaction mixture was diluted with water and cyclohexane. The precipitate was filtered off. The residue was crystallized from DMSO to give the title compound (20) as a white powder (67 mg, 83%). HPLC, Rt: 3.3 min (purity: 98.9%). UPLC/MS, M+(ESI): 410.2, M-(ESI): 408.3.
Example 21 : Formation of Λ/-[6-(3-nitrophenyl)-1 ,3-benzothiazol-2-yl]acetamide (21)
The title compound was prepared following procedure described in Method A (workup D) starting from 3-nitrophenylboronic acid. The title compound (21 ) was obtained as a red powder. HPLC, Rt: 3.9 min (purity: 92.4%). UPLC/MS, M+(ESI): 314.2, M- (ESI): 312.2.
Example 22: Formation of Λ/-[6-(3-methoxyphenyl)-1 ,3-benzothiazol-2- yljacetamide (22)
The title compound was prepared following procedure described in Method A (workup C) starting from 3-methoxybenzeneboronic acid. The title compound (22) was obtained as a beige powder. HPLC, Rt: 3.9 min (purity: 98.3%). UPLC/MS, M+(ESI): 299.2, M-(ESI): 297.2.
Example 23: Formation of Λ/-{6-[3-{[(2-hydroxyethyl)amino]sulfonyl}-5-
(trifluoromethyl)phenyl]-1 ,3-benzothiazol-2-yl}acetamide (23)
Step 1) Formation of 3-bromo-N-(2-hydroxyethyl)-5- (trifluoromethyl)benzenesulfonamide
To a solution of 3-bromo-5-(trifluoromethyl)benzenesulphonyl chloride (1.00 g, 3.09 mmol) and DIEA (0.79 ml_, 4.64 mmol) in anhydrous DCM (20 ml) cooled at 00C was added ethanolamine (0.37 ml_, 6.18 mmol). The resulting mixture was stirred at 00C for 1.5 hours. The reaction mixture was washed with a 1 N aqueous solution of HCI (2x20 ml.) and brine (20 ml_). The aqueous layers were extracted with DCM (20 ml_).
The organic layers were combined, dried (MgSO4) and the solvent was removed under reduced pressure to give a gummy solid. The solid was taken up with DCM (4 ml.) and then heptane was added until precipitation. The solid was filtered off, washed with heptane (3x) and dried under reduced pressure to give the title compound as a white powder (867 mg, 81%). HPLC, Rt: 3.5 min (purity: 100%).
UPLC/MS, M-(ESI): 346.1 and 348.1.
Step 2) Formation of N-{6-[3-{[(2-hydroxyethyl)amino]sulfonyl}-5- (trifluoromethyl) phenyl]- 1, 3-benzothiazol-2-yl}acetamide
The title compound was prepared following procedure described in Method B (workup A) starting from 3-bromo-Λ/-(2-hydroxyethyl)-5-
(trifluoromethyl)benzenesulfonamide. The title compound (23) was obtained as a white powder. HPLC, Rt: 3.6 min (purity: 99%). UPLC/MS, M+(ESI): 460.2, M-(ESI): 458.3.
Example 24: Formation of methyl 3-[2-(acetylamino)-1 ,3-benzothiazol-6- yl]benzoate (24)
The title compound was prepared following procedure described in Method A (workup C) starting from (3-methoxycarbonylphenyl)boronic acid. The title compound (24) was obtained as a pale beige powder. HPLC, Rt: 3.9 min (purity: 99.2%). UPLC/MS, M+(ESI): 327.2, M-(ESI): 325.2.
Example 25: Formation of 3-(2-amino-1 ,3-benzothiazol-6-yl)-Λ/- ethylbenzenesulfonamide (25)
The title compound was prepared following procedure described in Method A (work- up A + flash chromatography on silica using DCIWMeOH as eluent) starting from 2- amino-6-bromobenzothiazole and ethyl 3-boronobenzenesulfonamide. The title compound (25) was obtained as a pale pink powder. HPLC, Rt: 2.2 min (purity: 97.9%). UPLC/MS, M+(ESI): 334.2, M-(ESI): 332.3.
Example 26: Formation of Λ/-[2-(1 -isopropyl-1 H-imidazol-4-yl)ethyl]-/V-{6-[3-
(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}urea (26)
Step 1) Formation of N-{6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}-1 H- imidazole- 1 -carboxamide
A mixture of 6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-amine (2.00 g, 5.87 mmol) and 1 ,1 '-carbonyldiimidazole (1.43 g, 8.80 mmol) in anhydrous ACN was stirred at RT for 15 hours. The precipitate was filtered off, washed with CAN and dried under reduced pressure to give the title compound as a yellow powder (2.00 g, 86%). The crude compound was used in the next step without further purification.
Step 2) Formation of N-[2-(1 -isopropyl-1 H-imidazol-4-yl)ethyl]-N'-{6-[3- (methylsulfonyl)phenyl]-1,3-benzothiazol-2-yl}urea
A solution of Λ/-{6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}-1 /-/-imidazole-1- carboxamide (45 mg, 0.11 mmol), 2-(1 -isopropyl-1 /-/-imidazol-4-yl)-ethylamine dihydrochloride (38 mg, 0.17 mmol, WO2006125805) and Et3N (78 L, 0.55 mmol) in anhydrous DMF (1 ml.) was stirred at RT for 15 hours. The reaction mixture was
diluted with EtOAc and washed with a saturated solution of NH4CI. The organic layer was dried (MgSO4) and the solvents were removed under reduced pressure. The residue was purified by flash chromatography (silica, DCIWMeOH) to give the title compound (26) as a colorless oil. HPLC, Rt: 2.6 min (purity: 97.7%). UPLC/MS, M+(ESI): 484.3, M-(ESI): 482.4. 1H-NMR (CDCI3): δ 8.19 (m, 1 H), 7.96 (d, J=1.8 Hz,
1 H), 7.90 (m, 2H), 7.73 (d, J=8.5 Hz, 1 H), 7.65 (dd, J=7.8, 7.7 Hz, 1 H), 7.60 (dd, J=8.5, 1.8 Hz, 1 H), 7.54 (d, J=1.1 Hz, 1 H), 6.84 (d, J=1.1 Hz, 1 H), 4.28 (hept, J=6.7 Hz, 1 H), 3.70 (m, 2H), 3.13 (s, 3H), 2.90 (t, J=6.5 Hz, 2H), 1.45 (d, J=6.7 Hz, 6H).
Example 29: Formation of N-{6-[3-({[2-
(dimethylamino)ethyl]amino}sulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}acetamide
(29)
To a solution of 3-bromobenzenesulfonyl chloride (1.00 g, 3.9 mmol) in anhydrous DCM (20 ml) cooled at 00C was added 2-dimethylaminoethylamine (0.90 ml_, 8.2 mmol). The resulting mixture was stirred at 00C for 1.5 hours. The reaction mixture was diluted with DCM (20 ml_), washed with water (20 ml.) and brine (20 ml_). The aqueous layers were extracted with DCM (20 ml_). The organic layers were combined, dried (MgSO4) and the solvent was removed under reduced pressure. The residue was taken up with Et2O (5 ml_), cooled at 00C and then pentane was added until precipitation. The solid was filtered off, washed with pentane (3x) and dried under reduced pressure to give the title compound as a white powder (852 mg, 71%). HPLC, Rt: 2.4 min (purity: 99.9%). UPLC/MS, M+(ESI): 307.1 , 309.1 , M-(ESI): 305.1 ,
307.1.
Step2) Formation of N-{6-[3-({[2-(dimethylamino)ethyl]amino}sulfonyl)phenyl]-1, 3- benzothiazol-2-yl}acetamide
The title compound was prepared following procedure described in Method B (workup A) starting from 3-bromo-N-[2-(dimethylamino)ethyl]benzenesulfonamide. The title compound (29) was obtained as a white powder. HPLC, Rt: 2.8 min (purity: 100%). UPLC/MS, M+(ESI): 419.2, M-(ESI): 417.3. 1H-NMR (DMSOd6): δ 12.45 (s, 1 H), 8.37 (brs, 1 H), 8.13 (brs, 1 H), 8.00 (brd, J=7.6 Hz, 1 H), 7.85 (d, J=8.4 Hz, 1 H), 7.78 (m,
2H), 7.70 (dd, J=7.7, 7.6 Hz, 1 H), 7.62 (brs, 1 H), 2.87 (m, 2H), 2.25 (t, J=6.6 Hz, 2H), 2.22 (s, 3H), 2.04 (s, 6H).
Example 30: Formation of N-[6-(3-{[(2-morpholin-4- ylethyl)amino]sulfonyl}phenyl)-1 ,3-benzothiazol-2-yl]acetamide (30)
The title compound was prepared following procedure described in Example 29 Step 1 ), but starting from 4-(2-aminoethyl)morpholine. The title compound was obtained as a white powder (532 mg, 78%). HPLC, Rt: 2.5 min (purity: 99.9%). UPLC/MS,
M+(ESI): 349.1 , 351.1 , M-(ESI): 347.2, 349.2.
Step 2) Formation of N-[6-(3-{[(2-morpholin-4-ylethyl)amino]sulfonyl}phenyl)-1,3- benzothiazol-2-yl]acetamide
The title compound was prepared following procedure described in Method B (workup A) starting from 3-bromo-N-(2-morpholin-4-ylethyl)benzenesulfonamide. The title compound (30) was obtained as an off-white powder. HPLC, Rt: 2.9 min (purity: 96%). UPLC/MS, M+(ESI): 461.3, M-(ESI): 459.4. 1H-NMR (DMSOd6): δ 12.45 (s, 1 H), 8.37 (d, J=1.7 Hz, 1 H), 8.13 (m, 1 H), 8.00 (dm, J=7.8 Hz, 1 H), 7.85 (d, J=8.4 Hz,
1 H), 7.78 (m, 2H), 7.70 (dd, J=7.8, 7.7 Hz, 1 H), 7.63 (t, J=5.8 Hz, 1 H), 3.45 (m, 4H), 2.92 (m, 2H), 2.29 (t, J=6.7 Hz, 2H), 2.23 (m, 7H).
Example 31 : Formation of N-[6-(4-chloro-3-{[(2- hydroxyethyl)amino]sulfonyl}phenyl)-1 ,3-benzothiazol-2-yl]acetamide (31 )
The title compound was prepared following procedure described in Example 23 Step 1 ), but starting from 2,5-dichlorobenzenesulfonyl chloride. The title compound was obtained as a white powder (1.02 g, 93%). HPLC, Rt: 2.7 min (purity: 96%). UPLC/MS, M-(ESI): 268.1.
Step 2) Formation of N-[6-(4-chloro-3-{[(2-hydroxyethyl)amino]sulfonyl}phenyl)-1,3- benzothiazol-2-yl]acetamide
The title compound was prepared following procedure described in Method B (workup A) starting from 2,5-dichloro-N-(2-hydroxyethyl)benzenesulfonamide. The title compound (31 ) was obtained as a white powder. HPLC, Rt: 3 min (purity: 100%). UPLC/MS, M+(ESI): 426.2, M-(ESI): 424.3. 1H-NMR (DMSOd6): δ 12.43 (s, 1 H), 8.37 (d, J=1.7 Hz, 1 H), 8.24 (d, J=2.3 Hz, 1 H), 7.97 (dd, J=8.4, 2.3 Hz, 1 H), 7.90 (m, 1 H), 7.83 (d, J=8.4 Hz, 1 H), 7.76 (dd, J=8.4, 1.7 Hz, 1 H), 7.74 (d, J=8.4 Hz, 1 H), 4.73 (t,
J=5.6 Hz, 1 H), 3.40 (m, 2H), 2.96 (m, 2H), 2.21 (s, 3H).
Example 32: Formation of N-(6-{5-[(4-hydroxypiperidin-1 -yl)sulfonyl]-3-thienyl}- 1 ,3-benzothiazol-2-yl)acetamide (32) Step 1) Formation of 1-[(4,5-dibromo-2-thienyl)sulfonyl]piperidin-4-ol
A suspension of 4,5-dibromothiophene-2-sulfonyl chloride (10.0 g, 29.4 mmol) was prepared in anhydrous DCM (200 ml) and cooled at 00C. Et3N (20.4 mL, 147 mmol) was added, followed by 4-hydroxypiperidine (5.94 g, 58.8 mmol). The resulting mixture was stirred at 00C for one hour. The reaction mixture was washed with a saturated aqueous solution of NaHCO3 (70 mL), water (70 mL) and brine (70 mL). The organic layer was dried (MgSO4) and the solvent was removed under reduced pressure to give a beige solid. The solid was washed with water (3x40 mL) and dried under reduced pressure to give the title compound as a beige solid (10.2 g, 86%). HPLC, Rt: 3.8 min (purity: 98.9%).
Step 2) Formation of 1-[(4-bromo-2-thienyl)sulfonyl]piperidin-4-ol
Zinc (17.4 g, 267 mmol) was added portionwise over 30 min to a suspension of 1- [(4,5-dibromo-2-thienyl)sulfonyl]piperidin-4-ol (9.0 g, 22.2 mmol) in acetic acid (180 ml.) and then the reaction mixture was stirred at 600C for one hour. Water (200 ml.) was added. The resulting suspension was filtered off over a Celite pad and washed with DCM (200 ml_). The layers were separated and the aqueous layer was extracted with DCM (200 ml_). The combined organic layers were washed with a saturated aqueous solution of NaHCO3 (200 ml_), water (200 ml.) and brine (200 ml_), and then dried (MgSO4). The solvent was removed under reduced pressure to give the title compound as a white solid (5.8 g, 80%). HPLC, Rt: 3.0 min (purity: 100%).
Step 3) Formation of N-(6-{5-[(4-hydroxypiperidin-1-yl)sulfonyl]-3-thienyl}-1 ,3- benzothiazol-2-yl)acetamide
The title compound was prepared following procedure described in Method B (workup A) starting from 1-[(4-bromo-2-thienyl)sulfonyl]piperidin-4-ol. The title compound (32) was obtained as a white powder. HPLC, Rt: 3.2 min (purity: 98%). UPLC/MS, M+(ESI): 438.2, M-(ESI): 436.3. 1H-NMR (DMSO-d6): δ 12.42 (s, 1 H), 8.45 (d, J=1.5
Hz, 1 H), 8.35 (d, J=1.5 Hz, 1 H), 8.11 (d, J=1.7 Hz, 1 H), 7.87 (dd, J=8.4, 1.7 Hz, 1 H), 7.77 (d, J=8.4 Hz, 1 H), 4.73 (d, J=3.8 Hz, 1 H), 3.58 (m, 1 H), 3.24 (m, 2H), 2.86 (m, 2H), 2.22 (s, 3H), 1.79 (m, 2H), 1.51 (m, 2H).
Example 33: Formation of N-[6-(4-hydroxyphenyl)-1 ,3-benzothiazol-2- yljacetamide (33)
The title compound was prepared following procedure described in Method A (workup A) starting from 4-hydroxyphenylboronic acid. The title compound (33) was obtained as a pale orange powder. HPLC, Rt: 3.3 min (purity: 98.4%). UPLC/MS,
M+(ESI): 285.1 , M-(ESI): 283.2. 1H-NMR (DMSO-d6): δ 12.34 (s, 1 H), 9.55 (s, 1 H), 8.16 (brs, 1 H), 7.74 (d, J=8.5 Hz, 1 H), 7.63 (brd, J=8.5 Hz, 1 H), 7.54 (d, J=8.5 Hz, 2H), 6.86 (d, J=8.5 Hz, 2H), 2.21 (s, 3H).
Example 34: Formation of N-[6-(3-fluoro-4-hydroxyphenyl)-1 ,3-benzothiazol-2- yl]acetamide (34)
The title compound was prepared following procedure described in Method A (workup A) starting from (3-fluoro-4-hydroxyphenyl)boronic acid. The title compound (34) was obtained as a pale beige powder. HPLC, Rt: 3.2 min (purity: 98%). UPLC/MS,
M+(ESI): 303.1 , M-(ESI): 301.2. 1H-NMR (DMSOd6): δ 12.37 (s, 1 H), 9.99 (s, 1 H), 8.22 (s, 1 H), 7.75 (d, J=8.4 Hz, 1 H), 7.68 (d, J=8.4 Hz, 1 H), 7.53 (d, J=12.9 Hz, 1 H), 7.38 (d, J=8.0 Hz, 1 H), 7.03 (m, 1 H), 2.21 (s, 3H).
Example 35: Formation of N-[6-(5-formyl-3-thienyl)-1 ,3-benzothiazol-2- yl]acetamide (35)
The title compound was prepared following procedure described in Method A, starting from 5-formylthiophen-3-boronic acid. The reaction mixture was filtered, then the filtrate was diluted with EtOAc and washed with brine. A precipitate appeared in the aqueous layer, which was filtered off. After purification by flash chromatography (silica, DCM/MeOH) followed by precipitation from DCM/MeOH, the title compound (35) was obtained as a yellow powder. HPLC, Rt: 3.7 min (purity: 98.8%). UPLC/MS, M+(ESI): 303.2, M-(ESI): 301.1.
Example 36: Formation of N-(6-{3-[(3-hydroxypropyl)sulfonyl]phenyl}-1 ,3- benzothiazol-2-yl)acetamide (36)
Step 1 ) Formation of 3-[(3-bromophenyl)thio]propan-1-ol
A mixture of 3-bromothiophenol (5.0 g, 26.4 mmol), 3-bromo-propan-1-ol (4.4 g, 31.6 mmol) and cesium carbonate (17.2 g, 52.8 mmol) in anhydrous DMF (30 ml.) was heated at 500C for 12 hours. The solvent was removed under reduced pressure. The residue was taken up with DCM and washed with water and brine. The organic layer was dried (Na2SO4) and the solvent was removed under reduced pressure to give the title compound as a pale yellow oil (6.4 g, 98%). 1H-NMR (CDCI3, 400 MHz): δ 7.46 (s, 1 H), 7.27 (m, 2H), 7.14 (m, 1 H), 3.77 (t, 2H), 3.03 (m, 2H), 1.90 (m, 2H).
Step 2) Formation of 3-[(3-bromophenyl)sulfonyl]propan-1 -ol
m-Chloroperbenzoic acid (25.4 g, 148 mmol) was added to a solution of 3-[(3- bromophenyl)thio]propan-1-ol (7.0 g, 49.2 mmol) in anhydrous DCM (75 ml_). The reaction mixture was stirred at RT for 5 hours. The suspension was filtered off and the filtrate was washed with a saturated aqueous solution of NaHCO3, water and brine. The organic layer was dried (Na2SO4) and the solvent was removed under reduced pressure to give the title compound as gummy yellow solid (6.7 g, 93%). 1H- NMR (CDCI3, 400 MHz): δ 8.06 (s, 1 H), 7.85 (m, 1 H), 7.79 (m, 1 H), 7.46 (m, 1 H), 3.74 (m, 2H), 3.25 (m, 2H), 1.99 (m, 2H).
The title compound was prepared following procedure described in Method B (workup A) starting from 3-[(3-bromophenyl)sulfonyl]propan-1-ol. The title compound (36) was obtained as a pale orange powder. HPLC, Rt: 2.7 min (purity: 96%). UPLC/MS,
M+(ESI): 391.1 , M-(ESI): 389.3. 1H-NMR (DMSO-d6): δ 12.44 (s, 1 H), 8.43 (s, 1 H), 8.18 (s, 1 H), 8.11 (d, J=7.5 Hz, 1 H), 7.89-7.75 (m, 4H), 4.65 (t, J=5.4 Hz, 1 H), 3.42 (m, 4H), 2.22 (s, 3H), 1.72 (m, 2H).
Example 37: Formation of N-{6-[3-({[2-hydroxy-1 -
(hydroxymethyl)ethyl]amino}sulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}acetamide
(37)
Step 1) Formation 3-bromo-N-[2-hydroxy-1-
(hydroxymethyl)ethyl]benzenesulfonamide bis(2-aminopropane-1 ,3-diol) hydrochloride mixture
A mixture of 3-bromobenzenesulfonyl chloride (500 mg, 1.96 mmol) and 2-amino-1 ,3- propandiol (535 mg, 5.87 mmol) in anhydrous DCM (20 ml.) was stirred at 00C for 18 hours. The reaction mixture was evaporated under reduced pressure to give the title mixture as white powder. Used without further purification in the next step.
Step 2) Formation of N-{6-[3-({[2-hydroxy-1 - (hydroxymethyl)ethyl]amino}sulfonyl)phenyl]-1,3-benzothiazol-2-yl}acetamide
The title compound was prepared following procedure described in Method B (workup A) starting from 3-bromo-N-[2-hydroxy-1-
(hydroxymethyl)ethyl]benzenesulfonamide bis(2-aminopropane-1 ,3-diol) hydrochloride mixture. The title compound (37) was obtained as a pale beige powder. HPLC, Rt: 2.6 min (purity: 98.1 %). UPLC/MS, M+(ESI): 422.2, M-(ESI): 420.2. 1H-
NMR (DMSOd6): δ 12.43 (s, 1 H), 8.36 (brs, 1 H), 8.19 (brs, 1 H), 7.97 (d, J=7.8 Hz, 1 H), 7.82 (m, 3H), 7.67 (dd, J=7.8, 7.7 Hz, 1 H), 7.55 (d, J=7.4 Hz, 1 H), 4.61 (t, J=5.5 Hz, 2H), 3.34 (m, 4H), 3.12 (m, 1 H), 2.22 (s, 3H).
Example 38: Formation of N-[6-(3-{[(2,3- dihydroxypropyl)amino]sulfonyl}phenyl)-1 ,3-benzothiazol-2-yl]acetamide (38)
Step 1) Formation of 3-bromo-N-(2,3-dihydroxypropyl)benzenesulfonamide bis(3- aminopropane-1 ,2-diol) hydrochloride mixture
A mixture of 3-bromobenzenesulfonyl chloride (500 mg, 1.96 mmol) and 3-amino-1 ,2- propandiol (535 mg, 5.87 mmol) in anhydrous DCM (20 ml.) was stirred at 00C for 2 hours. The reaction mixture was evaporated under reduced pressure to give the title mixture as white powder. Used without further purification in the next step.
Step 2) Formation of N-[6-(3-{[(2,3-dihydroxypropyl)amino]sulfonyl}phenyl)-1 ,3- benzothiazol-2-yl]acetamide
The title compound was prepared following procedure described in Method B (workup A) starting from 3-bromo-N-(2,3-dihydroxypropyl)benzenesulfonamide bis(3- aminopropane-1 ,2-diol) hydrochloride mixture. The title compound (38) was obtained as a white powder. HPLC, Rt: 2.9 min (purity: 94%). UPLC/MS, M+(ESI): 422.2, M- (ESI): 420.2. 1H-NMR (DMSOd6): δ 12.43 (s, 1 H), 8.36 (brs, 1 H), 8.14 (brs, 1 H), 7.99 (d, J=7.5 Hz, 1 H), 7.85 (d, J=8.4 Hz, 1 H), 7.79 (m, 2H), 7.70 (dd, J=7.8, 7.5 Hz, 1 H),
7.57 (t, J=6.5 Hz, 1 H), 4.78 (d, J=5.1 Hz, 1 H), 4.54 (t, J=5.7 Hz, 1 H), 3.49 (m, 1 H), 3.27 (m, 2H), 2.92 (m, 1 H), 2.65 (m, 1 H), 2.22 (s, 3H).
Example 39: Formation of N-(6-{3-[(4-hydroxypiperidin-1 -yl)sulfonyl]phenyl}-1 ,3- benzothiazol-2-yl)acetamide (39)
Step 1) Formation of 1-[(3-bromophenyl)sulfonyl]piperidin-4-ol
The title compound was prepared following procedure described in Example 23 Step 1 ), but starting from 3-bromobenzenesulfonyl chloride and 4-hydroxypiperidine. The title compound was obtained as a white powder. HPLC, Rt: 3.1 min (purity: 100%).
UPLC/MS, M+(ESI): 320.1 , 322.1 , M-(ESI): 318.2, 320.2.
Step 2) Formation of N-(6-{3-[(4-hydroxypiperidin-1-yl)sulfonyl]phenyl}-1 ,3- benzothiazol-2-yl)acetamide
The title compound was prepared following procedure described in Method B (work- up A) starting from 1-[(3-bromophenyl)sulfonyl]piperidin-4-ol. The title compound (39) was obtained as an off-white powder. HPLC, Rt: 3.2 min (purity: 99.8%). UPLC/MS, M+(ESI): 432.2, M-(ESI): 430.3. 1H-NMR (DMSOd6): δ 12.43 (s, 1 H), 8.40 (brs, 1 H), 8.07 (d, J=7.0 Hz, 1 H), 7.97 (brs, 1 H), 7.86-7.71 (m, 4H), 4.68 (d, J=3.4 Hz, 1 H), 3.54 (m, 1 H), 3.21 (m, 2H), 2.78 (m, 2H), 2.22 (s, 3H), 1.75 (m, 2H), 1.46 (m, 2H).
Example 40: Formation of N-[6-(3-fluoro-5-hydroxyphenyl)-1 ,3-benzothiazol-2- yl]acetamide (40)
The title compound was prepared following procedure described in Method A (work- up A) starting from (3-fluoro-5-hydroxyphenyl)boronic acid. The title compound (40) was obtained as a red powder. HPLC, Rt: 3.8 min (purity: 98%). UPLC/MS, M+(ESI): 303.1 , M-(ESI): 301.1. 1H-NMR (DMSOd6): δ 12.39 (s, 1 H), 10.04 (s, 1 H), 8.25 (d, J=1.7 Hz, 1 H), 7.78 (d, J=8.5 Hz, 1 H), 7.68 (dd, J=8.5, 1.7 Hz, 1 H), 6.98 (dm, J=10.0 Hz, 1 H), 6.94 (m, 1 H), 6.56 (dm, J=10.7 Hz, 1 H), 2.22 (s, 3H).
Example 41 : Formation of N-{6-[3-(propylsulfonyl)phenyl]-1 ,3-benzothiazol-2- yl}acetamide (41)
Step 1) Formation of 1 -bromo-3-(propylthio)benzene
The title compound was prepared following procedure described in Example 36 Step
1 ), but starting from 1-bromopropane and potassium carbonate. The title compound was obtained as a pale yellow oil (5.5 g, 90%). 1H-NMR (CDCI3, 400 MHz): δ 7.44 (s, 1 H), 7.28 (m, 1 H), 7.22 (m, 1 H), 7.13 (m, 1 H), 2.90 (t, 2H), 1.68 (m, 2H), 1.04 (t, 3H).
Step 2) Formation of 1-bromo-3-(propylsulfonyl)benzene
The title compound was prepared following procedure described in Example 36 Step 2), but starting from 1-bromo-3-(propylthio)benzene. The title compound was obtained as a yellow oil (5.7 g, 91 %). 1H-NMR (CDCI3, 400 Hz): δ 8.05 (s, 1 H), 7.84 (m, 1 H), 7.78 (m, 1 H), 7.45 (t, 1 H), 3.08 (m, 2H), 1.75 (m, 2H), 1.01 (t, 3H).
Step 3) Formation of N-{6-[3-(propylsulfonyl)phenyl]-1,3-benzothiazol-2- yl}acetamide
The title compound was prepared following procedure described in Method B (workup B) starting from 1-bromo-3-(propylsulfonyl)benzene. The title compound (41 ) was obtained as a pale beige powder. HPLC, Rt: 3.7 min (purity: 100%). UPLC/MS, M+(ESI): 375.1 , M-(ESI): 373.2. 1H-NMR (DMSOd6): δ 12.44 (s, 1 H), 8.42 (brs, 1 H), 8.17 (m, 1 H), 8.11 (dm, J=7.9 Hz, 1 H), 7.87 (dm, J=8.1 Hz, 1 H), 7.84 (m, 2H), 7.77
(dd, J=7.9, 7.8 Hz, 1 H), 3.39 (m, 2H), 2.22 (s, 3H), 1.61 (m, 2H), 0.94 (t, J=7.5 Hz, 3H).
Example 42: Formation of N-(6-{3-[(2-hydroxyethyl)sulfonyl]phenyl}-1 ,3- benzothiazol-2-yl)acetamide (42)
A mixture of 3-bromothiophenol (5.0 g, 26.4 mmol), 2-bromoethanol (3.9 g, 31.7 mmol) and cesium carbonate (17.2 g, 52.8 mmol) in anhydrous DMF (30 ml.) was heated at 500C for 12 hours. The solvent was removed under reduced pressure. The residue was taken up with DCM and washed with water and brine. The organic layer was dried (Na2SC>4) and the solvent was removed under reduced pressure. Purification by flash chromatography (silica, PE/EtOAc) gave the title compound as a pale yellow solid (5.5 g, 90%). 1H-NMR (CDCI3, 400 MHz): δ 7.53 (s, 1 H), 7.35 (m, 1 H), 7.33 (m, 1 H), 7.16 (t, 1 H), 3.78 (t, 2H), 3.13 (t, 2H).
Step 2) Formation of 2-[(3-bromophenyl)sulfonyl]ethanol
m-Chloroperbenzoic acid (12.2 g, 70.7 mmol) was added to a solution of 2-[(3- bromophenyl)thio]ethanol (5.5 g, 23.5 mmol) in anhydrous DCM (75 ml_). The reaction mixture was stirred at RT for 5 hours. The solid formed was filtered and washed with cold DCM. The filtrate was washed with a 10% aqueous solution of NaOH, water and brine. The organic layer was dried (Na2SO4) and the solvent was removed under reduced pressure. Purification by flash chromatography (silica, chloroform/MeOH) gave the title compound as an off-white solid. 1H-NMR (DMSO-d6,
400 MHz): δ 8.04 (s, 1 H), 7.91 (m, 2H), 7.57 (m, 1 H), 4.89 (t, 1 H), 3.68 (m, 2H), 3.52 (t, 2H).
Step 3) Formation of N-(6-{3-[(2-hydroxyethyl)sulfonyl]phenyl}-1,3-benzothiazol- 2-yl)acetamide
The title compound was prepared following procedure described in Method B (workup A) starting from 2-[(3-bromophenyl)sulfonyl]ethanol. The title compound (42) was obtained as a pale grey powder. HPLC, Rt: 2.8 min (purity: 100%). UPLC/MS, M+(ESI): 377.1 , M-(ESI): 375.2. 1H-NMR (DMSO-d6): 12.44 (s, 1 H), 8.42 (brs, 1 H),
8.20 (m, 1 H), 8.10 (dm, J=7.8 Hz, 1 H), 7.88 (dm, J=8.4 Hz, 1 H), 7.83 (m, 2H), 7.75 (dd, J=7.8, 7.7 Hz, 1 H), 4.92 (t, J=5.4 Hz, 1 H), 3.73 (m, 2H), 3.56 (t, J=6.4 Hz, 2H), 2.22 (s, 3H).
Example 43: Formation of N-{6-[5-(aminosulfonyl)pyridin-3-yl]-1 ,3-benzothiazol-
2-yl}acetamide (43)
The title compound was prepared following procedure described in Method B (workup D) starting from 5-bromopyridine-3-sulfonamide. The title compound (43) was
obtained as a pale beige powder. HPLC, Rt: 2.2 min (purity: 96%). UPLC/MS, M+(ESI): 349.1 , M-(ESI): 347.1. 1H-NMR (DMSOd6): δ 12.48 (s, 1 H), 9.18 (d, J=1.9 Hz, 1 H), 8.95 (d, J=1.9 Hz, 1 H), 8.49 (brs, 1 H), 8.46 (s, 1 H), 7.86 (m, 2H), 7.66 (brs, 2H), 2.23 (s, 3H).
Example 44: Formation of N-[6-(3-hydroxyphenyl)-1 ,3-benzothiazol-2- yl]acetamide (44)
The title compound was prepared following procedure described in Method B (work- up A) starting from 3-bromophenol. The title compound (44) was obtained as a white powder. HPLC, Rt: 3.5 min (purity: 100%). UPLC/MS, M+(ESI): 285.1 , M-(ESI): 283.1. 1H-NMR (DMSOd6): δ 12.36 (s, 1 H), 9.53 (s, 1 H), 8.20 (d, J=1.8 Hz, 1 H), 7.77 (d, J=8.4 Hz, 1 H), 7.64 (dd, J=8.4, 1.8 Hz, 1 H), 7.26 (dd, J=7.9, 7.8 Hz, 1 H), 7.12 (brd, J=7.8 Hz, 1 H), 7.07 (m, 1 H), 6.76 (dd, J=7.9, 2.3 Hz, 1 H), 2.21 (s, 3H).
Example 45: Formation of N-(6-pyrimidin-5-yl-1 ,3-benzothiazol-2-yl)acetamide (45)
The title compound was prepared following procedure described in Method A (work- up B) starting from 5-pyrimidinylboronic acid. The title compound (45) was obtained as an orange powder. HPLC, Rt: 2.7 min (purity: 93%). UPLC/MS, M+(ESI): 271.1 , M-(ESI): 269.1. 1H-NMR (DMSO-d6): δ 9.19 (s, 2H), 9.17 (s, 1 H), 8.41 (brs, 1 H), 7.84 (dd, J=8.4, 1.7 Hz, 1 H), 7.80 (d, J=8.4 Hz, 1 H), 2.18 (s, 3H).
Example 46: Formation of ethyl 4-{[({6-[3-(methylsulfonyl)phenyl]-1 ,3- benzothiazol-2-yl}amino)carbonyl]amino}butanoate (46)
Ethyl 4-isocyanatobutyrate (69 mg, 0.44 mmol) was added to a solution of 6-[3- (methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-amine (50 mg, 0.15 mmol) in anhydrous pyridine (0.5 ml.) and the resulting mixture was heated at 600C for 15 hours. The reaction mixture was diluted with EtOAc and washed with a 5N aqueous solution of HCI. The organic layer was dried (MgSO4) and the solvent was removed under reduced pressure. The residue was purified by flash chromatography (silica, cHex/EtOAc) to give the title compound (46) as a white powder. HPLC, Rt: 3.8 min (purity: 96%). UPLC/MS, M+(ESI): 462.3, M-(ESI): 460.3. 1H-NMR (DMSO-d6): δ 10.79 (s, 1 H), 8.35 (brs, 1 H), 8.21 (m, 1 H), 8.08 (m, 1 H), 7.89 (m, 1 H), 7.79-7.71 (m, 3H), 6.81 (m, 1 H), 4.06 (q, J=7.2 Hz, 2H), 3.31 (s, 3H), 3.19 (m, 2H), 2.34 (t, J=7.6
Hz, 2H), 1.74 (m, 2H), 1.18 (t, J=7.2 Hz, 3H).
Example 47: Formation of N-{6-[6-(methylsulfonyl)pyridin-2-yl]-1 ,3-benzothiazol- 2-yl}acetamide (47)
The title compound was prepared following procedure described in Method B (workup D) starting from 2-bromo-6-methanesulfonyl-pyridine (Tetrahedron, 1985, 41 (7), 1373-1384). The title compound (47) was obtained as a white powder (140 mg, 85%). HPLC, Rt: 2.9 min (purity: 91 %). UPLC/MS, M+(ESI): 348.1 , M-(ESI): 346.2. 1H-NMR (DMSO-d6): δ 12.52 (brs, 1 H), 8.84 (brs, 1 H), 8.37 (d, J=8.3 Hz, 1 H), 8.24 (m, 2H),
7.96 (d, J=8.2 Hz, 1 H), 7.84 (d, J=8.7 Hz, 1 H), 3.44 (s, 3H), 2.22 (s, 3H).
Example 48: Formation of N-{6-[4-fluoro-3-(methylsulfonyl)phenyl]-1 ,3- benzothiazol-2-yl}acetamide (48)
The title compound was prepared following procedure described in Method B (workup D) starting from 4-bromo-1-fluoro-2-(methylsulfonyl)benzene. The title compound (48) was obtained as a brown powder. HPLC, Rt: 3.6 min (purity: 94%). UPLC/MS, M+(ESI): 365.1 , M-(ESI): 363.2. 1H-NMR (DMSO-d6): δ 12.44 (s, 1 H), 8.37 (d, J=1.8 Hz, 1 H), 8.14 (ddd, J=8.6, 4.7, 2.5 Hz, 1 H), 8.08 (dd, J=6.6, 2.5 Hz, 1 H), 7.84 (d,
J=8.5 Hz, 1 H), 7.75 (dd, J=8.5, 1.8 Hz, 1 H), 7.64 (dd, J=10.0, 8.6 Hz, 1 H), 3.40 (s, 3H), 2.22 (s, 3H).
Example 49: Formation of 3-{2-[({[2-(3-isopropyl-1 ,2,4-oxadiazol-5- yl)ethyl]amino}carbonyl)amino]-1 ,3-benzothiazol-6-yl}-N,N- dimethylbenzenesulfonamide (49)
Step 1) Formation of N-(6-bromo-1 ,3-benzothiazol-2-yl)-1 H-imidazole-1- carboxamide
A mixture of 2-amino-6-bromobenzothiazole (3.0 g, 13.1 mmol) and 1 ,1 '- carbonyldiimidazole (3.2 g, 19.6 mmol) in anhydrous ACN (60 ml.) was stirred at RT for 15 hours. The precipitate was filtered off, washed with ACN and dried under reduced pressure to give the title compound as a pink powder (4.1 g, 97%), which was used without further purification in the next step.
Step 2) Formation of N-(6-bromo-1 ,3-benzothiazol-2-yl)-N'-[2-(3-isopropyl-1 ,2,4- oxadiazol-5-yl)ethyl]urea
A mixture of N-(6-bromo-1 ,3-benzothiazol-2-yl)-1 H-imidazole-1-carboxamide (1.0 g, 3.1 mmol), 2-(3-isopropyl-1 ,2,4-oxadiazol-5-yl)ethanamine hydrochloride (0.53 g, 3.4 mmol) and Et3N (0.5 ml_, 3.4 mmol) in anhydrous DMF (12 ml.) was heated at 1000C for 15 hours. The reaction mixture was cooled at RT and the precipitate was removed by filtration. The filtrate was diluted with EtOAc, washed with water (5x), dried (MgSO4) and the solvents were removed under reduced pressure. The residue was purified by flash chromatography (silica, cHex/EtOAc) to give the title compound as a white powder. HPLC, Rt: 4.3 min (purity: 98.2%). UPLC/MS, M+(ESI): 410.1 , 412.1 , M-(ESI): 408.2, 410.2.
Step 3) Formation of 3-{2-[({[2-(3-isopropyl-1 ,2,4oxadiazol-5- yl)ethyl]amino}carbonyl)amino]- 1, 3-benzothiazol-6-yl}-N, N- dimethylbenzenesulfonamide
The title compound was prepared following procedure described in Method A (workup A) starting from N-(6-bromo-1 ,3-benzothiazol-2-yl)-N'-[2-(3-isopropyl-1 ,2,4- oxadiazol-5-yl)ethyl]urea and N,N-dimethyl-3-boronobenzenesulfonamide. The title compound (49) was obtained as a colorless oil. HPLC, Rt: 4.6 min (purity: 96%). UPLC/MS, M+(ESI): 515.3, M-(ESI): 513.3. 1H-NMR (CDCI3): δ 8.04 (m, 1 H), 7.99 (d, J=1.7 Hz, 1 H), 7.88 (dm, J=7.8 Hz, 1 H), 7.84 (d, J=8.4 Hz, 1 H), 7.78 (dm, J=7.9 Hz,
1 H), 7.68 (dd, J=8.4, 1.7 Hz, 1 H), 7.66 (dd, J=7.9, 7.8 Hz, 1 H), 3.94 (m, 2H), 3.26 (t, J=6.6 Hz, 2H), 3.10 (hept, J=6.9 Hz, 1 H), 2.79 (s, 6H), 1.34 (d, J=6.9 Hz, 6H).
Example 50: Formation of N-[6-(4-hydroxy-3-methoxyphenyl)-1 ,3-benzothiazol- 2-yl]-N'-[2-(3-isopropyl-1 ,2,4-oxadiazol-5-yl)ethyl]urea (50)
The title compound was prepared following procedure described in Method A (workup A) starting from N-(6-bromo-1 ,3-benzothiazol-2-yl)-N'-[2-(3-isopropyl-1 ,2,4- oxadiazol-5-yl)ethyl]urea and 2-methoxy-4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)phenol. The title compound (50) was obtained as a red foam. HPLC, Rt: 3.7 min
(purity: 92%). UPLC/MS, M+(ESI): 454.2, M-(ESI): 452.4. 1H-NMR (DMSO-d6): δ 10.87 (brs, 1 H), 9.06 (s, 1 H), 8.13 (brs, 1 H), 7.61 (brs, 2H), 7.24 (d, J=2.0 Hz, 1 H), 7.10 (dd, J=8.3, 2.0 Hz, 1 H), 6.99 (m, 1 H), 6.84 (d, J=8.3 Hz, 1 H), 3.87 (s, 3H), 3.60 (m, 2H), 3.14 (t, J=6.6 Hz, 2H), 3.04 (hept, J=7.0 Hz, 1 H), 1.25 (d, J=7.0 Hz, 6H).
Example 51 : Formation of N-{6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2- yl}-N-(2-morpholin-4-yl-2-oxoethyl)urea (51 )
A solution of Λ/-{6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}-1 /-/-imidazole-1- carboxamide (100 mg, 0.25 mmol) and 2-amino-1-morpholin-4-yl-ethanone (40 mg, 0.28 mmol) in anhydrous DMF (1.5 ml.) was heated at 1000C for 15 hours. The reaction mixture was diluted with EtOAc and a white precipitate appeared. The solid was filtered off, washed with EtOAc and dried under reduced pressure to give the title compound (51 ) as a white powder. HPLC, Rt: 3.0 min (purity: 75%). UPLC/MS, M+(ESI): 475.2, M-(ESI): 473.3. 1H-NMR (DMSO-d6): δ 11.08 (brs, 1 H), 8.36 (brs, 1 H), 8.21 (m, 1 H), 8.08 (dm, J=7.8 Hz, 1 H), 7.89 (dm, J=7.7 Hz, 1 H), 7.76 (m, 3H), 7.07 (t, J=4.8 Hz, 1 H), 4.11 (d, J=4.8 Hz, 2H), 3.60 (m, 4H), 3.45 (m, 4H), 3.31 (s,
3H).
Example 52: Formation of N,N-dimethyl-N-2-[({6-[3-(methylsulfonyl)phenyl]-1 ,3- benzothiazol-2-yl}amino)carbonyl]glycinamide (52)
The title compound was prepared following procedure described in Example 51 , but starting from glycine dimethylamide acetate and Et3N (1.2 eq). The title compound (52) was obtained as a white powder. HPLC, Rt: 3 min (purity: 94%). LC/MS, M+(ESI): 433.1 , M-(ESI): 431.1. 1H-NMR (DMSO-d6): δ 11.07 (s, 1 H), 8.36 (brs, 1 H), 8.21 (m, 1 H), 8.08 (dm, J=7.8 Hz, 1 H), 7.89 (dm, J=7.7 Hz, 1 H), 7.76 (m, 3H), 7.06 (t,
J=4.5 Hz, 1 H), 4.07 (d, J=4.5 Hz, 2H), 3.31 (s, 3H), 2.97 (s, 3H), 2.89 (s, 3H).
Example 53: Formation of tert-butyl N-[({6-[3-(methylsulfonyl)phenyl]-1 ,3- benzothiazol-2-yl}amino)carbonyl]-beta-alaninate (53)
A solution of Λ/-{6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}-1 /-/-imidazole-1- carboxamide (100 mg, 0.25 mmol), beta-alanine tert-butyl ester hydrochloride (50 mg, 0.28 mmol) and Et3N (0.040 mL, 0.28 mmol) in anhydrous DMF (1.5 mL) was heated
at 1000C for 15 hours. The reaction mixture was diluted with EtOAc and washed with water (5x). The organic layer was dried (MgSO4) and the solvents were removed under reduced pressure. The residue was purified by flash chromatography (silica, cHex/EtOAc) to give the title compound (53) as a white powder. HPLC, Rt: 4.1 min (purity: 99.7%). LC/MS, M+(ESI): 476, M-(ESI): 474.1. 1H-NMR (DMSO-d6): δ 10.90
(brs, 1 H), 8.35 (brs, 1 H), 8.21 (m, 1 H), 8.08 (dm, J=7.8 Hz, 1 H), 7.89 (dm, J=7.7 Hz, 1 H), 7.75 (m, 3H), 6.88 (m, 1 H), 3.38 (m, 2H), 3.31 (s, 3H), 2.46 (t, J=6.4 Hz, 2H), 1.42 (s, 9H).
Example 54: Formation of N-{6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2- yl}-N'-[2-(1 H-1 ,2,4-triazoM -yl)ethyl]urea (54)
The title compound was prepared following procedure described in Example 53, but starting from 2-(1 ,2,4-triazole-1-yl)-ethylamine hydrochloride. Purification by flash chromatography (silica, DCM/MeOH). The title compound (54) was obtained as a white powder. HPLC, Rt: 3.6 min (purity: 90%). UPLC/MS, M+(ESI): 443.2, M-(ESI): 441.3. 1H-NMR (DMSO-d6): δ 10.93 (s, 1 H), 8.55 (s, 1 H), 8.36 (brs, 1 H), 8.21 (brs, 1 H), 8.08 (brd, J=7.8 Hz, 1 H), 8.02 (s, 1 H), 7.89 (brd, J=7.9 Hz, 1 H), 7.76 (m, 3H), 6.88 (m, 1 H), 4.33 (t, J=5.8 Hz, 2H), 3.61 (m, 2H), 3.31 (s, 3H).
Example 55: Formation of N-(2-{[({6-[3-(methylsulfonyl)phenyl]-1 ,3- benzothiazol-2-yl}amino)carbonyl]amino}ethyl)acetamide (55)
A solution of Λ/-{6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}-1 /-/-imidazole-1- carboxamide (150 mg, 0.38 mmol) and N-acetylethylenediamine (42 mg, 0.41 mmol) in anhydrous DMF (3 mL) was heated at 1000C for 15 hours. The reaction mixture was diluted with EtOAc and washed with water (4x) and brine. The organic layer was dried (MgSO4) and the solvents were removed under reduced pressure. The residue was taken up with DCM and a precipitate appeared. The solid was filtered off and dried under reduced pressure to give the title compound (55) as a white powder.
HPLC, Rt: 2.7 min (purity: 88%). LC/MS, M+(ESI): 433.0, M-(ESI): 431.2. 1H-NMR (DMSO-d6): δ 10.91 (s, 1 H), 8.35 (brs, 1 H), 8.21 (brs, 1 H), 8.08 (brd, J=7.8 Hz, 1 H), 7.98 (m, 1 H), 7.89 (brd, J=7.8 Hz, 1 H), 7.76 (m, 3H), 6.82 (m, 1 H), 3.31 (s, 3H), 3.20 (m, 4H), 1.82 (s, 3H).
Example 56: Formation of tert-butyl N-{[(6-{3-[(dimethylamino)sulfonyl]phenyl}- 1 ,3-benzothiazol-2-yl)amino]carbonyl}-beta-alaninate (56)
Step 1) Formation of tert-butyl N-{[(6-bromo-1 ,3-benzothiazol-2-yl)amino]carbonyl}- beta-alaninate
A mixture of N-(6-bromo-1 ,3-benzothiazol-2-yl)-1 H-imidazole-1-carboxamide (2.00 g, 6.19 mmol), beta-alanine tert-butyl ester hydrochloride (1.24 g, 6.81 mmol) and Et3N (0.69 g, 6.81 mmol) in anhydrous DMF (50 ml_) was heated at 1000C for 15 hours. The reaction mixture was concentrated under reduced pressure. Purification by crystallization from a hot mixture of EtOAc/MeOH gave the title compound as a white powder. HPLC, Rt: 4.5 min (purity: 98.8%). LC/MS, M+(ESI): 400.0, 402.0, M-(ESI): 398.0, 400.0.
Step 2) Formation of tert-butyl N-{[(6-{3-[(dimethylamino)sulfonyl]phenyl}-1, 3- benzothiazol-2-yl)amino]carbonyl}-beta-alaninate
The title compound was prepared following procedure described in Method A (workup A) starting from tert-butyl N-{[(6-bromo-1 ,3-benzothiazol-2-yl)amino]carbonyl}- beta-alaninate and N,N-dimethyl-3-boronobenzenesulfonamide. The title compound (56) was obtained as a yellow powder. HPLC, Rt: 4.5 min (purity: 99.1 %). UPLC/MS,
M+(ESI): 505.2, M-(ESI): 503.3. 1H-NMR (DMSO-d6): δ 10.87 (s, 1 H), 8.33 (brs, 1 H), 8.06 (dm, J=7.0 Hz, 1 H), 7.97 (brs, 1 H), 7.72 (m, 4H), 6.87 (t, J=5.6 Hz, 1 H), 3.38 (m, 2H), 2.67 (s, 6H), 2.46 (t, J=6.5 Hz, 2H), 1.43 (s, 9H).
Example 57: Formation of tert-butyl N-({[6-(4-hydroxy-3-methoxyphenyl)-1 ,3- benzothiazol-2-yl]amino}carbonyl)-beta-alaninate (57)
The title compound was prepared following procedure described in Method A (work- up A) starting from tert-butyl N-{[(6-bromo-1 ,3-benzothiazol-2-yl)amino]carbonyl}- beta-alaninate and 2-methoxy-4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)phenol. The title compound (57) was obtained as a red solid. HPLC, Rt: 4.0 min (purity: 97%). UPLC/MS, M+(ESI): 444.2, M-(ESI): 442.3. 1H-NMR (DMSO-d6): δ 10.76 (s, 1 H), 9.06 (s, 1 H), 8.13 (s, 1 H), 7.61 (s, 2H), 7.24 (d, J=2.1 Hz, 1 H), 7.10 (dd, J=8.1 , 2.1 Hz, 1 H), 6.86 (m, 1 H), 6.84 (d, J=8.1 Hz, 1 H), 3.86 (s, 3H), 3.38 (m, 2H), 2.45 (t,
J=6.5 Hz, 2H), 1.42 (s, 9H).
Example 58: Formation of tert-butyl N-({[6-(3-{[(2- hydroxyethyl)amino]sulfonyl}phenyl)-1 ,3-benzothiazol-2-yl]amino}carbonyl)- beta-alaninate (58)
The title compound was prepared following procedure described in Method A (workup A) starting from tert-butyl N-{[(6-bromo-1 ,3-benzothiazol-2-yl)amino]carbonyl}- beta-alaninate and Λ/-(2-hydroxyethyl)-3-boronobenzenesulfonamide. The title compound (58) was obtained as a white powder. HPLC, Rt: 4.1 min (purity: 85%).
UPLC/MS, M+(ESI): 521.2, M-(ESI): 519.3. 1H-NMR (DMSO-d6): δ 10.88 (s, 1 H), 8.28 (brs, 1 H), 8.1 1 (brs, 1 H), 7.98 (dm, J=7.8 Hz, 1 H), 7.78-7.53 (m, 5H), 6.86 (t, J=5.4 Hz, 1 H), 4.72 (t, J=5.6 Hz, 1 H), 3.39 (m, 4H), 2.83 (m, 2H), 2.46 (t, J=6.4 Hz, 2H), 1.42 (s, 9H).
Example 59: Formation of N-[2-(4-methylpiperazin-1 -yl)ethyl]-N'-{6-[3- (methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}urea (59)
A solution of Λ/-{6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}-1 /-/-imidazole-1- carboxamide (100 mg, 0.25 mmol) and 1-(2-aminoethyl)-4-methyl-piperazine (36 mg, 0.25 mmol) in anhydrous DMA (2 ml.) was heated at 1800C for 15 min under microwave irradiation. The reaction mixture was diluted with EtOAc and washed with water (4x). The organic layer was dried (MgSO4) and the solvents were removed under reduced pressure. The residue was purified by flash chromatography (silica, DCM/MeOH) to give the title compound (59) as a yellow oil. HPLC, Rt: 2.4 min (purity: 99.8%). LC/MS, M+(ESI): 473.9, M-(ESI): 472.1.
Example 60: Formation of N-(2-hydroxyethyl)-3-{2-[({[2-(3-isopropyl-1 ,2,4- oxadiazol-5-yl)ethyl]amino}carbonyl)amino]-1 ,3-benzothiazol-6- yl}benzenesulfonamide (60)
The title compound was prepared following procedure described in Method A (workup A) starting from N-(6-bromo-1 ,3-benzothiazol-2-yl)-N'-[2-(3-isopropyl-1 ,2,4- oxadiazol-5-yl)ethyl]urea and Λ/-(2-hydroxyethyl)-3-boronobenzenesulfonamide. The title compound (60) was obtained as a white powder. HPLC, Rt: 3.2 min (purity: 98%). UPLC/MS, M+(ESI): 531.2, M-(ESI): 529.3. 1H-NMR (DMSO-d6): δ 1 1.04 (brs, 1 H), 8.28 (brs, 1 H), 8.10 (m, 1 H), 7.98 (dm, J=7.7 Hz, 1 H), 7.76 (dm, J=7.8 Hz, 1 H), 7.68
(m, 4H), 7.03 (m, 1 H), 4.71 (t, J=5.6 Hz, 1 H), 3.60 (m, 2H), 3.39 (m, 2H), 3.14 (t, J=6.6 Hz, 2H), 3.04 (hept, J=6.9 Hz, 1 H), 2.83 (m, 2H), 1.25 (d, J=6.9 Hz, 6H).
Example 61 : Formation of N-{6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2- yl}formamide (61)
In a sealed tube, a mixture of 6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-amine (150 mg, 0.44 mmol) and 2,2,2-trifluoroethyl formate (1400 mg, 1 1.0 mmol) in NMP
(1.5 ml.) was heated at 1800C for 30 min. The reaction mixture was cooled down to RT, diluted with EtOAc and washed with water (4x) and brine. The organic layer was dried (MgSO4) and the solvents were removed under reduced pressure. Purification by precipitation from a mixture of DCIWEtOAc gave the title compound (61 ) as a yellow powder. HPLC, Rt: 2.9 min (purity: 94%). UPLC/MS, M+(ESI): 333.1 , M-(ESI):
331.1. 1H-NMR (DMSO-d6): δ 12.58 (brs, 1 H), 8.62 (brs, 1 H), 8.46 (m, 1 H), 8.24 (m, 1 H), 8.10 (dm, J=7.8 Hz, 1 H), 7.92 (dm, J=7.7 Hz, 1 H), 7.89 (d, J=8.4 Hz, 1 H), 7.86 (dd, J=8.4, 1.7 Hz, 1 H), 7.77 (dd, J=7.8, 7.7 Hz, 1 H), 3.31 (s, 3H).
Example 62: Formation of N-[6-(4-hydroxy-3-methoxyphenyl)-1 ,3-benzothiazol-
2-yl]-N-(2-morpholin-4-yl-2-oxoethyl)urea (62)
Step 1) Formation of N-(6-bromo-1 ,3-benzothiazol-2-yl)-N'-(2-morpholin-4-yl-2- oxoethyl)urea
A mixture of N-(6-bromo-1 ,3-benzothiazol-2-yl)-1 H-imidazole-1 -carboxamide (500 mg, 1.55 mmol), 2-amino-1-morpholin-4-yl-ethanone (245 mg, 1.70 mmol) and DIEA (0.55 ml_, 3.10 mmol) in anhydrous DMA (5 mL) was heated at 1500C for 25 min. The reaction mixture was diluted with EtOAc and washed with water (4x) and brine. The expected compound precipitated out as a suspension into the aqueous layers. The aqueous layers were combined and the precipitate was filtered off, washed with water and MeOH and then dried under reduced pressure. The title compound was obtained as a white powder. HPLC, Rt: 3.4 min (purity: 92%). LC/MS, M+(ESI): 398.8, 400.7, M-(ESI): 397.0, 399.0.
Step 2) Formation of N-[6-(4-hydroxy-3-methoxyphenyl)-1, 3-benzothiazol-2-yl]-N-(2- morpholin-4-yl-2-oxoethyl)urea
The title compound was prepared following procedure described in Method A (workup A) starting from N-(6-bromo-1 ,3-benzothiazol-2-yl)-N'-(2-morpholin-4-yl-2- oxoethyl)urea and 2-methoxy-4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)phenol.
The title compound (62) was obtained as a brown powder. HPLC, Rt: 2.9 min (purity:
98.7%). UPLC/MS, M+(ESI): 443.2, M-(ESI): 441.3. 1H NMR (DMSO-d6): δ 10.96 (brs, 1 H), 9.06 (s, 1 H), 8.14 (s, 1 H), 7.62 (m, 2H), 7.24 (d, J=2.0 Hz, 1 H), 7.11 (dd, J=8.3, 2.0 Hz, 1 H), 7.06 (m, 1 H), 6.84 (d, J=8.3 Hz, 1 H), 4.10 (d, J=4.8 Hz, 2H), 3.86 (s, 3H), 3.59 (m, 4H), 3.44 (m, 4H).
Example 63: Λ/-{6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}-2-furamide (63)
2-Furoyl chloride (129 mg, 0.99 mmol) was added to a solution of 6-[3- (methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-amine (60 mg, 0.20 mmol) and pyridine
(80 μl , 0.99 mmol) in anhydrous DCM (2 ml_). The reaction mixture was stirred at RT for 1 hour. The reaction mixture was diluted with water and cyclohexane. The precipitate was filtered off and purified by AutoPrep to give after lyophilization of pure fractions the title compound (63) as a white powder. HPLC, Rt: 3.6 min (purity: 98.9%). UPLC/MS, M+(ESI): 399.2, M-(ESI): 397.3. 1H-NMR (DMSO-d6) δ 12.9 (brs,
1 H), 8.46 (brs, 1 H), 8.24 (s, 1 H), 8.1 1 (d, J=8.3 Hz, 1 H), 8.06 (s, 1 H), 8.16-8.02 (m, 3H), 7.82-7.65 (m, 2H), 6.77 (brs, 1 H), 3.32 (s, 3H).
Example 64: Λ/-{6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}-2-oxo-2- pyrrolidin-1 -ylacetamide (64)
A solution of ethyl {6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2- yl}amino)(oxo)acetate (30 mg, 0.07 mmol) in pyrrolidine (0.5 mL) was heated at 800C for 1 hour. Water was then added to the reaction mixture and the precipitate was filtered off, washed with water and dried under reduced pressure to give the title compound (64) as a yellow solid. HPLC, Rt: 3.9 min (purity: 89%). UPLC/MS, M+(ESI): 430.2, M-(ESI): 428.3. 1H-NMR (DMSO-d6) δ 12.9 (brs, 1 H), 8.49 (d, J=1.9
Hz, 1 H), 8.24 (t, J=1.6 Hz, 1 H), 8.11 (dt, J=7.9, 1.4 Hz, 1 H), 7.91 (t, J=7.7 Hz, 2H), 7.87 (dd, J=8.5, 1.8 Hz, 1 H), 7.77 (t, J=7.9 Hz, 1 H), 3.65 (t, J=6.5 Hz, 2H), 3.45 (t, J=6.7 Hz, 2H), 3.31 (s, 3H), 1.95 (m, 4H).
Example 65: Λ/-(6-{3-[(ethylamino)sulfonyl]phenyl}imidazo[1 ,2-a]pyridin-2-yl)- 2,2,2-trifluoroacetamide (65)
Λ/-(6-bromo-imidazo[1 ,2-a]pyridin-2-yl)-2,2,2-trifluoro-acetamide (100 mg, 0.32 mmol), ethyl 3-boronobenzenesulfonamide (149 mg, 0.65 mmol), cesium fluoride (99 mg, 0.65 mmol) and dichlorobis(triphenylphosphine)palladium(ll) (1 1.4 mg, 0.02 mmol) were introduced in a sealed tube and flushed with nitrogen. THF (1 ml.) and water (1 ml.) were then added and the reaction mixture was heated at 1200C for 1 hour under microwave irradiation. The reaction mixture was diluted with EtOAc and organic layer was washed with a saturated aqueous solution of NaHCC>3, brine, then directly filtered through a silica cartridge (3 g). The solvent was partially removed under reduced pressure and cyclohexane was added. The precipitate obtained was filtered off and dried under reduced pressure to give the title compound (65) as a yellow powder. HPLC, Rt: 3.2 min (purity: 95%). UPLC/MS, M+(ESI): 413.2, M-(ESI): 41 1.3. 1H-NMR (DMSO-d6) δ 12.5 (s, 1 H), 9.11 (s, 1 H), 8.31 (s, 1 H), 8.08 (t, J=1.7 Hz, 1 H), 7.98 (d, J=7.5 Hz, 1 H), 7.81 (d, J=7.9 Hz, 1 H), 7.74 (t, J=8.0 Hz, 1 H), 7.68 (m, 2H), 7.64 (t,
J=5.7 Hz, 1 H), 2.88 (m, 2H), 0.99 (t, J=7.3 Hz, 3H).
Example 66: 2,2,2-trifluoro-Λ/-[6-(3-{[(2- hydroxyethyl)amino]sulfonyl}phenyl)imidazo[1 ,2-a]pyridin-2-yl]acetamide (66)
The title compound was prepared following procedure described in example 65 from Λ/-(6-bromo-imidazo[1 ,2-a]pyridin-2-yl)-2,2,2-trifluoro-acetamide (100 mg, 0.32 mmol) and Λ/-(2-hydroxyethyl) 3-boronobenzenesulfonamide (159 mg, 0.65 mmol). The title compound (66) was obtained as a white powder after crystallization from MeOH. HPLC, Rt: 2.5 min (purity: 87%). UPLC/MS, M+(ESI): 429.2, M-(ESI): 427.3. 1H-NMR
(DMSO-d6) δ 12.50 (s, 1 H), 9.1 1 (s, 1 H), 8.32 (s, 1 H), 8.10 (s, 1 H), 7.98 (brd, J=7.4 Hz, 1 H), 7.82 (brd, J=7.4 Hz, 1 H), 7.76 (m, 4H), 4.72 (t, J=6.6 Hz, 1 H), 3.39 (q, J=6.1 Hz, 2H), 2.84 (q, J=6.1 Hz, 2H).
Example 67: Λ/-{6-[3-(methylsulfonyl)phenyl]imidazo[1 ,2-a]pyridin-2- yl}acetamide (67)
Step 1) Formation of 2,2,2-trifluoro-N-{6-[3-(methylsulfonyl)phenyl]imidazo[1,2- a]pyridin-2-yl}acetamide
(3-methylsulfonylphenyl)boronic acid (390 mg, 1.95 mmol), cesium fluoride (296 mg, 1.95 mmol) and dichlorobis(triphenylphosphine)palladium(ll) (34 mg, 0.05 mmol) were introduced in sealed tube and flushed with nitrogen. THF (3 ml.) and water (3 ml.) were then added and the reaction mixture was heated at 1200C for 1 hour under microwave irradiation. The reaction mixture was diluted with EtOAc and the organic layer was washed with a saturated aqueous solution of NaHCC>3, brine and dried (MgSO4). Cyclohexane was added to the solution and the resulting precipitate was filtered off and dried under reduced pressure to give the title compound as beige solid. HPLC, Rt: 2.78 min (purity: 82%). UPLC/MS, M+(ESI): 384.2, M-(ESI): 382.3. 1H-NMR (DMSO-d6) δ 12.50 (s, 1 H), 9.16 (q, J=0.9 Hz, 1 H), 8.3 (s, 1 H), 8.23 (t, J=1.7
Hz, 1 H), 8.08 (brd, J=8.0 Hz, 1 H), 7.95 (brd, J=8.2 Hz, 1 H), 7.79 (t, J=7.9 Hz, 1 H), 7.80 (dd, J=9.4, 2.0 Hz, 1 H), 7.66 (d, J=9.2 Hz, 1 H), 3.32 (s, 3H).
Step 2) Formation of 6-[3-(methylsulfonyl)phenyl]imidazo[1 ,2-a]pyridin-2-amine
A solution of 2,2,2-trifluoro-N-{7-[3-(methylsulfonyl)phenyl]imidazo[1 ,2-a]pyridin-2- yl}acetamide (236 mg, 14 mmol) in ammonia (2M solution in MeOH, 48.5 ml_, 97. mmol) was heated at 65°C for 48 hours. The reaction mixture was concentrated under reduced pressure and the resulting compound was used in the next step without further purification. HPLC, Rt: 1.4 min (purity: 88%). UPLC/MS, M+(ESI):
288.1.
Step 3) Formation of N-{6-[3-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-2- yl}acetamide
(methylsulfonyl)phenyl]imidazo[1 ,2-a]pyridin-2-amine (180 mg, 2.29 mmol) and pyridine (370 μl, 4.6 mmol) in anhydrous DCM (3.6 ml_). The reaction mixture was heated at reflux for 4 hours, then water was added. The resulting precipitate was filtered off, washed with EtOAc and dried under reduced pressure. The residue was purified by AutoPrep to give the title compound (67) as a white powder. HPLC, Rt: 1.9 min (purity: 95%). UPLC/MS, M+(ESI): 330.1 , M-(ESI): 328.0. 1H-NMR (DMSO-d6) δ 10.76 (s, 1 H), 9.08 (d, J=0.9 Hz, 1 H), 8.21 (t, J=1.7 Hz, 1 H), 8.15 (s, 1 H), 8.06 (d, J=8.4 Hz, 1 H), 7.93 (d, J=8.4 Hz, 1 H), 7.77 (t, J=7.8 Hz, 1 H), 7.66 (dd, J=9.4, 1.9 Hz, 1 H), 7.54 (d, J=9.3 Hz, 1 H), 3.31 (s, 3H), 2.09 (s, 3H).
Example 68: 2,2,2-trifluoro-Λ/-{6-[3-(methylsulfonyl)phenyl]imidazo[1 ,2- b]pyridazin-2-yl}acetamide (68)
Λ/-(6-chloro-imidazo[1 ,2-b]pyridazin-2-yl)-2,2,2-trifluoro-acetamide (1.0 g, 3.78 mmol), (3-methylsulfonylphenyl)boronic acid (1.13 g, 5.67 mmol), dichlorobis(triphenylphosphine)palladium(ll) (270 mg, 0.38 mmol) and cesium fluoride (1.72 g, 11.3 mmol) were flushed with nitrogen in a sealed vial. Dioxane (20 ml.) and water (10 ml.) were then added and the reaction mixture was heated at 900C for 3 hours. Reaction mixture was filtered through a celite pad, which was rinsed with EtOAc. Organic layer was then washed with a saturated aqueous solution of
NaHCOs, brine, dried (MgSO4) and concentrated. Purification of the residue (2.6 g) by flash chromatography on silica (DCM:MeOH, gradient 100:0 to 90:10) gave the title compound (68) as a yellow powder. HPLC, Rt: 3.6 min (purity: 91 %); UPLC/MS, M+(ESI): 385.1 , M-(ESI): 383.2. 1H-NMR (DMSO-d6) δ 12.7 (s, 1 H), 8.59 (t, J=1.7 Hz,
1 H), 8.49 (s, 1 H), 8.44 (dt, J=7.9, 1.4 Hz, 1 H), 8.27 (d, J=9.5 Hz, 1 H), 8.09 (dt, J=7.8,
0.9 Hz, 1 H), 8.02 (d, J=9.6 Hz, 1 H), 7.86 (t, J=7.9 Hz, 1 H), 3.35 (s, 3H).
A second fraction was isolated and contained compound described in example 69.
Example 69: 6-[3-(methylsulfonyl)phenyl]imidazo[1,2-b]pyridazin-2-amine (69)
The title compound (69) was obtained as a side product during the preparation of example 68 and was isolated as a yellow powder. HPLC, Rt: 1.5 min (purity: 87%); UPLC/MS, M+(ESI): 289.2, M-(ESI): 287.0. 1H-NMR (DMSO-d6) δ 8.51 (t, J=1.6 Hz, 1 H), 8.35 (d, J=8.1 Hz, 1 H), 8.02 (d, J=7.7 Hz, 1 H), 7.89 (m, J=5.5 Hz, 2H), 7.72 (d,
J=9.4 Hz, 1 H), 7.48 (s, 1 H), 3.3 (s, 3H).
Example 70: Λ/-{6-[3-(methylsulfonyl)phenyl]imidazo[1 ,2-b]pyridazin-2- yl}acetamide (70)
The title compound was prepared according to procedure described in example 67 step 3), but starting from 6-[3-(methylsulfonyl)phenyl]imidazo[1 ,2-b]pyridazin-2-amine (50 mg, 0.17 mmol). The title compound (70) was obtained as a beige powder. HPLC, Rt: 2.8 min (purity: 98%). UPLC/MS, M+(ESI): 331.1 , M-(ESI): 329.2. 1H-NMR (DMSO-d6) δ 10.9 (s, 1 H), 8.56 (t, J=1.7 Hz, 1 H), 8.41 (brd, J=7.9 Hz, 1 H), 8.4 (s,
1 H), 8.15 (d, J=9.2 Hz, 1 H), 8.07 (brd, J=7.9 Hz, 1 H), 7.92 (d, J=9.5 Hz, 1 H), 7.84 (t, J=7.9 Hz, 1 H), 3.41 (s, 3H), 2.12 (s, 3H).
Example 71 : N-(6-{3-[(tetrahydro-2H-pyran-3-ylamino)sulfonyl]phenyl}-1 ,3- benzothiazol-2-yl)acetamide
Step 1) 3-bromo-N-(tetrahydro-2H-pyran-3-yl)benzenesulfonamide
The title compound was prepared following procedure described in example 23 step 1 ), but starting from 3-bromobenzenesulfonyl chloride and tetrahydro-2H-pyran-3- amine hydrochloride (CBI). The title compound was obtained as a colorless oil (592 mg, 94%). HPLC, Rt: 4.0 min (purity: 99.6%). UPLC/MS, M+(ESI): 320.1 , 322.1 , M- (ESI): 318.0, 320.1.
Step 2) N-(6-{3-[(tetrahydro-2H-pyran-3-ylamino)sulfonyl]phenyl}-1, 3-benzothiazol-2- yl)acetamide
The title compound was prepared following procedure described in Method B (workup A) starting from 3-bromo-N-(tetrahydro-2H-pyran-3-yl)benzenesulfonamide. The title compound was obtained as a pale beige powder. HPLC, Rt: 3.6 min (purity: 100%). UPLC/MS, M+(ESI): 432.1 , M-(ESI): 430.2.
Example 72: N-[6-(3-{[(2-methoxyethyl)amino]sulfonyl}phenyl)-1 ,3-benzothiazol-
2-yl]acetamide
A mixture of 2-methoxyethylamine (150 mg, 2.0 mmol) and TBD-methyl polystyrene HL resin (1035 mg, 2.90 mmol/g, Novabiochem) was prepared in anhydrous DCM (10 mL) and cooled at 00C. A solution of 3-bromobenzenesulfonyl chloride (535 mg, 2.1 mmol) in anhydrous DCM (2 mL) was added dropwise. After 1.5 hours at 00C, aminomethyl resin was added to remove excess of sulfonyl chloride. After 1 hour at RT, the resins were filtered off and rinsed with DCM (3x). The filtrate was evaporated under reduced pressure to give the title compound as a colorless oil (425 mg, 72%).
HPLC, Rt: 3.3 min (purity: 95.7%). UPLC/MS, M+(ESI): 294.0, 296.0, M-(ESI): 292.1 , 294.0.
The title compound was prepared following procedure described in Method B (workup A) starting from 3-bromo-N-(2-methoxyethyl)benzenesulfonamide. The title compound was obtained as a pale beige powder. HPLC, Rt: 3.5 min (purity: 96.6%). UPLC/MS, M+(ESI): 406.1 , M-(ESI): 404.2.
Example 73: Λ/-(6-{3-[(3-hydroxypiperidin-1 -yl)sulfonyl]phenyl}-1 ,3-benzothiazol- 2-yl)acetamide
Step 1) 1-[(3-bromophenyl)sulfonyl]piperidin-3-ol
The title compound was prepared following procedure described in example 72 step 1 ), but starting from 3-hydroxypiperidine. After purification by flash chromatography (silica, DCM/MeOH), the title compound was obtained as a white powder. HPLC, Rt: 3.2 min (purity: 100%). UPLC/MS, M+(ESI): 320.0, 322.0.
Step 2) N-(6-{3-[(3-hydroxypiperidin-1-yl)sulfonyl]phenyl}-1 ,3-benzothiazol-2- yl)acetamide
The title compound was prepared following procedure described in Method B (work- up A) starting from 1-[(3-bromophenyl)sulfonyl]piperidin-3-ol. The title compound was obtained as a white powder. HPLC, Rt: 3.3 min (purity: 99.1 %). UPLC/MS, M+(ESI): 432.1 , M-(ESI): 430.2.
Example 74: N-[6-(3-{[(3-hydroxypropyl)amino]sulfonyl}phenyl)-1 ,3- benzothiazol-2-yl]acetamide
Step 1) 3-bromo-N-(3-hydroxypropyl)benzenesulfonamide
The title compound was prepared following procedure described in example 23 step 1 ), but starting from 3-bromobenzenesulfonyl chloride and 3-amino-1-propanol. The title compound was obtained as a white powder (535 mg, 93%). HPLC, Rt: 2.7 min (purity: 100%). UPLC/MS, M+(ESI): 294.0, 296.0, M-(ESI): 292.0, 294.0.
The title compound was prepared following procedure described in Method B (work- up A) starting from 3-bromo-N-(3-hydroxypropyl)benzenesulfonamide. The title compound was obtained as a white powder. HPLC, Rt: 2.9 min (purity: 98.5%). UPLC/MS, M+(ESI): 406.1 , M-(ESI): 404.2.
Example 75: N-[6-(3-{[(2-hydroxyethyl)(methyl)amino] sulfonyl}phenyl)-1 ,3- benzothiazol-2-yl]acetamide
The title compound was prepared following procedure described in example 23 step 1 ), but starting from 3-bromobenzenesulfonyl chloride and 2-(methylamino)ethanol. The title compound was obtained as a pale yellow powder (413 mg, 72%). HPLC, Rt:
3.3 min (purity: 98.9%). UPLC/MS, M+(ESI): 294.0, 296.0, M-(ESI): 292.1 , 294.1.
The title compound was prepared following procedure described in Method B (workup A) starting from 3-bromo-N-(2-hydroxyethyl)-N-methylbenzenesulfonamide. The title compound was obtained as a white powder. HPLC, Rt: 3.1 min (purity: 99.4%). UPLC/MS, M+(ESI): 406.1 , M-(ESI): 404.2.
Example 76: N-[6-(3-{[bis(2-hydroxyethyl)amino]sulfonyl}phenyl)-1 ,3- benzothiazol-2-yl]acetamide
Step 1) 3-bromo-N,N-bis(2-hydroxyethyl)benzenesulfonamide
The title compound was prepared following procedure described in example 72 step 1 ), but starting from diethanolamine. After purification by flash chromatography (silica, DCIWMeOH), the title compound was obtained as a white powder. HPLC, Rt: 2.5 min (purity: 99.9%). UPLC/MS, M+(ESI): 324.0, 326.0, M-(ESI): 322.0, 324.0.
Step 2) N-[6-(3-{[bis(2-hydroxyethyl)amino]sulfonyl}phenyl)-1, 3-benzothiazol-2- yljacetamide
The title compound was prepared following procedure described in Method B (work- up A) starting from 3-bromo-N,N-bis(2-hydroxyethyl)benzenesulfonamide. The title compound was obtained as a white powder. HPLC, Rt: 2.8 min (purity: 99.7%). UPLC/MS, M+(ESI): 436.1 , M-(ESI): 434.2.
Example 77: ethyl N-[({6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2- yl}amino)carbonyl]-beta-alaninate
The title compound was prepared following procedure described in Example 46, but starting from ethyl 3-isocyanatopropionate. The title compound was obtained as a white powder. HPLC, Rt: 4.0 min (purity: 97.0%). UPLC/MS, M+(ESI): 448.1 , M-(ESI): 446.2.
Example 78: Λ/-(6-{3-[(4-methyl-3-oxopiperazin-1 -yl)sulfonyl]phenyl}-1 ,3- benzothiazol-2-yl)acetamide
Step 1) 4-[(3-bromophenyl)sulfonyl]-1-methylpiperazin-2-one
The title compound was prepared following procedure described in example 23 step 1 ), but starting from 3-bromobenzenesulfonyl chloride and 1-methylpiperazin-2-one hydrochloride (Anichem). The title compound was obtained as a pale yellow powder. HPLC, Rt: 3.0 min (purity: 98.4%). UPLC/MS, M+(ESI): 333.0, 335.0.
Step 2) N-(6-{3-[(4-methyl-3-oxopiperazin- 1 -yl)sulfonyl]phenyl}- 1, 3-benzothiazol-2- yl)acetamide
The title compound was prepared following procedure described in Method B (workup A) starting from 4-[(3-bromophenyl)sulfonyl]-1-methylpiperazin-2-one. The title compound was obtained as a white powder. HPLC, Rt: 3.5 min (purity: 97.6%). UPLC/MS, M+(ESI): 445.1 , M-(ESI): 443.2.
Example 79: N-[6-(4-hydroxy-3-methoxyphenyl)imidazo[1,2-b]pyridazin-2- yl]acetamide
A suspension of N-(6-chloroimidazo[1 ,2-b]pyridazin-2-yl)acetamide (30 mg, 0.612 mmol), 4-hydroxy-3-methoxyphenylboronic acid, pinacol ester (53 mg, 0.21 mmol), cesium fluoride (65 mg, 0.43 mmol) and bis-(triphenylphosphine)Pd(ll) chloride (10 mg, 0.01 mmol) in degassed dioxane/water (0.6 mL:0.3 mL) was heated in MW at 1200C for 10 min. The reaction mixture was filtered through celite, concentrated under reduced pressure and purified by Autoprep to give the title compound as a white powder. HPLC, Rt: 1.89 min (purity: 100%). UPLC/MS, M+(ESI): 299.2, M-
(ESI): 297.2.1H NMR (DMSO-d6) δ 10.8 (s, 1 H), 9.51 (s, 1 H), 8.32 (s, 1 H), 7.98 (d, J=9.48 Hz, 1 H), 7.74 (d, J=9.57 Hz, 1 H), 7.60 (d, J=2.04 Hz, 1 H), 7.50 (dd, J=8.28
Hz, 1 H), 6.91 (d, J=8.28 Hz, 1 H),10.8 (s, 1 H), 9.51 (s, 1 H), 8.32 (s, 1 H), 7.98 (d, J=9.48 Hz, 1 H), 7.74 (d, J=9.57 Hz, 1 H), 7.60 (d, J=2.04 Hz, 1 H), 7.50 (dd, J=8.28 Hz, 1 H), 6.91 (d, J=8.28 Hz, 1 H), 3.89 (s, 3H), 2.1 (s, 3H), 3.89 (s, 3H), 2.1 (s, 3H).
Example 80: N-{6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}-N-(3- morpholin-4-yl-3-oxopropyl)urea
A solution of Λ/-{6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}-1 /-/-imidazole-1- carboxamide (150 mg, 0.38 mmol) and 3-amino-1-morpholin-4-yl-propan-1-one hydrochloride (73 mg, 0.38 mmol, Fluorochem) in anhydrous DMA (2 ml.) was heated at 1300C for 15 minutes under microwave irradiation conditions. The reaction mixture was diluted with EtOAc and washed with water (4x). The organic layer was dried (MgSO4) and the solvents were removed under reduced pressure. After purification by precipitation from EtOAc, the title compound was obtained as a white powder. HPLC, Rt: 3.4 min (purity: 88.5%). UPLC/MS, M+(ESI): 489.1 , M-(ESI): 487.2.
Example 81 : N-{6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}-N-(3-oxo-3- pyrrolidin-1 -ylpropyl)urea
A solution of Λ/-{6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}-1 /-/-imidazole-1 - carboxamide (150 mg, 0.38 mmol) , 3-amino-1-pyrrolidin-1-yl-propan-1-one hydrochloride (67 mg, 0.38 mmol, Fluorochem) and DIEA (0.14 ml_, 0.79 mmol) in anhydrous DMA (2 ml.) was heated at 1300C for 25 minutes under microwave irradiation conditions. The reaction mixture was diluted with EtOAc and washed with water (4x). The organic layer was dried (MgSO4) and the solvents were removed under reduced pressure. After purification by precipitation from EtOAc, the title compound was obtained as a yellow powder. HPLC, Rt: 3.8 min (purity: 89%). UPLC/MS, M+(ESI): 473.1 , M-(ESI): 471.2.
Example 82: tert-butyl 3-[({3-[2-(acetylamino)-1 ,3-benzothiazol-6- yl]phenyl}sulfonyl)amino]piperidine-1 -carboxylate
Step 1) tert-butyl 3-{[(3-bromophenyl)sulfonyl]amino}piperidine-1-carboxylate
The title compound was prepared following procedure described in example 72 step 1 ), but starting from 1-Boc-3-aminopiperidine (ABCR). The title compound was obtained as a pale yellow oil (666 mg, 79%). HPLC, Rt: 4.5 min (purity: 94.9%). UPLC/MS, M+(ESI): 363.0, 365.0 ([M-tBu+2H]+), M-(ESI): 417.2, 419.2.
Step 2) tert-butyl 3-[({3-[2-(acetylamino)-1,3-benzothiazol-6- yl]phenyl}sulfonyl)amino]piperidine- 1 -carboxylate
The title compound was prepared following procedure described in Method B (workup A) starting from tert-butyl 3-{[(3-bromophenyl)sulfonyl]amino}piperidine-1- carboxylate. The title compound was obtained as a white powder (175 mg, 70%). HPLC, Rt: 4.3 min (purity: 99.3%). UPLC/MS, M+(ESI): 531.2, M-(ESI): 529.3.
Example 83: tert-butyl [1 -({3-[2-(acetylamino)-1 ,3-benzothiazol-6- yl]phenyl}sulfonyl)piperidin-3-yl]carbamate
Step 1) tert-butyl {1-[(3-bromophenyl)sulfonyl]piperidin-3-yl}carbamate
The title compound was prepared following procedure described in example 72 step 1 ), but starting from 3-N-Boc-aminopiperidine (Astatech). The title compound was obtained as a white powder (746 mg, 89%). HPLC, Rt: 4.8 min (purity: 100%). UPLC/MS, M+(ESI): 436.0, 438.1 ([M+NH4]+), M-(ESI): 417.2, 419.1.
Step 2) tert-butyl [1-({3-[2-(acetylamino)-1 ,3-benzotriiazol-6- yl]phenyl}sulfonyl)piperidin-3-yl]carbamate
The title compound was prepared following procedure described in Method B (workup A) starting from tert-butyl {1-[(3-bromophenyl)sulfonyl]piperidin-3-yl}carbamate. The title compound was obtained as a yellow foam. HPLC, Rt: 4.1 min (purity: 97.8%). UPLC/MS, M+(ESI): 531.2, M-(ESI): 529.3.
Example 84: 3-[2-(acetylamino)-1 ,3-benzothiazol-6-yl]-N-(2- hydroxyethyl)benzamide
The title compound was prepared following procedure described in Method B (workup A) starting from 3-bromo-N-(2-hydroxyethyl)benzamide (Combi-Blocks). The title compound was obtained as a white powder. HPLC, Rt: 2.9 min (purity: 96.9%). UPLC/MS, M+(ESI): 356.1 , M-(ESI): 354.1.
Example 85: Λ/-(6-{3-[(3-aminopiperidin-1 -yl)sulfonyl]phenyl}-1 ,3-benzothiazol-2- yl)acetamide, hydrochloride salt
A solution of tert-butyl [1-({3-[2-(acetylamino)-1 ,3-benzothiazol-6- yl]phenyl}sulfonyl)piperidin-3-yl]carbamate (150 mg, 0.28 mmol, Example 83) was prepared in a 4N solution of HCI in dioxane (1.0 mL, 4.0 mmol) and stirred at RT for 4 hours. The reaction mixture was concentrated under reduced pressure to give the title compound as a pale yellow powder (125 mg, 95%). HPLC, Rt: 2.6 min (purity: 98.3%). UPLC/MS, M+(ESI): 431.1 , M-(ESI): 429.2.
Example 86: N-(6-{3-[(piperidin-3-ylamino)sulfonyl]phenyl}-1 ,3-benzothiazol-2- yl)acetamide, hydrochloride salt
A solution of tert-butyl 3-[({3-[2-(acetylamino)-1 ,3-benzothiazol-6- yl]phenyl}sulfonyl)amino]piperidine-1-carboxylate (166 mg, 0.31 mmol, Example 82) was prepared in a 4N solution of HCI in dioxane (1.0 ml_, 4.0 mmol) and stirred at RT for 4 hours. The reaction mixture was concentrated under reduced pressure to give the title compound as a pale green powder. HPLC, Rt: 2.5 min (purity: 93.7%). UPLC/MS, M+(ESI): 431.1 , M-(ESI): 429.2.
A solution of Λ/-{6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}-1 /-/-imidazole-1- carboxamide (100 mg, 0.25 mmol) and 3-(tert-butoxy)propylamine (50 mg, 0.38 mmol) in anhydrous DMA (2 ml.) was heated at 1300C for 25 minutes under microwave irradiation conditions. The reaction mixture was diluted with EtOAc and washed with water (4x). The organic layer was dried (MgSO4) and the solvents were removed under reduced pressure. After purification by AutoPrep, the title compound was obtained as a white powder. HPLC, Rt: 3.8 min (purity: 100%). UPLC/MS, M+(ESI): 462.1 , M-(ESI): 460.2.
Example 88: N-(6-{5-[(dimethylamino)sulfonyl]pyridin-3-yl}-1 ,3-benzothiazol-2- yl)acetamide
The title compound was prepared following procedure described in Method B (work- up D) starting from 5-bromo-Λ/,Λ/-dimethylpyridine-3-sulfonamide (Aalen Chemical).
The title compound was obtained as a white powder. HPLC, Rt: 3.1 min (purity: 95.0%). UPLC/MS, M+(ESI): 377.1 , M-(ESI): 375.1.
Example 89: N-[6-(3-{[(2-hydroxyethyl)amino] sulfonyl}phenyl) imidazo[1 ,2- b]pyridazin-2-yl]acetamide
Step 1 ) formation of 6-chloroimidazo[1 ,2-b]pyridazin-2-amine
A solution of N-(6-chloroimidazo[1 ,2-b]pyridazin-2-yl)-2,2,2-trifluoroacetamide
(intermediate 5, 0.6 g, 2.26 mmol, 1 eq.) and LiOH-H2O (0.47g, 11.3mmol) in THF/MeOH/H2O (3:1 :2) was heated at 500C for 6h. the reaction mixture was then concentrated and partitioned between EtOAc and water. Organic layer was separated, dried over magnesium sulfate, filtered and concentrated. The crude was purified by flash chromatography on silica (DCIWMeOH) to give the title compound
(0.34 g, 85%).
Step 2) Formation of 6-chloroimidazo[1 ,2-b]pyridazin-2-amine
Acetyl chloride (0.29 ml_l, 4.04 mmol) was added dropwise to a solution of 6- chloroimidazo[1 ,2-b]pyridazin-2-amine (0.34 g, 2.02mmol) and pyridine (0.5 ml_, 6.07 mmol) in DCM maintained at 00C. The reaction mixture was stirred at RT for 3h. After completion, it was neutralized with saturated sodium bicarbonate solution. The solid formed was filtered and dried to give the title compound (300 mg, 70%).
Step 3) Formation of N-[6-(3-{[(2-hydroxyethyl)amino] sulfonyljphenyl) imidazo[1,2- b]pyridazin-2-yl]acetamide
A suspension of 6-chloroimidazo[1 ,2-b]pyridazin-2-amine (0.2 g, 0.95 mmol), (3-{[(2-hydroxyethyl)amino]sulfonyl}phenyl)boronic acid (0.1 g,
0.47 mmol), cesium fluoride (108 mg, 0.71 mmol) and bis-(triphenylphosphine)Pd(ll) chloride (17 mg, 0.02 mmol) in degassed dioxane/water (1 mL, 0.5 mL) was heated in MW at 900C for 1 h. The solvent was removed under reduced pressure and the residue was filtered through celite, concentrated under reduced pressure and purified by Autoprep to give the title compound as a white solid (150 mg, 84% Yield). HPLC
(Atlantis-1 ), Rt: 3.96 min (purity: 99.6%). LC/MS (Atlantis), M+(ESI): 375.8. 1H NMR (DMSO-d6, 400MHz) δ 10.94 (1 H, s), 8.45 (1 H, s), 8.29-8.33 (2H, m), 8.1 1-8.13 (1 H, d), 7.90-7.92 (1 H, d), 7.81-7.84 (1 H, d), 7.73-7.78 (2H, m), 4.68-4.7 (1 H, t), 3.35-3.4 (2H, m), 2.81-2.85 (2H, m), 2.10 (3H, s).
Example 90: N-{6-[3-(methylsulfonyl)phenyl]imidazo[1 ,2-b]pyridazin-2- yl}ethanethioamide
A suspension of N-{6-[3-(methylsulfonyl)phenyl]imidazo[1 ,2-b]pyridazin-2- yl}acetamide (31.6 mg; 0.10 mmol) and lawesson's reagent (78 mg; 0.20 mmol) in toluene (0.3 ml.) was heated in MW at 1500C for 20 min. Reaction mixture was concentrated under reduced pressure and the crude was purified by Autoprep to give the title compound as a yellow solid . HPLC, Rt: 3.04 min (purity: 78%). UPLC/MS M+(ESI): 345.1 , M-(ESI): 345.2. 1 H NMR (DMSO-d6) δ 12.6 (s, 1 H), 9.33 (s, 1 H), 8.59 (t, J=1.72 Hz, 1 H), 8.45 (brd, J=7.53 Hz, 1 H), 8.25 (d, J=9.75 Hz, 1 H), 8.08 (brd,
J=7.74 Hz, 1 H), 8.02 (d, J=9.96 Hz, 1 H), 7.87 (d, J=7.92 Hz, 1 H), 3.3 (s, 3H), 2.69 (s, 3H),. 1 H NMR (DMSO-d6) δ 12.6 (s, 1 H), 9.33 (s, 1 H), 8.59 (t, J=1.72 Hz, 1 H), 8.45 (brd, J=7.53 Hz, 1 H), 8.25 (d, J=9.75 Hz, 1 H), 8.08 (brd, J=7.74 Hz, 1 H), 8.02 (d, J=9.96 Hz, 1 H), 7.87 (d, J=7.92 Hz, 1 H), 3.3 (s, 3H), 2.69 (s, 3H).
Example 91 : N-p-β-tert-butyl-i ^-oxazol^-yQethyll-N'-β-β-
(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}urea
Step 1) Formation of phenyl {6-[3-(methylsulfonyl)phenyl]-1,3-benzothiazol-2- yljcarbamate
Phenylchloroformate (0.8 ml_, 6.4 mmol) was added to a solution of 6-[3- (methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-amine (1.3 g, 4.27 mmol) and pyridine (0.7 ml_, 8.5 mmol ) in DCM/THF (1 :1 ) at 00C. The reaction mixture was then stirred
at RT overnight. The solvent was removed under reduced pressure and the crude was triturated with methanol, filtered and dried to give the title compound (1.7g, 95% Yield).
Step 2) formation of N-[2-(5-tert-butyl-1,3-oxazol-2-yl)ethyl]-N'-{6-[3- (methylsulfonyl)phenyl]-1,3-benzothiazol-2-yl}urea
A solution of phenyl {6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}carbamate (95 mg, 0.225 mmol), [2-(5-tert-butyl-1 ,3-oxazol-2-yl)ethyl]amine (58 mg, 0.34 mmol), triethylamine (37 uL, 0.27 mmol) in NMP was heated in MW at 800C for 30 min.
Water was added and the reaction mixture was extracted with EtOAc (twice). Combined organic layers were brine, dried over magnesium sulfate, filtered and concentrated. The crude was purified by flash chromatography on basic alumina (DCM/MeOH) to give the title compound as an Off-white solid. HPLC (Atlantis- 1 ), Rt: 4.55 min (purity: 97.2%). LC/MS (Atlantis), M+(ESI): 499.0.
Example 92: N-[2-(2-isopropyl-2H-tetrazol-5-yl)ethyl]-N'-{6-[3- (methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}urea
The title compound was prepared following procedure described in Example 53, but starting from 2-(2-isopropyl-2H-tetrazol-5-yl)ethanamine (446 mg; 1.66 mmol; 1.5 eq.). The title compound was obtained as a white powder. HPLC, Rt: 3.94 min (purity: 99.2%). 1H-NMR (DMSO-d6): δ 10.87 (brs, 1 H), 8.34 (s, 1 H), 8.20 (s, 1 H), 8.06 (d, J = 8.0 Hz, 1 H), 7.87 (d, J = 8.0 Hz, 1 H), 7.72 (m, 3H), 6.93 (m, 1 H), 5.05 (spt, J = 6.7 Hz, 1 H), 3.56 (m, 2H), 3.30 (s, 3H), 3.06 (m, 2H), 1.53 (d, J = 6.6 Hz, 6H).
Example 93: N-p-^yclopropyl^H-tetrazol^-yOethyll-N'-fθ-IS- (methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}urea
The title compound was prepared following procedure described in example 91 but starting from [2-(5-cyclopropyl-2H-tetrazol-2-yl)ethyl]amine. HPLC (Atlantis), Rt: 4.07 min (purity: 96.4%). LC/MS (Atlantis), M-(ESI): 482.0.
Example 99: N-(2-hydroxyethyl)-3-{2-[({[2-(2-isopropyl-2H-tetrazol-5- yl)ethyl]amino}carbonyl)amino]-1 ,3-benzothiazol-6-yl}benzenesulfonamide
The title compound was prepared following procedure described in Example 49, but starting from 2-(2-isopropyl-2H-tetrazol-5-yl)ethanamine and n-(2-hydroxyethyl) 3- boronobenzenesulfonamide. The title compound was obtained as a white powder. HPLC, Rt: 3.57 min (purity: 98.0%). 1H-NMR (DMSO-d6): δ 10.88 (brs, 1 H), 8.27 (s, 1 H), 8.09 (t, J = 1.7 Hz, 1 H), 7.97 (dt, J = 6.9,1.5 Hz, 1 H), 7.7 (m, 5H), 6.94 (t, J = 5.6 Hz, 1 H), 5.07 (spt, J = 6.7 Hz, 1 H), 4.70 (t, J = 5.6 Hz, 1 H), 3.56 (q, J = 6.5 Hz, 2H), 3.37 (q, J = 6.0 Hz, 2H), 3.09 (t, J = 6.8 Hz, 2H), 2.81 (q, J = 6.0 Hz, 2H), 1.53 (d, J =
6.3 Hz, 6H).
Example 100: N-[6-(3-{[(2-hydroxyethyl)amino]sulfonyl}phenyl) imidazo[1 ,2- a]pyridin-2-yl]acetamide
A suspension of N-(6-bromoimidazo[1 ,2-a]pyridin-2-yl)acetamide (155 mg, 0.612 mmol), N-(2-hydroxyethyl-3-bromobenzenesulfonamide (100 mg, 0.408 mmol), cesium fluoride (247 mg, 16.3 mmol) and bis-(triphenylphosphine)Pd(ll) chloride (43 mg, 0.612 mmol) in degassed dioxane/water (2:1 ) was heated in MW at 900C for 1 h
at 900C. The solvent was removed under reduced pressure and the residue was slurred with dichloromethane. The solid was filtered, washed with water and dried overnight to give the title compound. HPLC (Atlantis-1 ), Rt: 3.80 min (purity: 95%). LC/MS (Atlantis), M+(ESI): 375.0. 1H NMR (DMSOd6, 400MHz) δ 10.74 (1 H,s), 9 (1 H,s), 8.15 (1 H,s), 8.07 (1 Hs), 7.93-7.95 (1 H,m), 7.7-7.9 (1 H,m), 7.66-7.70 (2H,sO, 7.54-7.56 (2H,m), 4.69-4.72 (1 H,t), 3.36-3.40 (2H,s), 2.80-2.85 (2H,m), 2.07 (3H,s).
Example 101 : N-[6-(3-{[(2-hydroxyethyl)amino]sulfonyl}phenyl)imidazo[1 ,2- a]pyrazin-2-yl]acetamide
The title compound was prepared following procedure described in example 89 but starting from N-(6-Bromoimidazo[1 ,2-a]pyrazin-2-yl)-2,2,2-trifluoroacetamide. The title compound was obtained as a grey solid. HPLC (Atlantis-1 ), Rt: 3.96 min (purity: 99.6%). LC/MS (Atlantis), M+(ESI): 375.8.
Example 102: N-{6-[5-(methylsulfonyl)pyridin-3-yl][1,3]thiazolo[4,5-c]pyιϊdin-2- yl}acetamide
The title compound was prepared following procedure described in example 89, step 2 and 3 but starting from 6-chloro[1 ,3]thiazolo[4,5-c]pyridin-2-amine. The title compound was obtained as a pale green solid. HPLC, Rt: 2.32 min (purity: 98.7%). LC/MS (Atlantis), M+(ESI): 349.0.
Example 103: N-[5-(3-{[(2-hydroxyethyl)amino]sulfonyl}phenyl)[1,3] thiazolo[5,4- b]pyridin-2-yl]acetamide
The title compound was prepared following procedure described in example 89, step 2 and 3 but starting from 5-chloro[1 ,3]thiazolo[5,4-b]pyridin-2-amine. The title compound was obtained as a brown solid. HPLC (Atlantis-1 ), Rt: 3.01 min (purity: 94.8%). LC/MS (Atlantis), M+(ESI): 392.9.
Example 104: N-(6-{5-[(3-hydroxypyrrolidin-1 -yl)sulfonyl]pyridin-3-yl}-1 ,3- benzothiazol-2-yl)acetamide
A mixture of Λ/-[6-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,3-benzothiazol-2- yl]acetamide (39.4 mg, 0.124 mmol), 1-[(5-bromopyridin-3-yl)sulfonyl]pyrrolidin-3-ol (57 mg, 0.186 mmol) and cesium fluoride (75 mg, 0.49mmol) in dioxane/water (ratio 2:1 , 1.5 ml.) was purged with nitrogen in a MW vial. Bis(triphenylphosphine)palladium(ll) chloride (13 mg, 0.019 mmol 0.05 to 0.15 eq) was then added and the reaction mixture was heated at 900C for 1 h under MW irradiations. The solvent was removed under reduced pressure and the residue was slurred in DCM. The solid obtained was filtered, washed with water and dried to give the title compound as a white solid. HPLC (Atlantis-1 ), Rt: 3.08 min (purity 99.9%). LC/MS (Atlantis), M+(ESI): 418.8, 1H-NMR (DMSO-d6) δ 12.45 (brs, 1 H), 9.23 (s, 1 H), 8.91 (s, 1 H), 8.49 (s, 1 H), 8.40 (s, 1 H), 7.86 (m, 2H), 4.89 (s, 1 H), 4.17 (s, 1 H),
3.18-3.38 (m, 4H), 2.21 (s, 3H), 1.80 (m, 1 H), 1.69 (m, 1 H). Examples 105 to 128 were prepared following the same procedure:
Example 129: N-[6-(5-{[hydroxy(dimethyl)oxido-lambda~4~- sulfanyl]amino}pyridin-3-yl)imidazo[1 ,2-a]pyridin-2-yl]acetamide
A suspension of MC002_SC09 (100mg, 3.3mmol), MC002_SC11 (124mg, 4.98mmol), cesium fluoride (100 mg, 6.6 mmol) and bis-(triphenylphosphine)Pd(ll) chloride (0.05 eq) in degassed dioxane/water (2:1 ) was heated in MW at 900C for 1 h. The solvent was removed under reduced pressure and the residue was slurred with dichloromethane. The solid was filtered, washed with water and dried overnight to give the title compound. HPLC (Atlantis-2), Rt: 6.27 min (purity: 95.3%). LC/MS (Atlantis), M+(ESI): 346.0. 1H NMR (DMSOd6, 400MHz) δ 10.74 (1 H,s), 10.16 (1 H,s), 8.98 (1 H,s), 8.64-8.65 (1 H,s), 8.41 (1 H,s), 8.15 (1 H,s), 7.82 (1 H,s), 7.5-7.55 (2H,m), 3.13 (3H1S), 2.07 (3H,s). Examples 130-132 were prepared following the same procedure:
Example 133: N-p-fS-tert-butyl-i ^^-oxadiazol-S-yOethyll-N'-fθ-IS- (methylsulfonyl)pyridin-3-yl]-1 ,3-benzothiazol-2-yl}urea
The title compound was prepared following procedure described in example 129 but starting from N-[2-(5-tert-butyl-1 ,2,4-oxadiazol-3-yl)ethyl]-N'-[6-(4,4,5,5-tetramethyl-
1 ,3,2-dioxaborolan-2-yl)-1 ,3-benzothiazol-2-yl]urea. The title compound was obtained as a white solid. HPLC, Rt: 3.80 min (purity: 99.7%). LC/MS (Atlantis), M+(ESI):
500.9.
Examples 134-147 were prepared following the same procedure:
Example 148: 3-{2-[({[2-(5-tert-butyl-1 ,2,4-oxadiazol-3- yl)ethyl]amino}carbonyl)amino]imidazo[1 ,2-a]pyridin-6-yl}-N-(2- hydroxyethyl)benzenesulfonamide
The title compound was prepared following procedure described in example 129 but starting from N-[2-(5-tert-butyl-1 ,2,4-oxadiazol-3-yl)ethyl]-N'-[6-(4 ,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)imidazo[1 ,2-a]pyridin-2-yl]urea. The title compound was
obtained as a white solid. HPLC, Rt: 3.80 min (purity: 99.7%). LC/MS (Atlantis), M+(ESI): 500.9.
Examples 149 was prepared following the same procedure:
Example 150: 5-{2-[({[2-(5-tert-butyl-1 ,3-oxazol-2- yl)ethyl]amino}carbonyl)amino]-1 ,3-benzothiazol-6-yl}-N,N-dimethylpyridine-3- sulfonamide
The title compound was prepared following procedure described in example 129 but starting from N-[2-(5-tert-butyl-1 ,3-oxazol-2-yl)ethyl]-N'-[6-(4,4,5,5-tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 ,3-benzothiazol-2-yl]urea. The title compound was obtained as an off white solid. HPLC, Rt: 4.10 min (purity: 98.6%). LC/MS (Atlantis), M+(ESI): 528.9.
Examples 151 and 152 were prepared following the same procedure:
Example 153: N-p-fS-tert^utyM .S-oxazol^-yOethyll-N'-fθ-IS- (methylsulfonyl)pyridin-3-yl]imidazo[1,2-a]pyridin-2-yl}urea
The title compound was prepared following procedure described in example 129 but starting from N-[2-(5-tert-butyl-1 ,3-oxazol-2-yl)ethyl]-N'-[6-(4 ,4,5,5-tetramethyl-i ,3,2- dioxaborolan-2-yl)imidazo[1 ,2-a]pyridin-2-yl]urea. The title compound was obtained as a pale brown solid. HPLC, Rt: 3.04 min (purity: 96.0%). LC/MS (Atlantis), M+(ESI): 482.9.
Example 154: N-(6-{5-[(piperidin-3-ylamino)sulfonyl]pyridin-3-yl}-1 ,3- benzothiazol-2-yl)acetamide
Trifluoroacetic acid (2.2 eq) was added dropwise to a solution of tert-butyl [1-({5-[2- (acetylamino)-1 ,3-benzothiazol-6-yl]pyridin-3-yl}sulfonyl)piperidin-3-yl]carbamate in DCM. The reaction mixture was then stirred at RT for 4h and concentrated under reduced pressure. The crude was dissolved in DCM and washed with saturated sodium bicarbonate solution, water and brine. Organic phase was finally dried over magnesium sulfate, filtered and concentrated to give the title compound. HPLC
(Atlantis-1 ), Rt: 3.98 min (purity: 95.5%). LC/MS (Atlantis), M+(ESI): 432.1. 1H NMR (DMSO-d6, 400MHz) δ 9.18 (1 H,s), 8.91 (1 H,s), 8.43-8.46 (2H,d), 7.83-7.84 (2H,m), 3.06 (1 H,m), 2.61-2.75 (2H,dd), 2.26-2.28 (1.5H,m),2.23 (3H,s), 1.62 (1 H,m), 1.47- 1.48 (1 H,m), 1.24 (3H,m). Examples 155 and 156 were prepared following the same procedure:
Example 157: N-{6-[5-({[(1 S,2R,3S)-2,3-dihydroxycyclohexyl]amino} sulfonyl)pyridin-3-yl]-1 ,3-benzothiazol-2-yl}acetamide
A solution of N-{6-[5-({[(3aR,4S,7aS)-2,2-dimethylhexahydro-1 ,3-benzodioxol-4- yl]amino}sulfonyl)pyridin-3-yl]-1 ,3-benzothiazol-2-yl}acetamide (25 mg, 0.039 mmol) in acetic acid (0.8 ml.) and water (0.2 ml.) was stirred at RT for 5h. Then acetic acid was removed under reduced pressure and water was azeotroped with toluene (3 times) to give the title compound (15 mg, 81 % yield). HPLC (Atlantis-2), Rt: 4.47 min (purity: 92.1 %). LC/MS (Atlantis), M+(ESI): 462.9. 1H NMR (DMSOd6, 400MHz) δ 12.3 (1 H, s) 9.1 (1 H, s), 8.91 (1 H, s), 8.49 (1 H, s), 8.43 (1 H, s), 7.82-7.87 (3H, m),
4.44 (1 H, s), 4.37 (1 H, s), 3.72 (1 H, s), 3.24 (1.6H, m), 2.21 (3H, s), 1.66-1.68 (1 H, m), 1.52 (1 H, m), 1.4 (1.2H, m), 1.3 (2.4H, m), 1.28 (1.2H, m).
Example 158: N-[6-(1 ,1 -dioxido-2,3-dihydro-1 ,2-benzisothiazol-6-yl)-1 ,3- benzothiazol-2-yl]acetamide
Step a) Formation of (3-{[(2-hydroxyethyl)amino]sulfonyl}phenyl)boronic acid
The title compound was prepared following procedure described in example 104 but starting from 6-bromo-2-tert-butyl-2,3-dihydro-1 ,2-benzisothiazole 1 ,1 -dioxide.
Step 2) Formation of N-[6-(1 ,1-dioxido-2,3-dihydro-1 ,2-benzisothiazol-6-yl)-1 ,3- benzothiazol-2-yl]acetamide
A solution of (3-{[(2-hydroxyethyl)amino]sulfonyl}phenyl)boronic acid (95 mg, 0.228 mmol) in TFA (5 ml.) was stirred at RT overnight. The reaction mixture was neutralized carefully with sat. NaHCO3 solution at 00C and the aqueous layer was extracted with DCM (twice). Combined organic layers were then dried over magnesium sulfate, filtered and concentrated. The crude was triturated with MeOH, filtered and dried under vacuum to give the title compound. HPLC (Atlantis-1 ), Rt: 3.43 min (purity: 97.6%). LC/MS (Atlantis), M+(ESI): 360.0. 1H NMR (DMSO-d6, 400MHz) δ 12.42 (1 H,s), 8.42 (1 H,s), 8.12 (1 H,s), 8.03-8.05 (1 H,d), 7.65-7.82 (3H,m), 7.6 (1 H,d), 4.43 (2H,s), 2.2(3H,s).
Compounds 159-161 were prepared following same procedure as described in example 26:
Example 162: N-^-tS-tert-butyl-i ^^-oxadiazol-S-yOethyll-N'^θ-IS- (methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}urea
A solution of phenyl {6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}carbamate (0.3 g, 0.706 mmol), 2-(5-tert-butyl-1 ,2,4-oxadiazol-3-yl)ethanamine (0.143 g, 1.05 mmol), triethylamine (0.11 mL, 0.85 mmol) in NMP was heated in MW at 800C for 30 min. Water was added and the reaction mixture was extracted with EtOAc (twice). Combined organic layers were brine, dried over magnesium sulfate, filtered and concentrated. The crude was purified by flash chromatography on silica (DCM/MeOH) to give the title compound as a white solid (250 mg, 70% Yield). HPLC (Atlantis-1 ), Rt: 5.97 min (purity: 98.6%). LC/MS (Atlantis), M+(ESI): 500.0. 1H NMR (DMSOd6, 400MHz) δ 10.84-10.99 (1 H, s), 8.34 (1 H, s), 8.2 (1 H, s), 8.06-8.08 (1 H, d) ,7.87-7.89 (1 H, d) 7.7-7.77 (3H m), 6.89 (1 H, s), 3.51-3.56 (2H, m), 3.31 (3H, s), 2,89- 2.93 (2H, m), 1.36 (9H, s).
Example 210: N-methyl-3-{[({6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2- yl}amino)carbonyl]amino}cyclopentanecarboxamide
A solution of Methyl 3-{[({6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-yl}amino) carbonyl]amino}cyclopentanecarboxylate (50 mg, 0.105 mmol ), and methylamine (THF solution, 5ml_) was heated in a sealed tube at 1000C overnight. Solvent was
removed under reduced pressure and the solid obtained was washed with diethyl ether to give the title compound as a white solid. HPLC, Rt: 3.34 min (purity: 92.8%). LC/MS, M+(ESI): 472.9. 1H NMR (DMSOd6 400MHz) δ 10.78 (1 H, s) ,8.33 (1 H, s), 8.20 (1 H, s), 8,08 (1 H, m), 7.82-7.88 (2H, m), 7.70-7.72 (3H, m), 6.97 (1 H, m), 4.05- 4.08 (1 H, m), 3.31 (3H, s), 2.58-2.66 (1 H, m), 2.56 (3H, s), 2.08-2.11 (1 H, m), 1.82- 1.88 (1 H, m), 1.73-1.79 (1 H, m), 1.54-1.61 (2H, m).
Example 211 : N,N-dimethyl-3-{[({6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol- 2-yl}amino)carbonyl]amino}cyclopentanecarboxamide
The title compound was prepared following procedure described in example 210 but starting from dimethylamine. The title compound was obtained as a white solid. HPLC, Rt: 3.65 min (purity: 96.4%). LC/MS (Atlantis), M+(ESI): 486.9.
Example 212: tert-butyl N-{[(6-{5-[(dimethylamino)sulfonyl]pyridin-3-yl}-1 ,3- benzothiazol-2-yl)amino]carbonyl}-beta-alaninate
Step 1) formation of 5-(2-amino-1 ,3-benzothiazol-6-yl)-N,N-dimethylpyridine-3- sulfonamide
A solution N-(6-{5-[(dimethylamino)sulfonyl]pyridin-3-yl}-1 ,3-benzothiazol-2- yl)acetamide (900 mg, 2.39 mmol) in 6N HCI (20 mL) was refluxed for 2h. Reaction mixture was neutralized with saturated sodium bicarbonate solution and extracted with DCM (twice). Combined organic layer were dried over sodium sulphate, filtered and concentrated to give the title compound.
Step 2) formation of phenyl (6-{5-[(dimethylamino)sulfonyl]pyridin-3-yl}-1,3- benzothiazol-2-yl)carbamate
The title compound was prepared following procedure described in example 162, step 1 ) but starting from N-(6-{5-[(dimethylamino)sulfonyl]pyridin-3-yl}-1 ,3-benzothiazol-2- yl)acetamide (265 mg, 0.793 mmol). Water was added after completion of the reaction and the precipitate obtained was filtered, washed with water three times and dried overnight to give the title compound.
Step 3) formation of tert-butyl N-{[(6-{5-[(dimethylamino)sulfonyl]pyridin-3-yl}-1,3- benzothiazol-2-yl)amino]carbonyl}-beta-alaninate
A solution of phenyl (6-{5-[(dimethylamino)sulfonyl]pyridin-3-yl}-1 ,3-benzothiazol-2- yl)carbamate (100 mg, 0.22 mmol), H-β-ala-OtBu. HCI (52 mg, 0.286 mmol) and TEA (50 ml_, 0.33 mmol) in NMP was heated in MW at 800C for 10 min. Reaction mixture was diluted with water and stirred for 1 h. The precipitate obtained was filtered and dried overnight to give the itle compound as a brown solid. HPLC (Atlantis-1 ), Rt: 4.61 min (purity: 95.8%). LC/MS, M+(ESI): 503.9. 1H NMR (DMSOd6 400MHz) δ 10.90 (1 H, s), 9.25 (1 H, s) 8.87 (1 H, s), 8.44 (1 H, s), 8.34 (1 H, s), 7.82-7.84 (1 H, m), 7.72- 7.74 (1 H, m), 6.88 (1 H, s), 3.36-3.38 (2H, d), 2.71 (6H, s), 2.43-2.46 (2H, m),1.41 (9H, s).
Example 213: N-[2-(5-tert-butyl-1 ^^-oxadiazol-S-yOethyll-N'-fδ-IS-
(methylsulfonyl)phenyl][1 ,3]thiazolo[5,4-b]pyridin-2-yl}urea
Step 1) Formation of phenyl {5-[3-(methylsulfonyl)phenyl][1,3]thiazolo[5,4-b]pyridin-2- yljcarbamate
The title compound was prepared following procedure described in example 162, step 1 ) but starting from 5-[3-(methylsulfonyl)phenyl][1 ,3]thiazolo[5,4-b]pyridin-2-amine (1 g, 3.3 mmol) and using 4,6-trimethyl pyridine instead of pyridine. Water was added after completion of the reaction and the precipitate obtained was filtered, washed with water three times and dried overnight to give the title compound.
Step 2) Formation of N-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)ethyl]-N'-{5-[3- (methylsulfonyl)phenyl][1,3]thiazolo[5,4-b]pyridin-2-yl}urea
The title compound was prepared following procedure described in example 162, step 2) but starting from of phenyl {5-[3-(methylsulfonyl)phenyl][1 ,3]thiazolo[5,4-b]pyridin- 2-yl}carbamate
(100 mg, 0.235 mmol) and [2-(5-tert-butyl-1 ,2,4-oxadiazol-3-yl)ethyl]amine (58 mg, 0.284 mmol). The title compound was obtained as a beige solid. HPLC Rt: 4.09 min (purity: 98.2%). LC/MS (Atlantis), M+(ESI): 501.0. 1H NMR (DMSOd6, 400MHz) δ 1 1.12 (1 H, s), 8.61 (1 H, s), 8.43-8.45 (1 H, d), 8.06-8.14 (2H, m) 7.95-7.96 (1 H, d),7.75-7.78 (1 H, m), 6.92 (1 H, s), 3.53-3.54 (2H, d), 3.32 (3H, s)2.91-2.93 (2H, d), 1.36 (9H, s). Examples 214- 219 were prepared following the same procedure:
Example 220: N-[2-(5-tert-butyl-1 ^^-oxadiazol-S-yOethyll-N'^θ-IS- (methylsulfonyl)phenyl][1 ,3]thiazolo[4,5-c]pyridin-2-yl}urea
The title compound was prepared following procedure described in example 162, step 1 ) and 2) but starting from 6-[3-(methylsulfonyl)phenyl][1 ,3]thiazolo[4,5-c]pyridin-2- amine and 2-(5-tert-butyl-1 ,2,4-oxadiazol-3-yl)ethanamine. The title compound was obtained as a white solid. HPLC Rt: 3.45 min (purity: 98.7%). LC/MS (Atlantis), M+(ESI): 500.9.
Example 221 : N-^-tS-tert-butyl-i ^^-oxadiazol-S-yOethyll-N'^θ-IS- (methylsulfonyl)phenyl]imidazo[1,2-a]pyrazin-2-yl}urea
The title compound was prepared following procedure described in example 162, step 1 ) and 2) but starting from 6-[3-(methylsulfonyl)phenyl]imidazo[1 ,2-a]pyrazin-2-amine and 2-(5-tert-butyl-1 ,2,4-oxadiazol-3-yl)ethanamine. The title compound was obtained as a yellow solid. HPLC Rt: 3.54 min (purity: 97.7%). LC/MS (Atlantis), M+(ESI):
484.1.
Example 222: N-[3-(2-isopropylpyrrolidin-1 -yl)-3-oxopropyl]-N-[6-(5- methoxypyridin-3-yl)-1 ,3-benzothiazol-2-yl]urea Step 1 ) Formation of phenyl [6-(5-methoxypyridin-3-yl)-1 ,3-benzothiazol-2- yl]carbamate
The title compound was prepared following procedure described in example 162, step 1 ) but starting 6-(5-methoxypyridin-3-yl)-1 ,3-benzothiazol-2-amine (440 mg, 1.712 mmol) and using 2,4,6-trimethyl pyridine instead of pyridine in NMP. Water was added after completion of the reaction and the precipitate obtained was filtered, washed with water three times and dried overnight to give the title compound. Step 2) Formation of N-[3-(2-isopropylpyrrolidin-1-yl)-3-oxopropyl]-N-[6-(5- methoxypyridin-3-yl)-1 , 3-benzothiazol-2-yl]urea
The title compound was prepared following procedure described in example 162, step 2) but starting from phenyl [6-(5-methoxypyridin-3-yl)-1 ,3-benzothiazol-2-yl]carbamate (100 mg, 0.235 mmol) and 2-(5-tert-butyl-1 ,2,4-oxadiazol-3-yl)ethanamine (58 mg, 0.284 mmol). The title compound was obtained as an off white solid. HPLC Rt: 3.27 min (purity: 97.2%). LC/MS M+(ESI): 468.0. 1H NMR (DMSOd6, 400MHz) δ 10.83
(1 H, s), 8.52 (1 H, s), 8.30 (1 H, s), 8.25 (1 H, s), 7.66-7.75 (3H, m), 6.93 (1 H, s), 3.91
(3H, s), 3.89 (1 H, m), 3.6-3.87 (1 H, m), 3.44-3.49 (1 H, m), 3.36-3.39 (2H, m), 2.22-
2.23 (1 H, m), 1.69-1.84 (4H, m), 0.85 (6H, m).
Examples 223- 234 were prepared following the same procedure:
Example 235: N-{2-[5-(2-fluoro-1 ,1 -dimethylethyl)-1 ,2,4-oxadiazol-3-yl]ethyl}-N'- [5-(5-methoxypyridin-3-yl)[1 ,3]thiazolo[5,4-b]pyridin-2-yl]urea
Step 1) Formation of phenyl [5-(5-methoxypyridin-3-yl)[1 ,3]thiazolo[5,4-b]pyridin-2- yljcarbamate
The title compound was prepared following procedure described in example 162, step 1 ) but starting 5-(5-methoxypyridin-3-yl)[1 ,3]thiazolo[5,4-b]pyridin-2-amine (250 mg, 0.969 mmol) and using 2,4,6-trimethyl pyridine instead of pyridine in NMP. Water was added after completion of the reaction and the precipitate obtained was filtered, washed with water three times and dried overnight to give the title compound.
Step 2) formation of N-{2-[5-(2-fluoro-1 , 1-dimethylethyl)-1 ,2,4-oxadiazol-3-yl]ethyl}-N'- [5-(5-methoxypyridin-3-yl)[1,3]thiazolo[5,4-b]pyridin-2-yl]urea
7/?e f/Y/e compound was prepared following procedure described in example 162, step 2) but starting from Phenyl [5-(5-methoxypyridin-3-yl)[1,3]thiazolo[5,4-b]pyridin-2- yljcarbamate (20 mg, 0.053 mmol) and 2-[5-(2-fluoro-1 ,1-dimethylethyl)-1 ,2,4-oxadiazol-3- yl]ethanamine (16.4 mg, 0.0634 mmol),. The title compound was obtained as an off white solid. HPLC Rt: 3.1 1 min (purity: 87.6%). LC/MS M+(ESI): 472.2. 1H NMR (DMSO-d6, 400MHz) δ 1 1.15 (1 H, s), 8.87 (1 H, s), 8.31 (1 H, s), 8.08-8.10 (1 H, d), 8.02-8.04 (1 H, d), 7.98 (1 H, s), 6.95 (1 H, s), 4.63 (1 H, s), 4.51 (1 H, s), 3.92 (3H, s), 3.53-3.55 (2H, m), 2.94-2.96 (2H, m), 1.38 (6H, s).
Example 236: N-[2-(5-tert-butyl-1 ,2,4-oxadiazol-3-yl)ethyl]-N'-{5-[5- (methylsulfonyl)pyridin-3-yl][1 ,3]thiazolo[5,4-b]pyridin-2-yl}urea
Step 1) Formation of phenyl {5-[5-(methylsulfonyl)pyridin-3-yl][1,3]thiazolo[5,4- b]pyridin-2-yl}carbamate
The title compound was prepared following procedure described in example 235, step 1 ) but starting from 5-[5-(methylsulfonyl)pyridin-3-yl][1 ,3]thiazolo[5,4-b]pyridin-2- amine (0.21 g, 0.686 mmol). (0.27 g, 92% yield).
Step 2) Formation of N-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)ethyl]-N'-{5-[5- (methylsulfonyl)pyridin-3-yl][1,3]thiazolo[5,4-b]pyridin-2-yl}urea
The title compound was prepared following procedure described in example 162, step 2) but starting from of phenyl {5-[5-(methylsulfonyl)pyridin-3-yl][1 ,3]thiazolo[5,4- b]pyridin-2-yl}carbamate
(0.22g,0.516mmol.), and 2-(5-tert-butyl-1 ,2,4-oxadiazol-3-yl)ethanamine (0.129g, 0.629mmol.)- The title compound was obtained as a yellow solid. HPLC Rt: 3.75 min (purity: 98.4%). LC/MS M+(ESI): 502.0. 1H NMR (DMSOd6, 400MHz) δ 1 1.17 (1 H,s), 9.59-9.60 (1 H,s), 9.08-9.09 (1 H,s), 8.91-8.92(1 H,s), 8.24-8.26(1 H,d), 8.11-8.13 (1 H,d), 6.93(1 H1S), 3.52-3.56 (2H,m), 3.37-3.41 (3H,s), 32.90-2.93(2H,m), 1.36(9H,s). Examples 237 and 238 were prepared following the same procedure:
Example 239: N-[3-(3,3-difluoroazetidin-1 -yl)-3-oxopropyl]-N-{6-[5- (methylsulfonyl)pyridin-3-yl]-1 ,3-benzothiazol-2-yl}urea
A suspension of
N-[3-(3,3-difluoroazetidin-1-yl)-3-oxopropyl]-N-{6-bromo-1 ,3-benzothiazol-2-yl}urea (80 mg, 0.18 mmol), 3-(methylsulfonyl)-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)pyridine (77 mg, 0.272 mmol), cesium fluoride (1 10 mg, 0.725 mmol) and bis- (triphenylphosphine) Pd(II) chloride (0.15 eq) in degassed dioxane/water (2:1 ratio) was heated in MW at 900C for 60 min. Dioxane was removed under reduced pressure and the aqueous phase was extracted with EtOAc (twice). Combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated.
The crude was purified by flash chromatography on silica (HCCI3/MeOH) to give the title compound as a off white solid. HPLC Rt: 3.08 min (purity: 96.8%). LC/MS M+(ESI): 496.0. 1H NMR (DMSOd6, 400MHz) δ 10.88 (1 H,s), 9.27 (1 H,s), 9.0(1 H,s), 8.58 (1 H,s), 8.44 (1 H,s),7.84-7.86 (1 H,d), 7.74-7.76 (1 H,d), 6.91 (1 H,s), 4.57-4.63 ( 2H,t), 4.25-4.32 (2H,t), 3.4 (5H,m), 2.44 (2H,m). Examples 240 and 241 were prepared following the same procedure:
Example 242: N-(2-hydroxyethyl)-3-{2-[({[2-(5-phenyl-1 ,2,4-oxadiazol-3- yl)ethyl]amino}carbonyl)amino]imidazo[1 ,2-a]pyridin-6-yl}benzenesulfonamide
A suspension of
N-(6-bromoimidazo[1 ,2-a]pyridin-2-yl)-N'-[2-(5-phenyl-1 ,2,4-oxadiazol-3-yl)ethyl]urea (69 mg, 0.28 mmol), N-(2-hydroxyethyl)-3-boronobenzenesulphonamide (97 mg, 0.22 mmol) and {1 ,1 '-bis(diphenylphosphino)-ferrocene}dichloropalladium(ll).DCM (28 mg, 0.035 mmol) in aq. sodium carbonate (2M solution, 0.75 mL) and 1 ,2- dimethoxyethane was heated in MW at 1000C for 60 min. The reaction mixture was diluted with EtOAc and the organic phase was washed with water, brine, dried over sodium sulfate, filtered and concentrated. The crude was purified by flash chromatography on basic alumina (DCM/MeOH) to give the title compound as a off white solid. HPLC (Atlantis-1 ) Rt: 3.33 min (purity: 96.3%). LC/MS(Atlantis) M+(ESI):
548.0. 1H NMR (DMSO-d6, 400MHz) δ 9.05 (1 H, s), 8.94 (1 H, s), 8.10-8.12 (2H, d), 8.1 (1 H, s), 7.92-7.94 (1 H, d), 7.82 (1 H, s), 7.78 (1 H, d), 7.6-7.71 (5H, m), 7.49-7.52 (1 H, d), 7.43-7.45 (1 H, d), 6.89 (1 H, s), 4.68-4.71 (1 H, m), 3.55-3.66 (2H, m), 3.35- 3.4 (2H, m), 2.97-3.0 (2H, m), 2.8-2.85 (1 H, m). Examples 243 to 245 were prepared following the same procedure:
Example 246: N-{3-[3-(diethylamino)prop-1 -yn-1 -yl]-6-[3- (methylsulfonyl)phenyl]imidazo[1 ,2-a]pyridin-2-yl}acetamide
Step 1) Formation of N-{3-bromo-6-[3-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-2- yl}acetamide
N-bromo succinimide (0.475 g, 2.67 mmol) was added to a solution of N-{6-[3- (methylsulfonyl)phenyl]imidazo[1 ,2-a]pyridin-2-yl}acetamide (0.8 g, 2.42 mmol) in
ACN maintained at 00C. The reaction mixture was stirred at RT for 1 h. The suspension formed was filtered, washed with ACN and dried under vacuum to give the title compound.
Step 2) Formation ofN-{3-[3-(diethylamino)prop-1-yn-1-yl]-6-[3-
(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-2-yl}acetamide
A suspension of N-{3-bromo-6-[3-(methylsulfonyl)phenyl]imidazo[1 ,2-a]pyridin-2- yl}acetamide (0.1g, 0.244mmol), 3-(diethylamino)-1-propyne (0.051 ml, 0.36mmol), triethylamine (0.17ml, 1.22mmol), cuprous iodide (4.6mg, 0.024mmol and bis(triphenyl phosphine) palladium(ll) chloride (10.3mg, 0.014mmol) in degassed THF was heated at 700C for 8h in a sealed tube. Reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The crude was purified by flash chromatography on silica (DCIWMeOH) to give the title compound as a dark brown solid. HPLC (Atlantis-1 ) Rt: 3.80 min (purity: 97.1%). LC/MS (Atlantis)
M+(ESI): 439.1. 1H NMR (DMSOd6, 400MHz) δ 10.29 (1 H, s), 8.57 (1 H, s), 8.21 (1 H, s), 8.07-8.09 (1 H, d), 7.95-7.97 (1 H, d), 7.77-7.81 (2H, m), 7.69-7.71 (1 H, d), 3.81 (2H, s), 3.30 (3H, s), 2.61 (4H, s), 2.07 (3H, s), 1.06-1.08 (6H, m).
Example 247: tert-butyl (5-{2-[({[2-(5-tert-butyl-1 ,2,4-oxadiazol-3- yl)ethyl]amino}carbonyl)amino]-1 ,3-benzothiazol-6-yl}pyridin-3- yl)methylcarbamate
Step 1) Formation of tert-butyl {5-[2-(acetylamino)-1 ,3-benzothiazol-6-yl]pyridin-3- yljmethylcarbamate
A suspension of N-[6-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,3-benzothiazol- 2-yl]acetamide (500 mg, 1.75 mmol), tert-butyl (5-bromopyridin-3-yl)methylcarbamate
(670 mg, 2.106 mmol), cesium fluoride (1.06 g, 6.99 mmol) and bis- (triphenylphosphine) Pd(II) chloride (61.4 mg, 0.087 mmol) in degassed dioxane/water (2:1 ) was heated in MW at 900C for 1 h. Solvents were removed under reduced pressure and the residue was slurred with DCM. The solid obtained was filtered, washed with water and dried overnight to give the title compound (650mg,
93% Yield).
Step 2) Formation of tert-butyl [5-(2-amino-1 ,3-benzothiazol-6-yl)pyridin-3- yljmethylcarbamate
A solution of tert-butyl {5-[2-(acetylamino)-1 ,3-benzothiazol-6-yl]pyridin-3- yl}methylcarbamate (650 mg, 1.63 mmol) and potassium carbonate (650mg, 4.71 mmol) in MeOH/water (8:1 ) was heated at 600C for 6h. Solvent was removed under reduced pressure and the crude obtained was dissolved in dichloromethane and filtered through celite. The filtrate was concentrated, dissolved in EtOAc and passed through silica bed. Filtrate was concentrated under reduced pressure to give the title compound.
Step 3) Formation of phenyl (6-{5-[(tert-butoxycarbonyl)(methyl)amino]pyridin-3-yl}- 1, 3-benzothiazol-2-yl)carbamate
The title compound was prepared following procedure described in example 235, step 1 ) but starting from tert-butyl [5-(2-amino-1 ,3-benzothiazol-6-yl)pyridin-3- yl]methylcarbamate (25 Omg, 0.701 mmol).
Step 4) Formation of tert-butyl (5-{2-[({[2-(5-tert-butyl-1,2,4-oxadiazol-3- yl)ethyl]amino}carbonyl)amino]-1,3-benzothiazol-6-yl}pyridin-3-yl)methylcarbamate
The title compound was prepared following procedure described in example 162, step 2) but starting from of phenyl (6-{5-[(tert-butoxycarbonyl)(methyl)amino]pyridin-3-yl}- 1 ,3-benzothiazol-2-yl)carbamate (160mg, 0.336mmol) and 2-(5-tert-butyl-1 ,2,4- oxadiazol-3-yl)ethanamine (83mg, 0.403mmol). The title compound was obtained as an off white solid. HPLC Rt: 4.12 min (purity: 92.1%). LC/MS M+(ESI): 552.0.
Example 248: N-[2-(5-tert-butyl-1 ^^-oxadiazol-S-yOethyll-N'-fθ-IS- (methylamino)pyridin-3-yl]-1 ,3-benzothiazol-2-yl}urea
The title compound was prepared following procedure described in example 154, but starting from tert-butyl (5-{2-[({[2-(5-tert-butyl-1 ,2,4-oxadiazol-3- yl)ethyl]amino}carbonyl)amino]-1 ,3-benzothiazol-6-yl}pyridin-3-yl)methylcarbamate (120mg, 0.218mmol). The title compound was obtained as an off white solid. HPLC Rt: 3.26 min (purity: 98.2%). LC/MS M+(ESI): 451.9.
Example 249: N-(5-{2-[({[2-(5-tert-butyl-1 ,2,4-oxadiazol-3- yl)ethyl]amino}carbonyl)amino]-1 ,3-benzothiazol-6-yl}pyridin-3-yl)-N- methylmethanesulfonamide
A solution of N-[2-(5-tert-butyl-1 ,2,4-oxadiazol-3-yl)ethyl]-N'-{6-[5- (methylamino)pyridin-3-yl]-1 ,3-benzothiazol-2-yl}urea (44 mg, 0.098 mmol) and methanesulfonyl chloride (13.4 mg, 0.117 mmol) in pyridine/chloroform (1 :3) was stirred at RT overnight. After completion, the reaction mixture was concentrated under reduced pressure and the crude wa purified by flash chromatography on basic
alumina (MeOH/HCCI3) to give the title compound as a beige solid. HPLC Rt: 3.51 min (purity: 94.8%). LC/MS M+(ESI): 530.0. 1H NMR (DMSOd6, 400MHz) δ 10.93 (1 H, s), 8.84(1 H1S), 8.55 (1 H, s), 8.34 (1 H, s), 8.17 (1 H, s), 7.7-7.77 (2H, m), 6.89 (1 H, s), 3.51-3.54 (2H, m), 3.35 (3H, s), 3.05 (3H, s), 2.89-2.92 (2H, m), 1.36 (9H, s).
Example 250: 4-(5-tert-butyl-1 ,3-oxazol-2-yl)-N-{6-[3-(methylsulfonyl)phenyl]-1 ,3- benzothiazol-2-yl}butanamide
A solution of 6-[3-(methylsulfonyl)phenyl]-1 ,3-benzothiazol-2-amine (0.1 g, 0.328 mmol), 4-(5-tert-butyl-1 ,3-oxazol-2-yl)butanoic acid (0.097 g, 0.39 mmol), HOBt
(0.15g, 0.039mmol), EDCHCI (0.094g, 0.49mmol) and TEA (0.18 ml_, 1.3 mmol in DMF was stirred at RT overnight. Water was added to the reaction mixture and DMF was evaporated under reduced pressure. The residue was extracted with EtOAc (twice). Combined organic phases were washed with 10% NaHCOs, 1.5N HCI and water, dried over magnesium sulfate, filtered and concentrated. The crude was purified by flash chromatography on silica (DCM/MeOH) to give the title compound as an off white solid. HPLC (Atlantis-1 ) Rt: 4.83 min (purity: 91.4%). LC/MS (Atlantis) M+(ESI): 497.9. 1H NMR (DMSO-d6, 400MHz) δ 8.43 (1 H, s), 8.22 (1 H, s), 8.10-8.22 (1 H, d), 7.88-7.9 (1 H, d), 7.88 (1 H, s), 7.73-7.77 (1 H, m), 6.6 (1 H, ), 3.30 (3H, s), 2.74-2.77 (2H, m), 2.59-2.63 (2H, m), 1.99-2.03 (2H, m), 1.22 (9H, s).
Example 251 : 4-(5-tert-butyl-1 ,3-oxazol-2-yl)-N-{6-[5-(methylsulfonyl)pyridin-3- yl]-1 ,3-benzothiazol-2-yl}butanamide
3) but strating from N-(6-bromo-1 ,3-benzothiazol-2-yl)-4-(5-tert-butyl-1 ,3-oxazol-2- yl)butanamide
(20mg, 0.407mmol) and 3-(methylsulfonyl)-5-(4,4,5,5-tetramethyl-1 ,3,2- dioxaborolan-2-yl)pyridine (20mg, 0.071 mmol), The title compound was obtained as a
beige solid. HPLC Rt: 4.05 min (purity: 92.2%). LC/MS M+(ESI): 498.8. 1H NMR (DMSO-de, 400MHz) δ 9.17 (1 H,s), 9.13 (1 H,s), 8.45-8.46 (1 H,m), 8.08 (1 H,s), 7.92- 7.94 (1 H,d), 7.67-7.70 (1 H,m), 6.72 (1 H,s), 3.19 (3H,s), 2.90-2.93 (2H,t), 2,66-2.70 (2H,t), 2.20-2.27 (2H,m), 1.30 (9H,s).
Example 252: 3-(5-tert-butyl-1 ,3-oxazol-2-yl)-N-{6-[5-(methylsulfonyl)pyridin-3- yl]-1 ,3-benzothiazol-2-yl}propanamide
The title compound was prepared following procedure described in example 251 , step 1 and 2, but starting from 3-(5-tert-butyl-1 ,3-oxazol-2-yl)propanoic acid. The title compound was obtained as a grey solid. HPLC, Rt: 4.00 min (purity: 93.0%). LC/MS (Atlantis), M+(ESI): 484.8.
Example 253: N-[2-(5-tert-butyl-1 ,2,4-oxadiazol-3-yl)ethyl]-N'-(6-pyridin-3-yl-1 ,3- benzothiazol-2-yl)urea
A mixture of N-(6-bromo-1 ,3-benzothiazol-2-yl)-N'-[2-(5-tert-butyl-1 ,2,4-oxadiazol-3- yl)ethyl]urea (100 mg, 0.23 mmol), 3-pyridineboronic acid pinacol ester (72 mg, 0.35 mmol), potassium phosphate (150 mg, 0.7 mmol), tris-(dibenzylideneacetone) Palladium(O) (13 mg, 0.014 mmol) and tricyclohexylphosphine (8 mg, 0.028 mmol) in degassed dioxane/water (1 :2, 6 mL) was heated at 1000C overnight under nitrogen. The solvent was removed and the residue dissolved in EtOAc. Organic phase was washed with water and brine solution, dried over sodium sulphate, filtered and concentrated. The crude was purified by flash chromatography on silica (HCCI3:MeOH) to give the title compound as a beige solid. HPLC Rt: 3.03 min
(purity: 98.1 %). LC/MS M+(ESI): 423.2. 1H NMR (DMSO-d6, 400MHz) δ 10.89 (1 H,s), 8.93 (1 H,s), 8.53-8.54 (1 H,d), 8.29 (1 H,s), 8.09-8.1 1 (1 H,d), 7.71 (2H,s), 7.46-7.49 (1 H,m), 6.9 (1 H1S), 3.52-3.54 (2H,m), 2.89-2.93 (1 H,m), 1.36 (9H,s). Examples 254 to 268 were prepared following the same procedure:
Examples 269 to 280 were prepared following one of the above described procedure:
Example 317 : Λ/-{2-r5-(24Hydroxy-1 J ^imethylethvn-I ^Λ-oxadiazol-S-yllethyll- Λf-rδ-fδ-methoxypyridin-S-vπri .Slthiazolorδ^-folpyridin-Σ-yllurea
5-(5-Methoxypyridin-3-yl)[1 ,3]thiazolo[5,4-t)]pyridin-2-amine (1 g; 1.94 mmol), phenyl chloroformate (303 μL; 2.32 mmol), pyridine (3.12 ml_), 2-[3-(2-amino-ethyl)- [1 ,2,4]oxadiazol-5-yl]-2-methyl-propan-1-ol hydrochloride (644 mg; 2.90 mmol) and TEA (0.81 ml_; 5.81 mmol) in DCE (40 ml.) were reacted according to general procedure C except that the reaction mixture was stirred at 1000C for 30 min (microwave heating). Purification by column chromatography (DCIWMeOH, 98/2) afforded the title compound as a yellow solid. HPLC, Rt: 2.12 min (purity: 97.9%). LC/MS, M+(ESI): 470.0. 1H NMR (DMSOd6, 300 MHz) δ 8.91 (s, 1 H), 8.62 (s, 1 H), 7.81-7.94 (m, 3H), 7.60-7.63 (d, J = 6.0 Hz, 1 H), 7.41 (bs, 1 H), 3.50-3.63 (m, 5H), 1.86-1.95 (m, 2H), 1.18 (s, 3H), 1.16 (s, 3H).
Example 318 : Λ/-{2-r5-(lsopropylamino)-1 ,2,4-oxadiazol-3-vnethyl)-Λ/'-r6-(5- methoxypyridin-3-yl)-1 ,3-benzothiazol-2-vπurea
6-(5-Methoxypyridin-3-yl)-1 ,3-benzothiazol-2-amine (1 80 mg; 0.70 mmol), phenyl chloroformate (228 mg; 1.46 mmol), pyridine (1 ml_), 2-(5-fe/f-butyl-1 /-/-imidazol-2-yl)- ethylamine hydrochloride (214 mg; 1.05 mmol) and TEA (0.49 ml_; 3.50 mmol) in DCE (6 ml.) were reacted according to general procedure C. Purification by column chromatography on alumina (increasing amount of MeOH in DCM) followed by crystallization from ACN afforded the title compound as a pale yellow solid. HPLC, Rt:
2.01 min (purity: 95.0%). LC/MS, M+(ESI): 454.0. 1H NMR (DMSOd6, 300 MHz) δ
8.91 (s, 1 H), 8.62 (bs, 1 H), 7.81-7.94 (m, 3H), 7.60-7.63 (d, J = 6.0 Hz, 1 H), 7.41 (br s, 1 H), 3.50-3.63 (m, 5H), 1.86-1.95 (m, 2H), 1.17 (d, J = 6.6 Hz, 6H).
Example 319 : tert-Butyl (2-r(U6-(5-methoxypyridin-3-yl)-1 ,3-benzothiazol-2- yllamino)carbonyl)aminolethyl)carbamate
6-(5-Methoxypyridin-3-yl)-1 ,3-benzothiazol-2-amine (200 mg; 0.78 mmol), phenyl chloroformate (118 μl_; 0.93 mmol), pyridine (0.31 ml_; 3.89 mmol), Λ/-Boc- ethylenediamine (249 mg; 1.55 mmol) and TEA (0.54 ml_; 3.89 mmol) in DCE (6 ml.) were reacted according to general procedure C except that the reaction mixture was stirred at 1000C for 10 min (microwave heating). Purification by column chromatography (DCM/MeOH, 95/5) afforded the title compound as a white solid. HPLC, Rt: 2.59 min (purity: 99.6%). LC/MS, M+(ESI): 444.0. 1H NMR (DMSOd6, 300
MHz) δ 10.85 (brs, 1 H), 8.53 (d, J = 1.8 Hz, 1 H), 8.32 (br s, 1 H), 8.26 (d, J = 2.8 Hz,
1 H), 7.78 - 7.65 (m, 3H), 6.96 - 6.90 (m, 1 H), 6.80 - 6.73 (m, 1 H), 3.92 (s, 3H), 3.08 -
2.88 (m, 4H), 1.38 (s, 9H).
Example 320 : Λ/-{2-r5-(Methoxymethyl)-1 ,2Λ-oxadiazol-3-yllethyl)-Λ/'-r6-(5- methoxypyridin-3-yl)-1 ,3-benzothiazol-2-yllurea
6-(5-Methoxypyridin-3-yl)-1 ,3-benzothiazol-2-amine (450 mg; 1.75 mmol), phenyl chloroformate (0.28 ml_; 1.75 mmol), pyridine (0.56 ml_; 8.75 mmol), 2-[5- (methoxymethyl)-1 ,2,4-oxadiazol-3-yl]ethanamine trifluoroacetic acid salt (550 mg; 2.10 mmol) and TEA (1.21 ml_; 8.75 mmol) in DCE (40 ml_), THF (40 ml.) and DMF
(40 m l.) were reacted according to general procedure C. Purification by column chromatography (DCM/MeOH, 98/2 to 95/5) followed by recrystallization from ACN afforded the title compound as a yellow solid. HPLC, Rt: 2.20 min (purity: 96.8%). LC/MS, M+(ESI): 441.2. 1H NMR (DMSOd6, 300 MHz) δ 10.91 (s, 1 H), 8.52 (d, J = 1.7 Hz, 1 H), 8.13 (s, 1 H), 8.26 (d, J = 2.7 Hz, 1 H), 7.72 (m, 3H), 6.95 (s, 1 H), 4.74 (s,
2H), 3.91 (s, 3H), 3.56 (q, J = 6.3 Hz, 2H), 3.38 (s, 3H), 2.97 (t, J = 6.3 Hz, 2H). Example 321 : Λ/-f2-r5-(2-Fluoro-1 ,1 -dimethylethyl)-1 ,2,4-oxadiazol-3-vnethyl)-Λ/1- r6-(2-methoxypyridin-3-yl)-1 ,3-benzothiazol-2-vπurea
6-(2-Methoxypyridin-3-yl)-1 ,3-benzothiazol-2 -amine (224 mg; 0.87 mmol), phenyl chloroformate (0.14 ml_; 1.04 mmol; 1.20 eq.), pyridine (1 .5 ml_), 2-[5-(2-Fluoro-1 ,1- dimethyl-ethyl)-[1 ,2,4]oxadiazol-3-yl]-ethylamine hydrochloride (292 mg; 1.31 mmol) and TEA (0.37 ml.) in DCE (9 ml.) were reacted according to general procedure C except that the reaction mixture was stirred at 1000C for 10 min (microwave heating).
Purification by column chromatography (DCM then DCIWMeOH, 98/2) afforded the title compound as white foam. HPLC, Rt: 3.90 min (purity: 92.9%). LC/MS, M+(ESI): 471.0. 1H NMR (DMSOd6, 300 MHz) δ 10.88 (s, 1 H), 8.17 (dd, J = 1.8, 5.0 Hz, 1 H), 8.06 (d, J = 1.3 Hz, 1 H), 7.79 (dd, J = 1.9, 7.3 Hz, 1 H), 7.65 (d, J = 8.5 Hz, 1 H), 7.54 (dd, J = 1.8, 8.3 Hz, 1 H), 7.10 (dd, J = 5.0, 7.4 Hz, 1 H), 6.93 (bs, 1 H), 4.58 (d, J =
47.0 Hz, 2H), 3.89 (s, 3H), 3.55 (q, J = 6.7 Hz, 2H), 2.95 (t, J = 6.7 Hz, 2H), 1.39 (d, J = 1.7 Hz, 6H).
Example 322 : Λ/-r6-(5-Methoxypyridin-3-yl)-1 ,3-benzothiazol-2-vn-Λ/'-{2-r5- (trifluoromethyl)-1 ,2,4-oxadiazol-3-vllethyl}urea
6-(5-Methoxypyridin-3-yl)-1 ,3-benzothiazol-2-amine (280 mg; 1.09 mmol), phenyl ch loroformate ( 1 65 μ l_; 1 .31 m mol ), pyrid in e (440 μ l_) 2-(5-trifluoromethyl- [1 ,2,4]oxadiazol-3-yl)-ethylamine hydrochloride (474 mg; 2.18 mmol) and TEA (0.75 ml.) in DCE (7 ml.) were reacted according to general procedure C except that the reaction mixture was stirred at 1000C for 10 min (microwave heating). Purification by column chromatography (DCM to DCM/MeOH, 90/10) afforded the title compound as a white solid. HPLC, Rt: 2.98 min (purity: 97.3%). LC/MS, M+(ESI): 465.0. 1H NMR (DMSOd6, 300 MHz) δ 1 1.00 (s, 1 H), 8.54 (d, J = 1.8 Hz, 1 H), 8.33 (bs, 1 H), 8.27 (d, J = 8.3 Hz, 1 H), 7.78-7.67 (m, 3H), 7.02-6.92 (m, 1 H), 3.92 (s, 3H), 3.62-3.56 (m, 2H), 3.11 (t, J = 3.1 Hz, 2H).
Example 323 : 3-(lsopropoxymethyl)-Λ/-r6-(5-methoxypyridin-3-yl)-1 ,3- benzothiazol-2-yllpiperidine-1 -carboxamide
6-(5-Methoxypyridin-3-yl)-1 ,3-benzothiazol-2-amine (280 mg; 1.09 mmol), phenyl chloroformate (165 μl_; 1.31 mmol), pyridine (440 μl_), 3-(isopropoxymethyl)piperidine hydrochloride (422 mg; 2.18 mmol) and TEA (0.75 ml.) in DCE (7 ml.) were reacted according to general procedure C except that the reaction mixture was stirred at
1000C for 10 min (microwave heating). Purification by column chromatography (DCM to DCM/MeOH, 90/10) followed by recrystallization from ACN afforded the title compound as a pale yellow solid. H PLC, Rt: 3.12 min (purity: 98.3%). LC/MS, M+(ESI): 441.1. 1H NMR (DMSOd6, 300 MHz) δ 1 1.25 (s, 1 H), 8.53 (s, 1 H), 8.27 (d, J = 8.3 Hz, 2H), 7.79-7.64 (m, 3H), 4.29-4.01 (m, 2H), 3.92 (s, 3H), 3.55-3.47 (m, 1 H),
3.29-3.19 (m, 2H), 3.00-2.62 (m, 2H), 1.80-1.58 (m, 2H), 1.49-1.15 (m, 3H), 1.10 (d, J = 1.1 Hz, 6H).
Example 324 : Λ/-(2-{5-ri -(Dimethylamino)-1 -methylethyll-1 ,2,4-oxadiazol-3- yl}ethyl)WNf-r6-(5-methoxypyridin-3-yl)-1 ,343enzothiazol-2-vllurea
6-(5-Methoxypyridin-3-yl)-1 ,3-benzothiazol-2 -amine (350 mg; 1 .36 mmol), phenyl chloroformate (0.22 ml_; 1.36 mmol), pyridine (0.43 ml_; 6.80 mmol), 2-[3-(2- aminoethyl)-1 ,2,4-oxadiazol-5-yl]-Λ/,Λ/-dimethylpropan-2-amine bis trifluroacetic acid salt (700 mg; 1.64 mmol) and TEA (0.94 ml_; 6.80 mmol) in DCE (20 ml_), THF (20 ml.) and DMF (20 ml.) were reacted according to general procedure C except that the
reaction mixture was stirred at 1000C for 10 min (microwave heating). Purification by column chromatography (DCIWMeOH, 98/2 to 95/5) followed by crystallization from n-pentane afforded the title compound as a yellow solid. HPLC, Rt: 7.19 min (purity: 98.0%). LC/MS, M+(ESI): 482.2. 1H NMR (DMSOd6, 300 MHz) δ 10.92 (br s, 1 H), 8.53 (d, J = 1.8 Hz, 1 H), 8.32 (s, 1 H), 8.26 (d, J = 2.7 Hz, 1 H), 7.76 (dd, J = 1.8, 8.4 Hz, 1 H), 7.69 (m, 2H), 6.89 (br s, 1 H), 3.91 (s, 3H), 3.56 (q, J = 6.6 Hz, 2H), 2.95 (t, J = 6.6 Hz, 2H), 2.13 (s, 6H), 1.47 (s, 6H).
Example 325 : Λ/-r6-(5-Methoxypyridin-3-yl)-1 ,3-benzothiazol-2-vn-Λ/'-{2-r5- (tetrahydrofuran-3-yl)-1 ,2,4-oxadiazol-3-yllethyl}urea
6-(5-Methoxypyridin-3-yl)-1 ,3-benzothiazol-2-a m i n e (51 5 m g ; 2 m m ol ) , ph enyl chloroformate (0.25 ml_; 2 mmol), pyridine (0.81 ml_; 10 mmol), 2-[5-(tetrahydrofuran- 3-yl)-1 ,2,4-oxadiazol-3-yl]ethanamine hydrochloride (636 mg; 2.40 mol) and TEA (1.39 ml_; 10 mmol) in DCE (40 ml_), THF (40 ml.) and DMF (40 ml.) were reacted according to general procedure C. Purification by column chromatography
(DCM/MeOH, 98/2) followed by trituration in ACN afforded the title compound as a white solid. HPLC, Rt: 2.24 min (purity: 96.0%). LC/MS, M+(ESI): 467.0. 1H NMR (DMSOd6, 300 MHz) δ 10.92 (bs, 1 H), 8.52 (bs, 1 H), 8.32 (bs, 1 H), 8.26 (d, J = 2.7 Hz, 1 H), 7.75 (dd, J = 1.4, 8.5 Hz, 1 H), 7.69 (m, 2H), 6.93 (bs, 1 H), 4.03 (t, J = 7.6 Hz, 1 H), 3.86 (m, 7H), 3.54 (q, J = 6.5 Hz, 2H), 2.93 (t, J = 6.5 Hz, 2H), 2.42-2.28 (m,
1 H), 2.25-2.1 1 (m, 1 H).
Example 326 : 1 -({r6-(5-Methoxypyridin-3-yl)-1 ,3-benzothiazol-2- yllamino}carbonyl)piperidine-4-carboxylic acid
Following general procedure C starting from phenyl [6-(5-methoxypyridin-3-yl)-1 ,3- benzothiazol-2-yl]carbamate (200 mg; 0.26 mmol) and isonipecotic acid (68 mg; 0.53 mmol) followed by MD Autoprep purification to give the title compound as a beige powder. LC/MS, M+(ESI): 413.0. HPLC, Rt: 2.42 min (purity 92.9%). 1H NMR
(DMSOd6, 300 MHz) δ 12.02 (bs, 1 H), 8.52 (d, J = 1.8 Hz, 1 H), 8.27-8.26 (m, 2H), 7.74 (dd, J = 1.8, 8.4 Hz, 1 H), 7.67-7.66 (m, 1 H), 7.61-7.59 (m, 1 H), 4.18-4.14 (m, 2H), 3.91 (s, 3H), 3.05-2.97 (m, 2H), 2.50 (m, 1 H), 1.88-1.82 (m, 2H), 1.54-1.42 (m, 2H). Example 327 : 3-(lsopropoxymethyl)-Λ/-r6-(5-methoxypyridin-3-yl)-1 ,3- benzothiazol-2-yllpyrrolidine-i -carboxamide
6-(5-Methoxypyridin-3-yl)-1 ,3-benzothiazol-2-amine (280 mg; 1 .09 mmol), phenyl chloroformate (165 μl_; 1.31 mmol), pyridine (439 μl_) 3-(isopropoxymethyl)pyrrolidine hydrochloride (391 mg; 2.18 mmol) and TEA (0.75 ml.) in DCE (7 ml.) were reacted according to general procedure C except that the reaction mixture was stirred at 1000C for 10 min (microwave heating). Two purifications by column chromatography (DCM to DCM/MeOH, 98/2) afforded the title compound as a white solid. HPLC, Rt: 2.75 min (purity: 99.1 %). LC/MS, M+(ESI): 427.1 1H NMR (DMSOd6, 300 MHz) δ 1 1.08 (bs, 1 H), 8.56 (d, J = 1.8 Hz, 1 H), 8.31 (bs, 1 H), 8.27 (d, J = 2.7 Hz, 1 H), 7.73-
7.64 (m, 3H), 3.92 (s, 3H), 3.67-3.36 (m, 5H), 3.32-3.09 (m, 2H), 2.47-2.34 (m, 1 H),
2.07-1.87 (m, 1 H), 1.78-1.57 (m, 1 H), 1.14 (d, J = 6.1 Hz, 6H).
Example 328 : Λ/-r2-(5-tert-Butyl-1 ,2,4-oxadiazol-3-yl)ethyll-Λ/'-r6-(5- methoxypyridin-3-yl)imidazori ,2-folpyridazin-2-yllurea
6-(5-Methoxypyridin-3-yl)imidazo[1 ,2-t)]pyridazin-2-amine (250 mg; 1.04 mmol), phenyl chloroformate (0.16 ml_; 1.24 mmol), pyridine (0.42 ml_), 2-(5-te/f-butyl- [1 ,2,4]oxadiazol-3-yl)-ethylamine hydrochloride (426 mg; 2.07 mmol) and TEA (0.72 ml.) in DCE (7 ml.) were reacted according to general procedure C except that the reaction mixture was stirred at 1000C for 10 min (microwave heating). Purification by
MD Autoprep afforded the title compound (15 mg, 3%) as a white solid. HPLC, Rt: 2.57 min (purity: 95.7%). LC/MS, M+(ESI): 437.2. 1H NMR (DMSOd6, 300 MHz) δ 9.34 (s, 1 H), 8.83 (d, J = 1.7 Hz, 1 H), 8.42 (d, J = 2.8 Hz, 1 H), 8.08 (s, 1 H), 8.03 (d, J = 9.4 Hz, 1 H), 7.97-7.93 (m, 1 H), 7.83 (d, J = 9.4 Hz, 1 H), 6.76-6.67 (m, 1 H), 3.95 (s, 3H), 3.57-3.46 (m, 2H), 2.90 (t, J = 6.8 Hz, 2H), 1.38 (s, 9H).
Example 329: A/-(6-r5-(Methylsulfonyl)pyridin-3-yll-1 ,3-benzothiazol-2-yl)-Λ/1-(2- f5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-vnethyl)urea
Following general procedure C starting from 6-[5-(methylsulfonyl)pyridin-3-yl]-1 ,3- benzothiazol-2-amine (62 mg; 0.20 mmol) and 2-(5-trifluoromethyl-[1 ,2,4]oxadiazol-
3-yl)-ethylamine hydrochloride (50 mg; 0.23 mmol) and purification by MD Autoprep gave the title compound an off-white solid. LC/MS, M-(ESI): 511.1. HPLC, Rt: 3.57 min (purity: 83.4%). 1H NMR (DMSOd6, 300 MHz) δ 1 1.07 (s, 1 H), 9.30-9.28 (m, 1 H),
9.02-9.01 (m, 1 H), 8.60-8.58 (m, 1 H), 8.47 (m, 1 H), 7.89-7.85 (m, 1 H), 7.78-7.75 (m,
1 H), 6.98 (bs, 1 H), 3.62-3.56 (m, 2H), 3.42 (s, 3H), 3.14-3.09 (m, 2H).
Example 330: Λ/-f2-r5-(2-Hydroxy-1 ,1 -dimethylethylH ,2,4-oxadiazol-3-yllethyl)-
Λf-r6-(6-methoxypyridin-3-yl)-1 ,3-benzothiazol-2-vπurea
Following general procedure C starting from 6-(6-methoxypyridin-3-yl)-1 ,3- benzothiazol-2-amine (300 mg; 1.17 mmol) 2-[3-(2-amino-ethyl)-[1 ,2,4]oxadiazol-5- yl]-2-methyl-propan-1-ol hydrochloride (388 mg; 1.75 mmol) and trituration in DCM afforded the title compound as a white solid. LC/MS, M+(ESI): 469.1. HPLC, Rt: 3.44 min (purity: 97.7%). 1H NMR (DMSOd6, 300 MHz) δ 10.87 (bs, 1 H), 8.51 (d, J = 2.3 Hz, 1 H), 8.19 (s, 1 H), 8.05 (dd, J = 8.6, 2.6 Hz, 1 H), 7.69-7.62 (m, 2H), 6.92-6.82 (m, 2H), 5.07 (t, J = 5.7 Hz, 1 H), 3.89 (s, 3H), 3.56-3.50 (m, 4H), 2.94-2.89 (m, 2H), 1.31
(s, 6H).
Example 331 : tert-Butyl {2-r(U5-(5-methoxypyridin-3-yl)H ,31thiazolor5,4- folpyridin-2-yllamino)carbonyl)aminolethyl)carbamate
5-(5-Methoxypyridin-3-yl)[1 ,3]thiazolo[5,4-t)]pyridin-2-amine (1 50 mg; 0.58 mmol), phenyl chloroformate (91 μl_; 0.70 mmol), te/f-butyl Λ/-(2-aminoethyl)carbamate (137 μL; 0.87 mmol) and TEA (0.24 ml_; 1 .74 mmol) in DCE (6 ml.) and pyridine (1 ml.) were reacted according to general procedure C except that the reaction mixture was stirred at 1000C for 15 min (microwave heating). Purification by MD Autoprep afforded the title compound as a beige solid. HPLC, Rt: 2.52 min (purity: 96.5%). LC/MS, M+(ESI): 445.1. 1H NMR (DMSOd6, 300 MHz) δ 1 1.04 (br s, 1 H), 8.86-8.87 (d, J = 3.0 Hz, 1 H), 8.31-8.32 (d, J = 3.0 Hz, 1 H), 8.02-8.1 1 (m, 2H), 7.97-7.98 (m, 1 H), 6.84- 6.95 (m, 2H), 3.92 (s, 3H), 3.14-3.24 (m, 2H), 3.03-3.07 (m, 2H), 1.36 (s, 9H). Example 332 : Λ/-f2-r5-(2-Fluoro-1 ,1 -dimethylethyl)-1 ,2,4-oxadiazol-3-vnethyl)-N'- r6-(5-methoxypyridin-3-yl)imidazori ,2-a1pyridin-2-vπurea
Step 1) Formation of N-(6-bromoimidazo[1 ,2-a]pyridin-2-yl)-N'-{2-[5-(2-fluoro-1 , 1 '- dimethylethyl)-1 , 2, 4-oxadiazol-3-yl]ethyl}urea To a solution of (6-bromo-imidazo[1 ,2-a]pyridin-2-yl)-carbamic acid phenyl ester (400 mg; 1.20 mmol) in DCM (9 ml.) was added TEA (0.83 ml.) then 2-[5-(2-fluoro-1 ,1- dimethyl-ethyl)-[1 ,2,4]oxadiazol-3-yl]-ethylamine hydrochloride (539 mg; 2.41 mmol) and the reaction mixture was stirred at room temperature for 15 h whereupon 2-[5-(2- fluoro-1 ,1-dimethyl-ethyl)-[1 ,2,4]oxadiazol-3-yl]-ethylamine hyd roch loride (54 mg ; 0.24 mmol), TEA (0.6 ml.) and DMF (5 ml.) were added. The reaction mixture was stirred for a further 16 h then diluted with DCM, washed with sat. aq. NH4CI, dried over magnesium sulfate and concentrated in vacuo. Purification by column chromatography (DCM then DCM/MeOH, 98/2) afforded the title compound as a white solid. HPLC, Rt: 2.47 min (purity: 94.2%). 1H NMR (DMSOd6, 300 MHz) δ 9.10 (s, 1 H), 8.84 (dd, J = 0.8, 1.9 Hz, 1 H), 7.79 (s, 1 H), 7.73 (d, J = 9.4 Hz, 1 H), 7.26 (dd,
J = 1.9, 9.4 Hz, 1 H), 6.81-6.69 (m, 1 H), 4.58 (d, J = 4.7 Hz, 2H), 3.54-3.44 (m, 2H), 2.90 (t, J = 6.8 Hz, 2H), 1.39 (d, J = 1.7 Hz, 6H).
Step 2) Formation of N-{2-[5-(2-Fluoro-1 , 1-dimethylethyl)-1 ,2,4-oxadiazol-3-yl]ethyl}- N'-[6-(5-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-2-yl]urea
A mixture of /V-(6-bromoimidazo[1 ,2-a]pyridin-2-yl)-Λ/'-{2-[5-(2-fluoro-1 ,1- dimethylethyl)-1 ,2,4-oxadiazol-3-yl]ethyl}urea (160 mg; 0.38 mmol), 5-methoxy-3- pyridineboronic acid pinacol ester (133 mg; 0.56 mmol), PdCI2(PPh3)2 (26 mg; 0.04 mmol), cesium fluoride (171 mg; 1.13 mmol) in dioxane (10 ml.) and water (3 ml.) was stirred at 800C for 4 h whereupon 5-methoxy-3-pyridineboronic acid pinacol ester (133 mg; 0.56 mmol), PdCI2(PPh3)2 (26 mg; 0.04 mmol) and cesium fluoride (171 mg; 1.13 mmol) were added. The reaction mixture was stirred at 800C for a further 16 h then concentrated in vacuo. The residue was taken up in DCM washed with sat. aq.
NH4CI, dried over magnesium sulfate, filtered through a short plug of Celite® and concentrated in vacuo. Purification by MD Autoprep afforded the title compound as a white solid. HPLC, Rt: 2.1 1 min (purity: 96.9%). LC/MS, M+(ESI): 454.1 . 1H NMR (DMSOd6, 300 MHz) δ 9.10 (s, 1 H), 9.00 (bs, 1 H), 8.52 (d, J = 1.9 Hz, 1 H), 8.30 (d, J = 2.7 Hz, 1 H), 7.80 (s, 1 H), 7.69-7.66 (m, 1 H), 7.62-7.57 (m, 1 H), 7.46 (d, J = 9.3 Hz,
1 H), 6.84-6.75 (m, 1 H), 4.59 (d, J = 4.7 Hz, 2H), 3.92 (s, 3H), 3.57-3.47 (m, 2H), 2.92 (t, J = 6.6 Hz, 2H), 1.39 (d, J = 1.7 Hz, 6H).
Example 333 : Λ/-r2-(5-tert-Butyl-1 ,2,4-oxadiazol-3-yl)ethyll-Λ/'-r6-(5- methoxypyridin-3-yl)imidazori,2-alpyridin-2-vllurea
Step 1) Formation of N-(6-bromoimidazo[1,2-a]pyridin-2-yl)-N'-[2-(5-tert-butyl-1,2,4- oxadiazol-3-yl)ethyl]urea
(6-Bromo-imidazo[1 ,2-a]pyridin-2-yl)-carbamic acid phenyl ester (800 mg; 2.41 mmol), 2-(5-tert-butyl-[1 ,2,4]oxadiazol-3-yl)-ethylamine hydrochloride (991 mg; 4.82 mmol) and TEA (1.67 ml.) in DCM (9 ml.) were reacted according to the procedure describbed for Example 332 step 1. Purification by column chromatography (DCM then DCM/MeOH, 98/2) afforded the title compound as a white solid. HPLC, Rt: 2.73 min (purity: 100%). 1H NMR (DMSOd6, 300 MHz) δ 9.09 (s, 1 H), 8.84 (d, J = 1.1 Hz,
1 H), 7.79 (s, 1 H), 7.33 (d, J = 9.4 Hz, 1 H), 7.26 (dd, J = 1.9, 9.4 Hz, 1 H), 6.80-6.66 (m, 1 H), 3.54-3.43 (m, 2H), 2.87 (t, J = 6.7 Hz, 2H), 1.37 (s, 9H). Step 2) Formation of N-[2-(5-tert-Butyl-1,2,4-oxadiazol-3-yl)ethyl]-N'-[6-(5- methoxypyridin-3-yl)imidazo[1,2-a]pyridin-2-yl]urea Λ/-(6-Bromoimidazo[1 ,2-a]pyridin-2-yl)-/V-[2-(5-te/f-butyl-1 ,2,4-oxadiazol-3- yl)ethyl]urea (160 mg; 0.39 mmol), 5-methoxy-3-pyridineboronic acid pinacol ester (139 mg; 0.59 mmol), PdCI2(PPh3)2 (28 mg; 0.04 mmol) and cesium fluoride (179 mg; 1 .18 mmol) in dioxane (10 mL) and water (3 mL) were reacted according to the procedure describbed for Example 332 step 2. Purification by MD Autoprep afforded the title compound as a white solid. HPLC, Rt: 2.20 min (purity: 93.7%). LC/MS,
M+(ESI): 436.2. 1H NMR (DMSOd6, 300 MHz) δ 9.08 (s, 1 H), 9.00 (bs, 1 H), 8.52 (d, J = 1.9 Hz, 1 H), 8.30 (d, J = 2.7 Hz, 1 H), 7.80 (s, 1 H), 7.69-7.66 (m, 1 H), 7.60 (dd, J = 1.9, 9.3 Hz, 1 H), 7.46 (d, J = 9.3 Hz, 1 H), 6.85-6.73 (m, 1 H), 3.92 (s, 3H), 3.55-3.45 (m, 2H), 2.89 (t, J = 6.8 Hz, 2H), 1.38 (s, 9H). Example 334: Methyl ri -({r6-(5-methoxypyridin-3-yl)-1 ,3-benzothiazol-2- yllamino)carbonyl)piperidin-3-vllacetate
Following general procedure C starting from of phenyl [6-(5-methoxypyridin-3-yl)-1 ,3- benzothiazol-2-yl]carbamate (781 mg; 2.07 mmol) and piperidin-3-yl-acetic acid methyl ester (prepared according to Synlett. 2008, 1 125-1 128, 366 mg; 2.33 mmol) after which compound was purified by MD Autoprep gave the title compound as an off-white powder. LC/MS, M+(ESI): 441.1. HPLC, Rt: 2.66 min (purity: 97.4%). 1H NMR (DMSOd6, 300 MHz) δ 1 1.28 (s, 1 H), 8.54 (m, 1 H), 8.37-8.26 (m, 2H), 7.77- 7.68 (m, 3H), 4.11 (m, 2H), 3.92 (s, 3H), 3.62 (s, 3H), 2.96-2.88 (m, 1 H), 2.72 (m, 1 H), 2.38-2.19 (m, 2H), 1 .87-1 .76 (m, 2H), 1 .69-1 .62 (m, 1 H), 1 .48-1 .34 (m, 1 H),
1 .28-1 .15 (m, 1 H).
Example 335: 3-(5-terf-Butyl-1 ,2,4-oxadiazol-3-yl)-Λ/-f6-r5- (methylsulfonyl)pyridin-3-vn-1 ,3-benzothiazol-2-yl)pyrrolidine-1 -carboxamide
Following general procedure C starting from 6-[5-(methylsulfonyl)pyridin-3-yl]-1 ,3- benzothiazol-2-amine (305 mg; 1 mmol) and 5-te/f-butyl-3-pyrrolidin-3-yl-1 ,2,4- oxadiazole hydrochloride (354 mg; 1.53 mmol) and purification by MD Autoprep gave the title compound as as an off white solid. LC/MS, M+(ESI): 527.1. HPLC, Rt: 4.17 min (purity: 99.3%). 1H NMR (DMSOd6, 300 MHz) δ 1 1.47 (bs, 1 H), 9.29-9.28 (m, 1 H), 9.03-9.02 (m, 1 H), 8.60-8.58 (m, 1 H), 8.45 (m, 1 H), 7.89-7.85 (m, 1 H), 7.75-7.72 (m, 1 H), 3.90 (m, 1 H), 3.78-3.52 (m, 4H), 3.42 (s, 3H), 2.34 (bs, 1 H), 2.16 (bs, 1 H), 1.38 (s, 9H). Example 336 : Λ/-r2-(5-terf-Butyl-1 ,3,4-thiadiazol-2-yl)ethvn-Λ/l-r6-(5- methoxypyridin-3-yl)-1 ,3-benzothiazol-2-vllurea
Step 1) Formation of phenyl [6-(5-methoxypyridin-3-yl)-1,3-benzothiazol-2- yljcarbamate Phenyl chloroformate (1.4 ml_; 1 1.2 mmol) was added to a solution of 6-(5- methoxypyridin-3-yl)-1 ,3-benzothiazol-2-amine (2.4 g; 9.33 mmol) in pyridine (30 ml.) and the resulting mixture was stirred at room temperature for 17 h. DCM was added and the precipitate filtered off. The solid was washed several times with DCM and Et2O to afford the title compound (1.4 g, 40%) as a beige solid. LC/MS, M+(ESI): 378.0.
S t e p 2) F o rm a ti o n o f N-[2-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)ethyl]-N'-[6-(5- methoxypyridin-3-yl)-1 , 3-benzothiazol-2-yl]urea
A mixture of phenyl [6-(5-methoxypyridin-3-yl)-1 ,3-benzothiazol-2-yl]carbamate (150 mg; 0.40 mmol), 2-(5-te/f-butyl-1 ,3,4-thiadiazol-2-yl)ethanamine hydrochloride (110 mg; 0.60 mmol) and TEA (221 μl_; 1.59 mmol) in DCE (6 ml_), was stirred at 1000C for 30 min (microwave heating). The mixture was diluted with DCM, washed successively with sat. aq. NaHCO3, sat. aq. NH4CI and brine, dried over magnesium sulfate and concentrated in vacuo to afford the title compound as a beige solid.
HPLC, Rt: 2.69 min (purity: 97.5%). LC/MS, M-(ESI): 467.3. 1H NMR (DMSOd6, 300 MHz) δ 10.96 (bs, 1 H), 8.60 (s, 1 H), 8.35-8.33 (m, 2H), 7.84-7.83 (m, 1 H), 7.79-7.76
(m, 1 H), 7.71-7.69 (m, 1 H), 7.06 (bs, 1 H), 3.94 (s, 3H), 3.61-3.54 (m, 2H), 3.29-3.25
(m, 2H), 1.39 (s, 9H).
Example 337: Λ/-(2-r5-(2-Fluoro-1 ,1 -dimethylethylH .∑Λ-oxadiazol-S-yllethvD-Λ/1-
(5-pyridin-3-viri ,31thiazolor5,4-fo1pyridin-2-yl)urea
Following protocol C starting from 5-pyridin-3-yl[1 ,3]thiazolo[5,4-fc>]pyridin-2-amine (66 mg; 0.29 mmol) and 2-[5-(2-fluoro-1 ,1-dimethyl-ethyl)-[1 ,2,4]oxadiazol-3-yl]- ethylamine hydrochloride (97 mg; 0.43 mmol) and purification by MD Autoprep gave the title compound as a white solid. LC/MS, M+(ESI): 441.9. HPLC, Rt: 2.29 min
(purity: 98.1 %). 1H NMR (DMSOd6, 300 MHz) δ 1 1.16 (bs, 1 H), 9.28 (m, 1 H), 9.62- 9.60 (m, 1 H), 8.48-8.44 (m, 1 H), 8.09-8.03 (m, 2H), 7.54-7.50 (m, 1 H), 7.02-6.99 (m, 1 H), 4.59 (d, J = 47.1 Hz, 2H), 3.59-3.53 (m, 2H), 2.98-2.93 (m, 2H), 1.39 (d, J = 1.3 Hz, 6H). Example 338: Λ/-r2-(5-tert-butyl-1 ,2,4-oxadiazol-3-yl)ethyll-A/1-r6-r5-(2- methoxyethoxy)pyridin-3-vπ-1 ,3-benzothiazol-2-vl)urea
Following general procedure C starting from 6-[5-(2-methoxyethoxy)pyridin-3-yl]-1 ,3- benzothiazol-2-amine (83.60 mg; 0.28 mmol) and 2-(5-te/f-butyl-[1 ,2,4]oxadiazol-3- yl)-ethylamine hydrochloride (59 mg; 0.28 mmol) and purification by MD Autoprep gave the title compound as a white solid. LC/MS, M+(ESI): 497.1. HPLC, Rt: 3.35 min
(purity: 99.8%). 1H NMR (DMSOd6, 300 MHz) δ 10.92 (s, 1 H), 8.59-8.46 (m, 1 H), 8.39-8.30 (bs, 1 H), 8.30-8.22 (m, 1 H), 7.83-7.65 (m, 3H), 6.98-6.83 (m, 1 H), 4.37- 4.22 (m, 2H), 3.77-3.66 (m, 2H), 3.61-3.48 (m, 2H), 3.33 (s, 3H), 2.99-2.85 (m, 2H), 1.38 (s, 9H). Example 339 : Λ/-r2-(5-lsopropyl-1 ,2,4-oxadiazol-3-yl)ethyll-Λ/'-r6-(5- methoxypyridin-3-yl)-1 ,3-benzothiazol-2-yllurea
A mixture of phenyl [6-(5-methoxypyridin-3-yl)-1 ,3-benzothiazol-2-yl]carbamate (300 mg; 0.79 mmol), 2-(5-isopropyl-1 ,2,4-oxadiazol-3-yl)ethanamine (305 mg; 1.59 mmol) and TEA (0.55 ml.) in DCE (5 ml.) was stirred 5 min at 1400C (microwave heating).
The reaction mixture was diluted with DCM, washed with sat. aq. NH4CI, dried over magnesi u m su lfate a nd con centrated i n vacu o. Pu rification by col u m n chromatography on alumina (increasing amount of MeOH in DCM) afforded the title compound as a beige solid. HPLC, Rt: 3.04 min (purity: 93.8%). LC/MS, M+(ESI): 439.1. 1H NMR (DMSOd6, 300 MHz) δ 10.92 (bs, 1 H), 8.53 (d, J = 1.8 Hz, 1 H), 8.33
(bs, 1 H), 8.27 (d, J = 2.7 Hz, 1 H), 7.78-7.67 (m, 3H), 6.96-6.88 (m, 1 H), 3.92 (s, 3H), 3.59-3.49 (m, 2H), 3.31-3.22 (m, 1 H), 2.94-2.88 (m, 2H), 1.31 (d, J = 6.9 Hz, 6H). Example 340 : Λ/-r2-(5-ethyl-1 ,2,4-oxadiazol-3-yl)ethyllWNf-r6-(5-methoxypyridin- 3-yl)-1 ,3-benzothiazol-2-yllurea
A mixture of phenyl [6-(5-methoxypyridin-3-yl)-1 ,3-benzothiazol-2-yl]carbamate (300 mg; 0.79 mmol), 2-(5-ethyl-1 ,2,4-oxadiazol-3-yl)ethanamine hydrochloride (224 mg; 1.59 mmol) and TEA (0.55 ml.) in DCE (5 ml.) was stirred 5 min at 1400C (microwave heating). The reaction mixture was diluted with DCM, washed with sat. aq. NH4CI, dried over magnesium sulfate and concentrated in vacuo. Purification by column chromatography on alumina (increasing amount of MeOH in DCM) afforded the title compound as a beige solid. HPLC, Rt: 2.78 min (purity: 93.3%). LC/MS, M+(ESI): 425.1. 1H NMR (DMSOd6, 300 MHz) δ 10.90 (bs, 1 H), 8.53 (d, J = 1.8 Hz, 1 H), 8.33 (bs, 1 H), 8.27 (d, J = 2.7 Hz, 1 H), 7.78-7.67 (m, 3H), 6.97-6.88 (m, 1 H), 3.92 (s, 3H), 3.58-3.51 (m, 2H), 2.97-2.89 (m, 4H), 1.28 (t, J = 7.6 Hz, 3H).
Example 341 : Λ/-f2-r5-(1 -Hvdroxyethyl)-1 ,2,4-oxadiazol-3-vnethyl)-Λ/l-r6-(5- methoxypyridin-3-yl)-1 ,3-benzothiazol-2-yllurea
A mixture of 1-[3-(2-aminoethyl)-1 ,2,4-oxadiazol-5-yl]ethanol trifluoroacetic acid salt (380 mg ; 1 .40 m mol) and phenyl-[6-(5-methoxypyridin-3-yl)-1 ,3-benzothiazol-2-
yl]carbamate (870 mg; 1 .40 mmol) in DMF (4 ml.) and THF (1 1 ml.) was stirred at 10O0C for 10 min (microwave heating) then concentrated in vacuo. The residue was taken up in DCM, washed with sat. aq. NH4CI and brine, dried over sodium sulfate and concentrated in vacuo. Purification by column chromatography on alumina (DCM/MeOH from 99/1 to 95/5) afforded the title compound as a white solid. HPLC,
Rt: 2.00 min (purity: 79.5%). LC/MS, M+(ESI): 441.2. 1H NMR (DMSOd6, 300 MHz) δ 8.46 (d, J = 1.8 Hz, 1 H), 8.16 (d, J = 2.7 Hz, 1 H), 7.89 (s, 1 H), 7.74-7.65 (m, 1 H), 7.58 (t, J = 2.2 Hz, 1 H), 7.44 (d, J = 8.7 Hz, 1 H), 7.26 (d, J = 8.7 Hz, 1 H), 4.95 (q, J = 6.6 Hz, 1 H), 4.28-4.16 (s, 1 H), 3.9 (s, 3H), 2.86 (t, J = 7.6 Hz, 2H), 1.47 (d, J = 6.6 Hz, 3H), 6.23 (s, 1 H), 3.42-3.40 (m, 2H).
Example 342 : Λ/-r2-(5-terf-butyl-1 ,2,4-oxadiazol-3-yl)ethvn-Λ/'-r6-(5-cvanopyridin- 3-yl)-1,3-benzothiazol-2-yllurea
Fol lowi ng general proced u re C starti ng from 5-(2-amino-1 ,3-benzothiazol-6- yl)nicotinonitrile (123 mg; 0.49 mmol) and 2-(5-te/f-butyl-[1 ,2,4]oxadiazol-3-yl)- ethylamine hydrochloride (109 mg; 0.53 mmol) and purification by MD Autoprep gave the title compound as a white solid. LC/MS, M+(ESI): 448.1. HPLC, Rt: 3.86 min
(purity: 98.6%). 1H NMR (DMSOd6, 300 MHz) δ 10.99 (s, 1 H), 9.35-9.16 (m, 1 H),
9.05-8.90 (m, 1 H), 8.80-8.61 (m, 1 H), 8.53-8.33 (m, 1 H), 7.94-7.65 (m, 2H), 7.00-6.83 (m, 1 H), 3.66-3.46 (m, 2H), 3.03-2.82 (m, 2H), 1.38 (s, 9H).
Example 343 : Λ/-r2-(5-terf-Butyl-1 ,3,4-thiadiazol-2-yl)ethvn-Λ/'-r5-(5- methoxypyridin-3-yl)ri ,31thiazolor5,4-fo1pyridin-2-vπurea
5-(5-Methoxypyridin-3-yl)[1 ,3]thiazolo[5,4-ιb]pyridin-2-amine (150 mg; 0.58 mmol), pyridine (0.94 ml_), phenyl chloroformate (91 μl_; 0.70 mmol), 2-(5-te/f-butyl-1 ,3,4- thiadiazol-2-yl)ethanamine hydrochloride (161 mg; 0.87 mmol) and TEA (323 μl_; 2.32 mmol) in DCE (6 ml.) were reacted according to general procedure C except that the reaction mixture was stirred at 1000C for 30 min (microwave heating). Purification by several triturations in ACN afforded the title compound as a beige solid. HPLC, Rt: 2.59 min (purity: 91.9%). LC/MS, M+(ESI): 470.1. 1H NMR (DMSOd6, 300 MHz) δ 10.01 (bs, 1 H), 8.78 (s, 1 H), 8.34 (s, 1 H), 7.99-7.97 (d, J = 6.0 Hz, 1 H), 7.92 (s, 1 H), 7.78-7.76 (d, J = 6.0 Hz, 1 H), 3.94 (s, 3H), 3.92 (m, 2H), 3.46-3.42 (t, J = 6.0 Hz, 2H),
1.48 (s, 9H).
Example 344 : Λ/-f2-r5-(2-Hvdroxy-1 ,1 -dimethylethyl)-1 ,2,4-oxadiazol-3-vnethyl)- Λf-r6-(5-methoxypyridin-3-yl)imidazori ,2-fo1pyridazin-2-vπurea
Step 1) Formation of N-(6-cloroimidazo[1 ,2-b]pyridazin-2-yl)-N'-{2-[5-(2-hydroxy-1 , 1- dimethylethyl)-1 , 2, 4-oxadiazol-3-yl]ethyl}urea
A mixture of 6-chloro-imidazo[1 ,2-b]pyridazin-2-ylamine (1 g; 5.93 mmol), phenyl chloroformate (0.90 ml_; 7.12 mmol) and pyridine (2.4 ml.) in DCE (7 ml.) was stirred at 600C for 20 h whereupon 2-[3-(2-amino-ethyl)-[1 ,2,4]oxadiazol-5-yl]-2-methyl- propan-1-ol hydrochloride (2.63 g; 1 1.86 mmol) and TEA (4.1 ml.) were added. The
reaction mixture was stirred at room temperature for a further 16 h then diluted with DCM, washed with sat. aq. NH4CI, dried over magnesium sulfate and concentrated in vacuo. Purification by column chromatography (DCM then DCM/MeOH, 98/2) afforded the title compound as a yellow oil. HPLC, Rt: 2.98 min (purity: 87.3%). LC/MS, M+(ESI): 380.1. 1H NMR (DMSOd6, 300 MHz) δ 9.37 (s, 1 H), 8.03 (s, 1 H),
7.97 (d, J = 9.4 Hz, 1 H), 7.27 (d, J = 9.4 Hz, 1 H), 6.67 (t, J = 5.6 Hz, 1 H), 5.10-5.02 (m, 1 H), 4.15-4.08 (m, 2H), 3.53-3.46 (m, 2H), 2.90-2.86 (m, 2H), 1.35 (s, 6H). Step 2) Formation of N-{2-[5-(2-hdroxy-1, 1-dimethylethyl)-1,2,4-oxadiazol-3-yl]ethyl}- N'-[6-(5-methoxypyridin-3-yl)imidazo[1,2-b]pyridazin-2-yl]urea Λ/-(6-Chloroimidazo[1 ,2-b]pyridazin-2-yl)-/V-{2-[5-(2-hydroxy-1 ,1-dimethylethyl)-1 ,2,4- oxadiazol-3-yl]ethyl}urea (250 mg; 0.66 mmol), 3-methoxypyridine-5-boronic acid pinacol ester (217 mg; 0.92 mmol), cesium fluoride (400 mg; 2.63 mmol), 2- dicyclohexylphosphino-2',4',6'-tri-i-propyl-1 ,1 '-biphenyl (314 mg; 0.66 mmol) and palladium acetate (59 mg; 0.26 mmol) in dioxane (8 ml.) and water (4 ml.) were reacted according to the procedure describbed for Example 332 step 2. Purification by column chromatography (increasing amount of MeOH in DCM) afforded the title compound as a yellow solid. HPLC, Rt: 6.24 min (purity: 92.9%). LC/MS, M+(ESI): 453.1. 1H NMR (DMSOd6, 300 MHz) δ 9.36 (s, 1 H), 8.83 (d, J = 1.7 Hz, 1 H), 8.42 (d, J = 2.8 Hz, 1 H), 8.08 (s, 1 H), 8.04 (d, J = 9.4 Hz, 1 H), 7.96-7.94 (m, 1 H), 7.83 (d, J = 9.4 Hz, 1 H), 6.78-6.69 (m, 1 H), 5.08 (t, J = 5.6 Hz, 1 H), 3.95 (s, 3H), 3.57-3.46 (m,
4H), 2.90 (t, J = 6.6 Hz, 2H), 1.31 (s, 6H).
Example 345 : Λ/-r2-(5-tert-Butyl-1 ,2,4-oxadiazol-3-yl)ethvn-Λ/'-(5-pyridin-3- viri ,31thiazolor5,4-fo1pyridin-2-vl)urea
5-Pyridin-3-yl[1 ,3]thiazolo[5,4-t)]pyridin-2-amine (150 mg; 0.66 mmol), phenyl chloroformate (103 μL; 0.79 mmol), pyridine (1.1 mL), 2-(5-tert-butyl-[1 ,2,4]oxadiazol- 3-yl)-ethylamine hydrochloride (222 mg; 1.31 mmol) and TEA (457 μL; 3.29 mmol) in DCE (5 mL) were reacted according to general procedure C except that the reaction
mixture was stirred at 1000C for 30 min (microwave heating). Purification by MD Autoprep afforded the title compound as an off-white solid. HPLC, Rt: 2.48 min (purity: 99.0%). LC/MS, M+(ESI): 424.3. 1H NMR (DMSOd6, 300 MHz) δ 1 1.10 (s, 1 H), 9.27 (d, J = 3.0 Hz, 1 H), 8.60 (dd, J = 1.6, 4.8 Hz, 1 H), 8.48-8.42 (m, 1 H), 8.10- 8.00 (m, 2H), 7.48-7.53 (m, 1 H), 6.93-6.97 (m, 1 H), 3.50-3.57 (q, J = 6.5 Hz, 2H), 2.89-2.93 (t, J = 6.5 Hz, 2H), 1.36 (s, 9H).
Example 346 : Λ/-r2-(5-tert-Butyl-1 ,3,4-oxadiazol-2-yl)ethyll-Λ/'-r6-(5- methoxypyridin-3-yl)-1 ,3-benzothiazol-2-yllurea
A mixture of phenyl [6-(5-methoxypyridin-3-yl)-1 ,3-benzothiazol-2-yl]carbamate (150 mg; 0.40 mmol), 2-(5-te/f-butyl-1 ,3,4-oxadiazol-2-yl)ethanamine hydrochloride (101 mg; 0.60 mmol) and TEA (277 μl_; 1.99 mmol) in DCE (5 ml.) was stirred at 1000C for 30 min (microwave heating). The reaction mixture was diluted with DCM, washed with sat. aq. NaHCC>3 and sat. aq. NH4CI, dried over magnesium sulfate and concentrated in vacuo. Purification by MD Autoprep afforded the title compound as beige solid.
HPLC, Rt: 2.52 min (purity: 97.9%). LC/MS, M+(ESI): 453.1. 1H NMR (DMSOd6, 300 MHz) δ 10.82 (bs, 1 H), 8.52 (d, J = 1.7 Hz, 1 H), 8.31 (s, 1 H), 8.25 (d, J = 3.0 Hz, 1 H), 7.76-7.67 (m, 3H), 6.99-6.93 (m, 1 H), 3.90 (s, 3H), 3.57-3.53 (m, 2H), 3.03 (t, J = 6.0 Hz, 2H), 1.31 (s, 9H). Example 347 : Λ/-r6-(5-Methoxypyridin-3-yl)-1 ,3-benzothiazol-2-vn-Λ/'-r2-(5- methylisoxazol-3-yl)ethvnurea
Following general procedure C starting from phenyl [6-(5-methoxypyridin-3-yl)-1 ,3- benzothiazol-2-yl]carbamate (300 mg; 0.40 mmol) and 2-(5-methylisoxazol-3- yl)ethanamine (120 μl_) afforded the title compound as a beige powder. LC/MS, M+(ESI): 410.10. HPLC, Rt: 2.40 min (purity: 99.2%). 1H NMR ((DMSOd6, 300 MHz) δ 10.79 (bs, 1 H), 8.53 (s, 1 H), 8.32 (s, 1 H), 8.27-8.26 (m, 1 H), 7.76-7.67 (m, 3H), 6.92-6.88 (m, 1 H), 6.19 (s, 1 H), 3.91 (s, 3H), 3.50-3.44 (m, 2H), 2.82-2.78 (m, 2H), 2.37 (s, 3H).
Example 348 : Λ/-r6-(5-methoxypyridin-3-yl)-1 ,3-benzothiazol-2-vn-Λ/'-f2-r5-(3,3,3- trifluoro-1 -methylpropylH ,2,4-oxadiazol-3-yllethyl)urea
Following general procedure C starting from phenyl [6-(5-methoxypyridin-3-yl)-1 ,3- benzothiazol-2-yl]carbamate (170 mg; 0.45 mmol) and 2-[5-(3,3,3-trifluoro-1- methylpropyl)-1 ,2,4-oxadiazol-3-yl]ethanamine hydrochloride (130 mg; 0.50 mmol) gave the title compound as a yellow powder. LC/MS, M+(ESI): 507.4. HPLC, Rt: 3.04 min (purity: 97.8%). 1H NMR (DMSOd6, 300 MHz) δ 10.93 (bs, 1 H), 8.53 (s, 1 H), 8.32 (s, 1 H), 8.27-8.26 (m, 1 H), 7.77-7.67 (m, 3H), 6.93-6.90 (m, 1 H), 3.92 (s, 3H), 3.59-3.53 (m, 3H), 2.97-2.93 (m, 2H), 2.89-2.76 (m, 2H), 1.40 (d, J = 7 Hz, 3H). Example 349 : Λ/-{2-r5-(3,3-Dffluorocvclobutyl)-1 ,2Λ-oxadiazol-3-yllethyl)-Λ/'-r6- (5-methoxypyridin-3-yl)-1 ,3-benzothiazol-2-yllurea
Following general procedure C starting from phenyl [6-(5-methoxypyridin-3-yl)-1 ,3- benzothiazol-2-yl]carbamate (172.6 mg; 0.46 mmol) and 2-[5-(3,3-difluorocyclobutyl)- 1 ,2,4-oxadiazol-3-yl]ethanamine hydrochloride (121 mg; 0.50 mmol) gave a pale brown product that was purified by MD Autoprep. The residue was triturated in hot
ACN and filtered to give the title compound as an off-white solid. LC/MS, M+(ESI): 487.4. HPLC, Rt: 2.79 min (purity: 99.0%). 1H NMR (DMSOd6, 300 MHz) δ 10.92 (bs, 1 H), 8.53 (d, J = 1.6 Hz, 1 H), 8.32 (s, 1 H), 8.26 (d, J = 2.7 Hz, 1 H), 7.77-7.67 (m, 3H), 6.94-6.91 (m, 1 H), 3.92 (s, 3H), 3.83-3.77 (m, 1 H), 3.58-3.52 (m, 2H), 3.20-2.93 (m, 6H).
Example 350 : Λ/-r6-(5-Methoxypyridin-3-yl)-1 ,3-benzothiazol-2-vn-Λ/'-f2-r5-(2,2,2- trifluoro-1 ,1 -dimethylethylH ,2,4-oxadiazol-3-vllethyl)urea
Following general procedure C starting from phenyl [6-(5-methoxypyridin-3-yl)-1 ,3- benzothiazol-2-yl]carbamate (169.4 mg; 0.45 mmol) and 2-[5-(2,2,2-trifluoro-1 ,1- dimethylethyl)-1 ,2,4-oxadiazol-3-yl]ethanamine hydrochloride (129.1 mg; 0.50 mmol) gave a pale brown product that was purified by to give the title compound as a white powder. LC/MS, M+(ESI): 507.4. HPLC, Rt: 3.67 min (purity: 98.0%). 1H NMR (DMSO-de, 300 MHz) δ 10.96 (bs, 1 H), 8.53 (m, 1 H), 8.33 (m, 1 H), 8.30-8.22 (m, 1 H),
7.81-7.64 (m, 3H), 7.04-6.89 (m, 1H), 3.92 (s, 3H), 3.64-6.5 (m, 2H), 3.08-2.94 (m,
2H), 1.65 (s, 6H).
Example 351 : Λ/-f2-r5-(1-Fluoro-1-methylethyl)-1,2,4-oxadiazol-3-vnethyl)-Λ/'-r6-
(5-methoxypyridin-3-yl)-1,3-benzothiazol-2-yllurea
A mixture of phenyl [6-(5-methoxypyridin-3-yl)-1,3-benzothiazol-2-yl]carbamate (150 mg; 0.40 mmol), 2-[5-(1-fluoro-1-methylethyl)-1,2,4-oxadiazol-3-yl]ethanamine hydrochloride (125 mg; 0.60 mmol) and TEA (277 μl_; 1.99 mmol) in DCE (5 ml.) was stirred at 1000C for 30 min (microwave heating). The reaction mixture was diluted with DCM, washed with sat. aq. NaHCO3 and sat. aq. NH4CI, dried over magnesium sulfate and concentrated in vacuo. Purification by MD Autoprep afforded the title compound as a beige solid. HPLC, Rt: 2.64 min (purity: 99.1%). LC/MS, M+(ESI): 457.3.1H NMR (DMSOd6, 300 MHz) δ 10.91 (bs, 1H), 8.51 (s, 1H), 8.31 (s, 1H), 8.25 (s, 1H), 7.75-7.66 (m, 3H), 6.95 (bs, 1H), 3.90 (s, 3H), 3.56-3.54 (m, 2H), 2.96 (t, J = 6.0 Hz, 2H), 1.80 (d, J = 22.0 Hz, 6H).
Example 352 : Λ/-f2-r5-(1-Fluoroethyl)-1, 2,4-oxadiazol-3-yllethyl)-Λ/'-r6-(5- methoxypyridin-3-yl)-1,3-benzothiazol-2-yllurea
A mixture of phenyl [6-(5-methoxypyridin-3-yl)-1,3-benzothiazol-2-yl]carbamate (150 mg; 0.40 mmol), 2-[5-(1-fluoroethyl)-1,2,4-oxadiazol-3-yl]ethanamine hydrochloride
(1 17 mg; 0.60 mmol) and TEA (277 μl_; 1 .99 mmol) in DCE (5 ml.) ) was stirred at 10O0C for 30 min (microwave heating). The reaction mixture was diluted with DCM, washed with sat. aq. NaHCO3 and sat. aq. NH4CI, dried over magnesium sulfate and concentrated in vacuo. Purification by MD Autoprep afforded the title compound as a white solid. HPLC, Rt: 2.43 min (purity: 99.1 %). LC/MS, M+(ESI): 443.1. 1H NMR
(DMSOd6, 300 MHz) δ 10.88 (bs, 1 H), 8.51 (d, J = 3.0 Hz, 1 H), 8.30 (d, J = 3.0 Hz, 1 H), 8.25 (d, J = 2.7 Hz, 1 H), 7.65-7.76 (m, 3H), 6.96 (bs, 1 H), 6.08 (dq, J = 6.7, 46.6 Hz, 1 H), 3.90 (s, 3H), 3.58-3.52 (m, 2H), 2.99 (t, J = 6.7 Hz, 2H), 1.72 (dd, J = 6.6, 24.8 Hz, 3H). Example 353 : Λ/-r2-(5-tert-Butyl-1 ,2,4-oxadiazol-3-yl)ethyll-Λ/'-r6-(5- methoxypyridin-3-yl)f1 ,2,41triazolof1 ,5-alpyridin-2-yllurea
6-(5-Methoxypyridin-3-yl)[1 ,2,4]triazolo[1 ,5-a]pyridin-2-amine (235 mg; 0.97 mmol), phenyl chloroformate (153 μl_; 1.17 mmol), pyridine (1.6 ml_), 2-(5-te/f-butyl- [1 ,2,4]oxadiazol-3-yl)-ethylamine hydrochloride (330 mg; 1.95 mmol) and TEA (678 μl_; 4.87 mmol) in DCE (5 ml.) were reacted according to general procedure C except that the reaction mixture was stirred at 1000C for 30 min (microwave heating). Purification by MD Autoprep followed by trituration in DCM afforded the title compound as a white solid. HPLC, Rt: 2.42 min (purity: 98.9%). LC/MS, M+(ESI): 437.4. 1H NMR (DMSOd6, 300 MHz) δ 10.12 (bs, 1 H), 9.39 (bs, 1 H), 8.72 (bs, 1 H),
8.46 (bs, 1 H), 8.35 (bs, 1 H), 8.13 (d, J = 9.3 Hz, 1 H), 8.05 (bs, 1 H), 7.74 (d, J = 9.2 Hz, 1 H), 3.97 (s, 3H), 3.64-3.53 (m, 2H), 2.93 (t, J = 6.5 Hz, 2H), 1.34 (s, 9H). Example 354 : Λ/-r6-(5-Ethoxypyridin-3-yl)imidazori ,2-alpyridin-2-yll-Λ/'-r2-(2- isopropyl-2H-tetrazol-5-vl)ethvllurea
Step 1) Formation of N-(6-bromoimidazo[1,2-a]pyridin-2-yl)-N'-[2-(2-isopropyl-2H- tetrazol-5-yl)ethyl]urea
A mixture of (6-bromo-imidazo[1 ,2-a]pyridin-2-yl)-carbamic acid phenyl ester (250 mg; 0.75 mmol), 2-(2-isopropyl-2/-/-tetrazol-5-yl)ethanamine (304 mg; 1.13 mmol) and
DIEA (0.24 ml_; 1.88 mmol) in NMP (5 mL) was stirred at 75°C for 16 h. The reaction mixture was concentrated in vacuo. The residue was taken up in DCM, washed with sat. aq . NaH CO3, dried over magnesium sulfate and concentrated in vacuo. Purification by column chromatography (increasing amount of MeOH in DCM) afforded the title compound as an orange powder. HPLC, Rt: 2.66 min (purity:
90.2%). LC/MS, M+(ESI): 393.0. 1H NMR (DMSO-d6, 300 MHz) δ 9.07 (s, 1 H), 8.84- 8.82 (m, 1 H), 7.79 (s, 1 H), 7.32 (d, J = 9.5 Hz, 1 H), 7.25 (dd, J = 1.9, 9.5 Hz, 1 H), 6.73 (bs, 1 H), 5.07 (hept, J = 6.7 Hz, 1 H), 3.52 (q, J = 6.3 Hz, 2H), 3.03 (t, J = 6.7 Hz, 2H), 1.54 (d, J = 6.7 Hz, 6H). Step 2) Formation of N-[6-(5-ethoxypyridin-3-yl)imidazo[1,2-a]pyridin-2-yl]-N'-[2-(2- isopropyl-2H-tetrazol-5-yl)ethyl]urea
A mixture of /V-(6-bromoimidazo[1 ,2-a]pyridin-2-yl)-/V-[2-(2-isopropyl-2/-/-tetrazol-5- yl)ethyl]urea (150 mg; 0.38 mmol), (5-ethoxypyridin-3-yl)boronic acid (95 mg; 0.57 mmol), PdCl2(PPh3)2 (27 mg; 0.04 mmol) and cesium fluoride (174 mg; 1.14 mmol) in dioxane (4 mL) and water (0.50 mL) was stirred 800C for 2 h. The reaction mixture was filtered through a short plug of Celite® which was further rinsed with ethyl acetate. After concentration in vacuo, the residue was taken up in EtOAc, washed with sat. aq. NaHCO3, dried over magnesium sulfate and concentrated in vacuo. Purification by column chromatography (DCM/MeOH, 97/3) afforded the title compound as a pale orange solid. HPLC, Rt: 2.48 min (purity: 97.2%). LC/MS,
M+(ESI): 436.2. 1H NMR (DMSO-d6, 300 MHz) δ 9.10 (s, 1 H), 8.97 (s, 1 H), 8.51 (s, 1 H), 8.28 (s, 1 H), 7.79 (s, 1 H), 7.66 (s, 1 H), 7.58 (d, J = 7.5 Hz, 1 H), 7.45 (d, J = 7.5 Hz, 1 H), 6.90-6.75 (m, 1 H), 5.08 (m, 1 H), 4.21 (q, J = 8.0 Hz, 2H), 3.57 (t, J = 7.5 Hz,
2H), 3.03 (t, J = 7.5 Hz, 2H), 1.55 (d, J = 7.5 Hz, 6H), 1.37 (t, J = 8.0 Hz, 3H). m.p. =
195°C (decomposition).
Example 355 : Λ/-r2-(2-lsopropyl-2H-tetrazol-5-yl)ethvn-Λ/1-f6-r5-
(trifluoromethyl)pyridin-3-yllimidazori ,2-alpyridin-2-yl)urea
A mixture of /V-(6-bromoimidazo[1 ,2-a]pyridin-2-yl)-Λ/'-[2-(2-isopropyl-2/-/-tetrazol-5- yl)ethyl]urea (215 mg; 0.55 mmol), [5-(trifluoromethyl)pyridin-3-yl]boronic acid (157 mg; 0.82 mmol), PdCI2(PPh3)2 (38 mg; 0.05 mmol) and cesium fluoride (249 mg; 1.64 mmol) in dioxane (4 rtiL) and water (0.50 rtiL) was stirred at 800C for 2 h. The reaction mixture was filtered through a short plug of Celite® which was further rinsed with ethyl acetate. After concentration in vacuo, the residue was taken up in ethyl acetate, washed with sat. aq. NaHCO3 dried over magnesium sulfate and concentrated in vacuo. Purification by column chromatography (DCIWMeOH, 98/2) afforded the title compound as a pale orange solid. HPLC, Rt: 2.73 min (purity: 97.8%). LC/MS, M+(ESI): 460.2. 1H NMR (DMSO-d6, 300 MHz) δ 9.12-9.1 1 (m, 2H),
8.98-8.95 (m, 1 H), 9.32-9.28 (m, 1 H), 8.53-8.52 (m, 1 H), 7.81 (s, 1 H), 7.71-7.68 (m, 1 H), 7.52-7.49 (m, 1 H), 6.78-6.75 (m, 1 H), 5.08 (hept, J = 6.7 Hz, 1 H), 3.55 (q, J = 6.7 Hz, 2H), 3.04 (t, J = 6.9 Hz, 2H), 1.55 (d, J = 6.7 Hz, 6H). m.p. = 195°C (decomposition). Example 356: Λ/-r2-(5-lsobutyl-1 ,2,4-oxadiazol-3-yl)ethyll-Λ/'-r6-(5- methoxypyridin-3-yl)-1 ,3-benzothiazol-2-vllurea
Following general procedure C starting from phenyl [6-(5-methoxypyridin-3-yl)-1 ,3- benzothiazol-2-yl]carbamate (67.50 mg; 0.18 mmol) and 2-(5-isobutyl- [1 ,2,4]oxadiazol-3-yl)-ethylamine hydrochloride (42.60 mg; 0.21 mmol) gave an orange product that was purified by MD Autoprep. The residue was recrystalised from
ACN to give the title compound as a white solid. LC/MS, M+(ESI): 453.2. HPLC, Rt: 2.92 min (purity: 100%). 1H NMR (DMSOd6, 300 MHz) δ 10.90 (bs, 1 H), 8.56-8.51 (m, 1 H), 8.37-8.30 (m, 1 H), 8.23 (m, 1 H), 7.80-7.65 (m, 3H), 6.97-6.85 (m, 1 H), 3.92 (s, 3H), 3.62-3.48 (m, 2H), 2.99-2.88 (m, 2H), 2.81 (d, J = 7.1 Hz, 2H), 2.11 (m, 1 H), 0.95 (d, J = 6.7 Hz, 6H).
Example 357 : Λ/-r6-(5-Ethoxypyridin-3-yl)-1 ,3-benzothiazol-2-vn-Λ/'-r2-(2- isopropyl-2H-tetrazol-5-vl)ethvllurea
6-(5-Ethoxypyridin-3-yl)-1 ,3-benzothiazol-2 -amine (350 mg; 0.91 mmol), pyridine (5.75 ml_), 2-(2-isopropyl-2/-/-tetrazol-5-yl)ethanamine (493 mg; 3.18 mmol) and DIEA
(0.63 ml_; 4.54 mmol) in DCE (5 ml.) were reacted according to general procedure C except that the reaction mixture was stirrred at 1000C for 1 h. Purification by column chromatography (DCM/MeOH, 98/2) followed by crystallization from DCM/Et2O afforded the title compound as a white solid. HPLC, Rt: 2.71 min (purity: 98.0%). LC/MS, M+(ESI): 453.2. 1H NMR (DMSOd6, 300 MHz) δ
10.50-9.90 (m, 1 H), 8.51 (s, 1 H), 8.32 (s, 1 H), 7.95 (s, 1 H), 7.81 (d, J = 8.5 Hz, 1 H),
7.62 (d, J = 8.5 Hz, 1 H), 7.42 (s, 1 H), 7.28 (s, 1 H), 5.05 (hept, J = 6.5 Hz, 1 H), 4.19
(q, J = 6.9 Hz, 2H), 3.93 (q, J = 6.2 Hz, 2H), 3.29 (t, J = 6.3 Hz, 2H), 1.64 (d, J = 6.7
Hz, 6H), 1.51 (t, J = 6.9 Hz, 3H). m.p. = 2000C (decomposition).
Example 358 : Λ/-r2-(2-lsopropyl-2H-tetrazol-5-yl)ethvn-Λ/1-f6-r5-
(trifluoromethyl)pyridin-3-vπ-1 ,3-benzothiazol-2-yl)urea
6-[5-(Trifluoromethyl)pyridin-3-yl]-1 ,3-benzothiazol-2-amine (280 mg; 0.84 mmol), pyridine (5.34 ml_), phenyl chloroformate ((0.12 ml_; 0.93 mmol), 2-(2-isopropyl-2/-/- tetrazol-5-yl)ethanamine (458 mg; 2.95 mmol) and DIEA (0.58 ml_; 4.22 mmol) in
DCE (5 ml.) were reacted according to general procedure C. Purification by column chromatography (DCIWMeOH, 95/5) afforded the title compound as a white solid. HPLC, Rt: 4.40 min (purity: 99.5%). LC/MS, M+(ESI): 477.2. 1H NMR (DMSOd6, 300 MHz) δ 1 1.01 (bs, 1 H), 9.29 (bs, 1 H), 8.96 (bs, 1 H), 8.52 (bs, 1 H), 8.46 (bs, 1 H), 7.88 (d, J = 8.0 Hz, 1 H), 7.73 (d, J = 8.0 Hz, 1 H), 6.98 (bs, 1 H), 5.10 (hept, J = 6.7 Hz,
1 H), 3.59 (q, J = 6.6 Hz, 2H), 3.09 (t, J = 6.8 Hz, 2H), 1.56 (d, J = 6.8 Hz, 6H). m.p. = 2050C (decomposition).
Example 359 : Λ/-(5-Pyridin-3-viri ,31thiazolor5,4-b1Pyridin-2-yl)-Λ/1-f2-r5-(2,2,2- trifluoro-1 ,1 -dimethylethvD-1 ,2,4-oxadiazol-3-vllethyl)urea
Following general protocol C starting from phenyl (5-pyridin-3-yl[1 ,3]thiazolo[5,4- jb]pyridin-2-yl)carbamate (200 mg; 0.57 mmol) and 2-[5-(2,2,2-trifluoro-1 ,1- dimethylethyl)-1 ,2,4-oxadiazol-3-yl]ethanamine hydrochloride (297 mg; 1.14 mmol) and silica gel column chromatography (DCIWMeOH 98/2 to 80/20). Compound was triturated in a hot mixture of DCM and PE to give the title compound as a white solid.
LC/MS, M+(ESI): 478.2. HPLC, Rt: 3.32 min (purity: 98.3%). 1H NMR (DMSOd6, 300 MHz) δ 11.13 (s, 1 H), 9.32-9.24 (m, 1 H), 8.65-8.58 (m, 1 H), 8.51-8.42 (m, 1 H), 8.08 (m, 2H), 7.52 (m, 1 H), 6.96 (m, 1 H), 3.57 (m, 2H), 3.01 (m, 2H), 1.65 (s, 6H). Example 360 : Λ/-(5-Pyridin-3-viri ,31thiazolor5,4-b1Pyridin-2-yl)-Λ/1-f2-r5-(3,3,3- trifluoro-1 -methylpropylH ,2,4-oxadiazol-3-yllethyl)urea
Following general procedure C starting from phenyl (5-pyridin-3-yl[1 ,3]thiazolo[5,4- jb]pyridin-2-yl)carbamate (203.5 mg; 0.58 mmol) and 2-[5-(3,3,3-trifluoro-1- methylpropyl)-1 ,2,4-oxadiazol-3-yl]ethanamine (306 mg; 1.18 mmol) and purification by silica gel column chromatography (DCM/MeOH 98/2 to 80/20) gave the title compound as a white powder. LC/MS, M+(ESI): 478.2. HPLC, Rt: 3.15 min (purity: 95.3%). 1H NMR (DMSOd6, 300 MHz) δ 1 1.12 (bs, 1 H), 9.31-9.24 (m, 1 H), 8.67-8.58 (m, 1 H), 8.51-8.42 (m, 1 H), 8.14-8.01 (m, 2H), 7.58-7.47 (m, 1 H), 7.02-6.87 (m, 1 H), 3.64-3.48 (m, 3H), 3.02-2.66 (m, 4H), 1.41 (d, J = 7.0 Hz, 3H).
Example 361 : Λ/-f2-r5-(1 -Fluoroethyl)-1 ,2,4-oxadiazol-3-vnethyl)-Λ/'-(5-pyridin-3- viri ,31thiazolor5,4-folpyridin-2-vl)urea
Following general procedure C starting from phenyl (5-pyridin-3-yl[1 ,3]thiazolo[5,4- b]pyridin-2-yl)carbamate (101.80 mg; 0.29 mmol) and 2-[5-(1-fluoroethyl)-1 ,2,4- oxadiazol-3-yl]ethanamine hydrochloride (115 mg; 0.59 mmol) and purification by silica gel column chromatography (DCIWMeOH 98/2 to 80/20) gave the title compound as an off-white solid. LC/MS, M+(ESI): 478.2. HPLC, Rt: 2.56 min (purity: 95.6%). 1H (DMSOd6, 300 MHz) δ 1 1.10 (bs, 1 H), 9.32-9.25 (m, 1 H), 8.66-8.59 (m, 1 H), 8.51-8.43 (m, 1 H), 8.14-8.02 (m, 2H), 7.58-7.47 (m, 1 H), 7.04-6.90 (m, 1 H), 6.10 (dq, J = 6.4, 46.4 Hz, 1 H), 3.65-3.50 (m, 2H), 3.08-2.96 (m, 2H), 1.74 (dd, J = 6.7, 24.7, Hz, 3H).
Example 362 : Λ/-r2-(5-sec-Butyl-1 , 2,4-oxadiazol-3-yl)ethyll-Λ/'-r6-(5- methoxypyridin-3-yl)-1 ,3-benzothiazol-2-yllurea
Following general procedure C starting from phenyl (5-pyridin-3-yl[1 ,3]thiazolo[5,4- jb]pyridin-2-yl)carbamate (102 mg; 0.29 mmol) and 2-[5-(1 -fluoroethyl)-1 ,2,4- oxadiazol-3-yl]ethanamine hydrochloride (1 15 mg; 0.59 mmol) followed by purification by MD Autoprep. Residue was solubilised in ACN and slowly evaporated under vacuum to give the title compound as brown crystals. LC/MS, M+(ESI): 453.2. HPLC, Rt: 3.32 min (purity: 99.6%). 1H NMR (DMSOd6, 300 MHz) δ 10.90 (bs, 1 H), 8.53 (d, J = 1.7 Hz, 1 H), 8.32 (d, J = 1.3 Hz, 1 H), 8.26 (d, J = 2.6 Hz, 1 H), 7.75 (dd, J = 1.7,
8.5 Hz, 1 H), 7.72 (bs, 1 H), 7.68-7.66 (m, 1 H), 6.92-6.88 (m, 1 H), 3.91 (s, 3H), 3.54 (q,
J = 6.4 Hz, 2H), 3.15-3.09 (sext, J = 6.9 Hz, 1 H), 2.92 (t, J = 6.7 Hz, 1 H), 1.79-1.61
(m, 2H), 1.28 (d, J = 7.0 Hz, 3H), 0.85 (t, J = 7.4 Hz, 3H).
Example 363 : 2,2-Dimethyl-Λ/-r2-(fr(5-pyridin-3-viπ ,31thiazolor5,4-b1Pyridin-2- yl)aminolcarbonyl)amino)ethyllpropanamide
Following general procedure C starting from phenyl (5-pyridin-3-yl[1 ,3]thiazolo[5,4- t»]pyridin-2-yl)carbamate (104 mg; 0.30 mmol) and Λ/-(2-aminoethyl)-2,2- dimethylpropanamide (108 mg; 0.60 mmol) and purification by MD Autoprep gave the title compound as a white solid. LC/MS, M+(ESI): 399.2. HPLC, Rt: 2.35 min (purity:
99.8%). 1H NMR (DMSOd6, 300 MHz) δ 1 1.1 1 (bs, 1 H), 9.33-9.25 (m, 1 H), 8.66-8.58 (m, 1 H), 8.46 (m, 1 H), 8.13-8.01 (m, 2H), 7.59 (m, 1 H), 7.56-7.49 (m, 1 H), 6.78 (m, 1 H), 3.34-3.1 1 (m, 4H), 1.09 (s, 9H). Example 364 : Λ/-(2-{5-r2-(Dimethylamino)-1 ,1 -dimethylethvn-1 ,2,4-oxadiazol-3-
A mixture of phenyl [6-(5-methoxypyridin-3-yl)-1 ,3-benzothiazol-2-yl]carbamate (200 mg; 0.53 m m ol ) a n d {2-[3-(2-amino-ethyl)-[1 ,2,4]oxadiazol-5-yl]-2-methyl-propyl}- dimethyl-amine bis hydrochloride (227 mg; 0.79 mmol) and TEA (369 μl_; 2.65 mmol) in DCE (5 ml.) was stirred at 1000C for 30 min (microwave heating). The reaction
mixture was filtered and the solution diluted with DCM, washed with sat. aq. NaHCO3 and sat. aq. NH4CI, dried over magnesium sulfate and concentrated in vacuo. Purification by MD Autoprep afforded the title compound as a beige solid. HPLC, Rt: 1.88 min (purity: 97.9%). LC/MS, M+(ESI): 496.5. 1H NMR (DMSOd6, 300 MHz) δ 10.94 (bs, 1 H), 8.51 (d, J = 3.0 Hz, 1 H), 8.30 (d, J = 3.0 Hz, 1 H), 8.25 (d, J = 3.0 Hz, 1 H), 7.76-7.66 (m, 3H), 6.92 (bs, 1 H), 3.91 (s, 3H), 3.56-3.50 (m, 2H), 2.92 (t, J = 6.8 Hz, 2H), 2.66 (bs, 2H), 2.12 (bs, 6H), 1.34 (s, 6H).
Example 365 : Λ/-r2-(5-terf-Butyl-1 ,2,4-oxadiazol-3-yl)ethvn-Λ/'-r6-(5-morpholin-4- ylpyridin-3-yl)-1 ,3-penzothiazol-2-yl1urea
6-(5-Morpholin-4-ylpyridin-3-yl)-1 ,3-benzothiazol-2-a m i n e (273 m g ; 0.87 m mol ), pyridine (2 ml_), 2-(5-te/f-butyl-[1 ,2,4]oxadiazol-3-yl)-ethylamine hydrochloride (216 mg; 1.05 mmol), phenyl chloroformate (151 mg; 0.96 mmol) and TEA (1 ml.) in DCE (4 ml.) were reacted according to general procedure C except that the reaction mixture was stirred at 1000C for 10 min. Purification by column chromatography (from
CHCI3 to CHCI3/MeOH, 98/2) followed by trituration in n-pentane afforded the title compound (91 mg, 76%) as a white solid. HPLC, Rt: 2.89 min (purity: 99.6%). LC/MS, M+(ESI): 508.3. 1H NMR (DMSOd6, 300 MHz) δ 10.91 (s, 1 H), 8.37 (d, J = 1 .7 Hz, 1 H), 8.31-8.26 (m, 2H), 7.77-7.64 (m, 2H), 7.60-7.57 (m, 1 H), 6.98-6.88 (m, 1 H), 3.81-3.74 (m, 4H), 3.60-3.50 (m, 2H), 3.31-3.23 (m, 4H), 2.92 (t, J = 6.6 Hz, 2H), 1.38
(s, 9H).
Example 366 : Λ/-r2-(5-terf-Butyl-1 ,2,4-oxadiazol-3-yl)ethvn-Λ/l-f6-r3- (hvdroxymethyl)phenyll-1 ,3-benzothiazol-2-yl}urea
Step 1) Formation of N-(6-bromo-1 ,3-benzothiazol-2-yl)-N'-[2-(5-tert-butyl-1 ,2,4- oxadiazol-3-yl)ethyl]urea
2-Amino-6-bromobenzothiazole (10 g; 43.65 mmol), phenyl chloroformate (6.6 ml_; 52.38 mmol), TEA (31 ml.) and 2-(5-te/f-butyl-1 ,2,4-oxadiazol-3-yl)ethanamine hydrochloride (13.5 g; 65.5 mmol) in pyridine (150 ml.) were reacted according to general procedure C. After concentration in vacuo, the residue was taken up in DCM and washed successively with 0.1 M HCI (3x), water, 0.1 M NaOH(3x) and brine. The organic phase was let at 4°C for 16 h, the precipitate filtered off and washed with DCM to afford the title compound (13.1 g) as a white solid. Concentration of the mother liquor afforded a second crop of the title compound (1.9 g, overall yield 80%) as a white solid. 1H NMR (DMSOd6, 300 MHz) δ 10.94 (bs, 1 H), 8.15 (d, J = 1.8 Hz, 1 H), 7.55 (d, J = 8.6 Hz, 1 H), 7.49 (dd, J = 1.9, 8.6 Hz, 1 H), 6.90 (bs, 1 H), 3.53 (q, J = 6.7 Hz, 2H), 2.91 (t, J = 6.7 Hz, 2H), 1.37 (s, 9H). Step 2) Formation of N-[2-(5-tert-Butyl-1,2,4-oxadiazol-3-yl)ethyl]-N'-{6-[3-
(hydroxymethyl)phenyl]-1,3-benzothiazol-2-yl}urea
A mixture of /V-(6-bromo-1 ,3-benzothiazol-2-yl)-/V-[2-(5-te/f-butyl-1 ,2,4-oxadiazol-3- yl)ethyl]urea (100 mg; 0.24 mmol), 3-(hydroxymethyl)phenylboronic acid (107 mg; 0.71 mmol), PdC^dppf (31 mg; 0.04 mmol) and cesium fluoride (143 mg; 0.94 mmol) in dioxane (1 .2 ml.) and water (0.4 ml.) was stirred at 900C for 2 h. The reaction mixture was concentrated in vacuo, the residue triturated in water and filtered. The solid was purified by MD Autoprep to afford the title compound as a beige solid. HPLC, Rt: 3.69 min (purity: 99.2%). LC/MS, M+(ESI): 452.4. 1H NMR (DMSOd6, 300 MHz) δ 10.91 (bs, 1 H), 8.18 (bs, 1 H), 7.69-7.62 (m, 3H), 7.56 (d, J = 7.9 Hz, 1 H), 7.40 (t, J = 7.6 Hz, 1 H), 7.27 (d, J = 7.5 Hz, 1 H), 6.93 (bs, 1 H), 5.24 (t, J = 5.8 Hz, 1 H),
4.56 (d, J = 5.7 Hz, 2H), 3.53 (q, J = 6.1 Hz, 2H), 2.91 (t, J = 6.7 Hz, 2H), 1.36 (s, 9H).
Example 367 : Λ/-r2-(5-terf-Butyl-1 ,2,4-oxadiazol-3-yl)ethvn-Λ/l-f6-r5- (hvdroxymethyl)pyridin-3-vπ-1 ,3-benzothiazol-2-yl)urea
S t e p 1 ) F o r m a t i o n o f ( 5-{2-[({[2-(5-tert-butyl-1,2,4-oxadiazol-3- yl)ethyl]amino}carbonyl)amino]-1,3-benzothiazol-6-yl}pyridin-3-yl)methyl pivalate
[5-(2-Amino-1 ,3-benzothiazol-6-yl)pyridin-3-yl]methyl pivalate (260 mg; 0.76 mmol), pyridine (307 μl_), phenyl chloroformate (115 μl_; 0.91 mmol), 2-(5-te/f-butyl-1 ,2,4- oxadiazol-3-yl)ethanamine hydrochloride (235 mg; 1.14 mmol) and TEA (0.53 ml.) in DCE (7 ml.) were reacted according to general procedure C except that the reaction mixture was stirred at 1000C for 15 min. Purification by column chromatography
(increasing amount of ethyl acetate in heptane) afforded the title compound as a white solid. HPLC, Rt: 4.13 min (purity: 99.2%). LC/MS, M+(ESI): 537.3. 1H NMR (DMSOd6, 300 MHz) δ 10.93 (bs, 1 H), 8.91 (d, J = 2.2 Hz, 1 H), 8.56 (d, J = 1.9 Hz, 1 H), 8.31 (s, 1 H), 8.10 (t, J = 2.1 Hz, 1 H), 7.73 (s, 2H), 6.97-6.86 (m, 1 H), 5.21 (s, 2H), 3.57-3.49 (m, 2H), 2.93 (t, J = 6.7 Hz, 2H), 1.38 (s, 9H), 1.17 (s, 9H).
Step 2) Formation of N-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)ethyl]-N'-{6-[5- (hydroxymethyl)pyridin-3-yl]- 1, 3-benzothiazol-2-yl}urea
A mixture of (5-{2-[({[2-(5-te/f-butyl-1 ,2,4-oxadiazol-3-yl)ethyl]amino}carbonyl)amino]- 1 ,3-benzothiazol-6-yl}pyridin-3-yl)methyl pivalate (100 mg; 0.19 mmol) and 1 M NaOH (655 μl_, 0.74 mmol) in dioxane (3 ml.) was stirred at room temperature for 20 h. The reaction mixture was diluted with water, neutralized with 1 M HCI extracted with DCM, dried over magnesium sulfate and concentrated in vacuo. The residue was taken up in a mixture of DCM, dioxane and MeOH and filtered through a SPE-NH2 column to afford the title compound as a white solid. HPLC, Rt: 2.50 min (purity: 98.9%). LC/MS, M+(ESI): 453.2. 1H NMR (DMSO-d6, 300 MHz) δ 10.95 (s, 1 H), 8.82 (d, J =
2.3 Hz, 1 H), 8.50 (d, J = 1. 9 Hz, 1 H), 8.29 (s, 1 H), 8.03 (s, 1 H), 7.71 (bs, 2H), 6.98- 6.88 (m, 1 H), 5.40 (t, J = 5.7 Hz, 1 H), 4.62 (d, J = 5.6 Hz, 2H), 3.60-3.50 (m, 2H), 2.93 (t, J = 6.8 Hz, 2H), 1.37 (s, 9H).
Example 368 : Λ/-r2-(5-tert-Butyl-1 , 2,4-oxadiazol-3-yl)ethyll-A/l-r6-(1 H-indazol-5- yl)-1 ,3-benzothiazol-2-yllurea
6-(1 /-/-lndazol-5-yl)-1 ,3-benzothiazol-2-amine (130 mg; 0.49 mmol), phenyl chloroformate (74 μl_; 0.59 mmol), 2-(5-fe/f-butyl-1 ,2,4-oxadiazol-3-yl)ethanamine
(151 mg; 0.73 mmol) and TEA (0.34 ml.) in pyridine (2 ml.) were reacted according to general procedure C except that the reaction mixture was stirred at 1000C for 25 min
(microwave heating). Purification by MD Autoprep afforded the title compound as an off-white solid. HPLC, Rt: 3.68 min (purity: 94.0%). LC/MS, M+(ESI): 461.9. 1H NMR (DMSOd6, 300 MHz) δ 13.13 (bs, 1 H), 10.93 (bs, 1 H), 8.21 (bs, 1 H), 8.12 (bs, 1 H),
8.05 (bs, 1 H), 7.74-7.55 (m, 4H), 7.05-6.94 (m, 1 H), 3.60-3.49 (m, 2H), 2.93 (t, J = 6.7
Hz, 2H), 1.38 (s, 9H).
Example 369 : Λ/-r2-(5-terf-Butyl-1 ,2,4-oxadiazol-3-yl)ethvn-Λ/l-f6-r6- (hvdroxymethyl)pyridin-3-vπ-1 ,3-benzothiazol-2-vl)urea
A mixture of /V-(6-bromo-1 ,3-benzothiazol-2-yl)-/V-[2-(5-te/f-butyl-1 ,2,4-oxadiazol-3- yl)ethyl]urea (200 mg; 0.47 mmol), 6-(hydroxymethyl)pyridine-3-boronic acid (216 mg;
1.41 mmol), PdCI2dppf (62 mg; 0.08 mmol) and cesium fluoride (286 mg; 1.89 mmol) in dioxane (2.4 ml.) and water (0.8 ml.) was stirred at 900C for 5 h then concentrated in vacuo. The residue was triturated in water and filtered. The solid was purified by
MD Autoprep to afford the title compound as a grey solid. HPLC, Rt: 2.47 min (purity: 99.5%). LC/MS, M+(ESI): 453.2. 1H NMR (DMSOd6, 300 MHz) δ 10.94 (bs, 1 H), 8.81 (d, J = 3.0 Hz, 1 H), 8.26 (s, 1 H), 8.12-8.09 (m, 1 H), 7.68 (s, 2H), 7.52 (d, J = 9.0 Hz, 1 H), 6.98 (bs, 1 H), 5.44 (t, J = 6.0 Hz, 1 H), 4.59 (d, J = 6.0 Hz, 2H), 3.54-3.52 (m, 2H), 2.90 (t, J = 6.0 Hz, 2H), 1.36 (s, 9H).
Example 370 : Λ/-r2-(5-tert-Butyl-1 , 2,4-oxadiazol-3-yl)ethvπ-Λ/l-r6-(1 H-indazol-4- yl)-1 ,3-benzothiazol-2-yllurea
6-(1 /-/-lndazol-4-yl)-1 ,3-benzothiazol-2-amine (161 mg; 0.60 mmol), phenyl chloroformate (92 μl_; 0.73 mmol), 2-(5-te/f-butyl-[1 ,2,4]oxadiazol-3-yl)-ethylamine hydrochloride (224 mg; 1.09 mmol) and TEA (0.42 ml.) in pyridine (3.7 ml.) were reacted according to general procedure C. Purification by MD Autoprep afforded the title compound as a white solid. HPLC, Rt: 3.88 min (purity: 91.8%). LC/MS, M+(ESI): 462.2. 1H NMR (DMSOd6, 300 MHz) δ 13.24 (s, 1 H), 1 1.09 (bs, 1 H), 8.25 (d, J = 7.9 Hz, 2H), 7.74 (s, 2H), 7.54 (d, J = 8.3 Hz, 1 H), 7.46-7.41 (m, 1 H), 7.27 (d, J = 6.4 Hz,
1 H), 7.19-7.10 (m, 1 H), 3.61-3.49 (m, 2H), 2.93 (t, J = 6.7 Hz, 2H), 1.37 (s, 9H). Example 371 : Λ/-r2-(5-tert-Butyl-1 , 2,4-oxadiazol-3-yl)ethyll-A/1-r6-(3H- imidazor4,5-folpyridin-6-yl)-1,3-benzothiazol-2-yllurea
6-(3H-lmidazo[4,5-jb]pyridin-6-yl)-1 ,3-benzothiazol-2-amine (800 mg; 2.99 mmol), phenyl chloroformate (0.45 ml_; 3.59 mmol), 2-(5-te/f-butyl-[1 ,2,4]oxadiazol-3-yl)- ethylamine hydrochloride (1.1 g; 5.39 mmol) and TEA (2.1 ml.) in pyridine (4.83 ml.) were reacted according to general procedure C. The reaction mixture was concentrated in vacuo, the residue triturated in water and filtered. The solid was purified by MD Autoprep to afford the title compound as a yellow solid. HPLC, Rt: 2.64 min (purity: 92.1 %). LC/MS, M+(ESI): 463.1. 1H NMR (DMSOd6, 300 MHz) δ 10.89 (bs, 1 H), 8.74 (d, J = 2.1 Hz, 1 H), 8.57 (s, 1 H), 8.31 (bs, 2H), 7.74-7.68 (m, 2H), 6.96-6.87 (m, 1 H), 3.60-3.49 (m, 2H), 2.93 (t, J = 6.8 Hz, 2H), 1.38 (s, 9H). Example 372 : Λ/-r2-(5-terf-Butyl-1 ,2,4-oxadiazol-3-yl)ethvn-Λ/l-f6-r5-
(methoxymethyl)pyridin-3-yll-1 ,3-benzothiazol-2-yl}urea
6-[5-(Methoxymethyl)pyridin-3-yl]-1 ,3-benzothiazol-2-amine (300 mg; 1.11 mmol), phenyl chloroformate (168 μl_; 1.33 mmol), 2-(5-te/f-butyl-[1 ,2,4]oxadiazol-3-yl)- ethylamine hydrochloride (409 mg; 1.99 mmol) and TEA (753 μl_) in pyridine (1.78 ml.) were reacted according to general procedure C. Purification by MD Autoprep afforded the title compound as a white solid. HPLC, Rt: 2.84 min (purity: 99.8%). LC/MS, M+(ESI): 467.2. 1H NMR (DMSOd6, 300 MHz) δ 10.92 (bs, 1 H), 8.88 (d, J = 2.3 Hz, 1 H), 8.51 (d, J = 1.9 Hz, 1 H), 8.32 (bs, 1 H), 8.05 (t, J = 2.1 Hz, 1 H), 7.76-7.69 (m, 2H), 6.86-6.69 (m, 1 H), 4.54 (s, 2H), 3.60-3.50 (m, 2H), 3.36 (s, 3H), 2.93 (t, J =
6.7 Hz, 2H), 1.38 (s, 9H).
Example 373 : Λ/-r2-(5-tert-Butyl-1 , 2,4-oxadiazol-3-yl)ethvπ-Λ/l-r6-(1 -methyl-1 H- imidazol-5-yl)-1,3-benzothiazol-2-yllurea
6-(1 -Methyl-1 /-/-imidazol-5-yl)-1 ,3-benzothiazol-2 -amine (150 mg; 0.65 mmol), phenyl chloroformate (99 μl_; 0.78 mmol), 2-(5-te/f-butyl-[1 ,2,4]oxadiazol-3-yl)-ethylamine hydrochloride (241 mg; 1.17 mmol) and TEA (444 μl_) in pyridine (1.1 ml.) were reacted according to general procedure C. Purification by MD Autoprep afforded the title compound as a white solid. HPLC, Rt: 2.57 min (purity: 100%). LC/MS, M+(ESI): 426.1. 1H NMR (DMSOd6, 300 MHz) δ 10.90 (bs, 1 H), 8.03 (bs, 1 H), 7.70 (bs, 1 H), 7.66 (d, J = 8.5 Hz, 1 H), 7.46 (dd, J = 1.8, 8.4 Hz, 1 H), 7.05 (d, J = 1.1 Hz, 1 H), 6.92- 6.87 (m, 1 H), 3.70 (s, 3H), 3.59-3.48 (m, 2H), 2.92 (t, J = 6.7 Hz, 2H), 1.38 (s, 9H). Example 374 : Λ/-r6-(5-Methoxypyridin-3-yl)-1 ,3-benzothiazol-2-yll-4-(2- oxopyrrolidin-1 -yl)piperidine-1 -carboxamide
A mixture of phenyl [6-(5-methoxypyridin-3-yl)-1 ,3-benzothiazol-2-yl]carbamate (150 mg; 0.40 mmol), 2-pyrrolidinone)piperidine hydrochloride (122 mg; 0.60 mmol) and TEA (165 μl_; 1.2 mmol) in pyridine (5 ml.) was stirred at room temperature for 16 h.
The reaction mixture was diluted with DCM, washed with sat. aq. NH4CI, dried over magnesium and concentrated in vacuo. Purification by MD Autoprep afforded the title compound as a white solid. HPLC, Rt: 2.13 min (purity: 99.8%). LC/MS, M+(ESI): 452.1. 1H NMR (DMSOd6, 300 MHz) δ 1 1.34 (bs, 1 H), 8.53 (bs, 1 H), 8.27 (d, J = 2.7 Hz, 2H), 7.82-7.63 (m, 3H), 4.46-4.25 (m, 2H), 4.05-3.95 (m, 1 H), 3.92 (s, 3H), 3.32-
3.24 (m, 2H), 3.04-2.81 (m, 2H), 2.22 (t, J = 8.0 Hz, 2H), 1.96-1.83 (m, 2H), 1.66-1.48 (m, 4H).
Example 375 : A/-f6-(5-Methoxypyridin-3-yl)-1 ,3-benzothiazol-2-vn-4-morpholin- 4-ylpiperidine-1 -carboxamide
A mixture of phenyl [6-(5-methoxypyridin-3-yl)-1 ,3-benzothiazol-2-yl]carbamate (150 mg; 0.40 mmol), 4-(piperidin-4-yl)-morpholine (101 mg; 0.60 mmol) and TEA (165 μl_; 1.2 mmol) in pyridine (5 ml.) was stirred at room temperature for 16 h. The reaction mixture was diluted with DCM, washed with sat. aq. NH4CI, dried over magnesium sulfate and concentrated in vacuo. Purification by MD Autoprep afforded the title compound as a white solid. HPLC, Rt: 1.57 min (purity: 98.6%). LC/MS, M+(ESI): 454.1. 1H NMR (DMSOd6, 300 MHz) δ 1 1.50 (bs, 1 H), 8.53 (d, J = 1.8 Hz, 1 H), 8.27 (d, J = 2.7 Hz, 2H), 7.79-7.53 (m, 3H), 4.38-4.12 (m, 2H), 3.92 (s, 3H), 3.65-3.45 (m, 4H), 2.99-2.76 (m, 3H), 2.48-2.26 (m, 4H), 1.88-1.73 (m, 2H), 1.43-1.17 (m, 2H). Example 376 : Λ/-r2-(5-terf-Butyl-1 ,2,4-oxadiazol-3-yl)ethvn-Λ/'-r6-(2-methyl-3H- imidazor4,5-folpyridin-6-yl)-1,3-benzothiazol-2-yllurea
6-(2-Methyl-3H-imidazo[4,5-jb]pyridin-6-yl)-1 ,3-benzothiazol-2-amine (200 mg; 0.71 mmol), phenyl chloroformate (0.22 ml_; 1.7 mmol), 2-(5-te/f-butyl-[1 ,2,4]oxadiazol-3- yl)-ethylamine hydrochloride (263 mg; 1.28 mmol) and TEA (0.48 ml.) in pyridine
(1 .15 ml.) were reacted according to general procedure C. Purification by MD Autoprep afforded the title compound as a white solid. HPLC, Rt: 3.13 min (purity: 86.3%). LC/MS, M+(ESI): 477.2. 1H NMR (DMSOd6, 300 MHz) δ 12.74 (bs, 1 H), 10.86 (bs, 1 H), 8.59 (bs, 1 H), 8.27 (bs, 1 H), 8.12 (bs, 1 H), 7.75-7.66 (m, 2H), 6.91 (bs, 1 H), 3.55 (q, J = 6.5 Hz, 2H), 2.92 (t, J = 6.5 Hz, 2H), 2.54 (s, 3H), 1.38 (s, 9H). Example 377 : 4-(Dimethylamino)-Λ/-r6-(5-methoxypyridin-3-yl)-1 ,3-benzothiazol- 2-yl1piperidine-1 -carboxamide
A mixture of phenyl [6-(5-methoxypyridin-3-yl)-1 ,3-benzothiazol-2-yl]carbamate (150 mg; 0.40 mmol), 4-(dimethylamino)piperidine (76 mg; 0.60 mmol) and TEA (165 μl_;
1.19 mmol) in pyridine (5 ml.) was stirred at room temperature for 16 h. The reaction mixture was diluted with DCM, washed with sat. aq. NH4CI, dried over magnesium and concentrated in vacuo. Purification by MD Autoprep afforded the title compound as a white solid. HPLC, Rt: 1.96 min (purity: 98.4%). LC/MS, M+(ESI): 412.1. 1H NMR (DMSOd6, 300 MHz) δ 1 1.50 (bs, 1 H), 8.53 (d, J = 1.8 Hz, 1 H), 8.27 (d, J = 2.7 Hz,
2H), 7.77-7.61 (m, 3H), 4.29-4.20 (m, 2H), 3.92 (s, 3H), 2.88 (t, J = 12.1 Hz, 2H), 2.42-2.28 (m, 1 H), 2.20 (s, 6H), 1.86-1.72 (m, 2H), 1.40-1.21 (m, 2H). Example 378 : Λ/-f2-r5-(2-Fluoro-1 ,1 -dimethylethyl)-1 ,2,4-oxadiazol-3-vnethyl)-Λ/1- {6-f5-(methoxymethyl)pyridin-3-vn-1 ,3-benzothiazol-2-vl)urea
6-[5-(Methoxymethyl)pyridin-3-yl]-1 ,3-benzothiazol-2-amine (270 mg; 1 mmol), phenyl chloroformate (151 μl_; 1.19 mmol), 2-[5-(2-fluoro-1 ,1-dimethyl-ethyl)-[1 ,2,4]oxadiazol- 3-yl]-ethylamine hydrochloride (401 mg; 1.79 mmol) and TEA (678 μl_) in pyridine (1.6 ml.) were reacted according to general procedure C. Purification by MD Autoprep afforded the title compound as a white solid. HPLC, Rt: 2.71 min (purity: 95.9%).
LC/MS, M+(ESI): 485.1. 1H NMR (DMSOd6, 300 MHz) δ 10.93 (bs, 1 H), 8.88 (d, J = 2.3 Hz, 1 H), 8.51 (d, J = 1.9 Hz, 1 H), 8.31 (bs, 1 H), 8.05 (t, J = 2.1 Hz, 1 H), 7.76-7.69 (m, 2H), 6.99-6.89 (m, 1 H), 4.67 (s, 1 H), 4.58 (d, J = 47.1 Hz, 2H), 4.54 (s, 2H), 3.59 3.52 (m, 2H), 3.36 (s, 3H), 2.95 (t, J = 6.7 Hz, 2H), 1.39 (d, J = 1.7 Hz, 6H). Example 379 : Λ/-f2-r5-(2-Hvdroxy-1 ,1 -dimethylethyl)-1 ,2,4-oxadiazol-3-vnethyl)-
Λf-{6-r5-(methoxymethyl)pyridin-3-yll-1 ,343enzothiazol-2-vl}urea
6-[5-(Methoxymethyl)pyridin-3-yl]-1 ,3-benzothiazol-2-amine (174 mg; 0.64 mmol), phenyl chloroformate (97 μl_; 0.77 mmol), 2-[3-(2-amino-ethyl)-[1 ,2,4]oxadiazol-5-yl]- 2-methyl-propan-1-ol hydrochloride (256 mg; 1.15 mmol) and TEA (434 μl_) in pyridine (1.04 ml.) were reacted according to general procedure C. Purification by MD Autoprep afforded the title compound as a yellow oil. HPLC, Rt: 2.21 min (purity: 89.5%). LC/MS, M+(ESI): 483.1. 1H NMR (DMSOd6, 300 MHz) δ 10.88 (bs, 1 H), 8.87 (d, J = 2.3 Hz, 1 H), 8.51 (d, J = 1.9 Hz, 1 H), 8.30 (bs, 1 H), 8.05 (t, J = 2.1 Hz, 1 H), 7.75-7.68 (m, 1 H), 7.41-6.93 (m, 3H), 5.14-5.01 (m, 1 H), 4.54 (s, 2H), 3.57-3.51
(m, 3H), 3.36 (s, 3H), 2.95-2.85 (m, 2H), 1.49 (s, 6H).
Example 380 : Λ/-r2-(5-terf-Butyl-1 ,2,4-oxadiazol-3-yl)ethvn-Λ/'-r6-(1 ,3-dimethyl- 1 H-pyrazol-4-yl)-1 ,3-benzothiazol-2-yllurea
Following general procedure B starting from (/V-(6-bromo-1 ,3-benzothiazol-2-yl)-/V-[2- (5-te/f-butyl-1 ,2,4-oxadiazol-3-yl)ethyl]urea (305.10 mg; 0.72 mmol) and 1 ,3-dimethyl- 1 /-/-pyrazole-4-boronic acid pinacol ester and purification by MD Autoprep gave the title compound as a orange powder. LC/MS, M-(ESI): 438.2. HPLC, Rt: 3.45 min
(purity: 98.7%). 1H NMR (DMSOd6, 300 MHz) δ 10.83 (bs, 1 H), 8-7.74 (m, 2H), 7.74- 7.49 (m, 1 H), 7.49-7.27 (m, 1 H), 7.032-6.77 (m, 1 H), 3.79 (s, 3H), 3.64-3.46 (m, 2H), 3.01-2.83 (m, 2H), 2.31 (s, 3H), 1.37 (s, 9H).
Example 381 : Λ/-r2-(5-terf-Butyl-1 ,2,4-oxadiazol-3-yl)ethvn-Λ/l-f6-r5- (methylthio)pyridin-3-vπ-1 ,3-benzothiazol-2-yl)urea
6-[5-(Methylthio)pyridin-3-yl]-1 ,3-benzothiazol-2-amine (1.50 g; 4.84 mmol), phenyl chloroformate (0.73 ml_; 5.81 mmol), 2-(5-te/f-butyl-[1 ,2,4]oxadiazol-3-yl)-ethylamine hydrochloride (1.29 g; 6.29 mmol) and TEA (1.47 g; 14.52 mmol) in pyridine (40 ml.) were reacted according to gen eral proced u re C . Pu rifi cation by col u m n chromatography on alumina (DCM then DCM/MeOH, 98/2) followed by crystallization from ethyl acetate afforded the title compound as a white solid. HPLC, Rt: 3.06 min (purity: 99.4%). LC/MS, M+(ESI): 468.8. 1H NMR (DMSOd6, 300 MHz) δ 10.93 (bs, 1 H), 8.69 (d, J = 2.1 Hz, 1 H), 8.44 (d, J = 2.2 Hz, 1 H), 8.33 (bs, 1 H), 7.97 (t, J = 2.1
Hz, 1 H), 7.76 (dd, J = 1.8, 8.4 Hz, 1 H), 7.69 (d, J = 8.5 Hz, 1 H), 6.93 (bs, 1 H), 3.54
(q, J = 6.6 Hz, 2H), 2.92 (t, J = 6.5 Hz, 2H), 2.61 (s, 3H), 1.37 (s, 9H).
Example 382 : Λ/-r2-(5-terf-Butyl-1 ,2,4-oxadiazol-3-yl)ethvn-Λ/l-f6-r5-
(methylsulfinyl)pyridin-3-yll-1,3-benzothiazol-2-yl)urea
6-[5-(Methylsulfinyl)pyridin-3-yl]-1 ,3-benzothiazol-2-a m i n e (485 m g ; 1 .68 mmol), phenyl chloroformate (289 mg; 1.84 mmol), 2-(5-te/f-butyl-[1 ,2,4]oxadiazol-3-yl)- ethylamine hydrochloride (414 mg; 2.01 mmol) and TEA (509 mg; 5.03 mmol) in pyridine (17 ml.) were reacted according to general procedure C. Purification by column chromatography (DCM to DCIWMeOH, 95/5) followed by recrystallization from iPrOH/iPr2O afforded the title compound as a white solid. HPLC, Rt: 2.25 min (purity: 98.9%). LC/MS, M+(ESI): 485.1. 1H NMR (DMSOd6, 300 MHz) δ 10.99 (bs, 1 H), 9.10 (bs, 1 H), 8.81 (d, J = 1.9 Hz, 1 H), 8.43-8.36 (m, 2H), 7.82 (dd, J = 1.7, 8.6 Hz, 1 H), 7.73 (d, J = 8.5 Hz, 1 H), 6.94 (bs, 1 H), 3.54 (q, J = 6.5 Hz, 2H), 2.98-2.87 (m, 5H), 1.37 (s, 9H).
Example 383 : Λ/-r2-(5-terf-Butyl-1 ,2,4-oxadiazol-3-yl)ethvn-Λ/-methyl-Λ/'-f6-r5- (methylsulfonyl)pyridin-3-vπ-1 ,3-benzothiazol-2-yl)urea
6-(5-Methanesulfonyl-pyridin-3-yl)-benzothiazol-2-ylam ine (300 mg ; 0.98 m mol), phenyl chloroformate (0.15 ml_; 1.18 mmol), 2-(5-te/f-butyl-[1 ,2,4]oxadiazol-3-yl)-
ethylamine hydrochloride (281 mg; 1 .28 mmol) and TEA (298 mg; 2.95 mmol) in pyridine (10 mL) were reacted according to general procedure C. Purification by recrystallization from ACN afforded the title compound as an off-white solid. HPLC, Rt: 3.50 min (purity: 94.0%). LC/MS, M+(ESI): 514.9. 1H NMR (DMSOd6, 300 MHz) δ 1 1.34 (bs, 1 H), 9.28 (bs, 1 H), 9.02 (bs, 1 H), 8.59 (bs, 1 H), 8.40 (bs, 1 H), 7.86 (d, J = 8.5 Hz, 1 H), 7.68 (bs, 1 H), 3.77 (bs, 2H), 3.42 (s, 3H), 3.08-2.90 (m, 5H), 1.32 (s, 9H).
Example 384 : Λ/-r2-(5-terf-Butyl-1 ,3,4-oxadiazol-2-yl)ethvn-Λ/'-(6-pyridin-3-yl-1 ,3- benzothiazol-2-yl)urea
Following general procedure C starting from 6-pyridin-3-yl-1 ,3-benzothiazol-2-amine (100 mg; 0.44 mmol) and 2-(5-te/f-butyl-1 ,3,4-oxadiazol-2-yl)ethanamine (102 mg; 0.49 mmol) and purification by MD Autoprep to give the title compound as a white solid. LC/MS, M+(ESI): 423.1. HPLC, Rt: 2.16 min (Purity 98.9%). 1H NMR (DMSO- d6, 300 MHz) δ 10.95 (bs, 1 H), 8.94 (d, J = 1.8 Hz, 1 H), 8.55 (dd, J = 1.5, 4.7 Hz, 1 H),
8.30 (bs, 1 H), 8.15-8.1 1 (m, 2H), 7.75-7.69 (m, 2H), 1.52-1 Al (m, 1 H), 7.00-6.96 (m, 1 H), 3.58 (q, J = 6.1 Hz, 2H), 3.05 (t, J = 6.4 Hz, 2H), 1.33 (s, 9H). Example 385 : Λ/-U5-(2-mf2-r5-(2-Fluoro-1 J<^imethylethyl)-1 ,2,4-oxadiazol-3- yllethyl}amino)carbonyllamino}-1 ,34^enzothiazol-6-yl)pyridin-3- yllmethvDacetamide
Λ/-{[5-(2-Amino-1 !3-benzothiazol-6-yl)pyridin-3-yl]methyl}acetamide (200 mg; 0.67 mmol), phenyl chloroformate (0.10 ml_; 0.80 mmol), 2-[5-(2-fluoro-1 ,1-dimethyl-ethyl)- [1 ,2,4]oxadiazol-3-yl]-ethylamine hydrochloride (225 mg; 1.01 mmol) and triethylamine (456 μl_) in pyridine (1.1 ml.) were reacted according to general procedure C. Purification by MD Autoprep afforded the title compound as a white solid. HPLC, Rt: 2.78 min (purity: 94.5%). LC/MS, M+(ESI): 512.1. 1H NMR (DMSO- d6, 300 MHz) δ 10.94 (bs, 1 H), 8.82 (d, J = 2.2 Hz, 1 H), 8.50-8.40 (m, 2H), 8.28 (bs, 1 H), 7.98 (t, J = 2.1 Hz, 1 H), 7.71-7.66 (m, 2H), 6.97-6.87 (m, 1 H), 4.58 (d, J = 47.1 Hz, 2H), 4.35 (d, J = 5.8 Hz, 2H), 3.61-3.49 (m, 2H), 2.95 (t, J = 6.8 Hz, 2H), 1.90 (s,
3H), 1.39 (s, 6H).
Example 386 : Λ/-r2-(5-terf-Butyl-1 ,2,4-oxadiazol-3-yl)ethvn-Λ/l-f6-r5- (trifluoromethyl)pyridin-3-yll-1 ,3-benzothiazol-2-yl}urea
6-[5-(Trifluoromethyl)pyridin-3-yl]-1 ,3-benzothiazol-2-amine (115 mg; 0.39 mmol), phenyl chloroformate (76 μl_; 0.58 mmol), 2-(5-te/f-butyl-[1 ,2,4]oxadiazol-3-yl)- ethylamine hydrochloride (160 mg; 0.78 mmol) and TEA (0.27 ml_; 1.95 mmol) in pyridine (5 ml.) were reacted according to general procedure C. Purification by MD Autoprep followed by trituration in hot ACN afforded the title compound as a white solid. HPLC, Rt: 4.31 min (purity: 99.7%). LC/MS, M+(ESI): 490.9. 1H NMR (DMSO- d6, 300 MHz) δ 1 1.00 (bs, 1 H), 9.27 (bs, 1 H), 8.94 (bs, 1 H), 8.52 (bs, 1 H), 8.45 (bs, 1 H), 7.86 (dd, J = 1.9, 8.4 Hz, 1 H), 7.73 (d, J = 8.3 Hz, 1 H), 6.95 (bs, 1 H), 3.59-3.49 (m, 2H), 2.93 (t, J = 6.4 Hz, 2H), 1.38 (s, 9H).
Example 387 : Λ/-r(5-{2-r(U2-(5-tert-Butyl-1 ,2,4-oxadiazol-3- yl)ethvnamino)carbonyl)amino1-1 ,3-benzothiazol-6-yl)pyridin-3- vDmethyllmethanesulfonamide
Λ/-{[5-(2-Amino-1 ,3-benzothiazol-6-yl)pyridin-3-yl]methyl}methanesulfonamide (400 mg; 0.60 mmol), pyridine (0.97 ml_), phenyl chloroformate (0.09 ml_; 0.72 mmol), 2- (5-tert-butyl-[1 ,2,4]oxadiazol-3-yl)-ethylamine (221 mg; 1.08 mmol) and TEA (0.41 ml.) were reacted according to general procedure C. Purification by MD Autoprep afforded the title compound as a yellow solid. HPLC, Rt: 2.63 min (purity: 95.2%). LC/MS, M+(ESI): 530.1. 1H NMR (DMSOd6, 300 MHz) δ 10.90 (bs, 1 H), 8.86 (d, J =
2.2 Hz, 1 H), 8.53 (d, J = 2.0 Hz, 1 H), 8.30 (s, 1 H), 8.09 (t, J = 2.1 Hz, 1 H), 7.73 (s, 2H), 7.67 (t, J = 6.0 Hz, 1 H), 6.98-6.87 (m, 1 H), 4.29 (d, J = 6.1 Hz, 2H), 3.58-3.52 (m, 2H), 2.98-2.89 (m, 5H), 1.38 (s, 9H). Example 388 : Λ/-r2-(5-terf-Butyl-1 ,2,4-oxadiazol-3-yl)ethvn-Λ/l-f6-r5-(1 ,1 - dioxidothiomorpholin-4-yl)pyridin-3-yll-1 ,3-benzothiazol-2-yl)urea
6-[5-(1 ,1-Dioxidothiomorpholin-4-yl)pyridin-3-yl]-1 ,3-benzothiazol-2-am ine ( 1 50 mg; 0.42 mmol), phenyl chloroformate (0.06 ml_; 0.5 mmol), 2-(5-te/f-butyl- [1 ,2,4]oxadiazol-3-yl)-ethylamine hydrochloride (11 1 mg; 0.54 mmol) and TEA (126 mg; 1.25 mmol) in pyridine (5 ml.) were reacted according to general procedure C.
Purification by filtration through a short plug of silica (DCM/MeOH, 98/2) followed by MD Autoprep afforded the title compound as a white solid. HPLC, Rt: 1.92 min (purity:
97.2%). LC/MS, M+(ESI): 555.9. 1H NMR (DMSO-d6, 300 MHz) δ 1 1.01 (bs, 1 H),
8.39-8.35 (m, 2H), 8.31 (d, J = 1.6 Hz, 1 H), 7.75 (dd, J = M, 8.4 Hz, 1 H), 7.70-7.65
(m, 2H), 7.02 (bs, 1 H), 3.94 (bs, 4H), 3.54 (q, J = 6.5 Hz, 2H), 3.19 (bs, 4H), 2.92 (t, J
= 6.9 Hz, 2H), 1.37 (s, 9H).
Example 389 : Λ/-r6-(5-Methoxypyridin-3-yl)-1 ,3-benzothiazol-2-vn-Λ/l-f2-r5-(2,2,2- trifluoroethyl)-1 ,2,4-oxadiazol-3-yllethyl)urea
Following general procedure C starting from 6-(5-methoxypyridin-3-yl)-1 ,3- benzothiazol-2-amine (196 mg; 0.52 mmol) 2-[5-(2,2,2-trifluoro-ethyl)-
[1 ,2,4]oxadiazol-3-yl]-ethylamine hydrochloride(170 mg, 0.7 mmol) to give the title compound as a white solid. LC/MS, M+(ESI): 479.0. HPLC, Rt: 2.64 min (purity: 99.0%). 1H NMR (DMSO-d6, 300 MHz) δ 10.91 (s, 1 H), 8.57-8.49 (m, 1 H), 8.37-8.30 (m, 1 H), 8.30-8.22 (m, 1 H), 7.83-7.62 (m, 3H), 7.03-6.88 (m, 1 H), 4.46 (q, J = 10.7 Hz, 2H), 3.92 (s, 3H), 3.64-3.47 (m, 2H), 3.09-2.93 (m, 2H).
Example 390 : Λ/-r2-(5-tert-Butyl-1 , 2,4-oxadiazol-3-yl)ethvπ-Λ/l-r6-(1 -isobutyl-1 H- pyrazol-4-yl)-1 ,3-benzothiazol-2-yllurea
Following general protocol B starting from (/V-(6-bromo-1 ,3-benzothiazol-2-yl)-/V-[2- (5-te/f-butyl-1 ,2,4-oxadiazol-3-yl)ethyl]urea (307.20 mg; 0.72 mmol), and 1-isobutyl-4-
(4!4!5!5-tetramethyl-1 !3,2-dioxaborolan-2-yl)-1 /-/-pyrazole (271.19 μl_; 1.09 mmol) and purification by MD Autoprep gave the title compound as a beige solid. LC/MS, M+(ESI): 468.1. HPLC, Rt: 4.14 min (purity: 97.5%). 1H NMR (DMSOd6, 300 MHz) δ 10.80 (s, 1 H), 8.16 (s, 1 H), 8.12-8.03 (m, 1 H), 7.90 (m, 1 H), 7.66-7.49 (m, 2H), 6.97- 6.81 (m, 1 H), 4.02-3.83 (m, 2H), 3.63-3.46 (m, 2H), 3.01-2.84 (m, 2H), 2.27-2.03 (m, 1 H), 1.37 (s, 9H), 0.87 (d, J = 6.7 Hz, 6H).
Example 391 : Λ/-r2-(5-tert-Butyl-1 , 2,4-oxadiazol-3-yl)ethyll-A/l-r6-(1, 3,5-trimethyl- 1 H-pyrazol-4-yl)-1 ,3-benzothiazol-2-yllurea
Following general protocol B starting from (Λ/-(6-bromo-1 ,3-benzothiazol-2-yl)-/V-[2-
(5-te/f-butyl-1 ,2,4-oxadiazol-3-yl)ethyl]urea (304 mg; 0.72 mmol), and 1 ,3,5-trimethyl- 4-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-1 /-/-pyrazole (253 mg; 1.07 mmol) and purification by MD Autoprep gave the title compound as an orange solid. LC/MS, M+(ESI): 468.1. HPLC, Rt: 3.1 1 min (purity: 100%). 1H NMR (DMSOd6, 300 MHz) δ 10.79 (s, 1 H), 7.80-7.70 (m, 1 H), 7.70-7.56 (m, 1 H), 7.28-7.17 (m, 1 H), 6.98-6.82 (m,
1 H), 3.71 (s, 3H), 3.62-3.46 (m, 2H), 3.00-2.84 (m, 2H), 2.22 (s, 3H), 2.13 (s, 3H), 1.38 (s, 9H).
Example 392 : Λ/-r2-(5-terf-Butyl-1 ,2,4-oxadiazol-3-yl)ethvn-Λ/'-r6-(2,5-dimethyl-3- thienyl)-1,3-benzothiazol-2-yllurea
Following general protocol B starting from (/V-(6-bromo-1 ,3-benzothiazol-2-yl)-/V-[2- (5-te/f-butyl-1 ,2,4-oxadiazol-3-yl)ethyl]urea (303 mg; 0.71 mmol), and (2,5-dimethyl-3- thienyl)boronic acid (173 mg; 1.11 mmol) and purification by MD Autoprep gave the title compound as a pale brown powder. LC/MS, M+(ESI): 454.1. HPLC, Rt: 4.99 min (purity: 99.5%). 1H NMR (DMSOd6, 300 MHz) δ 10.83 (s, 1 H), 7.96-7.84 (m, 1 H), 7.70-7.56 (m, 1 H), 7.42-7.32 (m, 1 H), 6.97-6.85 (m, 1 H), 6.85-6.78 (m, 1 H), 3.61-3.45 (m, 2H), 2.98-2.86 (m, 2H), 2.43-2.37 (m, 6H), 1.37 (s, 9H).
Example 393 : Λ/-r2-(5-Ethyl-1 ,3,4-thiadiazol-2-yl)ethvn-Λ/l-r6-(5-methoxypyridin- 3-yl)-1 ,3-benzothiazol-2-yllurea
Fol l owi n g gen era l proced u re C starti n g from 6-(5-methoxypyridin-3-yl)-1 ,3- benzothiazol-2-amine (151 mg; 0.59 mmol) and 2-(5-ethyl-[1 ,3,4]thiadiazol-2-yl)- ethylamine hydrochloride (155 mg; 0.80 mmol) and purification by MD Autoprep gave the title compound as an off-white solid. LC/MS, M+(ESI): 441.1. HPLC Rt: 2.68 min (purity: 98.5%). 1H NMR (DMSOd6, 300 MHz) δ 1 1.10 (bs, 1 H), 8.63-8.44 (m, 1 H),
8.44-8.21 (m, 2H), 7.87-7.59 (m, 3H), 7.17-6.96 (m, 1 H), 3.92 (s, 3H), 3.70-3.50 (m, 2H), 3.34-3.21 (m, 2H), 3.07 (q, 2H), 1.30 (t, J = 7.5 Hz, 3H).
Example 394 : Λ/-r2-(5-terf-Butyl-1 ,2,4-oxadiazol-3-yl)ethvn-Λ/l-(6-f5- f(methylsulfonyl)methvnpyridin-3-yl)-1 ,3-benzothiazol-2-vl)urea
6-{5-[(Methylsulfonyl)methyl]pyridin-3-yl}-1 ,3-benzothiazol-2-am i ne ( 1 20 mg ; 0.38 mmol), phenyl chloroformate (57 μl_; 0.45 mmol), 2-(5-te/f-butyl-[1 ,2,4]oxadiazol-3-yl)- ethylamine hydrochloride (1 16 mg; 0.56 mmol) and TEA (0.26 ml.) in pyridine (1 ml.) were reacted according to general procedure C except that the reaction mixture was stirred at 1000C for 15 min. Purification by MD Autoprep afforded the title compound as a white solid. HPLC, Rt: 2.75 min (purity: 100%). LC/MS, M+(ESI): 515.0. 1H NMR (DMSOd6, 300 MHz) δ 1 1.06-10.82 (m, 1 H), 8.95 (br s, 1 H), 8.57 (br s, 1 H), 8.30 (s, 1 H), 8.17 (s, 1 H), 7.79-7.66 (m, 2H), 6.97-6.84 (m, 1 H), 4.64 (s, 2H), 3.62-3.39 (m, 2H), 3.01 (s, 3H), 2.93 (t, J = 6.7 Hz, 2H), 1.38 (s, 9H). Example 395 : Λ/-r6-(5-Methoxypyridin-3-yl)-1 ,3-benzothiazol-2-vn-3-r(4- methylpentanoyl)amino1pyrrolidine-1 -carboxamide
Following general procedure C starting from 6-(5-methoxypyridin-3-yl)-1 ,3- benzothiazol-2-amine (250 mg; 0.97 mmol) and 4-methyl-Λ/-pyrrolidin-3- ylpentanamide (318 mg; 1.07 mmol) gave an orange solid that was triturated with
ACN and filtered to give the title compound as as a white powder. LC/MS, M+(ESI): 468.1. HPLC, Rt: 2.69 min (purity: 97.6%). 1H NMR (DMSOd6, 300 MHz) δ 1 1.1 1 (bs, 1 H), 8.53 (d, J = 1.4 Hz, 1 H), 8.33 (bs, 1 H), 8.26 (d, J = 2.6 Hz, 1 H), 8.10-8.08 (m, 1 H), 7.77-7.67 (m, 3H), 4.26 (bs, 1 H), 3.92 (s, 3H), 3.62-3.54 (m, 3H), 3.35-3.33 (m, 1 H), 2.09-2.04 (m, 3H), 1.81 (bs, 1 H), 1.53-1.45 (m, 1 H), 1.42-1.35 (m, 2H), 0.84 (d, J
= 6.4 Hz, 6H).
In vitro Assays.
PI3K Delta
The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay. The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 1251, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.
To a 96 wells MTP containing 10 μl of the test compound of Formula (I) (solubilized in 10% DMSO; to yield a concentration of 100, 25, 6.25, 1 .56, 0.39, 0.097, 0.024, 0.0061 , 0.0015 and 0.00038 μM of the test compound), the following assay components are added: 1) 10 μl of lipid micelles 2) 20μl of
Kinase buffer ([33P]γATP67.5μM/300 nCi , MgCI2 2.5mM , DTT 2.5mM , Na3VO4 25μM in Hepes 40 mM, pH 7.4) and 3) 1 0μl (1 00ng) of Human recombinant GST-PI3d (in Hepes 4OmM, pH 7.4, Sucrose 27OmM). After incubation at room temperature for 1 20 minutes, with gentle agitation, the reaction is stopped by addition of 200 μl of a solution containing 150 μg of neomycin-coated PVT SPA beads, ATP 6mM and EDTA 6mM in PBS. The assay is further incubated at room temperature for 60 minutes with gentle agitation to allow binding of phospholipids to neomycin-SPA beads. After settle the neomycin-coated PVT SPA for δhours, radioactive Ptdlns(3)P is quantified by scintillation counting in a Wallac MicroBeta TM plate counter.
The values indicated in Table I below refer to the IC50 (μM) with respect to PI3K, i.e. the amount necessary to achieve 50 % inhibition of said target. Said values show a considerable inhibitory potency of compounds with regard to PI3KDelta.
PI3Kgamma
The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay. The assay combines the scintillation proximity assay technology (SPA,
Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 1 251 , 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.
To a 96 wells MTP containing 10 μl of the test compound of Formula (I) (solubilized in 10% DMSO; to yield a concentration of 100, 25, 6.25, 1 .56,
0.39, 0.097, 0.024, 0.0061 , 0.0015 and 0.00038 μM of the test compound), the following assay components are added: 1) 10 μl of lipid micelles 2) 20μl of Ki nase buffer ([33P]γATP75μM/1 00 nCi, MgCI2 1 2.5mM , DTT 2.5mM , Na3VO4 250μM in Hepes 40 mM, pH 7.4, CHAPS 0.125%, Sodium Cholate 0.25%) and 3) 10μl (100ng) of Human recombinant GST-PI3gamma (in Hepes
4OmM, pH 7.4, ethylenglycol 4%). After incubation at 300C for 120 minutes, with gentle agitation, the reaction is stopped by addition of 200 μl of a solution containing 300 μg of neomycin-coated PVT SPA beads, ATP 6 mM and EDTA 6mM in PBS. The assay is further incubated at room temperature for 60 minutes with gentle agitation to allow binding of phospholipids to neomycin-
SPA beads. After settle the neomycin-coated PVT SPA for δhours, radioactive Ptdlns(3)P is quantified by scintillation counting in a Wallac MicroBeta TM plate counter. The values indicated in Table I below refer to the IC50 (μM) with respect to PI3K, i.e. the amount necessary to achieve 50 % inhibition of said target. Said values show a considerable inhibitory potency of the compounds with regard to PI3Kgamma.
PI3K Beta
The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay. The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 1251, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.
To a 96 wells MTP containing 10 μl of the test compound of Formula (I)
(solubilized in 10% DMSO; to yield a concentration of 100, 25, 6.25, 1 .56, 0.39, 0.097, 0.024, 0.0061 , 0.0015 and 0.00038 μM of the test compound), the following assay components are added: 1) 10 μl of lipid micelles 2) 20μl of Kinase buffer ([33P]γATP175μM/300 nCi, MgCI2 1 OmM, DTT 2.5mM, Na3VO4 250μM, Sodium cholate 0.5% in Hepes 40 mM, pH 7.4) and 3) 10μl (100ng) of
Human recombinant GST-PI3beta (in Hepes 4OmM, pH 7.4, ethylenglycol 2.5%). After incubation at 300C for 120 minutes, with gentle agitation, the reaction is stopped by addition of 200 μl of a solution containing 250 μg of neomycin-coated PVT SPA beads, ATP 6mM and EDTA 6mM in PBS. The assay is further incubated at room temperature for 60 minutes with gentle agitation to allow binding of phosphol ipids to neomycin-SPA beads. After settle the neomycin-coated PVT SPA for δhours, radioactive Ptdlns(3)P is quantified by scintillation counting in a Wallac MicroBeta TM plate counter. The values indicated in Table I below refer to the IC50 (μM) with respect to PI3K, i.e. the amount necessary to achieve 50 % inhibition of said target. Said values show a considerable inhibitory potency of the compounds with regard to PI3K.
PI3K Alpha
The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay. The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 1251, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.
To a 96 wells MTP containing 10 μl of the test compound of Formula (I) (solubilized in 10% DMSO; to yield a concentration of 100, 25, 6.25, 1 .56,
0.39, 0.097, 0.024, 0.0061 , 0.0015 and 0.00038 μM of the test compound), the following assay components are added: 1) 10 μl of lipid micelles 2) 20μl of Kinase buffer ([33P]γATP250μM/300 nCi, MgCI2 25mM, DTT 2.5mM, Na3VO4 0.25mM in Hepes 40 mM, pH 7.4) and 3) 10μl (100ng) of Human recombinant GST-PI3alpha (in Hepes 4OmM, pH 7.4, ethylenglycol 2.5%). After incubation at 300C for 120 minutes, with gentle agitation, the reaction is stopped by addition of 200 μl of a solution containing 150 μg of neomycin-coated PVT SPA beads, ATP 6mM and EDTA 6mM in PBS. The assay is further incubated at room temperature for 60 minutes with gentle agitation to allow binding of phospholipids to neomycin-SPA beads. After settle the neomycin-coated PVT
SPA for δhours, radioactive Ptdlns(3)P is quantified by scintillation counting in a Wallac MicroBeta TM plate counter.
The values indicated in Table I below refer to the IC50 (μM) with respect to PI3K, i.e. the amount necessary to achieve 50 % inhibition of said target. Said values show a considerable inhibitory potency of the compounds with regard to PI3K.
Table I **** : <1 uM *** : <5 uM ** : <20 uM * : >20 uM
Claims
1. A compound according to formula (I)
Wherein denotes either a single bond or a double bond
U denotes CRC, CH, or S;
V denotes C or N
W denotes N or CR1
X denotes CO, SO, SO2, CS or a bond
Y denotes CR2 or N,
Ra denotes NH-Ab, NA2, -NH-(CH2)P-Ab, -NH-(CH2)P-Ar, -NH-(CH2)P-Het4, -NH- (CH2)pCHOR6-Het1, , -NH-(CH2)pCOAr, -NH-(CH2)pCOHet1, -NH-cycloalkyl, COHet1,
CS, also H, or if V denotes C, also Ar or Het1
or if Rb is Ar, Het3, or one of the following groups: , Ra also denotes A, -(CH2)S-Ar, -(CH2)S-Het1, Het1, Het4, or perfluoroalkyl, or if Rb denotes Ar, Ra is also -OA or cycloalkyl.
R', R" are independently hydrogen, alkyl, Ar, Het1, Het2 or A. R and R , together with the nitrogen atom to which they are attached, can optionally form a 3-8- membered heterocyclic ring.
Rc denotes H, A, alkyl, Ar, Het1,
Ar denotes a monocyclic or bicyclic, aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by, Hal, CF3, OCF3, NO2, CN, perfluoroalkyl, A, OA, OH, NH2, COH, CONH21-NHCOA, -NHCO2A, -NHCO2(CH2)sHet1, -(CH2)pHet1, -NHSO2A, -NHSO2- N(H)2-m(A)m, N(H)1-qAqC0A, N(H)1-qASO2-N(H)2-m(A)m, N(H)1-qAqCON(H)2-m(A)m,
COOA, COA, -SO2A, -SO2N(H)2-m(A)m, -SO2Het1, -SO2NHHet1, Het1, - NHSO2NHHet1, or cycloalkyl.
Het1 denotes a monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms and/or 1 CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by alkyl having 1 to 8 carbon atoms, alkoxy having 1 to 8 carbon atoms, Hal, CF3, OCF3, NO2, CN, perfluoroalkyl, A, OA, O(CH2)sAr, O(CH2)sHet1, -(CH2)pHet2, OH, amino, CONH2, - NHCOA, -NHCO2A, -NHCO2(CH2)sAr, -NHSO2-N(H)2-m(A)m, COA, COOA, -SO2A, - SO2N(H)2-m(A)m, -SO2Het2, -SO2NHHet2, -NHSO2NHHet2, Ar, -NHSO2NHAr, - SO2NHAr, SO2Ar, cycloalkyl.
Het2 denotes a monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms and/or 1 CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by alkyl having 1 to 8 carbon atoms, alkoxy having 1 to 8 carbon atoms, Hal, CF3, OCF3, NO2, CN, perfluoroalkyl, A, OA, O(CH2)sAr, O(CH2)sHet1, -(CH2)pHet1, OH, NA2, CONH2, - NHCOA, -NHCO2A, , -NHCO2(CH2)sHet1, -NHCO2(CH2)sAr, -NHSO2-N(H)2-m(A)m, COA, COOA, -SO2A, -SO2N(H)2-m(A)m, -SO2Het1, SO2NHHet2, Ar, SO2Ar, or cycloalkyl.
Het3 denotes a monocyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms and/or 1 CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by NO2, CN, perfluoroalkyl, OH, CONH2, -NHCOA, -NHCO2A, -NHCO2(CH2)sHet1, -NHCO2(CH2)sAr, -NHSO2A, - NHSO2-N(H)2-m(A)m, COA, COOA, -COH, -SO2A, -SO2N(H)2-m(A)m, -SO2Het1, SO2NHHet2, or cycloalkyl or Het3 denotes one of the following groups:
Het4 denotes a monocyclic or bicyclic unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms and/or 1 CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by alkyl having 1 to 8 carbon atoms, alkoxy having 1 to 8 carbon atoms, Hal, CF3, OCF3, NO2, CN, perfluoroalkyl, A, OA, O(CH2)sAr, O(CH2)sHet1, -(CH2)pHet2, OH, amino, CONH2, -NHCOA, -NHCO2A, - NHCO2(CH2)sAr, -NHSO2-N(H)2-m(A)m, COA, COOA, -SO2A, -SO2N(H)2-m(A)m, - SO2Het2, -SO2NHHet2, "NHSO2NHHet2, Ar, -NHSO2NHAr, -SO2NHAr, SO2Ar,
m denotes O, 1 or 2;
n denotes 1 , 2 ,3 or 4;
p denotes O, 1 , 2, 3, 4;
q denotes O or 1
s denotes 1 , 2, 3 , 4
A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by Hal, Ar, Het1, Het2, OR6, CN, NHCO, CONR'R" COOR6 or NR R and wherein one or more, preferably 1 to 7 non-adjacent CH2-groups may be replaced by O, NR6 or S and/or by -CH=CH- or -C≡C- groups, or denotes cycloalkyl, cycloalken or cycloalkylalkylen having 3-7 ring C atoms wherein the cycloalkylen is optionally substituted by 1 or 2 OH groups; Ab is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by Hal, Ar, OR6, CN, NHCO, CONR'R" COOR6 or NR R and wherein one or more, preferably 1 to 7 non-adjacent CH2- groups may be replaced by O, NR6 or S and/or by -CH=CH- or -C≡C- groups, or denotes cycloalkyl, cycloalken or cycloalkylalkylen having 3-7 ring C atoms wherein the cycloalkylen is optionally substituted by 1 or 2 OH groups;
R 11, D R2 are each independently H, Hal, CF3, A; Ar Het1 or Het2
R3 is H or Hal
R , R denote each independently H, Ar, Het1, Het2, or A, and if R'or R" is bond to a C atom also OA.
R6 is H, a branched or linear alkyl or hydroxyalkyl having 1 to 12 C-atoms
and pharmaceutically acceptable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.
2. A compound according to formulae l-a tol-f or (I-Z):
wherein Ra and Rb are as defined in claim 1 ,
Wherein G1 is C or N, G2 is H, OA, SO2A,
G3 is a linear or branched alkyl group optionally substituted with 1 to 3 groups selected from OH, OMe, Hal, N(CH3)2, G4 is O or S, G5 is N or C, and pharmaceutically acceptable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.
3. A compound according to claim 1 or 2 wherein Rb denotes Ar or Het2.
4. A compound according to claim 1 to 3 wherein Rb denotes Het3 and Ra denotes A.
5. A compound according to claim 1 to 4 wherein Rb is Ar optionally substituted by the groups listed in the definitions of Ar or a pyridine group optionally substituted by the groups listed in the definitions of Het2, and wherein Ra is - NH-(CH2)P-Het4.
6. A compound according to claim 1 to 5 wherein R3 denotes H.
7. A compound according to any one of preceding claims selected from the following group:
and pharmaceutically acceptable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.
8. Process for the preparation of compounds of formula (I) according to claim 1 , comprising the step of reacting a compound of Formula (l-l)
9. A compound according to Claim 1 to 8 for use in the treatment and prophylaxis of cancer diseases.
10. A compound according to Claim 1 to 8 for use in the treatment and prophylaxis of cancer diseases that are associated with a tumor from the group of tumours of the squamous epithelium, of the bladder, of the stomach, of the kidneys, of head and neck, of the oesophagus, of the cervix, of the thyroid, of the intestine, of the liver, of the brain, of the prostate, of the urogenital tract, of the lymphatic system, of the stomach, of the larynx and/or of the lung.
1 1. A compound according to Claim 1 to 8 for use as a medicament.
12. A compound according to Claim 1 to 8 for use in the treatment and prophylaxis diseases in which the inhibition, activation, regulation, and/or modulation of PI3K receptor signal transduction plays a role.
13. A compound according to Claim 1 to 8 for use in the prophylaxis and/or treatment of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, allergy, asthma, pancreatitis, multi-organe failure, kidney diseases, platelet aggregation, cancer, transplantation, sperm motility, erythrocyte deficiency, graft rejection or lung injuries.
14. Pharmaceutical composition comprising at least one compound according to claims 1 to 8 and/or pharmaceutically usable derivatives, tautomers, salts, sol- vates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.
15. A pharmaceutical composition comprising at least one compound according to claims 1 to 8and/or pharmaceutically usable derivatives, tautomers, salts, sol- vates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further active ingredient.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09154345 | 2009-03-04 | ||
EP09154345.4 | 2009-03-04 | ||
US23913709P | 2009-09-02 | 2009-09-02 | |
US61/239,137 | 2009-09-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010100144A1 true WO2010100144A1 (en) | 2010-09-10 |
Family
ID=40577951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/052615 WO2010100144A1 (en) | 2009-03-04 | 2010-03-02 | Fused bicyclic compounds as inhibitors for pi3 kinase |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR076076A1 (en) |
WO (1) | WO2010100144A1 (en) |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2311842A3 (en) * | 2008-06-24 | 2011-07-13 | Takeda Pharmaceutical Company Limited | PI3K/M TOR inhibitors |
US20120088750A1 (en) * | 2010-10-08 | 2012-04-12 | Biota Europe Ltd. | Antibacterial compounds |
WO2012174312A3 (en) * | 2011-06-15 | 2013-02-28 | Glaxosmithkline Llc | Benzimidazole derivatives as antiviral agents |
US8415376B2 (en) | 2008-05-30 | 2013-04-09 | Amgen Inc. | Inhibitors of PI3 kinase |
WO2014008992A1 (en) | 2012-07-10 | 2014-01-16 | Ares Trading S.A. | Pyrimidine pyrazolyl derivatives |
US8729074B2 (en) | 2009-03-20 | 2014-05-20 | Amgen Inc. | Inhibitors of PI3 kinase |
WO2014083327A1 (en) * | 2012-11-27 | 2014-06-05 | Md Pharma Ab | Adenine derivatives suitable for the treatment of (inter alia) muscular dystrophy |
JP2014528412A (en) * | 2011-09-30 | 2014-10-27 | キネタ・インコーポレイテツド | Antiviral compounds |
CN104402875A (en) * | 2014-12-25 | 2015-03-11 | 西安山川医药科技有限公司 | Synthesis method and application N-(2-aminoethyl)-N'-(6-substituted-2-benzothiazolyl)urea and salt compounds thereof |
WO2015134171A1 (en) | 2014-03-06 | 2015-09-11 | Takeda Pharmaceutical Company Limited | Heteroarylamide inhibitors of tbk1 |
US20160297824A1 (en) * | 2015-03-16 | 2016-10-13 | Ligand Pharmaceuticals, Inc. | Imidazo-fused heterocycles and uses thereof |
WO2017197151A1 (en) * | 2016-05-11 | 2017-11-16 | Emory University | Phosphotidylinositol 3-kinase inhibitors |
WO2018017435A1 (en) | 2016-07-22 | 2018-01-25 | Accro Bioscience Inc. | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof |
CN108558869A (en) * | 2018-05-10 | 2018-09-21 | 西安培华学院 | Compound for treating liver cancer and its preparation |
WO2018176343A1 (en) | 2017-03-30 | 2018-10-04 | Xw Laboratories Inc. | Bicyclic heteroaryl derivatives and preparation and uses thereof |
WO2018237370A1 (en) * | 2017-06-23 | 2018-12-27 | Accro Bioscience Inc. | Heteroaryl compounds as inhibitors of necrosis, composition and method using the same |
CN109111464A (en) * | 2017-06-23 | 2019-01-01 | 爱科诺生物医药股份有限公司 | A kind of heterocyclic compound with meronecrosis inhibitory activity |
KR20190028546A (en) * | 2016-07-22 | 2019-03-18 | 에이씨씨알오 바이오사이언스 인코퍼레이티드 | Heteroaryl compounds as inhibitors of necrosis, compositions thereof and uses thereof |
WO2019070093A1 (en) * | 2017-10-02 | 2019-04-11 | 1ST Biotherapeutics, Inc. | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders |
US10385046B1 (en) | 2019-03-19 | 2019-08-20 | 1ST Biotherapeutics, Inc. | Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders |
US10508113B2 (en) | 2018-03-12 | 2019-12-17 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
US10689344B2 (en) * | 2013-11-07 | 2020-06-23 | University Of Kansas | Biphenylamide derivative Hsp90 inhibitors |
CN111434661A (en) * | 2019-01-11 | 2020-07-21 | 爱科诺生物医药股份有限公司 | Aromatic heterocyclic compound with cell necrosis inhibitory activity and application thereof |
WO2020178795A1 (en) * | 2019-03-07 | 2020-09-10 | 1ST Biotherapeutics, Inc. | [ 18f]-labeled benzothiazole derivative as pet radiotracer |
WO2020194260A1 (en) * | 2019-03-28 | 2020-10-01 | 1ST Biotherapeutics, Inc. | Pharmaceutical salts of benzothiazol compounds, polymorphs and methods for preparation thereof |
US11098044B2 (en) | 2019-02-22 | 2021-08-24 | 1ST Biotherapeutics, Inc. | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders |
WO2021242955A1 (en) * | 2020-05-28 | 2021-12-02 | Senda Biosciences, Inc. | Fused azole heterocycles as ahr antagonists |
WO2022064459A1 (en) * | 2020-09-28 | 2022-03-31 | 1ST Biotherapeutics, Inc. | Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same |
RU2778370C2 (en) * | 2017-10-02 | 2022-08-18 | 1Ст Биотерапьютикс, Инк. | Benzothiazole compounds and methods for their use for treatment of neurodegenerative disorders |
CN115298177A (en) * | 2019-10-11 | 2022-11-04 | 因赛特公司 | Bicyclic amines as CDK2 inhibitors |
WO2023012081A1 (en) | 2021-08-05 | 2023-02-09 | Syngenta Crop Protection Ag | Method for controlling diamide resistant pests & compounds therefor |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US12084458B2 (en) | 2021-02-19 | 2024-09-10 | Sudo Biosciences Limited | Substituted pyridines, pyridazines, and pyrimidines as TYK2 inhibitors |
US12122785B2 (en) | 2021-02-19 | 2024-10-22 | Sudo Biosciences Limited | Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors |
US12312331B2 (en) | 2019-08-14 | 2025-05-27 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007016392A2 (en) * | 2005-08-01 | 2007-02-08 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
WO2007095588A1 (en) * | 2006-02-14 | 2007-08-23 | Novartis Ag | Pi-3 kinase inhibitors and methods of their use |
WO2008119734A2 (en) * | 2007-03-29 | 2008-10-09 | Novartis Ag | Process for the manufacture of organic compounds |
WO2009017822A2 (en) * | 2007-08-02 | 2009-02-05 | Amgen Inc. | Pi3 kinase modulators and methods of use |
-
2010
- 2010-03-02 WO PCT/EP2010/052615 patent/WO2010100144A1/en active Application Filing
- 2010-03-03 AR ARP100100635A patent/AR076076A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007016392A2 (en) * | 2005-08-01 | 2007-02-08 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
WO2007095588A1 (en) * | 2006-02-14 | 2007-08-23 | Novartis Ag | Pi-3 kinase inhibitors and methods of their use |
WO2008119734A2 (en) * | 2007-03-29 | 2008-10-09 | Novartis Ag | Process for the manufacture of organic compounds |
WO2009017822A2 (en) * | 2007-08-02 | 2009-02-05 | Amgen Inc. | Pi3 kinase modulators and methods of use |
Cited By (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8415376B2 (en) | 2008-05-30 | 2013-04-09 | Amgen Inc. | Inhibitors of PI3 kinase |
EP2311842A3 (en) * | 2008-06-24 | 2011-07-13 | Takeda Pharmaceutical Company Limited | PI3K/M TOR inhibitors |
US8729074B2 (en) | 2009-03-20 | 2014-05-20 | Amgen Inc. | Inhibitors of PI3 kinase |
US20120088750A1 (en) * | 2010-10-08 | 2012-04-12 | Biota Europe Ltd. | Antibacterial compounds |
JP2013542204A (en) * | 2010-10-08 | 2013-11-21 | ビオタ ヨーロッパ リミテッド | Bacterial topoisomerase II inhibitory 2-ethylcarbamoylamino-1,3-benzothiazol-5-yls |
US9181234B2 (en) * | 2010-10-08 | 2015-11-10 | Biota Europe Ltd. | Antibacterial compounds |
WO2012174312A3 (en) * | 2011-06-15 | 2013-02-28 | Glaxosmithkline Llc | Benzimidazole derivatives as antiviral agents |
JP2014528412A (en) * | 2011-09-30 | 2014-10-27 | キネタ・インコーポレイテツド | Antiviral compounds |
US9216991B2 (en) | 2012-07-10 | 2015-12-22 | Ares Trading S.A. | Pyrimidine pyrazolyl derivatives |
WO2014008992A1 (en) | 2012-07-10 | 2014-01-16 | Ares Trading S.A. | Pyrimidine pyrazolyl derivatives |
WO2014083327A1 (en) * | 2012-11-27 | 2014-06-05 | Md Pharma Ab | Adenine derivatives suitable for the treatment of (inter alia) muscular dystrophy |
US10689344B2 (en) * | 2013-11-07 | 2020-06-23 | University Of Kansas | Biphenylamide derivative Hsp90 inhibitors |
WO2015134171A1 (en) | 2014-03-06 | 2015-09-11 | Takeda Pharmaceutical Company Limited | Heteroarylamide inhibitors of tbk1 |
US9598424B2 (en) | 2014-03-06 | 2017-03-21 | Takeda Pharmaceutical Company Limited | Heteroarylamide inhibitors of TBK1 |
CN104402875A (en) * | 2014-12-25 | 2015-03-11 | 西安山川医药科技有限公司 | Synthesis method and application N-(2-aminoethyl)-N'-(6-substituted-2-benzothiazolyl)urea and salt compounds thereof |
US11858938B2 (en) | 2015-03-16 | 2024-01-02 | Ligand Pharmaceuticals, Inc. | Imidazo-fused heterocycles and uses thereof |
US10807983B2 (en) * | 2015-03-16 | 2020-10-20 | Ligand Pharmaceuticals, Inc. | Imidazo-fused heterocycles and uses thereof |
US20160297824A1 (en) * | 2015-03-16 | 2016-10-13 | Ligand Pharmaceuticals, Inc. | Imidazo-fused heterocycles and uses thereof |
WO2017197151A1 (en) * | 2016-05-11 | 2017-11-16 | Emory University | Phosphotidylinositol 3-kinase inhibitors |
US10947225B2 (en) | 2016-05-11 | 2021-03-16 | Emory University | Phosphotidylinositol 3-kinase inhibitors |
EP3487498A4 (en) * | 2016-07-22 | 2020-05-20 | Xiaohu Zhang | HETERARYARYLIC COMPOUNDS FOR USE AS NECROSIS INHIBITORS, COMPOSITION AND APPLICATION THEREOF |
WO2018017435A1 (en) | 2016-07-22 | 2018-01-25 | Accro Bioscience Inc. | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof |
KR102441864B1 (en) * | 2016-07-22 | 2022-09-08 | 에이씨씨알오 바이오사이언스 (에이치케이) 리미티드 | Heteroaryl compounds, compositions and uses thereof as inhibitors of necrosis |
JP2019521994A (en) * | 2016-07-22 | 2019-08-08 | アクロ バイオサイエンス インク. | Heteroaryl compounds that are necrosis inhibitors, compositions and uses thereof |
JP7025359B2 (en) | 2016-07-22 | 2022-02-24 | アクロ バイオサイエンス (エイチケー) リミテッド | Heteroaryl compounds that are necrosis inhibitors, their compositions and uses |
KR20190028546A (en) * | 2016-07-22 | 2019-03-18 | 에이씨씨알오 바이오사이언스 인코퍼레이티드 | Heteroaryl compounds as inhibitors of necrosis, compositions thereof and uses thereof |
WO2018176343A1 (en) | 2017-03-30 | 2018-10-04 | Xw Laboratories Inc. | Bicyclic heteroaryl derivatives and preparation and uses thereof |
WO2018237370A1 (en) * | 2017-06-23 | 2018-12-27 | Accro Bioscience Inc. | Heteroaryl compounds as inhibitors of necrosis, composition and method using the same |
CN109111464A (en) * | 2017-06-23 | 2019-01-01 | 爱科诺生物医药股份有限公司 | A kind of heterocyclic compound with meronecrosis inhibitory activity |
US10669246B2 (en) | 2017-10-02 | 2020-06-02 | 1ST Biotherapeutics, Inc. | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders |
CN111315727A (en) * | 2017-10-02 | 2020-06-19 | 第一生物治疗股份有限公司 | Benzothiazole compounds and methods of using the same for treating neurodegenerative diseases |
RU2778370C2 (en) * | 2017-10-02 | 2022-08-18 | 1Ст Биотерапьютикс, Инк. | Benzothiazole compounds and methods for their use for treatment of neurodegenerative disorders |
WO2019070093A1 (en) * | 2017-10-02 | 2019-04-11 | 1ST Biotherapeutics, Inc. | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders |
CN111315727B (en) * | 2017-10-02 | 2023-09-29 | 第一生物治疗股份有限公司 | Benzothiazole compounds and methods of treating neurodegenerative diseases using the same |
US10968188B2 (en) | 2017-10-02 | 2021-04-06 | 1ST Biotherapeutics, Inc. | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders |
US10508113B2 (en) | 2018-03-12 | 2019-12-17 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
CN108558869A (en) * | 2018-05-10 | 2018-09-21 | 西安培华学院 | Compound for treating liver cancer and its preparation |
CN108558869B (en) * | 2018-05-10 | 2019-04-09 | 西安培华学院 | Compounds for treating liver cancer and preparations thereof |
CN111434661B (en) * | 2019-01-11 | 2023-09-12 | 爱科诺生物医药(香港)有限公司 | Aromatic heterocyclic compound with cell necrosis inhibition activity and application thereof |
CN111434661A (en) * | 2019-01-11 | 2020-07-21 | 爱科诺生物医药股份有限公司 | Aromatic heterocyclic compound with cell necrosis inhibitory activity and application thereof |
EP3908277A4 (en) * | 2019-01-11 | 2022-12-28 | Xiaohu Zhang | Heteroaryl compounds as necrosis inhibitors, composition and method using the same |
US11098044B2 (en) | 2019-02-22 | 2021-08-24 | 1ST Biotherapeutics, Inc. | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders |
US11802126B2 (en) | 2019-02-22 | 2023-10-31 | 1ST Biotherapeutics, Inc. | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders |
WO2020178795A1 (en) * | 2019-03-07 | 2020-09-10 | 1ST Biotherapeutics, Inc. | [ 18f]-labeled benzothiazole derivative as pet radiotracer |
JP2022523827A (en) * | 2019-03-07 | 2022-04-26 | ファースト・バイオセラピューティクス・インコーポレイテッド | [18F] labeled benzothiazole derivative as PET radiotracer |
JP7456641B2 (en) | 2019-03-07 | 2024-03-27 | ファースト・バイオセラピューティクス・インコーポレイテッド | [18F]-labeled benzothiazole derivatives as PET radiotracers |
US10385046B1 (en) | 2019-03-19 | 2019-08-20 | 1ST Biotherapeutics, Inc. | Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders |
CN113631554A (en) * | 2019-03-28 | 2021-11-09 | 第一生物治疗股份有限公司 | Pharmaceutically acceptable salts, polymorphs of benzothiazole compounds and processes for their preparation |
US12304905B2 (en) | 2019-03-28 | 2025-05-20 | 1ST Biotherapeutics, Inc. | Pharmaceutical salts of benzothiazol compounds, polymorphs and methods for preparation thereof |
WO2020194260A1 (en) * | 2019-03-28 | 2020-10-01 | 1ST Biotherapeutics, Inc. | Pharmaceutical salts of benzothiazol compounds, polymorphs and methods for preparation thereof |
US12312331B2 (en) | 2019-08-14 | 2025-05-27 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors |
CN115298177A (en) * | 2019-10-11 | 2022-11-04 | 因赛特公司 | Bicyclic amines as CDK2 inhibitors |
WO2021242955A1 (en) * | 2020-05-28 | 2021-12-02 | Senda Biosciences, Inc. | Fused azole heterocycles as ahr antagonists |
US11649255B2 (en) | 2020-09-28 | 2023-05-16 | 1ST Biotherapeutics, Inc. | Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same |
WO2022064459A1 (en) * | 2020-09-28 | 2022-03-31 | 1ST Biotherapeutics, Inc. | Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same |
CN114599651A (en) * | 2020-09-28 | 2022-06-07 | 第一生物治疗股份有限公司 | Indazoles as inhibitors of hematopoietic progenitor kinase 1(HPK1) and methods of use thereof |
CN114599653A (en) * | 2020-09-28 | 2022-06-07 | 第一生物治疗股份有限公司 | Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods of use |
EP4217358A4 (en) * | 2020-09-28 | 2025-01-08 | 1st Biotherapeutics, Inc. | Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same |
US12103937B2 (en) | 2021-02-19 | 2024-10-01 | Sudo Biosciences Limited | Substituted pyridines and pyridazines as TYK2 inhibitors |
US12084458B2 (en) | 2021-02-19 | 2024-09-10 | Sudo Biosciences Limited | Substituted pyridines, pyridazines, and pyrimidines as TYK2 inhibitors |
US12122785B2 (en) | 2021-02-19 | 2024-10-22 | Sudo Biosciences Limited | Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
WO2023012081A1 (en) | 2021-08-05 | 2023-02-09 | Syngenta Crop Protection Ag | Method for controlling diamide resistant pests & compounds therefor |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Also Published As
Publication number | Publication date |
---|---|
AR076076A1 (en) | 2011-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010100144A1 (en) | Fused bicyclic compounds as inhibitors for pi3 kinase | |
WO2009133127A1 (en) | Fused bicyclic compounds and use thereof as pi3k inhibitors | |
ES2534095T3 (en) | Aminopyridine derivatives for the treatment of tumors and inflammatory diseases | |
US9073940B2 (en) | Tricyclic pyrazol amine derivatives | |
US11053234B2 (en) | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | |
RU2738232C2 (en) | Benzodiazepine derivatives as rsv inhibitors | |
JP6109195B2 (en) | Heterocycle-substituted pyridyl compounds useful as kinase inhibitors | |
JP6096807B2 (en) | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors | |
JP5290972B2 (en) | 2- (Heterocyclylbenzyl) pyridazinone derivatives | |
JP6001048B2 (en) | Thiazolopyrimidine compounds | |
TW201919640A (en) | Combination agent as an RSV inhibitor | |
KR20180132629A (en) | Glycosidase inhibitor | |
JP2017505346A (en) | Novel 3- (indol-3-yl) -pyridine derivatives, pharmaceutical compositions and methods of use | |
KR20180132626A (en) | Glycosidase inhibitor | |
JP2014510105A (en) | Azole compounds as PIM inhibitors | |
WO2010037765A2 (en) | 4-morpholino-pyrido[3,2-d]pyrimidines | |
EP2375899A1 (en) | Piperidine-containing compounds and use thereof | |
AU2009327133B2 (en) | Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis | |
WO2014111871A1 (en) | 4,5-dihydroisoxazole derivatives as nampt inhibitors | |
AU2007206860A1 (en) | Thiazole derivatives and use thereof | |
AU2009316795A1 (en) | Inhibitors of diacylglycerol acyltransferase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10706236 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10706236 Country of ref document: EP Kind code of ref document: A1 |